SMILES,Toxicity ,Effect,Probability
CCCCCCC(=O)O,Human Intestinal Absorption,+,0.9936
CCCCCCC(=O)O,Caco-2,+,0.852
CCCCCCC(=O)O,Blood Brain Barrier,+,0.85
CCCCCCC(=O)O,Human oral bioavailability,-,0.6714
CCCCCCC(=O)O,Subcellular localzation,Mitochondria,0.5152
CCCCCCC(=O)O,OATP2B1 inhibitior,-,0.8374
CCCCCCC(=O)O,OATP1B1 inhibitior,+,0.8902
CCCCCCC(=O)O,OATP1B3 inhibitior,-,0.3662
CCCCCCC(=O)O,MATE1 inhibitior,-,1
CCCCCCC(=O)O,OCT2 inhibitior,-,0.925
CCCCCCC(=O)O,BSEP inhibitior,-,0.9383
CCCCCCC(=O)O,P-glycoprotein inhibitior,-,0.9892
CCCCCCC(=O)O,P-glycoprotein substrate,-,0.9647
CCCCCCC(=O)O,CYP3A4 substrate,-,0.7568
CCCCCCC(=O)O,CYP2C9 substrate,+,0.672
CCCCCCC(=O)O,CYP2D6 substrate,-,0.8901
CCCCCCC(=O)O,CYP3A4 inhibition,-,0.9484
CCCCCCC(=O)O,CYP2C9 inhibition,-,0.8808
CCCCCCC(=O)O,CYP2C19 inhibition,-,0.9578
CCCCCCC(=O)O,CYP2D6 inhibition,-,0.9554
CCCCCCC(=O)O,CYP1A2 inhibition,+,0.8326
CCCCCCC(=O)O,CYP2C8 inhibition,-,0.9749
CCCCCCC(=O)O,CYP inhibitory promiscuity,-,0.9647
CCCCCCC(=O)O,UGT catelyzed,-,0
CCCCCCC(=O)O,Carcinogenicity (binary),-,0.7035
CCCCCCC(=O)O,Carcinogenicity (trinary),Non-required,0.7057
CCCCCCC(=O)O,Eye corrosion,+,0.9827
CCCCCCC(=O)O,Eye irritation,+,0.9768
CCCCCCC(=O)O,Skin irritation,+,0.7702
CCCCCCC(=O)O,Skin corrosion,+,0.7927
CCCCCCC(=O)O,Ames mutagenesis,-,1
CCCCCCC(=O)O,Human Ether-a-go-go-Related Gene inhibition,-,0.8351
CCCCCCC(=O)O,Micronuclear,-,1
CCCCCCC(=O)O,Hepatotoxicity,+,0.7625
CCCCCCC(=O)O,skin sensitisation,+,0.8147
CCCCCCC(=O)O,Respiratory toxicity,-,0.7333
CCCCCCC(=O)O,Reproductive toxicity,-,0.6972
CCCCCCC(=O)O,Mitochondrial toxicity,+,0.55
CCCCCCC(=O)O,Nephrotoxicity,-,0.572
CCCCCCC(=O)O,Acute Oral Toxicity (c),IV,0.6378
CCCCCCC(=O)O,Estrogen receptor binding,-,0.9679
CCCCCCC(=O)O,Androgen receptor binding,-,0.9011
CCCCCCC(=O)O,Thyroid receptor binding,-,0.8868
CCCCCCC(=O)O,Glucocorticoid receptor binding,-,0.8846
CCCCCCC(=O)O,Aromatase binding,-,0.8732
CCCCCCC(=O)O,PPAR gamma,-,0.7437
CCCCCCC(=O)O,Honey bee toxicity,-,0.9981
CCCCCCC(=O)O,Biodegradation,+,0.975
CCCCCCC(=O)O,Crustacea aquatic toxicity,+,0.741
CCCCCCC(=O)O,Fish aquatic toxicity,+,0.9178
CCCCCCC(=O)O,Water solubility,-3.502,logS
CCCCCCC(=O)O,Plasma protein binding,0.312,100%
CCCCCCC(=O)O,Acute Oral Toxicity,1.469,log(1/(mol/kg))
CCCCCCC(=O)O,Tetrahymena pyriformis,-0.168,pIGC50 (ug/L)
,,,
CCOC(=O)C,Human Intestinal Absorption,+,1
CCOC(=O)C,Caco-2,+,0.6795
CCOC(=O)C,Blood Brain Barrier,+,0.95
CCOC(=O)C,Human oral bioavailability,+,0.5857
CCOC(=O)C,Subcellular localzation,Mitochondria,0.7194
CCOC(=O)C,OATP2B1 inhibitior,-,0.8616
CCOC(=O)C,OATP1B1 inhibitior,+,0.9686
CCOC(=O)C,OATP1B3 inhibitior,+,0.9522
CCOC(=O)C,MATE1 inhibitior,-,0.92
CCOC(=O)C,OCT2 inhibitior,-,0.9
CCOC(=O)C,BSEP inhibitior,-,0.8748
CCOC(=O)C,P-glycoprotein inhibitior,-,0.9864
CCOC(=O)C,P-glycoprotein substrate,-,0.9952
CCOC(=O)C,CYP3A4 substrate,-,0.6976
CCOC(=O)C,CYP2C9 substrate,-,1
CCOC(=O)C,CYP2D6 substrate,-,0.8836
CCOC(=O)C,CYP3A4 inhibition,-,0.9801
CCOC(=O)C,CYP2C9 inhibition,-,0.9386
CCOC(=O)C,CYP2C19 inhibition,-,0.9506
CCOC(=O)C,CYP2D6 inhibition,-,0.9531
CCOC(=O)C,CYP1A2 inhibition,-,0.6609
CCOC(=O)C,CYP2C8 inhibition,-,0.9885
CCOC(=O)C,CYP inhibitory promiscuity,-,0.8869
CCOC(=O)C,UGT catelyzed,-,0
CCOC(=O)C,Carcinogenicity (binary),+,0.5574
CCOC(=O)C,Carcinogenicity (trinary),Non-required,0.6906
CCOC(=O)C,Eye corrosion,+,0.992
CCOC(=O)C,Eye irritation,+,0.995
CCOC(=O)C,Skin irritation,+,0.9359
CCOC(=O)C,Skin corrosion,-,0.8424
CCOC(=O)C,Ames mutagenesis,-,0.92
CCOC(=O)C,Human Ether-a-go-go-Related Gene inhibition,-,0.8425
CCOC(=O)C,Micronuclear,-,0.99
CCOC(=O)C,Hepatotoxicity,+,0.5185
CCOC(=O)C,skin sensitisation,+,0.5
CCOC(=O)C,Respiratory toxicity,-,0.9889
CCOC(=O)C,Reproductive toxicity,-,0.6556
CCOC(=O)C,Mitochondrial toxicity,-,1
CCOC(=O)C,Nephrotoxicity,+,0.7185
CCOC(=O)C,Acute Oral Toxicity (c),IV,0.636
CCOC(=O)C,Estrogen receptor binding,-,0.9394
CCOC(=O)C,Androgen receptor binding,-,0.9413
CCOC(=O)C,Thyroid receptor binding,-,0.9242
CCOC(=O)C,Glucocorticoid receptor binding,-,0.948
CCOC(=O)C,Aromatase binding,-,0.8892
CCOC(=O)C,PPAR gamma,-,0.9268
CCOC(=O)C,Honey bee toxicity,-,0.9477
CCOC(=O)C,Biodegradation,+,0.975
CCOC(=O)C,Crustacea aquatic toxicity,-,0.8255
CCOC(=O)C,Fish aquatic toxicity,+,0.746
CCOC(=O)C,Water solubility,-0.103,logS
CCOC(=O)C,Plasma protein binding,-0.19,1
CCOC(=O)C,Acute Oral Toxicity,1.34,log(1/(mol/kg))
CCOC(=O)C,Tetrahymena pyriformis,-1.384,pIGC50 (ug/L)
,,,
CCC(=O)O,Human Intestinal Absorption,+,0.9942
CCC(=O)O,Caco-2,+,0.644
CCC(=O)O,Blood Brain Barrier,+,0.825
CCC(=O)O,Human oral bioavailability,+,0.7286
CCC(=O)O,Subcellular localzation,Mitochondria,0.5849
CCC(=O)O,OATP2B1 inhibitior,-,0.8637
CCC(=O)O,OATP1B1 inhibitior,+,0.9599
CCC(=O)O,OATP1B3 inhibitior,+,0.935
CCC(=O)O,MATE1 inhibitior,-,1
CCC(=O)O,OCT2 inhibitior,-,1
CCC(=O)O,BSEP inhibitior,-,0.9395
CCC(=O)O,P-glycoprotein inhibitior,-,0.9889
CCC(=O)O,P-glycoprotein substrate,-,0.9936
CCC(=O)O,CYP3A4 substrate,-,0.8419
CCC(=O)O,CYP2C9 substrate,+,0.672
CCC(=O)O,CYP2D6 substrate,-,0.8901
CCC(=O)O,CYP3A4 inhibition,-,0.9763
CCC(=O)O,CYP2C9 inhibition,-,0.9639
CCC(=O)O,CYP2C19 inhibition,-,0.9794
CCC(=O)O,CYP2D6 inhibition,-,0.9667
CCC(=O)O,CYP1A2 inhibition,-,0.8922
CCC(=O)O,CYP2C8 inhibition,-,0.9914
CCC(=O)O,CYP inhibitory promiscuity,-,0.9876
CCC(=O)O,UGT catelyzed,-,0
CCC(=O)O,Carcinogenicity (binary),+,0.5765
CCC(=O)O,Carcinogenicity (trinary),Non-required,0.7073
CCC(=O)O,Eye corrosion,+,0.9968
CCC(=O)O,Eye irritation,+,0.9832
CCC(=O)O,Skin irritation,+,0.9441
CCC(=O)O,Skin corrosion,+,0.993
CCC(=O)O,Ames mutagenesis,-,0.98
CCC(=O)O,Human Ether-a-go-go-Related Gene inhibition,-,0.8258
CCC(=O)O,Micronuclear,-,0.9626
CCC(=O)O,Hepatotoxicity,-,0.65
CCC(=O)O,skin sensitisation,-,0.6043
CCC(=O)O,Respiratory toxicity,-,0.9333
CCC(=O)O,Reproductive toxicity,+,0.7556
CCC(=O)O,Mitochondrial toxicity,-,0.9625
CCC(=O)O,Nephrotoxicity,-,0.6939
CCC(=O)O,Acute Oral Toxicity (c),III,0.9124
CCC(=O)O,Estrogen receptor binding,-,0.9554
CCC(=O)O,Androgen receptor binding,-,0.9389
CCC(=O)O,Thyroid receptor binding,-,0.8968
CCC(=O)O,Glucocorticoid receptor binding,-,0.9318
CCC(=O)O,Aromatase binding,-,0.9111
CCC(=O)O,PPAR gamma,-,0.8545
CCC(=O)O,Honey bee toxicity,-,0.9954
CCC(=O)O,Biodegradation,+,1
CCC(=O)O,Crustacea aquatic toxicity,-,0.91
CCC(=O)O,Fish aquatic toxicity,-,0.809
CCC(=O)O,Water solubility,0.607,logS
CCC(=O)O,Plasma protein binding,-0.025,1
CCC(=O)O,Acute Oral Toxicity,1.05,log(1/(mol/kg))
CCC(=O)O,Tetrahymena pyriformis,-0.506,pIGC50 (ug/L)
,,,
CC(C)N,Human Intestinal Absorption,+,0.9965
CC(C)N,Caco-2,-,0.6456
CC(C)N,Blood Brain Barrier,+,0.925
CC(C)N,Human oral bioavailability,+,0.7857
CC(C)N,Subcellular localzation,Lysosomes,0.9252
CC(C)N,OATP2B1 inhibitior,-,1
CC(C)N,OATP1B1 inhibitior,+,0.9853
CC(C)N,OATP1B3 inhibitior,+,0.96
CC(C)N,MATE1 inhibitior,-,0.96
CC(C)N,OCT2 inhibitior,-,0.95
CC(C)N,BSEP inhibitior,-,0.9364
CC(C)N,P-glycoprotein inhibitior,-,0.9864
CC(C)N,P-glycoprotein substrate,-,0.9879
CC(C)N,CYP3A4 substrate,-,0.8728
CC(C)N,CYP2C9 substrate,-,1
CC(C)N,CYP2D6 substrate,+,0.3682
CC(C)N,CYP3A4 inhibition,-,0.9752
CC(C)N,CYP2C9 inhibition,-,0.9599
CC(C)N,CYP2C19 inhibition,-,0.9588
CC(C)N,CYP2D6 inhibition,-,0.8757
CC(C)N,CYP1A2 inhibition,-,0.9376
CC(C)N,CYP2C8 inhibition,-,0.9989
CC(C)N,CYP inhibitory promiscuity,-,0.966
CC(C)N,UGT catelyzed,-,0
CC(C)N,Carcinogenicity (binary),+,0.59
CC(C)N,Carcinogenicity (trinary),Non-required,0.6063
CC(C)N,Eye corrosion,+,0.996
CC(C)N,Eye irritation,+,0.9841
CC(C)N,Skin irritation,+,0.8234
CC(C)N,Skin corrosion,+,0.977
CC(C)N,Ames mutagenesis,-,0.9683
CC(C)N,Human Ether-a-go-go-Related Gene inhibition,-,0.8018
CC(C)N,Micronuclear,-,0.58
CC(C)N,Hepatotoxicity,+,0.85
CC(C)N,skin sensitisation,-,0.7673
CC(C)N,Respiratory toxicity,-,0.6556
CC(C)N,Reproductive toxicity,-,0.9
CC(C)N,Mitochondrial toxicity,-,0.85
CC(C)N,Nephrotoxicity,+,0.5332
CC(C)N,Acute Oral Toxicity (c),II,0.7282
CC(C)N,Estrogen receptor binding,-,0.9429
CC(C)N,Androgen receptor binding,-,0.9514
CC(C)N,Thyroid receptor binding,-,0.849
CC(C)N,Glucocorticoid receptor binding,-,0.9298
CC(C)N,Aromatase binding,-,0.8899
CC(C)N,PPAR gamma,-,0.9154
CC(C)N,Honey bee toxicity,-,0.769
CC(C)N,Biodegradation,+,0.575
CC(C)N,Crustacea aquatic toxicity,-,0.83
CC(C)N,Fish aquatic toxicity,-,0.7953
CC(C)N,ADMET predicted profile --- Regressions,Value,Unit
CC(C)N,Water solubility,0.255,logS
CC(C)N,Plasma protein binding,0.866,100%
CC(C)N,Acute Oral Toxicity,2.474,log(1/(mol/kg))
CC(C)N,Tetrahymena pyriformis,-0.791,pIGC50 (ug/L)
,,,
C(CNCCN)N,Human Intestinal Absorption,+,0.8869
C(CNCCN)N,Caco-2,+,0.6784
C(CNCCN)N,Blood Brain Barrier,+,0.75
C(CNCCN)N,Human oral bioavailability,+,0.9
C(CNCCN)N,Subcellular localzation,Lysosomes,0.8849
C(CNCCN)N,OATP2B1 inhibitior,-,0.8631
C(CNCCN)N,OATP1B1 inhibitior,+,0.9716
C(CNCCN)N,OATP1B3 inhibitior,+,0.9524
C(CNCCN)N,MATE1 inhibitior,-,1
C(CNCCN)N,OCT2 inhibitior,-,0.7
C(CNCCN)N,BSEP inhibitior,-,0.9581
C(CNCCN)N,P-glycoprotein inhibitior,-,0.9813
C(CNCCN)N,P-glycoprotein substrate,-,0.7105
C(CNCCN)N,CYP3A4 substrate,-,0.8126
C(CNCCN)N,CYP2C9 substrate,-,1
C(CNCCN)N,CYP2D6 substrate,+,0.4754
C(CNCCN)N,CYP3A4 inhibition,-,0.975
C(CNCCN)N,CYP2C9 inhibition,-,0.9162
C(CNCCN)N,CYP2C19 inhibition,-,0.8959
C(CNCCN)N,CYP2D6 inhibition,-,0.9611
C(CNCCN)N,CYP1A2 inhibition,-,0.8571
C(CNCCN)N,CYP2C8 inhibition,-,0.9713
C(CNCCN)N,CYP inhibitory promiscuity,-,0.9608
C(CNCCN)N,UGT catelyzed,-,0
C(CNCCN)N,Carcinogenicity (binary),-,0.52
C(CNCCN)N,Carcinogenicity (trinary),Non-required,0.6425
C(CNCCN)N,Eye corrosion,+,0.9963
C(CNCCN)N,Eye irritation,+,0.913
C(CNCCN)N,Skin irritation,+,0.8472
C(CNCCN)N,Skin corrosion,+,0.9875
C(CNCCN)N,Ames mutagenesis,+,0.64
C(CNCCN)N,Human Ether-a-go-go-Related Gene inhibition,-,0.7115
C(CNCCN)N,Micronuclear,-,0.85
C(CNCCN)N,Hepatotoxicity,-,0.8375
C(CNCCN)N,skin sensitisation,+,0.9333
C(CNCCN)N,Respiratory toxicity,+,0.9222
C(CNCCN)N,Reproductive toxicity,-,0.5382
C(CNCCN)N,Mitochondrial toxicity,+,0.95
C(CNCCN)N,Nephrotoxicity,+,0.5
C(CNCCN)N,Acute Oral Toxicity (c),III,0.8436
C(CNCCN)N,Estrogen receptor binding,-,0.937
C(CNCCN)N,Androgen receptor binding,-,0.9354
C(CNCCN)N,Thyroid receptor binding,-,0.8316
C(CNCCN)N,Glucocorticoid receptor binding,-,0.8709
C(CNCCN)N,Aromatase binding,-,0.9207
C(CNCCN)N,PPAR gamma,-,0.8664
C(CNCCN)N,Honey bee toxicity,-,0.9572
C(CNCCN)N,Biodegradation,-,0.875
C(CNCCN)N,Crustacea aquatic toxicity,-,0.68
C(CNCCN)N,Fish aquatic toxicity,-,0.8941
C(CNCCN)N,ADMET predicted profile --- Regressions,Value,Unit
C(CNCCN)N,Water solubility,-0.109,logS
C(CNCCN)N,Plasma protein binding,0.275,100%
C(CNCCN)N,Acute Oral Toxicity,1.987,log(1/(mol/kg))
C(CNCCN)N,Tetrahymena pyriformis,-1.356,pIGC50 (ug/L)
,,,
C1CCC(=O)CC1,Human Intestinal Absorption,+,0.9954
C1CCC(=O)CC1,Caco-2,+,0.8005
C1CCC(=O)CC1,Blood Brain Barrier,+,0.8
C1CCC(=O)CC1,Human oral bioavailability,+,0.8857
C1CCC(=O)CC1,Subcellular localzation,Mitochondria,0.7061
C1CCC(=O)CC1,OATP2B1 inhibitior,-,0.8477
C1CCC(=O)CC1,OATP1B1 inhibitior,+,0.9836
C1CCC(=O)CC1,OATP1B3 inhibitior,+,0.9703
C1CCC(=O)CC1,MATE1 inhibitior,-,0.98
C1CCC(=O)CC1,OCT2 inhibitior,-,0.825
C1CCC(=O)CC1,BSEP inhibitior,-,0.9566
C1CCC(=O)CC1,P-glycoprotein inhibitior,-,0.9888
C1CCC(=O)CC1,P-glycoprotein substrate,-,0.9971
C1CCC(=O)CC1,CYP3A4 substrate,-,0.8125
C1CCC(=O)CC1,CYP2C9 substrate,-,0.8484
C1CCC(=O)CC1,CYP2D6 substrate,-,0.7422
C1CCC(=O)CC1,CYP3A4 inhibition,-,0.9755
C1CCC(=O)CC1,CYP2C9 inhibition,-,0.8553
C1CCC(=O)CC1,CYP2C19 inhibition,-,0.9532
C1CCC(=O)CC1,CYP2D6 inhibition,-,0.9743
C1CCC(=O)CC1,CYP1A2 inhibition,-,0.8979
C1CCC(=O)CC1,CYP2C8 inhibition,-,0.9965
C1CCC(=O)CC1,CYP inhibitory promiscuity,-,0.9431
C1CCC(=O)CC1,UGT catelyzed,-,0
C1CCC(=O)CC1,Carcinogenicity (binary),-,0.82
C1CCC(=O)CC1,Carcinogenicity (trinary),Non-required,0.7278
C1CCC(=O)CC1,Eye corrosion,+,0.9905
C1CCC(=O)CC1,Eye irritation,+,0.9953
C1CCC(=O)CC1,Skin irritation,+,0.8623
C1CCC(=O)CC1,Skin corrosion,+,0.6526
C1CCC(=O)CC1,Ames mutagenesis,-,0.99
C1CCC(=O)CC1,Human Ether-a-go-go-Related Gene inhibition,-,0.7341
C1CCC(=O)CC1,Micronuclear,-,0.94
C1CCC(=O)CC1,Hepatotoxicity,+,0.8375
C1CCC(=O)CC1,skin sensitisation,-,0.5537
C1CCC(=O)CC1,Respiratory toxicity,-,0.9111
C1CCC(=O)CC1,Reproductive toxicity,-,0.7549
C1CCC(=O)CC1,Mitochondrial toxicity,-,0.9875
C1CCC(=O)CC1,Nephrotoxicity,+,0.5247
C1CCC(=O)CC1,Acute Oral Toxicity (c),III,0.7974
C1CCC(=O)CC1,Estrogen receptor binding,-,0.9712
C1CCC(=O)CC1,Androgen receptor binding,-,0.9507
C1CCC(=O)CC1,Thyroid receptor binding,-,0.9313
C1CCC(=O)CC1,Glucocorticoid receptor binding,-,0.9236
C1CCC(=O)CC1,Aromatase binding,-,0.8197
C1CCC(=O)CC1,PPAR gamma,-,0.9095
C1CCC(=O)CC1,Honey bee toxicity,-,0.9293
C1CCC(=O)CC1,Biodegradation,+,0.975
C1CCC(=O)CC1,Crustacea aquatic toxicity,-,0.61
C1CCC(=O)CC1,Fish aquatic toxicity,-,0.6523
C1CCC(=O)CC1,Water solubility,-0.537,logS
C1CCC(=O)CC1,Plasma protein binding,0.107,100%
C1CCC(=O)CC1,Acute Oral Toxicity,1.78,log(1/(mol/kg))
C1CCC(=O)CC1,Tetrahymena pyriformis,-1.086,pIGC50 (ug/L)
,,,
CCOC(=O)OCC,Human Intestinal Absorption,+,0.9948
CCOC(=O)OCC,Caco-2,+,0.7877
CCOC(=O)OCC,Blood Brain Barrier,+,0.875
CCOC(=O)OCC,Human oral bioavailability,+,0.5857
CCOC(=O)OCC,Subcellular localzation,Mitochondria,0.8266
CCOC(=O)OCC,OATP2B1 inhibitior,-,0.837
CCOC(=O)OCC,OATP1B1 inhibitior,+,0.9615
CCOC(=O)OCC,OATP1B3 inhibitior,+,0.9567
CCOC(=O)OCC,MATE1 inhibitior,-,1
CCOC(=O)OCC,OCT2 inhibitior,-,0.925
CCOC(=O)OCC,BSEP inhibitior,-,0.8962
CCOC(=O)OCC,P-glycoprotein inhibitior,-,0.9873
CCOC(=O)OCC,P-glycoprotein substrate,-,0.9975
CCOC(=O)OCC,CYP3A4 substrate,-,0.7033
CCOC(=O)OCC,CYP2C9 substrate,-,0.8046
CCOC(=O)OCC,CYP2D6 substrate,-,0.7646
CCOC(=O)OCC,CYP3A4 inhibition,-,0.9718
CCOC(=O)OCC,CYP2C9 inhibition,-,0.921
CCOC(=O)OCC,CYP2C19 inhibition,-,0.9101
CCOC(=O)OCC,CYP2D6 inhibition,-,0.947
CCOC(=O)OCC,CYP1A2 inhibition,-,0.8183
CCOC(=O)OCC,CYP2C8 inhibition,-,0.9872
CCOC(=O)OCC,CYP inhibitory promiscuity,-,0.8229
CCOC(=O)OCC,UGT catelyzed,-,0
CCOC(=O)OCC,Carcinogenicity (binary),+,0.5077
CCOC(=O)OCC,Carcinogenicity (trinary),Non-required,0.6562
CCOC(=O)OCC,Eye corrosion,+,0.9635
CCOC(=O)OCC,Eye irritation,+,1
CCOC(=O)OCC,Skin irritation,+,0.7421
CCOC(=O)OCC,Skin corrosion,-,0.8459
CCOC(=O)OCC,Ames mutagenesis,-,0.98
CCOC(=O)OCC,Human Ether-a-go-go-Related Gene inhibition,-,0.839
CCOC(=O)OCC,Micronuclear,-,0.92
CCOC(=O)OCC,Hepatotoxicity,+,0.6009
CCOC(=O)OCC,skin sensitisation,-,0.9393
CCOC(=O)OCC,Respiratory toxicity,-,0.9444
CCOC(=O)OCC,Reproductive toxicity,-,0.6222
CCOC(=O)OCC,Mitochondrial toxicity,-,0.9875
CCOC(=O)OCC,Nephrotoxicity,+,0.6515
CCOC(=O)OCC,Acute Oral Toxicity (c),IV,0.5495
CCOC(=O)OCC,Estrogen receptor binding,-,0.9209
CCOC(=O)OCC,Androgen receptor binding,-,0.9471
CCOC(=O)OCC,Thyroid receptor binding,-,0.8853
CCOC(=O)OCC,Glucocorticoid receptor binding,-,0.9129
CCOC(=O)OCC,Aromatase binding,-,0.8666
CCOC(=O)OCC,PPAR gamma,-,0.9242
CCOC(=O)OCC,Honey bee toxicity,-,0.9601
CCOC(=O)OCC,Biodegradation,+,0.8
CCOC(=O)OCC,Crustacea aquatic toxicity,-,0.8089
CCOC(=O)OCC,Fish aquatic toxicity,+,0.8486
CCOC(=O)OCC,Water solubility,-0.97,logS
CCOC(=O)OCC,Plasma protein binding,0.09,100%
CCOC(=O)OCC,Acute Oral Toxicity,1.177,log(1/(mol/kg))
CCOC(=O)OCC,Tetrahymena pyriformis,-0.781,pIGC50 (ug/L)
,,,
CC1COC(=O)O1,Human Intestinal Absorption,+,0.9928
CC1COC(=O)O1,Caco-2,+,0.5553
CC1COC(=O)O1,Blood Brain Barrier,+,0.8
CC1COC(=O)O1,Human oral bioavailability,+,0.6857
CC1COC(=O)O1,Subcellular localzation,Mitochondria,0.7888
CC1COC(=O)O1,OATP2B1 inhibitior,-,0.8589
CC1COC(=O)O1,OATP1B1 inhibitior,+,0.9643
CC1COC(=O)O1,OATP1B3 inhibitior,+,0.9497
CC1COC(=O)O1,MATE1 inhibitior,-,0.98
CC1COC(=O)O1,OCT2 inhibitior,-,0.85
CC1COC(=O)O1,BSEP inhibitior,-,0.934
CC1COC(=O)O1,P-glycoprotein inhibitior,-,0.9833
CC1COC(=O)O1,P-glycoprotein substrate,-,0.9614
CC1COC(=O)O1,CYP3A4 substrate,-,0.706
CC1COC(=O)O1,CYP2C9 substrate,-,0.756
CC1COC(=O)O1,CYP2D6 substrate,-,0.7912
CC1COC(=O)O1,CYP3A4 inhibition,-,0.9843
CC1COC(=O)O1,CYP2C9 inhibition,-,0.9228
CC1COC(=O)O1,CYP2C19 inhibition,-,0.8406
CC1COC(=O)O1,CYP2D6 inhibition,-,0.9378
CC1COC(=O)O1,CYP1A2 inhibition,-,0.6869
CC1COC(=O)O1,CYP2C8 inhibition,-,0.9967
CC1COC(=O)O1,CYP inhibitory promiscuity,-,0.9283
CC1COC(=O)O1,UGT catelyzed,-,0
CC1COC(=O)O1,Carcinogenicity (binary),-,0.8917
CC1COC(=O)O1,Carcinogenicity (trinary),Non-required,0.5084
CC1COC(=O)O1,Eye corrosion,+,0.491
CC1COC(=O)O1,Eye irritation,+,0.9916
CC1COC(=O)O1,Skin irritation,-,0.8721
CC1COC(=O)O1,Skin corrosion,-,0.9639
CC1COC(=O)O1,Ames mutagenesis,+,0.6
CC1COC(=O)O1,Human Ether-a-go-go-Related Gene inhibition,-,0.8316
CC1COC(=O)O1,Micronuclear,-,0.67
CC1COC(=O)O1,Hepatotoxicity,+,0.675
CC1COC(=O)O1,skin sensitisation,-,0.7542
CC1COC(=O)O1,Respiratory toxicity,-,0.7889
CC1COC(=O)O1,Reproductive toxicity,-,0.6667
CC1COC(=O)O1,Mitochondrial toxicity,-,0.85
CC1COC(=O)O1,Nephrotoxicity,+,0.6223
CC1COC(=O)O1,Acute Oral Toxicity (c),IV,0.6199
CC1COC(=O)O1,Estrogen receptor binding,-,0.8985
CC1COC(=O)O1,Androgen receptor binding,-,0.8291
CC1COC(=O)O1,Thyroid receptor binding,-,0.9224
CC1COC(=O)O1,Glucocorticoid receptor binding,-,0.9293
CC1COC(=O)O1,Aromatase binding,-,0.8372
CC1COC(=O)O1,PPAR gamma,-,0.9132
CC1COC(=O)O1,Honey bee toxicity,-,0.854
CC1COC(=O)O1,Biodegradation,+,0.9
CC1COC(=O)O1,Crustacea aquatic toxicity,+,0.58
CC1COC(=O)O1,Fish aquatic toxicity,-,0.6961
CC1COC(=O)O1,Water solubility,-0.39,logS
CC1COC(=O)O1,Plasma protein binding,0.08,100%
CC1COC(=O)O1,Acute Oral Toxicity,0.348,log(1/(mol/kg))
CC1COC(=O)O1,Tetrahymena pyriformis,-0.488,pIGC50 (ug/L)
,,,
CCCCOC(=O)C=C,Human Intestinal Absorption,+,0.9968
CCCCOC(=O)C=C,Caco-2,+,0.9272
CCCCOC(=O)C=C,Blood Brain Barrier,+,0.925
CCCCOC(=O)C=C,Human oral bioavailability,-,0.6429
CCCCOC(=O)C=C,Subcellular localzation,Plasma membrane,0.494
CCCCOC(=O)C=C,OATP2B1 inhibitior,-,0.8502
CCCCOC(=O)C=C,OATP1B1 inhibitior,+,0.9233
CCCCOC(=O)C=C,OATP1B3 inhibitior,+,0.9229
CCCCOC(=O)C=C,MATE1 inhibitior,-,0.74
CCCCOC(=O)C=C,OCT2 inhibitior,-,0.975
CCCCOC(=O)C=C,BSEP inhibitior,-,0.9357
CCCCOC(=O)C=C,P-glycoprotein inhibitior,-,0.9884
CCCCOC(=O)C=C,P-glycoprotein substrate,-,0.9745
CCCCOC(=O)C=C,CYP3A4 substrate,-,0.5926
CCCCOC(=O)C=C,CYP2C9 substrate,+,0.6063
CCCCOC(=O)C=C,CYP2D6 substrate,-,0.8854
CCCCOC(=O)C=C,CYP3A4 inhibition,-,0.9159
CCCCOC(=O)C=C,CYP2C9 inhibition,-,0.9126
CCCCOC(=O)C=C,CYP2C19 inhibition,-,0.7751
CCCCOC(=O)C=C,CYP2D6 inhibition,-,0.9434
CCCCOC(=O)C=C,CYP1A2 inhibition,+,0.6392
CCCCOC(=O)C=C,CYP2C8 inhibition,-,0.8969
CCCCOC(=O)C=C,CYP inhibitory promiscuity,-,0.8344
CCCCOC(=O)C=C,UGT catelyzed,-,0
CCCCOC(=O)C=C,Carcinogenicity (binary),-,0.58
CCCCOC(=O)C=C,Carcinogenicity (trinary),Non-required,0.5283
CCCCOC(=O)C=C,Eye corrosion,+,0.9866
CCCCOC(=O)C=C,Eye irritation,+,0.9884
CCCCOC(=O)C=C,Skin irritation,+,0.9226
CCCCOC(=O)C=C,Skin corrosion,-,0.7871
CCCCOC(=O)C=C,Ames mutagenesis,-,0.99
CCCCOC(=O)C=C,Human Ether-a-go-go-Related Gene inhibition,-,0.7344
CCCCOC(=O)C=C,Micronuclear,-,0.98
CCCCOC(=O)C=C,Hepatotoxicity,+,0.5625
CCCCOC(=O)C=C,skin sensitisation,+,0.9332
CCCCOC(=O)C=C,Respiratory toxicity,-,0.9444
CCCCOC(=O)C=C,Reproductive toxicity,-,1
CCCCOC(=O)C=C,Mitochondrial toxicity,-,0.9875
CCCCOC(=O)C=C,Nephrotoxicity,+,0.6965
CCCCOC(=O)C=C,Acute Oral Toxicity (c),III,0.7892
CCCCOC(=O)C=C,Estrogen receptor binding,-,0.8679
CCCCOC(=O)C=C,Androgen receptor binding,+,0.5594
CCCCOC(=O)C=C,Thyroid receptor binding,-,0.8662
CCCCOC(=O)C=C,Glucocorticoid receptor binding,-,0.758
CCCCOC(=O)C=C,Aromatase binding,-,0.8828
CCCCOC(=O)C=C,PPAR gamma,-,0.8545
CCCCOC(=O)C=C,Honey bee toxicity,-,0.9767
CCCCOC(=O)C=C,Biodegradation,+,0.975
CCCCOC(=O)C=C,Crustacea aquatic toxicity,-,0.56
CCCCOC(=O)C=C,Fish aquatic toxicity,+,0.9238
CCCCOC(=O)C=C,Water solubility,-1.824,logS
CCCCOC(=O)C=C,Plasma protein binding,0.463,100%
CCCCOC(=O)C=C,Acute Oral Toxicity,1.804,log(1/(mol/kg))
CCCCOC(=O)C=C,Tetrahymena pyriformis,0.574,pIGC50 (ug/L)
,,,
C(COCCOCCO)O,Human Intestinal Absorption,+,0.679
C(COCCOCCO)O,Caco-2,+,0.7566
C(COCCOCCO)O,Blood Brain Barrier,-,0.525
C(COCCOCCO)O,Human oral bioavailability,+,0.6143
C(COCCOCCO)O,Subcellular localzation,Mitochondria,0.675
C(COCCOCCO)O,OATP2B1 inhibitior,-,0.8586
C(COCCOCCO)O,OATP1B1 inhibitior,+,0.8943
C(COCCOCCO)O,OATP1B3 inhibitior,+,0.941
C(COCCOCCO)O,MATE1 inhibitior,-,1
C(COCCOCCO)O,OCT2 inhibitior,-,0.825
C(COCCOCCO)O,BSEP inhibitior,-,0.9199
C(COCCOCCO)O,P-glycoprotein inhibitior,-,0.9788
C(COCCOCCO)O,P-glycoprotein substrate,-,0.9912
C(COCCOCCO)O,CYP3A4 substrate,-,0.7538
C(COCCOCCO)O,CYP2C9 substrate,-,1
C(COCCOCCO)O,CYP2D6 substrate,-,0.7539
C(COCCOCCO)O,CYP3A4 inhibition,-,0.9509
C(COCCOCCO)O,CYP2C9 inhibition,-,0.9171
C(COCCOCCO)O,CYP2C19 inhibition,-,0.9138
C(COCCOCCO)O,CYP2D6 inhibition,-,0.9671
C(COCCOCCO)O,CYP1A2 inhibition,-,0.9373
C(COCCOCCO)O,CYP2C8 inhibition,-,0.9884
C(COCCOCCO)O,CYP inhibitory promiscuity,-,0.9547
C(COCCOCCO)O,UGT catelyzed,-,0.6
C(COCCOCCO)O,Carcinogenicity (binary),-,0.74
C(COCCOCCO)O,Carcinogenicity (trinary),Non-required,0.7098
C(COCCOCCO)O,Eye corrosion,+,0.7399
C(COCCOCCO)O,Eye irritation,+,0.9786
C(COCCOCCO)O,Skin irritation,-,0.7267
C(COCCOCCO)O,Skin corrosion,-,0.9858
C(COCCOCCO)O,Ames mutagenesis,-,0.8962
C(COCCOCCO)O,Human Ether-a-go-go-Related Gene inhibition,-,0.6262
C(COCCOCCO)O,Micronuclear,-,1
C(COCCOCCO)O,Hepatotoxicity,+,0.5303
C(COCCOCCO)O,skin sensitisation,-,0.5751
C(COCCOCCO)O,Respiratory toxicity,+,0.7111
C(COCCOCCO)O,Reproductive toxicity,-,0.9778
C(COCCOCCO)O,Mitochondrial toxicity,+,0.7375
C(COCCOCCO)O,Nephrotoxicity,+,0.706
C(COCCOCCO)O,Acute Oral Toxicity (c),IV,0.6404
C(COCCOCCO)O,Estrogen receptor binding,-,0.8949
C(COCCOCCO)O,Androgen receptor binding,-,0.9342
C(COCCOCCO)O,Thyroid receptor binding,-,0.8624
C(COCCOCCO)O,Glucocorticoid receptor binding,-,0.8661
C(COCCOCCO)O,Aromatase binding,-,0.8314
C(COCCOCCO)O,PPAR gamma,-,0.8658
C(COCCOCCO)O,Honey bee toxicity,-,0.8775
C(COCCOCCO)O,Biodegradation,+,0.875
C(COCCOCCO)O,Crustacea aquatic toxicity,-,0.98
C(COCCOCCO)O,Fish aquatic toxicity,-,0.9093
C(COCCOCCO)O,Water solubility,-0.19,logS
C(COCCOCCO)O,Plasma protein binding,0.713,100%
C(COCCOCCO)O,Acute Oral Toxicity,0.876,log(1/(mol/kg))
C(COCCOCCO)O,Tetrahymena pyriformis,-1.257,pIGC50 (ug/L)
,,,
C1COCCO1,Human Intestinal Absorption,+,0.9754
C1COCCO1,Caco-2,+,0.8186
C1COCCO1,Blood Brain Barrier,+,0.95
C1COCCO1,Human oral bioavailability,+,0.8429
C1COCCO1,Subcellular localzation,Mitochondria,0.5943
C1COCCO1,OATP2B1 inhibitior,-,0.8632
C1COCCO1,OATP1B1 inhibitior,+,0.9838
C1COCCO1,OATP1B3 inhibitior,+,0.9518
C1COCCO1,MATE1 inhibitior,-,1
C1COCCO1,OCT2 inhibitior,-,0.825
C1COCCO1,BSEP inhibitior,-,0.9619
C1COCCO1,P-glycoprotein inhibitior,-,0.9879
C1COCCO1,P-glycoprotein substrate,-,0.9971
C1COCCO1,CYP3A4 substrate,-,0.8344
C1COCCO1,CYP2C9 substrate,-,0.8019
C1COCCO1,CYP2D6 substrate,-,0.7619
C1COCCO1,CYP3A4 inhibition,-,0.982
C1COCCO1,CYP2C9 inhibition,-,0.8987
C1COCCO1,CYP2C19 inhibition,-,0.8661
C1COCCO1,CYP2D6 inhibition,-,0.9587
C1COCCO1,CYP1A2 inhibition,-,0.8674
C1COCCO1,CYP2C8 inhibition,-,0.9922
C1COCCO1,CYP inhibitory promiscuity,-,0.9459
C1COCCO1,UGT catelyzed,-,0
C1COCCO1,Carcinogenicity (binary),-,0.84
C1COCCO1,Carcinogenicity (trinary),Warning,0.5245
C1COCCO1,Eye corrosion,+,0.9313
C1COCCO1,Eye irritation,+,0.9953
C1COCCO1,Skin irritation,+,0.8301
C1COCCO1,Skin corrosion,-,0.7928
C1COCCO1,Ames mutagenesis,-,1
C1COCCO1,Human Ether-a-go-go-Related Gene inhibition,-,0.7263
C1COCCO1,Micronuclear,-,0.97
C1COCCO1,Hepatotoxicity,+,0.9625
C1COCCO1,skin sensitisation,-,0.7783
C1COCCO1,Respiratory toxicity,-,0.9556
C1COCCO1,Reproductive toxicity,-,0.9667
C1COCCO1,Mitochondrial toxicity,-,1
C1COCCO1,Nephrotoxicity,+,0.7388
C1COCCO1,Acute Oral Toxicity (c),III,0.8787
C1COCCO1,Estrogen receptor binding,-,0.9268
C1COCCO1,Androgen receptor binding,-,0.9574
C1COCCO1,Thyroid receptor binding,-,0.8937
C1COCCO1,Glucocorticoid receptor binding,-,0.8333
C1COCCO1,Aromatase binding,-,0.8458
C1COCCO1,PPAR gamma,-,0.9233
C1COCCO1,Honey bee toxicity,-,0.8428
C1COCCO1,Biodegradation,+,0.725
C1COCCO1,Crustacea aquatic toxicity,-,0.79
C1COCCO1,Fish aquatic toxicity,-,0.9327
C1COCCO1,Water solubility,-0.352,logS
C1COCCO1,Plasma protein binding,0.653,100%
C1COCCO1,Acute Oral Toxicity,2.353,log(1/(mol/kg))
C1COCCO1,Tetrahymena pyriformis,-0.502,pIGC50 (ug/L)
,,,
CC(C)OC(C)C,Human Intestinal Absorption,+,0.9928
CC(C)OC(C)C,Caco-2,-,0.547
CC(C)OC(C)C,Blood Brain Barrier,+,0.975
CC(C)OC(C)C,Human oral bioavailability,+,0.7857
CC(C)OC(C)C,Subcellular localzation,Mitochondria,0.6048
CC(C)OC(C)C,OATP2B1 inhibitior,-,0.8678
CC(C)OC(C)C,OATP1B1 inhibitior,+,0.9687
CC(C)OC(C)C,OATP1B3 inhibitior,+,0.9687
CC(C)OC(C)C,MATE1 inhibitior,-,0.98
CC(C)OC(C)C,OCT2 inhibitior,-,1
CC(C)OC(C)C,BSEP inhibitior,-,0.9549
CC(C)OC(C)C,P-glycoprotein inhibitior,-,0.9753
CC(C)OC(C)C,P-glycoprotein substrate,-,0.988
CC(C)OC(C)C,CYP3A4 substrate,-,0.7945
CC(C)OC(C)C,CYP2C9 substrate,-,0.806
CC(C)OC(C)C,CYP2D6 substrate,-,0.7521
CC(C)OC(C)C,CYP3A4 inhibition,-,0.9812
CC(C)OC(C)C,CYP2C9 inhibition,-,0.9458
CC(C)OC(C)C,CYP2C19 inhibition,-,0.9178
CC(C)OC(C)C,CYP2D6 inhibition,-,0.9566
CC(C)OC(C)C,CYP1A2 inhibition,-,0.8662
CC(C)OC(C)C,CYP2C8 inhibition,-,0.9946
CC(C)OC(C)C,CYP inhibitory promiscuity,-,0.835
CC(C)OC(C)C,UGT catelyzed,-,0
CC(C)OC(C)C,Carcinogenicity (binary),+,0.6483
CC(C)OC(C)C,Carcinogenicity (trinary),Warning,0.4812
CC(C)OC(C)C,Eye corrosion,+,0.9699
CC(C)OC(C)C,Eye irritation,+,0.985
CC(C)OC(C)C,Skin irritation,+,0.5357
CC(C)OC(C)C,Skin corrosion,-,0.9781
CC(C)OC(C)C,Ames mutagenesis,-,0.74
CC(C)OC(C)C,Human Ether-a-go-go-Related Gene inhibition,-,0.8277
CC(C)OC(C)C,Micronuclear,-,0.99
CC(C)OC(C)C,Hepatotoxicity,+,0.6802
CC(C)OC(C)C,skin sensitisation,-,0.895
CC(C)OC(C)C,Respiratory toxicity,-,0.9
CC(C)OC(C)C,Reproductive toxicity,-,0.9889
CC(C)OC(C)C,Mitochondrial toxicity,-,0.9655
CC(C)OC(C)C,Nephrotoxicity,+,0.6852
CC(C)OC(C)C,Acute Oral Toxicity (c),IV,0.6481
CC(C)OC(C)C,Estrogen receptor binding,-,0.9158
CC(C)OC(C)C,Androgen receptor binding,-,0.9393
CC(C)OC(C)C,Thyroid receptor binding,-,0.8425
CC(C)OC(C)C,Glucocorticoid receptor binding,-,0.9317
CC(C)OC(C)C,Aromatase binding,-,0.7841
CC(C)OC(C)C,PPAR gamma,-,0.8545
CC(C)OC(C)C,Honey bee toxicity,-,0.6882
CC(C)OC(C)C,Biodegradation,-,0.925
CC(C)OC(C)C,Crustacea aquatic toxicity,-,0.71
CC(C)OC(C)C,Fish aquatic toxicity,-,0.7238
CC(C)OC(C)C,Water solubility,-0.869,logS
CC(C)OC(C)C,Plasma protein binding,0.69,100%
CC(C)OC(C)C,Acute Oral Toxicity,1.197,log(1/(mol/kg))
CC(C)OC(C)C,Tetrahymena pyriformis,-1.407,pIGC50 (ug/L)
,,,
CCOC(=O)C1=CC=CC=C1,Human Intestinal Absorption,+,1
CCOC(=O)C1=CC=CC=C1,Caco-2,+,0.9115
CCOC(=O)C1=CC=CC=C1,Blood Brain Barrier,+,0.9
CCOC(=O)C1=CC=CC=C1,Human oral bioavailability,+,0.7429
CCOC(=O)C1=CC=CC=C1,Subcellular localzation,Mitochondria,0.7797
CCOC(=O)C1=CC=CC=C1,OATP2B1 inhibitior,-,1
CCOC(=O)C1=CC=CC=C1,OATP1B1 inhibitior,+,0.9572
CCOC(=O)C1=CC=CC=C1,OATP1B3 inhibitior,+,0.9674
CCOC(=O)C1=CC=CC=C1,MATE1 inhibitior,-,0.98
CCOC(=O)C1=CC=CC=C1,OCT2 inhibitior,-,0.925
CCOC(=O)C1=CC=CC=C1,BSEP inhibitior,-,0.8658
CCOC(=O)C1=CC=CC=C1,P-glycoprotein inhibitior,-,0.9909
CCOC(=O)C1=CC=CC=C1,P-glycoprotein substrate,-,0.9915
CCOC(=O)C1=CC=CC=C1,CYP3A4 substrate,-,0.7168
CCOC(=O)C1=CC=CC=C1,CYP2C9 substrate,-,0.7945
CCOC(=O)C1=CC=CC=C1,CYP2D6 substrate,-,0.8429
CCOC(=O)C1=CC=CC=C1,CYP3A4 inhibition,-,0.9817
CCOC(=O)C1=CC=CC=C1,CYP2C9 inhibition,-,0.886
CCOC(=O)C1=CC=CC=C1,CYP2C19 inhibition,-,0.8897
CCOC(=O)C1=CC=CC=C1,CYP2D6 inhibition,-,0.9525
CCOC(=O)C1=CC=CC=C1,CYP1A2 inhibition,+,0.7888
CCOC(=O)C1=CC=CC=C1,CYP2C8 inhibition,-,0.7175
CCOC(=O)C1=CC=CC=C1,CYP inhibitory promiscuity,-,0.7227
CCOC(=O)C1=CC=CC=C1,UGT catelyzed,-,0
CCOC(=O)C1=CC=CC=C1,Carcinogenicity (binary),-,0.5239
CCOC(=O)C1=CC=CC=C1,Carcinogenicity (trinary),Non-required,0.6038
CCOC(=O)C1=CC=CC=C1,Eye corrosion,+,0.8185
CCOC(=O)C1=CC=CC=C1,Eye irritation,+,1
CCOC(=O)C1=CC=CC=C1,Skin irritation,+,0.8823
CCOC(=O)C1=CC=CC=C1,Skin corrosion,-,0.8782
CCOC(=O)C1=CC=CC=C1,Ames mutagenesis,-,0.99
CCOC(=O)C1=CC=CC=C1,Human Ether-a-go-go-Related Gene inhibition,-,0.8512
CCOC(=O)C1=CC=CC=C1,Micronuclear,-,0.94
CCOC(=O)C1=CC=CC=C1,Hepatotoxicity,+,0.5285
CCOC(=O)C1=CC=CC=C1,skin sensitisation,+,0.7518
CCOC(=O)C1=CC=CC=C1,Respiratory toxicity,-,0.8778
CCOC(=O)C1=CC=CC=C1,Reproductive toxicity,-,0.7889
CCOC(=O)C1=CC=CC=C1,Mitochondrial toxicity,-,0.975
CCOC(=O)C1=CC=CC=C1,Nephrotoxicity,-,0.5908
CCOC(=O)C1=CC=CC=C1,Acute Oral Toxicity (c),III,0.9356
CCOC(=O)C1=CC=CC=C1,Estrogen receptor binding,-,0.7528
CCOC(=O)C1=CC=CC=C1,Androgen receptor binding,-,0.8428
CCOC(=O)C1=CC=CC=C1,Thyroid receptor binding,-,0.914
CCOC(=O)C1=CC=CC=C1,Glucocorticoid receptor binding,-,0.9731
CCOC(=O)C1=CC=CC=C1,Aromatase binding,-,0.804
CCOC(=O)C1=CC=CC=C1,PPAR gamma,-,0.9176
CCOC(=O)C1=CC=CC=C1,Honey bee toxicity,-,0.9884
CCOC(=O)C1=CC=CC=C1,Biodegradation,+,0.8
CCOC(=O)C1=CC=CC=C1,Crustacea aquatic toxicity,-,0.7055
CCOC(=O)C1=CC=CC=C1,Fish aquatic toxicity,+,0.9145
CCOC(=O)C1=CC=CC=C1,Water solubility,-2.383,logS
CCOC(=O)C1=CC=CC=C1,Plasma protein binding,0.462,100%
CCOC(=O)C1=CC=CC=C1,Acute Oral Toxicity,1.649,log(1/(mol/kg))
CCOC(=O)C1=CC=CC=C1,Tetrahymena pyriformis,0.624,pIGC50 (ug/L)
,,,
CCCCCCN,Human Intestinal Absorption,+,0.9888
CCCCCCN,Caco-2,+,0.9297
CCCCCCN,Blood Brain Barrier,+,1
CCCCCCN,Human oral bioavailability,+,0.5571
CCCCCCN,Subcellular localzation,Lysosomes,0.9614
CCCCCCN,OATP2B1 inhibitior,-,0.8533
CCCCCCN,OATP1B1 inhibitior,+,0.9631
CCCCCCN,OATP1B3 inhibitior,+,0.9381
CCCCCCN,MATE1 inhibitior,-,0.88
CCCCCCN,OCT2 inhibitior,-,0.525
CCCCCCN,BSEP inhibitior,-,0.9629
CCCCCCN,P-glycoprotein inhibitior,-,0.9876
CCCCCCN,P-glycoprotein substrate,-,0.8612
CCCCCCN,CYP3A4 substrate,-,0.7806
CCCCCCN,CYP2C9 substrate,-,1
CCCCCCN,CYP2D6 substrate,+,0.5
CCCCCCN,CYP3A4 inhibition,-,0.9234
CCCCCCN,CYP2C9 inhibition,-,0.9267
CCCCCCN,CYP2C19 inhibition,-,0.8809
CCCCCCN,CYP2D6 inhibition,-,0.6964
CCCCCCN,CYP1A2 inhibition,+,0.5959
CCCCCCN,CYP2C8 inhibition,-,0.9498
CCCCCCN,CYP inhibitory promiscuity,-,0.8505
CCCCCCN,UGT catelyzed,-,0
CCCCCCN,Carcinogenicity (binary),-,0.62
CCCCCCN,Carcinogenicity (trinary),Non-required,0.7297
CCCCCCN,Eye corrosion,+,0.9945
CCCCCCN,Eye irritation,+,0.9071
CCCCCCN,Skin irritation,+,0.8894
CCCCCCN,Skin corrosion,+,0.9802
CCCCCCN,Ames mutagenesis,-,0.92
CCCCCCN,Human Ether-a-go-go-Related Gene inhibition,-,0.7278
CCCCCCN,Micronuclear,-,0.99
CCCCCCN,Hepatotoxicity,-,0.6092
CCCCCCN,skin sensitisation,+,0.7656
CCCCCCN,Respiratory toxicity,+,1
CCCCCCN,Reproductive toxicity,-,1
CCCCCCN,Mitochondrial toxicity,+,1
CCCCCCN,Nephrotoxicity,+,0.5909
CCCCCCN,Acute Oral Toxicity (c),III,0.837
CCCCCCN,Estrogen receptor binding,-,0.9368
CCCCCCN,Androgen receptor binding,-,0.7871
CCCCCCN,Thyroid receptor binding,-,0.8509
CCCCCCN,Glucocorticoid receptor binding,-,0.8576
CCCCCCN,Aromatase binding,-,0.9131
CCCCCCN,PPAR gamma,-,0.8789
CCCCCCN,Honey bee toxicity,-,0.9928
CCCCCCN,Biodegradation,+,0.8
CCCCCCN,Crustacea aquatic toxicity,+,0.97
CCCCCCN,Fish aquatic toxicity,+,0.8193
CCCCCCN,Water solubility,-1.913,logS
CCCCCCN,Plasma protein binding,0.575,100%
CCCCCCN,Acute Oral Toxicity,2.449,log(1/(mol/kg))
CCCCCCN,Tetrahymena pyriformis,-0.211,pIGC50 (ug/L)
,,,
CC1=CC(=O)CC(C1)(C)C,Human Intestinal Absorption,+,0.9951
CC1=CC(=O)CC(C1)(C)C,Caco-2,+,0.955
CC1=CC(=O)CC(C1)(C)C,Blood Brain Barrier,+,0.725
CC1=CC(=O)CC(C1)(C)C,Human oral bioavailability,+,0.8429
CC1=CC(=O)CC(C1)(C)C,Subcellular localzation,Mitochondria,0.5982
CC1=CC(=O)CC(C1)(C)C,OATP2B1 inhibitior,-,0.8628
CC1=CC(=O)CC(C1)(C)C,OATP1B1 inhibitior,+,0.956
CC1=CC(=O)CC(C1)(C)C,OATP1B3 inhibitior,+,0.9506
CC1=CC(=O)CC(C1)(C)C,MATE1 inhibitior,-,0.9
CC1=CC(=O)CC(C1)(C)C,OCT2 inhibitior,-,0.85
CC1=CC(=O)CC(C1)(C)C,BSEP inhibitior,-,0.8513
CC1=CC(=O)CC(C1)(C)C,P-glycoprotein inhibitior,-,0.9827
CC1=CC(=O)CC(C1)(C)C,P-glycoprotein substrate,-,0.9791
CC1=CC(=O)CC(C1)(C)C,CYP3A4 substrate,-,0.5908
CC1=CC(=O)CC(C1)(C)C,CYP2C9 substrate,-,0.8078
CC1=CC(=O)CC(C1)(C)C,CYP2D6 substrate,-,0.8705
CC1=CC(=O)CC(C1)(C)C,CYP3A4 inhibition,-,0.8979
CC1=CC(=O)CC(C1)(C)C,CYP2C9 inhibition,-,0.8195
CC1=CC(=O)CC(C1)(C)C,CYP2C19 inhibition,-,0.7521
CC1=CC(=O)CC(C1)(C)C,CYP2D6 inhibition,-,0.9439
CC1=CC(=O)CC(C1)(C)C,CYP1A2 inhibition,-,0.876
CC1=CC(=O)CC(C1)(C)C,CYP2C8 inhibition,-,0.9881
CC1=CC(=O)CC(C1)(C)C,CYP inhibitory promiscuity,-,0.8593
CC1=CC(=O)CC(C1)(C)C,UGT catelyzed,-,0
CC1=CC(=O)CC(C1)(C)C,Carcinogenicity (binary),-,0.6336
CC1=CC(=O)CC(C1)(C)C,Carcinogenicity (trinary),Warning,0.5339
CC1=CC(=O)CC(C1)(C)C,Eye corrosion,-,0.6292
CC1=CC(=O)CC(C1)(C)C,Eye irritation,+,0.9717
CC1=CC(=O)CC(C1)(C)C,Skin irritation,+,0.6706
CC1=CC(=O)CC(C1)(C)C,Skin corrosion,-,0.9562
CC1=CC(=O)CC(C1)(C)C,Ames mutagenesis,-,0.86
CC1=CC(=O)CC(C1)(C)C,Human Ether-a-go-go-Related Gene inhibition,-,0.7635
CC1=CC(=O)CC(C1)(C)C,Micronuclear,-,0.97
CC1=CC(=O)CC(C1)(C)C,Hepatotoxicity,+,0.6212
CC1=CC(=O)CC(C1)(C)C,skin sensitisation,+,0.9559
CC1=CC(=O)CC(C1)(C)C,Respiratory toxicity,-,0.7667
CC1=CC(=O)CC(C1)(C)C,Reproductive toxicity,-,0.6667
CC1=CC(=O)CC(C1)(C)C,Mitochondrial toxicity,-,0.9875
CC1=CC(=O)CC(C1)(C)C,Nephrotoxicity,+,0.7839
CC1=CC(=O)CC(C1)(C)C,Acute Oral Toxicity (c),III,0.8109
CC1=CC(=O)CC(C1)(C)C,Estrogen receptor binding,-,0.9833
CC1=CC(=O)CC(C1)(C)C,Androgen receptor binding,-,0.8233
CC1=CC(=O)CC(C1)(C)C,Thyroid receptor binding,-,0.909
CC1=CC(=O)CC(C1)(C)C,Glucocorticoid receptor binding,-,0.8943
CC1=CC(=O)CC(C1)(C)C,Aromatase binding,-,0.9255
CC1=CC(=O)CC(C1)(C)C,PPAR gamma,-,0.9056
CC1=CC(=O)CC(C1)(C)C,Honey bee toxicity,-,0.9575
CC1=CC(=O)CC(C1)(C)C,Biodegradation,+,0.6
CC1=CC(=O)CC(C1)(C)C,Crustacea aquatic toxicity,+,0.51
CC1=CC(=O)CC(C1)(C)C,Fish aquatic toxicity,+,0.8808
CC1=CC(=O)CC(C1)(C)C,Water solubility,-1.515,logS
CC1=CC(=O)CC(C1)(C)C,Plasma protein binding,0.086,100%
CC1=CC(=O)CC(C1)(C)C,Acute Oral Toxicity,1.864,log(1/(mol/kg))
CC1=CC(=O)CC(C1)(C)C,Tetrahymena pyriformis,-0.51,pIGC50 (ug/L)
,,,
CCCCOC(=O)C,Human Intestinal Absorption,+,0.9965
CCCCOC(=O)C,Caco-2,+,0.874
CCCCOC(=O)C,Blood Brain Barrier,+,0.95
CCCCOC(=O)C,Human oral bioavailability,-,0.5857
CCCCOC(=O)C,Subcellular localzation,Mitochondria,0.6303
CCCCOC(=O)C,OATP2B1 inhibitior,-,0.8409
CCCCOC(=O)C,OATP1B1 inhibitior,+,0.943
CCCCOC(=O)C,OATP1B3 inhibitior,+,0.9246
CCCCOC(=O)C,MATE1 inhibitior,-,0.88
CCCCOC(=O)C,OCT2 inhibitior,-,0.975
CCCCOC(=O)C,BSEP inhibitior,-,0.9288
CCCCOC(=O)C,P-glycoprotein inhibitior,-,0.9871
CCCCOC(=O)C,P-glycoprotein substrate,-,0.9741
CCCCOC(=O)C,CYP3A4 substrate,-,0.6392
CCCCOC(=O)C,CYP2C9 substrate,-,0.7977
CCCCOC(=O)C,CYP2D6 substrate,-,0.8679
CCCCOC(=O)C,CYP3A4 inhibition,-,0.9688
CCCCOC(=O)C,CYP2C9 inhibition,-,0.9411
CCCCOC(=O)C,CYP2C19 inhibition,-,0.9213
CCCCOC(=O)C,CYP2D6 inhibition,-,0.9408
CCCCOC(=O)C,CYP1A2 inhibition,+,0.5111
CCCCOC(=O)C,CYP2C8 inhibition,-,0.9602
CCCCOC(=O)C,CYP inhibitory promiscuity,-,0.8855
CCCCOC(=O)C,UGT catelyzed,-,0
CCCCOC(=O)C,Carcinogenicity (binary),-,0.6
CCCCOC(=O)C,Carcinogenicity (trinary),Non-required,0.6127
CCCCOC(=O)C,Eye corrosion,+,0.9901
CCCCOC(=O)C,Eye irritation,+,0.9931
CCCCOC(=O)C,Skin irritation,+,0.7942
CCCCOC(=O)C,Skin corrosion,-,0.89
CCCCOC(=O)C,Ames mutagenesis,-,0.98
CCCCOC(=O)C,Human Ether-a-go-go-Related Gene inhibition,-,0.7401
CCCCOC(=O)C,Micronuclear,-,1
CCCCOC(=O)C,Hepatotoxicity,+,0.6
CCCCOC(=O)C,skin sensitisation,+,0.6907
CCCCOC(=O)C,Respiratory toxicity,-,1
CCCCOC(=O)C,Reproductive toxicity,-,0.9778
CCCCOC(=O)C,Mitochondrial toxicity,-,1
CCCCOC(=O)C,Nephrotoxicity,+,0.8073
CCCCOC(=O)C,Acute Oral Toxicity (c),III,0.5153
CCCCOC(=O)C,Estrogen receptor binding,-,0.9364
CCCCOC(=O)C,Androgen receptor binding,-,0.7855
CCCCOC(=O)C,Thyroid receptor binding,-,0.9087
CCCCOC(=O)C,Glucocorticoid receptor binding,-,0.9392
CCCCOC(=O)C,Aromatase binding,-,0.9195
CCCCOC(=O)C,PPAR gamma,-,0.9336
CCCCOC(=O)C,Honey bee toxicity,-,0.9902
CCCCOC(=O)C,Biodegradation,+,1
CCCCOC(=O)C,Crustacea aquatic toxicity,-,0.52
CCCCOC(=O)C,Fish aquatic toxicity,+,0.7179
CCCCOC(=O)C,Water solubility,-1.085,logS
CCCCOC(=O)C,Plasma protein binding,0.236,100%
CCCCOC(=O)C,Acute Oral Toxicity,1.405,log(1/(mol/kg))
CCCCOC(=O)C,Tetrahymena pyriformis,-0.572,pIGC50 (ug/L)
,,,
COS(=O)(=O)C,Human Intestinal Absorption,+,0.9076
COS(=O)(=O)C,Caco-2,-,0.5742
COS(=O)(=O)C,Blood Brain Barrier,+,0.85
COS(=O)(=O)C,Human oral bioavailability,+,0.8857
COS(=O)(=O)C,Subcellular localzation,Mitochondria,0.5268
COS(=O)(=O)C,OATP2B1 inhibitior,-,1
COS(=O)(=O)C,OATP1B1 inhibitior,+,0.969
COS(=O)(=O)C,OATP1B3 inhibitior,+,0.948
COS(=O)(=O)C,MATE1 inhibitior,-,1
COS(=O)(=O)C,OCT2 inhibitior,-,1
COS(=O)(=O)C,BSEP inhibitior,-,0.941
COS(=O)(=O)C,P-glycoprotein inhibitior,-,0.9847
COS(=O)(=O)C,P-glycoprotein substrate,-,0.995
COS(=O)(=O)C,CYP3A4 substrate,-,0.7081
COS(=O)(=O)C,CYP2C9 substrate,-,0.8426
COS(=O)(=O)C,CYP2D6 substrate,-,0.8039
COS(=O)(=O)C,CYP3A4 inhibition,-,0.9887
COS(=O)(=O)C,CYP2C9 inhibition,-,0.8351
COS(=O)(=O)C,CYP2C19 inhibition,-,0.7607
COS(=O)(=O)C,CYP2D6 inhibition,-,0.9289
COS(=O)(=O)C,CYP1A2 inhibition,-,0.7946
COS(=O)(=O)C,CYP2C8 inhibition,-,0.9941
COS(=O)(=O)C,CYP inhibitory promiscuity,-,0.9328
COS(=O)(=O)C,UGT catelyzed,-,0
COS(=O)(=O)C,Carcinogenicity (binary),+,0.8596
COS(=O)(=O)C,Carcinogenicity (trinary),Non-required,0.6287
COS(=O)(=O)C,Eye corrosion,+,0.9784
COS(=O)(=O)C,Eye irritation,+,0.9357
COS(=O)(=O)C,Skin irritation,+,0.868
COS(=O)(=O)C,Skin corrosion,+,0.9639
COS(=O)(=O)C,Ames mutagenesis,+,0.6446
COS(=O)(=O)C,Human Ether-a-go-go-Related Gene inhibition,-,0.7072
COS(=O)(=O)C,Micronuclear,+,0.82
COS(=O)(=O)C,Hepatotoxicity,+,0.5733
COS(=O)(=O)C,skin sensitisation,+,0.9333
COS(=O)(=O)C,Respiratory toxicity,-,0.9
COS(=O)(=O)C,Reproductive toxicity,-,0.6556
COS(=O)(=O)C,Mitochondrial toxicity,-,0.7375
COS(=O)(=O)C,Nephrotoxicity,+,0.8329
COS(=O)(=O)C,Acute Oral Toxicity (c),II,0.7586
COS(=O)(=O)C,Estrogen receptor binding,-,0.9034
COS(=O)(=O)C,Androgen receptor binding,-,0.9153
COS(=O)(=O)C,Thyroid receptor binding,-,0.8639
COS(=O)(=O)C,Glucocorticoid receptor binding,-,0.9366
COS(=O)(=O)C,Aromatase binding,-,0.8526
COS(=O)(=O)C,PPAR gamma,-,0.9317
COS(=O)(=O)C,Honey bee toxicity,-,0.5414
COS(=O)(=O)C,Biodegradation,+,0.775
COS(=O)(=O)C,Crustacea aquatic toxicity,-,0.72
COS(=O)(=O)C,Fish aquatic toxicity,+,0.7356
COS(=O)(=O)C,Water solubility,-1.231,logS
COS(=O)(=O)C,Plasma protein binding,0.071,100%
COS(=O)(=O)C,Acute Oral Toxicity,2.506,log(1/(mol/kg))
COS(=O)(=O)C,Tetrahymena pyriformis,-1.289,pIGC50 (ug/L)
,,,
CCN1CCCC1=O,Human Intestinal Absorption,+,0.9893
CCN1CCCC1=O,Caco-2,+,0.9455
CCN1CCCC1=O,Blood Brain Barrier,+,0.975
CCN1CCCC1=O,Human oral bioavailability,+,0.7857
CCN1CCCC1=O,Subcellular localzation,Lysosomes,0.6053
CCN1CCCC1=O,OATP2B1 inhibitior,-,0.8476
CCN1CCCC1=O,OATP1B1 inhibitior,+,0.9739
CCN1CCCC1=O,OATP1B3 inhibitior,+,0.9458
CCN1CCCC1=O,MATE1 inhibitior,-,1
CCN1CCCC1=O,OCT2 inhibitior,+,0.55
CCN1CCCC1=O,BSEP inhibitior,-,0.9192
CCN1CCCC1=O,P-glycoprotein inhibitior,-,0.9915
CCN1CCCC1=O,P-glycoprotein substrate,-,0.9642
CCN1CCCC1=O,CYP3A4 substrate,-,0.7155
CCN1CCCC1=O,CYP2C9 substrate,-,0.8117
CCN1CCCC1=O,CYP2D6 substrate,-,0.8612
CCN1CCCC1=O,CYP3A4 inhibition,-,0.9614
CCN1CCCC1=O,CYP2C9 inhibition,-,0.5801
CCN1CCCC1=O,CYP2C19 inhibition,+,0.5616
CCN1CCCC1=O,CYP2D6 inhibition,-,0.5739
CCN1CCCC1=O,CYP1A2 inhibition,-,0.7379
CCN1CCCC1=O,CYP2C8 inhibition,-,0.9974
CCN1CCCC1=O,CYP inhibitory promiscuity,-,0.899
CCN1CCCC1=O,UGT catelyzed,-,0
CCN1CCCC1=O,Carcinogenicity (binary),-,0.87
CCN1CCCC1=O,Carcinogenicity (trinary),Non-required,0.6132
CCN1CCCC1=O,Eye corrosion,-,0.7975
CCN1CCCC1=O,Eye irritation,+,0.9807
CCN1CCCC1=O,Skin irritation,-,0.6903
CCN1CCCC1=O,Skin corrosion,-,0.7365
CCN1CCCC1=O,Ames mutagenesis,-,0.8
CCN1CCCC1=O,Human Ether-a-go-go-Related Gene inhibition,-,0.757
CCN1CCCC1=O,Micronuclear,-,0.93
CCN1CCCC1=O,Hepatotoxicity,+,0.7981
CCN1CCCC1=O,skin sensitisation,-,0.9436
CCN1CCCC1=O,Respiratory toxicity,-,0.6333
CCN1CCCC1=O,Reproductive toxicity,+,0.7222
CCN1CCCC1=O,Mitochondrial toxicity,-,0.6125
CCN1CCCC1=O,Nephrotoxicity,-,0.6057
CCN1CCCC1=O,Acute Oral Toxicity (c),III,0.79
CCN1CCCC1=O,Estrogen receptor binding,-,0.9728
CCN1CCCC1=O,Androgen receptor binding,-,0.9016
CCN1CCCC1=O,Thyroid receptor binding,-,0.9371
CCN1CCCC1=O,Glucocorticoid receptor binding,-,0.9111
CCN1CCCC1=O,Aromatase binding,-,0.8707
CCN1CCCC1=O,PPAR gamma,-,0.9234
CCN1CCCC1=O,Honey bee toxicity,-,0.9842
CCN1CCCC1=O,Biodegradation,+,0.675
CCN1CCCC1=O,Crustacea aquatic toxicity,-,0.59
CCN1CCCC1=O,Fish aquatic toxicity,-,0.7663
CCN1CCCC1=O,Water solubility,-0.78,logS
CCN1CCCC1=O,Plasma protein binding,-0.033,100%
CCN1CCCC1=O,Acute Oral Toxicity,1.463,log(1/(mol/kg))
CCN1CCCC1=O,Tetrahymena pyriformis,-0.421,pIGC50 (ug/L)
,,,
CC(C)(C)O,Human Intestinal Absorption,+,0.9825
CC(C)(C)O,Caco-2,+,0.5947
CC(C)(C)O,Blood Brain Barrier,+,1
CC(C)(C)O,Human oral bioavailability,+,0.5714
CC(C)(C)O,Subcellular localzation,Mitochondria,0.5311
CC(C)(C)O,OATP2B1 inhibitior,-,1
CC(C)(C)O,OATP1B1 inhibitior,+,0.9731
CC(C)(C)O,OATP1B3 inhibitior,+,0.9657
CC(C)(C)O,MATE1 inhibitior,-,1
CC(C)(C)O,OCT2 inhibitior,-,0.95
CC(C)(C)O,BSEP inhibitior,-,0.9401
CC(C)(C)O,P-glycoprotein inhibitior,-,0.9843
CC(C)(C)O,P-glycoprotein substrate,-,0.9946
CC(C)(C)O,CYP3A4 substrate,-,0.8063
CC(C)(C)O,CYP2C9 substrate,-,1
CC(C)(C)O,CYP2D6 substrate,-,0.7954
CC(C)(C)O,CYP3A4 inhibition,-,0.9391
CC(C)(C)O,CYP2C9 inhibition,-,0.9071
CC(C)(C)O,CYP2C19 inhibition,-,0.9231
CC(C)(C)O,CYP2D6 inhibition,-,0.9568
CC(C)(C)O,CYP1A2 inhibition,-,0.9045
CC(C)(C)O,CYP2C8 inhibition,-,0.9959
CC(C)(C)O,CYP inhibitory promiscuity,-,0.9253
CC(C)(C)O,UGT catelyzed,+,0.9
CC(C)(C)O,Carcinogenicity (binary),+,0.6083
CC(C)(C)O,Carcinogenicity (trinary),Non-required,0.5809
CC(C)(C)O,Eye corrosion,+,0.9809
CC(C)(C)O,Eye irritation,+,0.9839
CC(C)(C)O,Skin irritation,+,0.9043
CC(C)(C)O,Skin corrosion,+,0.6369
CC(C)(C)O,Ames mutagenesis,-,0.97
CC(C)(C)O,Human Ether-a-go-go-Related Gene inhibition,-,0.7618
CC(C)(C)O,Micronuclear,-,0.96
CC(C)(C)O,Hepatotoxicity,+,0.8177
CC(C)(C)O,skin sensitisation,-,0.9321
CC(C)(C)O,Respiratory toxicity,-,0.9333
CC(C)(C)O,Reproductive toxicity,-,0.9889
CC(C)(C)O,Mitochondrial toxicity,-,0.9577
CC(C)(C)O,Nephrotoxicity,+,0.6517
CC(C)(C)O,Acute Oral Toxicity (c),III,0.8522
CC(C)(C)O,Estrogen receptor binding,-,0.9161
CC(C)(C)O,Androgen receptor binding,-,0.9514
CC(C)(C)O,Thyroid receptor binding,-,0.8504
CC(C)(C)O,Glucocorticoid receptor binding,-,0.9107
CC(C)(C)O,Aromatase binding,-,0.9343
CC(C)(C)O,PPAR gamma,-,0.9054
CC(C)(C)O,Honey bee toxicity,-,0.9618
CC(C)(C)O,Biodegradation,-,0.625
CC(C)(C)O,Crustacea aquatic toxicity,-,0.56
CC(C)(C)O,Fish aquatic toxicity,-,0.8223
CC(C)(C)O,Water solubility,-0.558,logS
CC(C)(C)O,Plasma protein binding,0.687,100%
CC(C)(C)O,Acute Oral Toxicity,1.226,log(1/(mol/kg))
CC(C)(C)O,Tetrahymena pyriformis,-1.755,pIGC50 (ug/L)
,,,
C1COCO1,Human Intestinal Absorption,+,0.9777
C1COCO1,Caco-2,+,0.784
C1COCO1,Blood Brain Barrier,+,0.95
C1COCO1,Human oral bioavailability,+,0.7286
C1COCO1,Subcellular localzation,Mitochondria,0.4956
C1COCO1,OATP2B1 inhibitior,-,0.8702
C1COCO1,OATP1B1 inhibitior,+,0.9827
C1COCO1,OATP1B3 inhibitior,+,0.949
C1COCO1,MATE1 inhibitior,-,0.98
C1COCO1,OCT2 inhibitior,-,0.85
C1COCO1,BSEP inhibitior,-,0.9518
C1COCO1,P-glycoprotein inhibitior,-,0.987
C1COCO1,P-glycoprotein substrate,-,0.9961
C1COCO1,CYP3A4 substrate,-,0.8034
C1COCO1,CYP2C9 substrate,-,0.8046
C1COCO1,CYP2D6 substrate,-,0.805
C1COCO1,CYP3A4 inhibition,-,0.943
C1COCO1,CYP2C9 inhibition,-,0.8406
C1COCO1,CYP2C19 inhibition,-,0.7797
C1COCO1,CYP2D6 inhibition,-,0.8661
C1COCO1,CYP1A2 inhibition,-,0.743
C1COCO1,CYP2C8 inhibition,-,0.9916
C1COCO1,CYP inhibitory promiscuity,-,0.8763
C1COCO1,UGT catelyzed,-,0
C1COCO1,Carcinogenicity (binary),-,0.86
C1COCO1,Carcinogenicity (trinary),Warning,0.4799
C1COCO1,Eye corrosion,+,0.8882
C1COCO1,Eye irritation,+,0.994
C1COCO1,Skin irritation,+,0.697
C1COCO1,Skin corrosion,-,0.5994
C1COCO1,Ames mutagenesis,-,0.95
C1COCO1,Human Ether-a-go-go-Related Gene inhibition,-,0.7841
C1COCO1,Micronuclear,-,0.98
C1COCO1,Hepatotoxicity,+,0.8875
C1COCO1,skin sensitisation,-,0.9436
C1COCO1,Respiratory toxicity,-,0.9333
C1COCO1,Reproductive toxicity,+,0.7444
C1COCO1,Mitochondrial toxicity,-,0.9625
C1COCO1,Nephrotoxicity,+,0.7926
C1COCO1,Acute Oral Toxicity (c),III,0.7968
C1COCO1,Estrogen receptor binding,-,0.9145
C1COCO1,Androgen receptor binding,-,0.9471
C1COCO1,Thyroid receptor binding,-,0.8618
C1COCO1,Glucocorticoid receptor binding,-,0.876
C1COCO1,Aromatase binding,-,0.8825
C1COCO1,PPAR gamma,-,0.8909
C1COCO1,Honey bee toxicity,-,0.796
C1COCO1,Biodegradation,+,0.775
C1COCO1,Crustacea aquatic toxicity,-,0.88
C1COCO1,Fish aquatic toxicity,-,0.9137
C1COCO1,Water solubility,0.128,logS
C1COCO1,Plasma protein binding,0.262,100%
C1COCO1,Acute Oral Toxicity,1.45,log(1/(mol/kg))
C1COCO1,Tetrahymena pyriformis,-0.951,pIGC50 (ug/L)
,,,
C(=C(Cl)Cl)Cl,Human Intestinal Absorption,+,0.991
C(=C(Cl)Cl)Cl,Caco-2,+,0.7881
C(=C(Cl)Cl)Cl,Blood Brain Barrier,+,1
C(=C(Cl)Cl)Cl,Human oral bioavailability,+,0.6714
C(=C(Cl)Cl)Cl,Subcellular localzation,Lysosomes,0.4668
C(=C(Cl)Cl)Cl,OATP2B1 inhibitior,-,0.8733
C(=C(Cl)Cl)Cl,OATP1B1 inhibitior,+,0.9646
C(=C(Cl)Cl)Cl,OATP1B3 inhibitior,+,0.9555
C(=C(Cl)Cl)Cl,MATE1 inhibitior,-,1
C(=C(Cl)Cl)Cl,OCT2 inhibitior,-,1
C(=C(Cl)Cl)Cl,BSEP inhibitior,-,0.9205
C(=C(Cl)Cl)Cl,P-glycoprotein inhibitior,-,0.9868
C(=C(Cl)Cl)Cl,P-glycoprotein substrate,-,0.9969
C(=C(Cl)Cl)Cl,CYP3A4 substrate,-,0.7879
C(=C(Cl)Cl)Cl,CYP2C9 substrate,-,0.7594
C(=C(Cl)Cl)Cl,CYP2D6 substrate,-,0.7902
C(=C(Cl)Cl)Cl,CYP3A4 inhibition,-,0.8826
C(=C(Cl)Cl)Cl,CYP2C9 inhibition,-,0.8139
C(=C(Cl)Cl)Cl,CYP2C19 inhibition,-,0.7217
C(=C(Cl)Cl)Cl,CYP2D6 inhibition,-,0.9331
C(=C(Cl)Cl)Cl,CYP1A2 inhibition,-,0.632
C(=C(Cl)Cl)Cl,CYP2C8 inhibition,-,0.9714
C(=C(Cl)Cl)Cl,CYP inhibitory promiscuity,-,0.706
C(=C(Cl)Cl)Cl,UGT catelyzed,-,0
C(=C(Cl)Cl)Cl,Carcinogenicity (binary),+,0.7639
C(=C(Cl)Cl)Cl,Carcinogenicity (trinary),Non-required,0.5111
C(=C(Cl)Cl)Cl,Eye corrosion,+,0.8156
C(=C(Cl)Cl)Cl,Eye irritation,+,0.9807
C(=C(Cl)Cl)Cl,Skin irritation,+,0.8698
C(=C(Cl)Cl)Cl,Skin corrosion,+,0.8485
C(=C(Cl)Cl)Cl,Ames mutagenesis,-,0.62
C(=C(Cl)Cl)Cl,Human Ether-a-go-go-Related Gene inhibition,-,0.7708
C(=C(Cl)Cl)Cl,Micronuclear,-,0.97
C(=C(Cl)Cl)Cl,Hepatotoxicity,+,1
C(=C(Cl)Cl)Cl,skin sensitisation,+,0.7322
C(=C(Cl)Cl)Cl,Respiratory toxicity,-,0.7889
C(=C(Cl)Cl)Cl,Reproductive toxicity,-,0.8556
C(=C(Cl)Cl)Cl,Mitochondrial toxicity,-,0.925
C(=C(Cl)Cl)Cl,Nephrotoxicity,+,0.7127
C(=C(Cl)Cl)Cl,Acute Oral Toxicity (c),III,0.6495
C(=C(Cl)Cl)Cl,Estrogen receptor binding,-,0.8703
C(=C(Cl)Cl)Cl,Androgen receptor binding,-,0.949
C(=C(Cl)Cl)Cl,Thyroid receptor binding,-,0.7734
C(=C(Cl)Cl)Cl,Glucocorticoid receptor binding,-,0.7977
C(=C(Cl)Cl)Cl,Aromatase binding,-,0.8661
C(=C(Cl)Cl)Cl,PPAR gamma,-,0.7948
C(=C(Cl)Cl)Cl,Honey bee toxicity,-,0.5089
C(=C(Cl)Cl)Cl,Biodegradation,-,0.95
C(=C(Cl)Cl)Cl,Crustacea aquatic toxicity,+,0.76
C(=C(Cl)Cl)Cl,Fish aquatic toxicity,+,0.906
C(=C(Cl)Cl)Cl,Water solubility,-2.603,logS
C(=C(Cl)Cl)Cl,Plasma protein binding,0.35,100%
C(=C(Cl)Cl)Cl,Acute Oral Toxicity,1.274,log(1/(mol/kg))
C(=C(Cl)Cl)Cl,Tetrahymena pyriformis,1.477,pIGC50 (ug/L)
,,,
CCCCCCC(=O)O,Human Intestinal Absorption,+,0.9936
CCCCCCC(=O)O,Caco-2,+,0.852
CCCCCCC(=O)O,Blood Brain Barrier,+,0.85
CCCCCCC(=O)O,Human oral bioavailability,-,0.6714
CCCCCCC(=O)O,Subcellular localzation,Mitochondria,0.5152
CCCCCCC(=O)O,OATP2B1 inhibitior,-,0.8374
CCCCCCC(=O)O,OATP1B1 inhibitior,+,0.8902
CCCCCCC(=O)O,OATP1B3 inhibitior,-,0.3662
CCCCCCC(=O)O,MATE1 inhibitior,-,1
CCCCCCC(=O)O,OCT2 inhibitior,-,0.925
CCCCCCC(=O)O,BSEP inhibitior,-,0.9383
CCCCCCC(=O)O,P-glycoprotein inhibitior,-,0.9892
CCCCCCC(=O)O,P-glycoprotein substrate,-,0.9647
CCCCCCC(=O)O,CYP3A4 substrate,-,0.7568
CCCCCCC(=O)O,CYP2C9 substrate,+,0.672
CCCCCCC(=O)O,CYP2D6 substrate,-,0.8901
CCCCCCC(=O)O,CYP3A4 inhibition,-,0.9484
CCCCCCC(=O)O,CYP2C9 inhibition,-,0.8808
CCCCCCC(=O)O,CYP2C19 inhibition,-,0.9578
CCCCCCC(=O)O,CYP2D6 inhibition,-,0.9554
CCCCCCC(=O)O,CYP1A2 inhibition,+,0.8326
CCCCCCC(=O)O,CYP2C8 inhibition,-,0.9749
CCCCCCC(=O)O,CYP inhibitory promiscuity,-,0.9647
CCCCCCC(=O)O,UGT catelyzed,-,0
CCCCCCC(=O)O,Carcinogenicity (binary),-,0.7035
CCCCCCC(=O)O,Carcinogenicity (trinary),Non-required,0.7057
CCCCCCC(=O)O,Eye corrosion,+,0.9827
CCCCCCC(=O)O,Eye irritation,+,0.9768
CCCCCCC(=O)O,Skin irritation,+,0.7702
CCCCCCC(=O)O,Skin corrosion,+,0.7927
CCCCCCC(=O)O,Ames mutagenesis,-,1
CCCCCCC(=O)O,Human Ether-a-go-go-Related Gene inhibition,-,0.8351
CCCCCCC(=O)O,Micronuclear,-,1
CCCCCCC(=O)O,Hepatotoxicity,+,0.7625
CCCCCCC(=O)O,skin sensitisation,+,0.8147
CCCCCCC(=O)O,Respiratory toxicity,-,0.7333
CCCCCCC(=O)O,Reproductive toxicity,-,0.6972
CCCCCCC(=O)O,Mitochondrial toxicity,+,0.55
CCCCCCC(=O)O,Nephrotoxicity,-,0.572
CCCCCCC(=O)O,Acute Oral Toxicity (c),IV,0.6378
CCCCCCC(=O)O,Estrogen receptor binding,-,0.9679
CCCCCCC(=O)O,Androgen receptor binding,-,0.9011
CCCCCCC(=O)O,Thyroid receptor binding,-,0.8868
CCCCCCC(=O)O,Glucocorticoid receptor binding,-,0.8846
CCCCCCC(=O)O,Aromatase binding,-,0.8732
CCCCCCC(=O)O,PPAR gamma,-,0.7437
CCCCCCC(=O)O,Honey bee toxicity,-,0.9981
CCCCCCC(=O)O,Biodegradation,+,0.975
CCCCCCC(=O)O,Crustacea aquatic toxicity,+,0.741
CCCCCCC(=O)O,Fish aquatic toxicity,+,0.9178
CCCCCCC(=O)O,ADMET predicted profile --- Regressions,Value,Unit
CCCCCCC(=O)O,Water solubility,-3.502,logS
CCCCCCC(=O)O,Plasma protein binding,0.312,100%
CCCCCCC(=O)O,Acute Oral Toxicity,1.469,log(1/(mol/kg))
CCCCCCC(=O)O,Tetrahymena pyriformis,-0.168,pIGC50 (ug/L)
, ,,
 CCOC(=O)C,Human Intestinal Absorption,+,1
 CCOC(=O)C,Caco-2,+,0.6795
 CCOC(=O)C,Blood Brain Barrier,+,0.95
 CCOC(=O)C,Human oral bioavailability,+,0.5857
 CCOC(=O)C,Subcellular localzation,Mitochondria,0.7194
 CCOC(=O)C,OATP2B1 inhibitior,-,0.8616
 CCOC(=O)C,OATP1B1 inhibitior,+,0.9686
 CCOC(=O)C,OATP1B3 inhibitior,+,0.9522
 CCOC(=O)C,MATE1 inhibitior,-,0.92
 CCOC(=O)C,OCT2 inhibitior,-,0.9
 CCOC(=O)C,BSEP inhibitior,-,0.8748
 CCOC(=O)C,P-glycoprotein inhibitior,-,0.9864
 CCOC(=O)C,P-glycoprotein substrate,-,0.9952
 CCOC(=O)C,CYP3A4 substrate,-,0.6976
 CCOC(=O)C,CYP2C9 substrate,-,1
 CCOC(=O)C,CYP2D6 substrate,-,0.8836
 CCOC(=O)C,CYP3A4 inhibition,-,0.9801
 CCOC(=O)C,CYP2C9 inhibition,-,0.9386
 CCOC(=O)C,CYP2C19 inhibition,-,0.9506
 CCOC(=O)C,CYP2D6 inhibition,-,0.9531
 CCOC(=O)C,CYP1A2 inhibition,-,0.6609
 CCOC(=O)C,CYP2C8 inhibition,-,0.9885
 CCOC(=O)C,CYP inhibitory promiscuity,-,0.8869
 CCOC(=O)C,UGT catelyzed,-,0
 CCOC(=O)C,Carcinogenicity (binary),+,0.5574
 CCOC(=O)C,Carcinogenicity (trinary),Non-required,0.6906
 CCOC(=O)C,Eye corrosion,+,0.992
 CCOC(=O)C,Eye irritation,+,0.995
 CCOC(=O)C,Skin irritation,+,0.9359
 CCOC(=O)C,Skin corrosion,-,0.8424
 CCOC(=O)C,Ames mutagenesis,-,0.92
 CCOC(=O)C,Human Ether-a-go-go-Related Gene inhibition,-,0.8425
 CCOC(=O)C,Micronuclear,-,0.99
 CCOC(=O)C,Hepatotoxicity,+,0.5185
 CCOC(=O)C,skin sensitisation,+,0.5
 CCOC(=O)C,Respiratory toxicity,-,0.9889
 CCOC(=O)C,Reproductive toxicity,-,0.6556
 CCOC(=O)C,Mitochondrial toxicity,-,1
 CCOC(=O)C,Nephrotoxicity,+,0.7185
 CCOC(=O)C,Acute Oral Toxicity (c),IV,0.636
 CCOC(=O)C,Estrogen receptor binding,-,0.9394
 CCOC(=O)C,Androgen receptor binding,-,0.9413
 CCOC(=O)C,Thyroid receptor binding,-,0.9242
 CCOC(=O)C,Glucocorticoid receptor binding,-,0.948
 CCOC(=O)C,Aromatase binding,-,0.8892
 CCOC(=O)C,PPAR gamma,-,0.9268
 CCOC(=O)C,Honey bee toxicity,-,0.9477
 CCOC(=O)C,Biodegradation,+,0.975
 CCOC(=O)C,Crustacea aquatic toxicity,-,0.8255
 CCOC(=O)C,Fish aquatic toxicity,+,0.746
 CCOC(=O)C,ADMET predicted profile --- Regressions,Value,Unit
 CCOC(=O)C,Water solubility,-0.103,logS
 CCOC(=O)C,Plasma protein binding,-0.19,100%
 CCOC(=O)C,Acute Oral Toxicity,1.34,log(1/(mol/kg))
 CCOC(=O)C,Tetrahymena pyriformis,-1.384,pIGC50 (ug/L)
,  ,,
CCC(=O)O,Human Intestinal Absorption,+,0.9942
CCC(=O)O,Caco-2,+,0.644
CCC(=O)O,Blood Brain Barrier,+,0.825
CCC(=O)O,Human oral bioavailability,+,0.7286
CCC(=O)O,Subcellular localzation,Mitochondria,0.5849
CCC(=O)O,OATP2B1 inhibitior,-,0.8637
CCC(=O)O,OATP1B1 inhibitior,+,0.9599
CCC(=O)O,OATP1B3 inhibitior,+,0.935
CCC(=O)O,MATE1 inhibitior,-,1
CCC(=O)O,OCT2 inhibitior,-,1
CCC(=O)O,BSEP inhibitior,-,0.9395
CCC(=O)O,P-glycoprotein inhibitior,-,0.9889
CCC(=O)O,P-glycoprotein substrate,-,0.9936
CCC(=O)O,CYP3A4 substrate,-,0.8419
CCC(=O)O,CYP2C9 substrate,+,0.672
CCC(=O)O,CYP2D6 substrate,-,0.8901
CCC(=O)O,CYP3A4 inhibition,-,0.9763
CCC(=O)O,CYP2C9 inhibition,-,0.9639
CCC(=O)O,CYP2C19 inhibition,-,0.9794
CCC(=O)O,CYP2D6 inhibition,-,0.9667
CCC(=O)O,CYP1A2 inhibition,-,0.8922
CCC(=O)O,CYP2C8 inhibition,-,0.9914
CCC(=O)O,CYP inhibitory promiscuity,-,0.9876
CCC(=O)O,UGT catelyzed,-,0
CCC(=O)O,Carcinogenicity (binary),+,0.5765
CCC(=O)O,Carcinogenicity (trinary),Non-required,0.7073
CCC(=O)O,Eye corrosion,+,0.9968
CCC(=O)O,Eye irritation,+,0.9832
CCC(=O)O,Skin irritation,+,0.9441
CCC(=O)O,Skin corrosion,+,0.993
CCC(=O)O,Ames mutagenesis,-,0.98
CCC(=O)O,Human Ether-a-go-go-Related Gene inhibition,-,0.8258
CCC(=O)O,Micronuclear,-,0.9626
CCC(=O)O,Hepatotoxicity,-,0.65
CCC(=O)O,skin sensitisation,-,0.6043
CCC(=O)O,Respiratory toxicity,-,0.9333
CCC(=O)O,Reproductive toxicity,+,0.7556
CCC(=O)O,Mitochondrial toxicity,-,0.9625
CCC(=O)O,Nephrotoxicity,-,0.6939
CCC(=O)O,Acute Oral Toxicity (c),III,0.9124
CCC(=O)O,Estrogen receptor binding,-,0.9554
CCC(=O)O,Androgen receptor binding,-,0.9389
CCC(=O)O,Thyroid receptor binding,-,0.8968
CCC(=O)O,Glucocorticoid receptor binding,-,0.9318
CCC(=O)O,Aromatase binding,-,0.9111
CCC(=O)O,PPAR gamma,-,0.8545
CCC(=O)O,Honey bee toxicity,-,0.9954
CCC(=O)O,Biodegradation,+,1
CCC(=O)O,Crustacea aquatic toxicity,-,0.91
CCC(=O)O,Fish aquatic toxicity,-,0.809
CCC(=O)O,ADMET predicted profile --- Regressions,Value,Unit
CCC(=O)O,Water solubility,0.607,logS
CCC(=O)O,Plasma protein binding,-0.025,100%
CCC(=O)O,Acute Oral Toxicity,1.05,log(1/(mol/kg))
CCC(=O)O,Tetrahymena pyriformis,-0.506,pIGC50 (ug/L)
,  ,,
CC(C)N,Human Intestinal Absorption,+,0.9965
CC(C)N,Caco-2,-,0.6456
CC(C)N,Blood Brain Barrier,+,0.925
CC(C)N,Human oral bioavailability,+,0.7857
CC(C)N,Subcellular localzation,Lysosomes,0.9252
CC(C)N,OATP2B1 inhibitior,-,1
CC(C)N,OATP1B1 inhibitior,+,0.9853
CC(C)N,OATP1B3 inhibitior,+,0.96
CC(C)N,MATE1 inhibitior,-,0.96
CC(C)N,OCT2 inhibitior,-,0.95
CC(C)N,BSEP inhibitior,-,0.9364
CC(C)N,P-glycoprotein inhibitior,-,0.9864
CC(C)N,P-glycoprotein substrate,-,0.9879
CC(C)N,CYP3A4 substrate,-,0.8728
CC(C)N,CYP2C9 substrate,-,1
CC(C)N,CYP2D6 substrate,+,0.3682
CC(C)N,CYP3A4 inhibition,-,0.9752
CC(C)N,CYP2C9 inhibition,-,0.9599
CC(C)N,CYP2C19 inhibition,-,0.9588
CC(C)N,CYP2D6 inhibition,-,0.8757
CC(C)N,CYP1A2 inhibition,-,0.9376
CC(C)N,CYP2C8 inhibition,-,0.9989
CC(C)N,CYP inhibitory promiscuity,-,0.966
CC(C)N,UGT catelyzed,-,0
CC(C)N,Carcinogenicity (binary),+,0.59
CC(C)N,Carcinogenicity (trinary),Non-required,0.6063
CC(C)N,Eye corrosion,+,0.996
CC(C)N,Eye irritation,+,0.9841
CC(C)N,Skin irritation,+,0.8234
CC(C)N,Skin corrosion,+,0.977
CC(C)N,Ames mutagenesis,-,0.9683
CC(C)N,Human Ether-a-go-go-Related Gene inhibition,-,0.8018
CC(C)N,Micronuclear,-,0.58
CC(C)N,Hepatotoxicity,+,0.85
CC(C)N,skin sensitisation,-,0.7673
CC(C)N,Respiratory toxicity,-,0.6556
CC(C)N,Reproductive toxicity,-,0.9
CC(C)N,Mitochondrial toxicity,-,0.85
CC(C)N,Nephrotoxicity,+,0.5332
CC(C)N,Acute Oral Toxicity (c),II,0.7282
CC(C)N,Estrogen receptor binding,-,0.9429
CC(C)N,Androgen receptor binding,-,0.9514
CC(C)N,Thyroid receptor binding,-,0.849
CC(C)N,Glucocorticoid receptor binding,-,0.9298
CC(C)N,Aromatase binding,-,0.8899
CC(C)N,PPAR gamma,-,0.9154
CC(C)N,Honey bee toxicity,-,0.769
CC(C)N,Biodegradation,+,0.575
CC(C)N,Crustacea aquatic toxicity,-,0.83
CC(C)N,Fish aquatic toxicity,-,0.7953
CC(C)N,ADMET predicted profile --- Regressions,Value,Unit
CC(C)N,Water solubility,0.255,logS
CC(C)N,Plasma protein binding,0.866,100%
CC(C)N,Acute Oral Toxicity,2.474,log(1/(mol/kg))
CC(C)N,Tetrahymena pyriformis,-0.791,pIGC50 (ug/L)
,  ,,
C(CNCCN)N,Human Intestinal Absorption,+,0.8869
C(CNCCN)N,Caco-2,+,0.6784
C(CNCCN)N,Blood Brain Barrier,+,0.75
C(CNCCN)N,Human oral bioavailability,+,0.9
C(CNCCN)N,Subcellular localzation,Lysosomes,0.8849
C(CNCCN)N,OATP2B1 inhibitior,-,0.8631
C(CNCCN)N,OATP1B1 inhibitior,+,0.9716
C(CNCCN)N,OATP1B3 inhibitior,+,0.9524
C(CNCCN)N,MATE1 inhibitior,-,1
C(CNCCN)N,OCT2 inhibitior,-,0.7
C(CNCCN)N,BSEP inhibitior,-,0.9581
C(CNCCN)N,P-glycoprotein inhibitior,-,0.9813
C(CNCCN)N,P-glycoprotein substrate,-,0.7105
C(CNCCN)N,CYP3A4 substrate,-,0.8126
C(CNCCN)N,CYP2C9 substrate,-,1
C(CNCCN)N,CYP2D6 substrate,+,0.4754
C(CNCCN)N,CYP3A4 inhibition,-,0.975
C(CNCCN)N,CYP2C9 inhibition,-,0.9162
C(CNCCN)N,CYP2C19 inhibition,-,0.8959
C(CNCCN)N,CYP2D6 inhibition,-,0.9611
C(CNCCN)N,CYP1A2 inhibition,-,0.8571
C(CNCCN)N,CYP2C8 inhibition,-,0.9713
C(CNCCN)N,CYP inhibitory promiscuity,-,0.9608
C(CNCCN)N,UGT catelyzed,-,0
C(CNCCN)N,Carcinogenicity (binary),-,0.52
C(CNCCN)N,Carcinogenicity (trinary),Non-required,0.6425
C(CNCCN)N,Eye corrosion,+,0.9963
C(CNCCN)N,Eye irritation,+,0.913
C(CNCCN)N,Skin irritation,+,0.8472
C(CNCCN)N,Skin corrosion,+,0.9875
C(CNCCN)N,Ames mutagenesis,+,0.64
C(CNCCN)N,Human Ether-a-go-go-Related Gene inhibition,-,0.7115
C(CNCCN)N,Micronuclear,-,0.85
C(CNCCN)N,Hepatotoxicity,-,0.8375
C(CNCCN)N,skin sensitisation,+,0.9333
C(CNCCN)N,Respiratory toxicity,+,0.9222
C(CNCCN)N,Reproductive toxicity,-,0.5382
C(CNCCN)N,Mitochondrial toxicity,+,0.95
C(CNCCN)N,Nephrotoxicity,+,0.5
C(CNCCN)N,Acute Oral Toxicity (c),III,0.8436
C(CNCCN)N,Estrogen receptor binding,-,0.937
C(CNCCN)N,Androgen receptor binding,-,0.9354
C(CNCCN)N,Thyroid receptor binding,-,0.8316
C(CNCCN)N,Glucocorticoid receptor binding,-,0.8709
C(CNCCN)N,Aromatase binding,-,0.9207
C(CNCCN)N,PPAR gamma,-,0.8664
C(CNCCN)N,Honey bee toxicity,-,0.9572
C(CNCCN)N,Biodegradation,-,0.875
C(CNCCN)N,Crustacea aquatic toxicity,-,0.68
C(CNCCN)N,Fish aquatic toxicity,-,0.8941
C(CNCCN)N,ADMET predicted profile --- Regressions,Value,Unit
C(CNCCN)N,Water solubility,-0.109,logS
C(CNCCN)N,Plasma protein binding,0.275,100%
C(CNCCN)N,Acute Oral Toxicity,1.987,log(1/(mol/kg))
C(CNCCN)N,Tetrahymena pyriformis,-1.356,pIGC50 (ug/L)
,  ,,
C1CCC(=O)CC1,Human Intestinal Absorption,+,0.9954
C1CCC(=O)CC1,Caco-2,+,0.8005
C1CCC(=O)CC1,Blood Brain Barrier,+,0.8
C1CCC(=O)CC1,Human oral bioavailability,+,0.8857
C1CCC(=O)CC1,Subcellular localzation,Mitochondria,0.7061
C1CCC(=O)CC1,OATP2B1 inhibitior,-,0.8477
C1CCC(=O)CC1,OATP1B1 inhibitior,+,0.9836
C1CCC(=O)CC1,OATP1B3 inhibitior,+,0.9703
C1CCC(=O)CC1,MATE1 inhibitior,-,0.98
C1CCC(=O)CC1,OCT2 inhibitior,-,0.825
C1CCC(=O)CC1,BSEP inhibitior,-,0.9566
C1CCC(=O)CC1,P-glycoprotein inhibitior,-,0.9888
C1CCC(=O)CC1,P-glycoprotein substrate,-,0.9971
C1CCC(=O)CC1,CYP3A4 substrate,-,0.8125
C1CCC(=O)CC1,CYP2C9 substrate,-,0.8484
C1CCC(=O)CC1,CYP2D6 substrate,-,0.7422
C1CCC(=O)CC1,CYP3A4 inhibition,-,0.9755
C1CCC(=O)CC1,CYP2C9 inhibition,-,0.8553
C1CCC(=O)CC1,CYP2C19 inhibition,-,0.9532
C1CCC(=O)CC1,CYP2D6 inhibition,-,0.9743
C1CCC(=O)CC1,CYP1A2 inhibition,-,0.8979
C1CCC(=O)CC1,CYP2C8 inhibition,-,0.9965
C1CCC(=O)CC1,CYP inhibitory promiscuity,-,0.9431
C1CCC(=O)CC1,UGT catelyzed,-,0
C1CCC(=O)CC1,Carcinogenicity (binary),-,0.82
C1CCC(=O)CC1,Carcinogenicity (trinary),Non-required,0.7278
C1CCC(=O)CC1,Eye corrosion,+,0.9905
C1CCC(=O)CC1,Eye irritation,+,0.9953
C1CCC(=O)CC1,Skin irritation,+,0.8623
C1CCC(=O)CC1,Skin corrosion,+,0.6526
C1CCC(=O)CC1,Ames mutagenesis,-,0.99
C1CCC(=O)CC1,Human Ether-a-go-go-Related Gene inhibition,-,0.7341
C1CCC(=O)CC1,Micronuclear,-,0.94
C1CCC(=O)CC1,Hepatotoxicity,+,0.8375
C1CCC(=O)CC1,skin sensitisation,-,0.5537
C1CCC(=O)CC1,Respiratory toxicity,-,0.9111
C1CCC(=O)CC1,Reproductive toxicity,-,0.7549
C1CCC(=O)CC1,Mitochondrial toxicity,-,0.9875
C1CCC(=O)CC1,Nephrotoxicity,+,0.5247
C1CCC(=O)CC1,Acute Oral Toxicity (c),III,0.7974
C1CCC(=O)CC1,Estrogen receptor binding,-,0.9712
C1CCC(=O)CC1,Androgen receptor binding,-,0.9507
C1CCC(=O)CC1,Thyroid receptor binding,-,0.9313
C1CCC(=O)CC1,Glucocorticoid receptor binding,-,0.9236
C1CCC(=O)CC1,Aromatase binding,-,0.8197
C1CCC(=O)CC1,PPAR gamma,-,0.9095
C1CCC(=O)CC1,Honey bee toxicity,-,0.9293
C1CCC(=O)CC1,Biodegradation,+,0.975
C1CCC(=O)CC1,Crustacea aquatic toxicity,-,0.61
C1CCC(=O)CC1,Fish aquatic toxicity,-,0.6523
C1CCC(=O)CC1,ADMET predicted profile --- Regressions,Value,Unit
C1CCC(=O)CC1,Water solubility,-0.537,logS
C1CCC(=O)CC1,Plasma protein binding,0.107,100%
C1CCC(=O)CC1,Acute Oral Toxicity,1.78,log(1/(mol/kg))
C1CCC(=O)CC1,Tetrahymena pyriformis,-1.086,pIGC50 (ug/L)
,  ,,
CCOC(=O)OCC,Human Intestinal Absorption,+,0.9948
CCOC(=O)OCC,Caco-2,+,0.7877
CCOC(=O)OCC,Blood Brain Barrier,+,0.875
CCOC(=O)OCC,Human oral bioavailability,+,0.5857
CCOC(=O)OCC,Subcellular localzation,Mitochondria,0.8266
CCOC(=O)OCC,OATP2B1 inhibitior,-,0.837
CCOC(=O)OCC,OATP1B1 inhibitior,+,0.9615
CCOC(=O)OCC,OATP1B3 inhibitior,+,0.9567
CCOC(=O)OCC,MATE1 inhibitior,-,1
CCOC(=O)OCC,OCT2 inhibitior,-,0.925
CCOC(=O)OCC,BSEP inhibitior,-,0.8962
CCOC(=O)OCC,P-glycoprotein inhibitior,-,0.9873
CCOC(=O)OCC,P-glycoprotein substrate,-,0.9975
CCOC(=O)OCC,CYP3A4 substrate,-,0.7033
CCOC(=O)OCC,CYP2C9 substrate,-,0.8046
CCOC(=O)OCC,CYP2D6 substrate,-,0.7646
CCOC(=O)OCC,CYP3A4 inhibition,-,0.9718
CCOC(=O)OCC,CYP2C9 inhibition,-,0.921
CCOC(=O)OCC,CYP2C19 inhibition,-,0.9101
CCOC(=O)OCC,CYP2D6 inhibition,-,0.947
CCOC(=O)OCC,CYP1A2 inhibition,-,0.8183
CCOC(=O)OCC,CYP2C8 inhibition,-,0.9872
CCOC(=O)OCC,CYP inhibitory promiscuity,-,0.8229
CCOC(=O)OCC,UGT catelyzed,-,0
CCOC(=O)OCC,Carcinogenicity (binary),+,0.5077
CCOC(=O)OCC,Carcinogenicity (trinary),Non-required,0.6562
CCOC(=O)OCC,Eye corrosion,+,0.9635
CCOC(=O)OCC,Eye irritation,+,1
CCOC(=O)OCC,Skin irritation,+,0.7421
CCOC(=O)OCC,Skin corrosion,-,0.8459
CCOC(=O)OCC,Ames mutagenesis,-,0.98
CCOC(=O)OCC,Human Ether-a-go-go-Related Gene inhibition,-,0.839
CCOC(=O)OCC,Micronuclear,-,0.92
CCOC(=O)OCC,Hepatotoxicity,+,0.6009
CCOC(=O)OCC,skin sensitisation,-,0.9393
CCOC(=O)OCC,Respiratory toxicity,-,0.9444
CCOC(=O)OCC,Reproductive toxicity,-,0.6222
CCOC(=O)OCC,Mitochondrial toxicity,-,0.9875
CCOC(=O)OCC,Nephrotoxicity,+,0.6515
CCOC(=O)OCC,Acute Oral Toxicity (c),IV,0.5495
CCOC(=O)OCC,Estrogen receptor binding,-,0.9209
CCOC(=O)OCC,Androgen receptor binding,-,0.9471
CCOC(=O)OCC,Thyroid receptor binding,-,0.8853
CCOC(=O)OCC,Glucocorticoid receptor binding,-,0.9129
CCOC(=O)OCC,Aromatase binding,-,0.8666
CCOC(=O)OCC,PPAR gamma,-,0.9242
CCOC(=O)OCC,Honey bee toxicity,-,0.9601
CCOC(=O)OCC,Biodegradation,+,0.8
CCOC(=O)OCC,Crustacea aquatic toxicity,-,0.8089
CCOC(=O)OCC,Fish aquatic toxicity,+,0.8486
CCOC(=O)OCC,ADMET predicted profile --- Regressions,Value,Unit
CCOC(=O)OCC,Water solubility,-0.97,logS
CCOC(=O)OCC,Plasma protein binding,0.09,100%
CCOC(=O)OCC,Acute Oral Toxicity,1.177,log(1/(mol/kg))
CCOC(=O)OCC,Tetrahymena pyriformis,-0.781,pIGC50 (ug/L)
,  ,,
CC1COC(=O)O2,Human Intestinal Absorption,+,0.9928
CC1COC(=O)O3,Caco-2,+,0.5553
CC1COC(=O)O4,Blood Brain Barrier,+,0.8
CC1COC(=O)O5,Human oral bioavailability,+,0.6857
CC1COC(=O)O6,Subcellular localzation,Mitochondria,0.7888
CC1COC(=O)O7,OATP2B1 inhibitior,-,0.8589
CC1COC(=O)O8,OATP1B1 inhibitior,+,0.9643
CC1COC(=O)O9,OATP1B3 inhibitior,+,0.9497
CC1COC(=O)O10,MATE1 inhibitior,-,0.98
CC1COC(=O)O11,OCT2 inhibitior,-,0.85
CC1COC(=O)O12,BSEP inhibitior,-,0.934
CC1COC(=O)O13,P-glycoprotein inhibitior,-,0.9833
CC1COC(=O)O14,P-glycoprotein substrate,-,0.9614
CC1COC(=O)O15,CYP3A4 substrate,-,0.706
CC1COC(=O)O16,CYP2C9 substrate,-,0.756
CC1COC(=O)O17,CYP2D6 substrate,-,0.7912
CC1COC(=O)O18,CYP3A4 inhibition,-,0.9843
CC1COC(=O)O19,CYP2C9 inhibition,-,0.9228
CC1COC(=O)O20,CYP2C19 inhibition,-,0.8406
CC1COC(=O)O21,CYP2D6 inhibition,-,0.9378
CC1COC(=O)O22,CYP1A2 inhibition,-,0.6869
CC1COC(=O)O23,CYP2C8 inhibition,-,0.9967
CC1COC(=O)O24,CYP inhibitory promiscuity,-,0.9283
CC1COC(=O)O25,UGT catelyzed,-,0
CC1COC(=O)O26,Carcinogenicity (binary),-,0.8917
CC1COC(=O)O27,Carcinogenicity (trinary),Non-required,0.5084
CC1COC(=O)O28,Eye corrosion,+,0.491
CC1COC(=O)O29,Eye irritation,+,0.9916
CC1COC(=O)O30,Skin irritation,-,0.8721
CC1COC(=O)O31,Skin corrosion,-,0.9639
CC1COC(=O)O32,Ames mutagenesis,+,0.6
CC1COC(=O)O33,Human Ether-a-go-go-Related Gene inhibition,-,0.8316
CC1COC(=O)O34,Micronuclear,-,0.67
CC1COC(=O)O35,Hepatotoxicity,+,0.675
CC1COC(=O)O36,skin sensitisation,-,0.7542
CC1COC(=O)O37,Respiratory toxicity,-,0.7889
CC1COC(=O)O38,Reproductive toxicity,-,0.6667
CC1COC(=O)O39,Mitochondrial toxicity,-,0.85
CC1COC(=O)O40,Nephrotoxicity,+,0.6223
CC1COC(=O)O41,Acute Oral Toxicity (c),IV,0.6199
CC1COC(=O)O42,Estrogen receptor binding,-,0.8985
CC1COC(=O)O43,Androgen receptor binding,-,0.8291
CC1COC(=O)O44,Thyroid receptor binding,-,0.9224
CC1COC(=O)O45,Glucocorticoid receptor binding,-,0.9293
CC1COC(=O)O46,Aromatase binding,-,0.8372
CC1COC(=O)O47,PPAR gamma,-,0.9132
CC1COC(=O)O48,Honey bee toxicity,-,0.854
CC1COC(=O)O49,Biodegradation,+,0.9
CC1COC(=O)O50,Crustacea aquatic toxicity,+,0.58
CC1COC(=O)O51,Fish aquatic toxicity,-,0.6961
CC1COC(=O)O52,ADMET predicted profile --- Regressions,Value,Unit
CC1COC(=O)O53,Water solubility,-0.39,logS
CC1COC(=O)O54,Plasma protein binding,0.08,100%
CC1COC(=O)O55,Acute Oral Toxicity,0.348,log(1/(mol/kg))
CC1COC(=O)O56,Tetrahymena pyriformis,-0.488,pIGC50 (ug/L)
,  ,,
CC(=C)C(=O)OC,Human Intestinal Absorption,+,0.9938
CC(=C)C(=O)OC,Caco-2,+,0.637
CC(=C)C(=O)OC,Blood Brain Barrier,+,0.95
CC(=C)C(=O)OC,Human oral bioavailability,+,0.5857
CC(=C)C(=O)OC,Subcellular localzation,Mitochondria,0.6246
CC(=C)C(=O)OC,OATP2B1 inhibitior,-,0.8737
CC(=C)C(=O)OC,OATP1B1 inhibitior,+,0.976
CC(=C)C(=O)OC,OATP1B3 inhibitior,+,0.9563
CC(=C)C(=O)OC,MATE1 inhibitior,-,0.86
CC(=C)C(=O)OC,OCT2 inhibitior,-,0.975
CC(=C)C(=O)OC,BSEP inhibitior,-,0.9465
CC(=C)C(=O)OC,P-glycoprotein inhibitior,-,0.9799
CC(=C)C(=O)OC,P-glycoprotein substrate,-,0.9795
CC(=C)C(=O)OC,CYP3A4 substrate,-,0.6509
CC(=C)C(=O)OC,CYP2C9 substrate,-,1
CC(=C)C(=O)OC,CYP2D6 substrate,-,0.868
CC(=C)C(=O)OC,CYP3A4 inhibition,-,0.9308
CC(=C)C(=O)OC,CYP2C9 inhibition,-,0.941
CC(=C)C(=O)OC,CYP2C19 inhibition,-,0.8858
CC(=C)C(=O)OC,CYP2D6 inhibition,-,0.9574
CC(=C)C(=O)OC,CYP1A2 inhibition,-,0.9044
CC(=C)C(=O)OC,CYP2C8 inhibition,-,0.9842
CC(=C)C(=O)OC,CYP inhibitory promiscuity,-,0.843
CC(=C)C(=O)OC,UGT catelyzed,-,0
CC(=C)C(=O)OC,Carcinogenicity (binary),+,0.6947
CC(=C)C(=O)OC,Carcinogenicity (trinary),Non-required,0.7112
CC(=C)C(=O)OC,Eye corrosion,+,0.9514
CC(=C)C(=O)OC,Eye irritation,+,0.9839
CC(=C)C(=O)OC,Skin irritation,+,0.6985
CC(=C)C(=O)OC,Skin corrosion,-,0.9563
CC(=C)C(=O)OC,Ames mutagenesis,-,0.94
CC(=C)C(=O)OC,Human Ether-a-go-go-Related Gene inhibition,-,0.7496
CC(=C)C(=O)OC,Micronuclear,-,0.96
CC(=C)C(=O)OC,Hepatotoxicity,+,0.6034
CC(=C)C(=O)OC,skin sensitisation,+,0.9371
CC(=C)C(=O)OC,Respiratory toxicity,+,0.7333
CC(=C)C(=O)OC,Reproductive toxicity,-,0.9889
CC(=C)C(=O)OC,Mitochondrial toxicity,+,0.675
CC(=C)C(=O)OC,Nephrotoxicity,+,0.8623
CC(=C)C(=O)OC,Acute Oral Toxicity (c),IV,0.6239
CC(=C)C(=O)OC,Estrogen receptor binding,-,0.918
CC(=C)C(=O)OC,Androgen receptor binding,-,0.9684
CC(=C)C(=O)OC,Thyroid receptor binding,-,0.8726
CC(=C)C(=O)OC,Glucocorticoid receptor binding,-,0.9239
CC(=C)C(=O)OC,Aromatase binding,-,0.7997
CC(=C)C(=O)OC,PPAR gamma,-,0.9374
CC(=C)C(=O)OC,Honey bee toxicity,-,0.7266
CC(=C)C(=O)OC,Biodegradation,+,0.9
CC(=C)C(=O)OC,Crustacea aquatic toxicity,-,0.79
CC(=C)C(=O)OC,Fish aquatic toxicity,+,0.8484
CC(=C)C(=O)OC,ADMET predicted profile --- Regressions,Value,Unit
CC(=C)C(=O)OC,Water solubility,-0.737,logS
CC(=C)C(=O)OC,Plasma protein binding,0.513,100%
CC(=C)C(=O)OC,Acute Oral Toxicity,1.633,log(1/(mol/kg))
CC(=C)C(=O)OC,Tetrahymena pyriformis,-1.092,pIGC50 (ug/L)
,  ,,
CCCCOC(=O)C=C,Human Intestinal Absorption,+,0.9968
CCCCOC(=O)C=C,Caco-2,+,0.9272
CCCCOC(=O)C=C,Blood Brain Barrier,+,0.925
CCCCOC(=O)C=C,Human oral bioavailability,-,0.6429
CCCCOC(=O)C=C,Subcellular localzation,Plasma membrane,0.494
CCCCOC(=O)C=C,OATP2B1 inhibitior,-,0.8502
CCCCOC(=O)C=C,OATP1B1 inhibitior,+,0.9233
CCCCOC(=O)C=C,OATP1B3 inhibitior,+,0.9229
CCCCOC(=O)C=C,MATE1 inhibitior,-,0.74
CCCCOC(=O)C=C,OCT2 inhibitior,-,0.975
CCCCOC(=O)C=C,BSEP inhibitior,-,0.9357
CCCCOC(=O)C=C,P-glycoprotein inhibitior,-,0.9884
CCCCOC(=O)C=C,P-glycoprotein substrate,-,0.9745
CCCCOC(=O)C=C,CYP3A4 substrate,-,0.5926
CCCCOC(=O)C=C,CYP2C9 substrate,+,0.6063
CCCCOC(=O)C=C,CYP2D6 substrate,-,0.8854
CCCCOC(=O)C=C,CYP3A4 inhibition,-,0.9159
CCCCOC(=O)C=C,CYP2C9 inhibition,-,0.9126
CCCCOC(=O)C=C,CYP2C19 inhibition,-,0.7751
CCCCOC(=O)C=C,CYP2D6 inhibition,-,0.9434
CCCCOC(=O)C=C,CYP1A2 inhibition,+,0.6392
CCCCOC(=O)C=C,CYP2C8 inhibition,-,0.8969
CCCCOC(=O)C=C,CYP inhibitory promiscuity,-,0.8344
CCCCOC(=O)C=C,UGT catelyzed,-,0
CCCCOC(=O)C=C,Carcinogenicity (binary),-,0.58
CCCCOC(=O)C=C,Carcinogenicity (trinary),Non-required,0.5283
CCCCOC(=O)C=C,Eye corrosion,+,0.9866
CCCCOC(=O)C=C,Eye irritation,+,0.9884
CCCCOC(=O)C=C,Skin irritation,+,0.9226
CCCCOC(=O)C=C,Skin corrosion,-,0.7871
CCCCOC(=O)C=C,Ames mutagenesis,-,0.99
CCCCOC(=O)C=C,Human Ether-a-go-go-Related Gene inhibition,-,0.7344
CCCCOC(=O)C=C,Micronuclear,-,0.98
CCCCOC(=O)C=C,Hepatotoxicity,+,0.5625
CCCCOC(=O)C=C,skin sensitisation,+,0.9332
CCCCOC(=O)C=C,Respiratory toxicity,-,0.9444
CCCCOC(=O)C=C,Reproductive toxicity,-,1
CCCCOC(=O)C=C,Mitochondrial toxicity,-,0.9875
CCCCOC(=O)C=C,Nephrotoxicity,+,0.6965
CCCCOC(=O)C=C,Acute Oral Toxicity (c),III,0.7892
CCCCOC(=O)C=C,Estrogen receptor binding,-,0.8679
CCCCOC(=O)C=C,Androgen receptor binding,+,0.5594
CCCCOC(=O)C=C,Thyroid receptor binding,-,0.8662
CCCCOC(=O)C=C,Glucocorticoid receptor binding,-,0.758
CCCCOC(=O)C=C,Aromatase binding,-,0.8828
CCCCOC(=O)C=C,PPAR gamma,-,0.8545
CCCCOC(=O)C=C,Honey bee toxicity,-,0.9767
CCCCOC(=O)C=C,Biodegradation,+,0.975
CCCCOC(=O)C=C,Crustacea aquatic toxicity,-,0.56
CCCCOC(=O)C=C,Fish aquatic toxicity,+,0.9238
CCCCOC(=O)C=C,ADMET predicted profile --- Regressions,Value,Unit
CCCCOC(=O)C=C,Water solubility,-1.824,logS
CCCCOC(=O)C=C,Plasma protein binding,0.463,100%
CCCCOC(=O)C=C,Acute Oral Toxicity,1.804,log(1/(mol/kg))
CCCCOC(=O)C=C,Tetrahymena pyriformis,0.574,pIGC50 (ug/L)
,  ,,
C(COCCOCCO)O  ,Human Intestinal Absorption,+,0.679
C(COCCOCCO)O  ,Caco-2,+,0.7566
C(COCCOCCO)O  ,Blood Brain Barrier,-,0.525
C(COCCOCCO)O  ,Human oral bioavailability,+,0.6143
C(COCCOCCO)O  ,Subcellular localzation,Mitochondria,0.675
C(COCCOCCO)O  ,OATP2B1 inhibitior,-,0.8586
C(COCCOCCO)O  ,OATP1B1 inhibitior,+,0.8943
C(COCCOCCO)O  ,OATP1B3 inhibitior,+,0.941
C(COCCOCCO)O  ,MATE1 inhibitior,-,1
C(COCCOCCO)O  ,OCT2 inhibitior,-,0.825
C(COCCOCCO)O  ,BSEP inhibitior,-,0.9199
C(COCCOCCO)O  ,P-glycoprotein inhibitior,-,0.9788
C(COCCOCCO)O  ,P-glycoprotein substrate,-,0.9912
C(COCCOCCO)O  ,CYP3A4 substrate,-,0.7538
C(COCCOCCO)O  ,CYP2C9 substrate,-,1
C(COCCOCCO)O  ,CYP2D6 substrate,-,0.7539
C(COCCOCCO)O  ,CYP3A4 inhibition,-,0.9509
C(COCCOCCO)O  ,CYP2C9 inhibition,-,0.9171
C(COCCOCCO)O  ,CYP2C19 inhibition,-,0.9138
C(COCCOCCO)O  ,CYP2D6 inhibition,-,0.9671
C(COCCOCCO)O  ,CYP1A2 inhibition,-,0.9373
C(COCCOCCO)O  ,CYP2C8 inhibition,-,0.9884
C(COCCOCCO)O  ,CYP inhibitory promiscuity,-,0.9547
C(COCCOCCO)O  ,UGT catelyzed,-,0.6
C(COCCOCCO)O  ,Carcinogenicity (binary),-,0.74
C(COCCOCCO)O  ,Carcinogenicity (trinary),Non-required,0.7098
C(COCCOCCO)O  ,Eye corrosion,+,0.7399
C(COCCOCCO)O  ,Eye irritation,+,0.9786
C(COCCOCCO)O  ,Skin irritation,-,0.7267
C(COCCOCCO)O  ,Skin corrosion,-,0.9858
C(COCCOCCO)O  ,Ames mutagenesis,-,0.8962
C(COCCOCCO)O  ,Human Ether-a-go-go-Related Gene inhibition,-,0.6262
C(COCCOCCO)O  ,Micronuclear,-,1
C(COCCOCCO)O  ,Hepatotoxicity,+,0.5303
C(COCCOCCO)O  ,skin sensitisation,-,0.5751
C(COCCOCCO)O  ,Respiratory toxicity,+,0.7111
C(COCCOCCO)O  ,Reproductive toxicity,-,0.9778
C(COCCOCCO)O  ,Mitochondrial toxicity,+,0.7375
C(COCCOCCO)O  ,Nephrotoxicity,+,0.706
C(COCCOCCO)O  ,Acute Oral Toxicity (c),IV,0.6404
C(COCCOCCO)O  ,Estrogen receptor binding,-,0.8949
C(COCCOCCO)O  ,Androgen receptor binding,-,0.9342
C(COCCOCCO)O  ,Thyroid receptor binding,-,0.8624
C(COCCOCCO)O  ,Glucocorticoid receptor binding,-,0.8661
C(COCCOCCO)O  ,Aromatase binding,-,0.8314
C(COCCOCCO)O  ,PPAR gamma,-,0.8658
C(COCCOCCO)O  ,Honey bee toxicity,-,0.8775
C(COCCOCCO)O  ,Biodegradation,+,0.875
C(COCCOCCO)O  ,Crustacea aquatic toxicity,-,0.98
C(COCCOCCO)O  ,Fish aquatic toxicity,-,0.9093
C(COCCOCCO)O  ,ADMET predicted profile --- Regressions,Value,Unit
C(COCCOCCO)O  ,Water solubility,-0.19,logS
C(COCCOCCO)O  ,Plasma protein binding,0.713,100%
C(COCCOCCO)O  ,Acute Oral Toxicity,0.876,log(1/(mol/kg))
C(COCCOCCO)O  ,Tetrahymena pyriformis,-1.257,pIGC50 (ug/L)
,  ,,
C1COCCO1,,,
C1COCCO1,Human Intestinal Absorption,+,0.9754
C1COCCO1,Caco-2,+,0.8186
C1COCCO1,Blood Brain Barrier,+,0.95
C1COCCO1,Human oral bioavailability,+,0.8429
C1COCCO1,Subcellular localzation,Mitochondria,0.5943
C1COCCO1,OATP2B1 inhibitior,-,0.8632
C1COCCO1,OATP1B1 inhibitior,+,0.9838
C1COCCO1,OATP1B3 inhibitior,+,0.9518
C1COCCO1,MATE1 inhibitior,-,1
C1COCCO1,OCT2 inhibitior,-,0.825
C1COCCO1,BSEP inhibitior,-,0.9619
C1COCCO1,P-glycoprotein inhibitior,-,0.9879
C1COCCO1,P-glycoprotein substrate,-,0.9971
C1COCCO1,CYP3A4 substrate,-,0.8344
C1COCCO1,CYP2C9 substrate,-,0.8019
C1COCCO1,CYP2D6 substrate,-,0.7619
C1COCCO1,CYP3A4 inhibition,-,0.982
C1COCCO1,CYP2C9 inhibition,-,0.8987
C1COCCO1,CYP2C19 inhibition,-,0.8661
C1COCCO1,CYP2D6 inhibition,-,0.9587
C1COCCO1,CYP1A2 inhibition,-,0.8674
C1COCCO1,CYP2C8 inhibition,-,0.9922
C1COCCO1,CYP inhibitory promiscuity,-,0.9459
C1COCCO1,UGT catelyzed,-,0
C1COCCO1,Carcinogenicity (binary),-,0.84
C1COCCO1,Carcinogenicity (trinary),Warning,0.5245
C1COCCO1,Eye corrosion,+,0.9313
C1COCCO1,Eye irritation,+,0.9953
C1COCCO1,Skin irritation,+,0.8301
C1COCCO1,Skin corrosion,-,0.7928
C1COCCO1,Ames mutagenesis,-,1
C1COCCO1,Human Ether-a-go-go-Related Gene inhibition,-,0.7263
C1COCCO1,Micronuclear,-,0.97
C1COCCO1,Hepatotoxicity,+,0.9625
C1COCCO1,skin sensitisation,-,0.7783
C1COCCO1,Respiratory toxicity,-,0.9556
C1COCCO1,Reproductive toxicity,-,0.9667
C1COCCO1,Mitochondrial toxicity,-,1
C1COCCO1,Nephrotoxicity,+,0.7388
C1COCCO1,Acute Oral Toxicity (c),III,0.8787
C1COCCO1,Estrogen receptor binding,-,0.9268
C1COCCO1,Androgen receptor binding,-,0.9574
C1COCCO1,Thyroid receptor binding,-,0.8937
C1COCCO1,Glucocorticoid receptor binding,-,0.8333
C1COCCO1,Aromatase binding,-,0.8458
C1COCCO1,PPAR gamma,-,0.9233
C1COCCO1,Honey bee toxicity,-,0.8428
C1COCCO1,Biodegradation,+,0.725
C1COCCO1,Crustacea aquatic toxicity,-,0.79
C1COCCO1,Fish aquatic toxicity,-,0.9327
C1COCCO1,ADMET predicted profile --- Regressions,Value,Unit
C1COCCO1,Water solubility,-0.352,logS
C1COCCO1,Plasma protein binding,0.653,100%
C1COCCO1,Acute Oral Toxicity,2.353,log(1/(mol/kg))
C1COCCO1,Tetrahymena pyriformis,-0.502,pIGC50 (ug/L)
,  ,,
CC(C)OC(C)C,Human Intestinal Absorption,+,0.9928
CC(C)OC(C)C,Caco-2,-,0.547
CC(C)OC(C)C,Blood Brain Barrier,+,0.975
CC(C)OC(C)C,Human oral bioavailability,+,0.7857
CC(C)OC(C)C,Subcellular localzation,Mitochondria,0.6048
CC(C)OC(C)C,OATP2B1 inhibitior,-,0.8678
CC(C)OC(C)C,OATP1B1 inhibitior,+,0.9687
CC(C)OC(C)C,OATP1B3 inhibitior,+,0.9687
CC(C)OC(C)C,MATE1 inhibitior,-,0.98
CC(C)OC(C)C,OCT2 inhibitior,-,1
CC(C)OC(C)C,BSEP inhibitior,-,0.9549
CC(C)OC(C)C,P-glycoprotein inhibitior,-,0.9753
CC(C)OC(C)C,P-glycoprotein substrate,-,0.988
CC(C)OC(C)C,CYP3A4 substrate,-,0.7945
CC(C)OC(C)C,CYP2C9 substrate,-,0.806
CC(C)OC(C)C,CYP2D6 substrate,-,0.7521
CC(C)OC(C)C,CYP3A4 inhibition,-,0.9812
CC(C)OC(C)C,CYP2C9 inhibition,-,0.9458
CC(C)OC(C)C,CYP2C19 inhibition,-,0.9178
CC(C)OC(C)C,CYP2D6 inhibition,-,0.9566
CC(C)OC(C)C,CYP1A2 inhibition,-,0.8662
CC(C)OC(C)C,CYP2C8 inhibition,-,0.9946
CC(C)OC(C)C,CYP inhibitory promiscuity,-,0.835
CC(C)OC(C)C,UGT catelyzed,-,0
CC(C)OC(C)C,Carcinogenicity (binary),+,0.6483
CC(C)OC(C)C,Carcinogenicity (trinary),Warning,0.4812
CC(C)OC(C)C,Eye corrosion,+,0.9699
CC(C)OC(C)C,Eye irritation,+,0.985
CC(C)OC(C)C,Skin irritation,+,0.5357
CC(C)OC(C)C,Skin corrosion,-,0.9781
CC(C)OC(C)C,Ames mutagenesis,-,0.74
CC(C)OC(C)C,Human Ether-a-go-go-Related Gene inhibition,-,0.8277
CC(C)OC(C)C,Micronuclear,-,0.99
CC(C)OC(C)C,Hepatotoxicity,+,0.6802
CC(C)OC(C)C,skin sensitisation,-,0.895
CC(C)OC(C)C,Respiratory toxicity,-,0.9
CC(C)OC(C)C,Reproductive toxicity,-,0.9889
CC(C)OC(C)C,Mitochondrial toxicity,-,0.9655
CC(C)OC(C)C,Nephrotoxicity,+,0.6852
CC(C)OC(C)C,Acute Oral Toxicity (c),IV,0.6481
CC(C)OC(C)C,Estrogen receptor binding,-,0.9158
CC(C)OC(C)C,Androgen receptor binding,-,0.9393
CC(C)OC(C)C,Thyroid receptor binding,-,0.8425
CC(C)OC(C)C,Glucocorticoid receptor binding,-,0.9317
CC(C)OC(C)C,Aromatase binding,-,0.7841
CC(C)OC(C)C,PPAR gamma,-,0.8545
CC(C)OC(C)C,Honey bee toxicity,-,0.6882
CC(C)OC(C)C,Biodegradation,-,0.925
CC(C)OC(C)C,Crustacea aquatic toxicity,-,0.71
CC(C)OC(C)C,Fish aquatic toxicity,-,0.7238
CC(C)OC(C)C,ADMET predicted profile --- Regressions,Value,Unit
CC(C)OC(C)C,Water solubility,-0.869,logS
CC(C)OC(C)C,Plasma protein binding,0.69,100%
CC(C)OC(C)C,Acute Oral Toxicity,1.197,log(1/(mol/kg))
CC(C)OC(C)C,Tetrahymena pyriformis,-1.407,pIGC50 (ug/L)
,  ,,
,,,
CCOC(=O)C1=CC=CC=C1,Human Intestinal Absorption,+,1
CCOC(=O)C1=CC=CC=C1,Caco-2,+,0.9115
CCOC(=O)C1=CC=CC=C1,Blood Brain Barrier,+,0.9
CCOC(=O)C1=CC=CC=C1,Human oral bioavailability,+,0.7429
CCOC(=O)C1=CC=CC=C1,Subcellular localzation,Mitochondria,0.7797
CCOC(=O)C1=CC=CC=C1,OATP2B1 inhibitior,-,1
CCOC(=O)C1=CC=CC=C1,OATP1B1 inhibitior,+,0.9572
CCOC(=O)C1=CC=CC=C1,OATP1B3 inhibitior,+,0.9674
CCOC(=O)C1=CC=CC=C1,MATE1 inhibitior,-,0.98
CCOC(=O)C1=CC=CC=C1,OCT2 inhibitior,-,0.925
CCOC(=O)C1=CC=CC=C1,BSEP inhibitior,-,0.8658
CCOC(=O)C1=CC=CC=C1,P-glycoprotein inhibitior,-,0.9909
CCOC(=O)C1=CC=CC=C1,P-glycoprotein substrate,-,0.9915
CCOC(=O)C1=CC=CC=C1,CYP3A4 substrate,-,0.7168
CCOC(=O)C1=CC=CC=C1,CYP2C9 substrate,-,0.7945
CCOC(=O)C1=CC=CC=C1,CYP2D6 substrate,-,0.8429
CCOC(=O)C1=CC=CC=C1,CYP3A4 inhibition,-,0.9817
CCOC(=O)C1=CC=CC=C1,CYP2C9 inhibition,-,0.886
CCOC(=O)C1=CC=CC=C1,CYP2C19 inhibition,-,0.8897
CCOC(=O)C1=CC=CC=C1,CYP2D6 inhibition,-,0.9525
CCOC(=O)C1=CC=CC=C1,CYP1A2 inhibition,+,0.7888
CCOC(=O)C1=CC=CC=C1,CYP2C8 inhibition,-,0.7175
CCOC(=O)C1=CC=CC=C1,CYP inhibitory promiscuity,-,0.7227
CCOC(=O)C1=CC=CC=C1,UGT catelyzed,-,0
CCOC(=O)C1=CC=CC=C1,Carcinogenicity (binary),-,0.5239
CCOC(=O)C1=CC=CC=C1,Carcinogenicity (trinary),Non-required,0.6038
CCOC(=O)C1=CC=CC=C1,Eye corrosion,+,0.8185
CCOC(=O)C1=CC=CC=C1,Eye irritation,+,1
CCOC(=O)C1=CC=CC=C1,Skin irritation,+,0.8823
CCOC(=O)C1=CC=CC=C1,Skin corrosion,-,0.8782
CCOC(=O)C1=CC=CC=C1,Ames mutagenesis,-,0.99
CCOC(=O)C1=CC=CC=C1,Human Ether-a-go-go-Related Gene inhibition,-,0.8512
CCOC(=O)C1=CC=CC=C1,Micronuclear,-,0.94
CCOC(=O)C1=CC=CC=C1,Hepatotoxicity,+,0.5285
CCOC(=O)C1=CC=CC=C1,skin sensitisation,+,0.7518
CCOC(=O)C1=CC=CC=C1,Respiratory toxicity,-,0.8778
CCOC(=O)C1=CC=CC=C1,Reproductive toxicity,-,0.7889
CCOC(=O)C1=CC=CC=C1,Mitochondrial toxicity,-,0.975
CCOC(=O)C1=CC=CC=C1,Nephrotoxicity,-,0.5908
CCOC(=O)C1=CC=CC=C1,Acute Oral Toxicity (c),III,0.9356
CCOC(=O)C1=CC=CC=C1,Estrogen receptor binding,-,0.7528
CCOC(=O)C1=CC=CC=C1,Androgen receptor binding,-,0.8428
CCOC(=O)C1=CC=CC=C1,Thyroid receptor binding,-,0.914
CCOC(=O)C1=CC=CC=C1,Glucocorticoid receptor binding,-,0.9731
CCOC(=O)C1=CC=CC=C1,Aromatase binding,-,0.804
CCOC(=O)C1=CC=CC=C1,PPAR gamma,-,0.9176
CCOC(=O)C1=CC=CC=C1,Honey bee toxicity,-,0.9884
CCOC(=O)C1=CC=CC=C1,Biodegradation,+,0.8
CCOC(=O)C1=CC=CC=C1,Crustacea aquatic toxicity,-,0.7055
CCOC(=O)C1=CC=CC=C1,Fish aquatic toxicity,+,0.9145
CCOC(=O)C1=CC=CC=C1,ADMET predicted profile --- Regressions,Value,Unit
CCOC(=O)C1=CC=CC=C1,Water solubility,-2.383,logS
CCOC(=O)C1=CC=CC=C1,Plasma protein binding,0.462,100%
CCOC(=O)C1=CC=CC=C1,Acute Oral Toxicity,1.649,log(1/(mol/kg))
CCOC(=O)C1=CC=CC=C1,Tetrahymena pyriformis,0.624,pIGC50 (ug/L)
,  ,,
CCCCCCN,Human Intestinal Absorption,+,0.9888
CCCCCCN,Caco-2,+,0.9297
CCCCCCN,Blood Brain Barrier,+,1
CCCCCCN,Human oral bioavailability,+,0.5571
CCCCCCN,Subcellular localzation,Lysosomes,0.9614
CCCCCCN,OATP2B1 inhibitior,-,0.8533
CCCCCCN,OATP1B1 inhibitior,+,0.9631
CCCCCCN,OATP1B3 inhibitior,+,0.9381
CCCCCCN,MATE1 inhibitior,-,0.88
CCCCCCN,OCT2 inhibitior,-,0.525
CCCCCCN,BSEP inhibitior,-,0.9629
CCCCCCN,P-glycoprotein inhibitior,-,0.9876
CCCCCCN,P-glycoprotein substrate,-,0.8612
CCCCCCN,CYP3A4 substrate,-,0.7806
CCCCCCN,CYP2C9 substrate,-,1
CCCCCCN,CYP2D6 substrate,+,0.5
CCCCCCN,CYP3A4 inhibition,-,0.9234
CCCCCCN,CYP2C9 inhibition,-,0.9267
CCCCCCN,CYP2C19 inhibition,-,0.8809
CCCCCCN,CYP2D6 inhibition,-,0.6964
CCCCCCN,CYP1A2 inhibition,+,0.5959
CCCCCCN,CYP2C8 inhibition,-,0.9498
CCCCCCN,CYP inhibitory promiscuity,-,0.8505
CCCCCCN,UGT catelyzed,-,0
CCCCCCN,Carcinogenicity (binary),-,0.62
CCCCCCN,Carcinogenicity (trinary),Non-required,0.7297
CCCCCCN,Eye corrosion,+,0.9945
CCCCCCN,Eye irritation,+,0.9071
CCCCCCN,Skin irritation,+,0.8894
CCCCCCN,Skin corrosion,+,0.9802
CCCCCCN,Ames mutagenesis,-,0.92
CCCCCCN,Human Ether-a-go-go-Related Gene inhibition,-,0.7278
CCCCCCN,Micronuclear,-,0.99
CCCCCCN,Hepatotoxicity,-,0.6092
CCCCCCN,skin sensitisation,+,0.7656
CCCCCCN,Respiratory toxicity,+,1
CCCCCCN,Reproductive toxicity,-,1
CCCCCCN,Mitochondrial toxicity,+,1
CCCCCCN,Nephrotoxicity,+,0.5909
CCCCCCN,Acute Oral Toxicity (c),III,0.837
CCCCCCN,Estrogen receptor binding,-,0.9368
CCCCCCN,Androgen receptor binding,-,0.7871
CCCCCCN,Thyroid receptor binding,-,0.8509
CCCCCCN,Glucocorticoid receptor binding,-,0.8576
CCCCCCN,Aromatase binding,-,0.9131
CCCCCCN,PPAR gamma,-,0.8789
CCCCCCN,Honey bee toxicity,-,0.9928
CCCCCCN,Biodegradation,+,0.8
CCCCCCN,Crustacea aquatic toxicity,+,0.97
CCCCCCN,Fish aquatic toxicity,+,0.8193
CCCCCCN,ADMET predicted profile --- Regressions,Value,Unit
CCCCCCN,Water solubility,-1.913,logS
CCCCCCN,Plasma protein binding,0.575,100%
CCCCCCN,Acute Oral Toxicity,2.449,log(1/(mol/kg))
CCCCCCN,Tetrahymena pyriformis,-0.211,pIGC50 (ug/L)
,  ,,
COC(=O)OC,Human Intestinal Absorption,+,0.9917
COC(=O)OC,Caco-2,+,0.5322
COC(=O)OC,Blood Brain Barrier,+,0.875
COC(=O)OC,Human oral bioavailability,+,0.6857
COC(=O)OC,Subcellular localzation,Mitochondria,0.8276
COC(=O)OC,OATP2B1 inhibitior,-,0.8693
COC(=O)OC,OATP1B1 inhibitior,+,0.9726
COC(=O)OC,OATP1B3 inhibitior,+,0.9619
COC(=O)OC,MATE1 inhibitior,-,1
COC(=O)OC,OCT2 inhibitior,-,0.975
COC(=O)OC,BSEP inhibitior,-,0.9396
COC(=O)OC,P-glycoprotein inhibitior,-,0.9851
COC(=O)OC,P-glycoprotein substrate,-,0.9918
COC(=O)OC,CYP3A4 substrate,-,0.755
COC(=O)OC,CYP2C9 substrate,-,0.8046
COC(=O)OC,CYP2D6 substrate,-,0.7358
COC(=O)OC,CYP3A4 inhibition,-,0.9824
COC(=O)OC,CYP2C9 inhibition,-,0.9497
COC(=O)OC,CYP2C19 inhibition,-,0.9427
COC(=O)OC,CYP2D6 inhibition,-,0.9687
COC(=O)OC,CYP1A2 inhibition,-,0.883
COC(=O)OC,CYP2C8 inhibition,-,0.998
COC(=O)OC,CYP inhibitory promiscuity,-,0.9341
COC(=O)OC,UGT catelyzed,-,0
COC(=O)OC,Carcinogenicity (binary),+,0.5724
COC(=O)OC,Carcinogenicity (trinary),Non-required,0.68
COC(=O)OC,Eye corrosion,+,0.9565
COC(=O)OC,Eye irritation,+,0.9929
COC(=O)OC,Skin irritation,+,0.8381
COC(=O)OC,Skin corrosion,-,0.6884
COC(=O)OC,Ames mutagenesis,-,0.84
COC(=O)OC,Human Ether-a-go-go-Related Gene inhibition,-,0.7833
COC(=O)OC,Micronuclear,-,0.86
COC(=O)OC,Hepatotoxicity,-,0.5091
COC(=O)OC,skin sensitisation,-,0.5514
COC(=O)OC,Respiratory toxicity,-,0.9
COC(=O)OC,Reproductive toxicity,-,0.6243
COC(=O)OC,Mitochondrial toxicity,-,0.925
COC(=O)OC,Nephrotoxicity,+,0.7005
COC(=O)OC,Acute Oral Toxicity (c),IV,0.6291
COC(=O)OC,Estrogen receptor binding,-,0.9198
COC(=O)OC,Androgen receptor binding,-,0.9175
COC(=O)OC,Thyroid receptor binding,-,0.8904
COC(=O)OC,Glucocorticoid receptor binding,-,0.8982
COC(=O)OC,Aromatase binding,-,0.8514
COC(=O)OC,PPAR gamma,-,0.9224
COC(=O)OC,Honey bee toxicity,-,0.8457
COC(=O)OC,Biodegradation,+,0.675
COC(=O)OC,Crustacea aquatic toxicity,-,0.89
COC(=O)OC,Fish aquatic toxicity,-,0.4465
COC(=O)OC,ADMET predicted profile --- Regressions,Value,Unit
COC(=O)OC,Water solubility,-0.179,logS
COC(=O)OC,Plasma protein binding,0.315,100%
COC(=O)OC,Acute Oral Toxicity,1.01,log(1/(mol/kg))
COC(=O)OC,Tetrahymena pyriformis,-1.378,pIGC50 (ug/L)
,  ,,
CCCCOC(=O)C,Human Intestinal Absorption,+,0.9965
CCCCOC(=O)C,Caco-2,+,0.874
CCCCOC(=O)C,Blood Brain Barrier,+,0.95
CCCCOC(=O)C,Human oral bioavailability,-,0.5857
CCCCOC(=O)C,Subcellular localzation,Mitochondria,0.6303
CCCCOC(=O)C,OATP2B1 inhibitior,-,0.8409
CCCCOC(=O)C,OATP1B1 inhibitior,+,0.943
CCCCOC(=O)C,OATP1B3 inhibitior,+,0.9246
CCCCOC(=O)C,MATE1 inhibitior,-,0.88
CCCCOC(=O)C,OCT2 inhibitior,-,0.975
CCCCOC(=O)C,BSEP inhibitior,-,0.9288
CCCCOC(=O)C,P-glycoprotein inhibitior,-,0.9871
CCCCOC(=O)C,P-glycoprotein substrate,-,0.9741
CCCCOC(=O)C,CYP3A4 substrate,-,0.6392
CCCCOC(=O)C,CYP2C9 substrate,-,0.7977
CCCCOC(=O)C,CYP2D6 substrate,-,0.8679
CCCCOC(=O)C,CYP3A4 inhibition,-,0.9688
CCCCOC(=O)C,CYP2C9 inhibition,-,0.9411
CCCCOC(=O)C,CYP2C19 inhibition,-,0.9213
CCCCOC(=O)C,CYP2D6 inhibition,-,0.9408
CCCCOC(=O)C,CYP1A2 inhibition,+,0.5111
CCCCOC(=O)C,CYP2C8 inhibition,-,0.9602
CCCCOC(=O)C,CYP inhibitory promiscuity,-,0.8855
CCCCOC(=O)C,UGT catelyzed,-,0
CCCCOC(=O)C,Carcinogenicity (binary),-,0.6
CCCCOC(=O)C,Carcinogenicity (trinary),Non-required,0.6127
CCCCOC(=O)C,Eye corrosion,+,0.9901
CCCCOC(=O)C,Eye irritation,+,0.9931
CCCCOC(=O)C,Skin irritation,+,0.7942
CCCCOC(=O)C,Skin corrosion,-,0.89
CCCCOC(=O)C,Ames mutagenesis,-,0.98
CCCCOC(=O)C,Human Ether-a-go-go-Related Gene inhibition,-,0.7401
CCCCOC(=O)C,Micronuclear,-,1
CCCCOC(=O)C,Hepatotoxicity,+,0.6
CCCCOC(=O)C,skin sensitisation,+,0.6907
CCCCOC(=O)C,Respiratory toxicity,-,1
CCCCOC(=O)C,Reproductive toxicity,-,0.9778
CCCCOC(=O)C,Mitochondrial toxicity,-,1
CCCCOC(=O)C,Nephrotoxicity,+,0.8073
CCCCOC(=O)C,Acute Oral Toxicity (c),III,0.5153
CCCCOC(=O)C,Estrogen receptor binding,-,0.9364
CCCCOC(=O)C,Androgen receptor binding,-,0.7855
CCCCOC(=O)C,Thyroid receptor binding,-,0.9087
CCCCOC(=O)C,Glucocorticoid receptor binding,-,0.9392
CCCCOC(=O)C,Aromatase binding,-,0.9195
CCCCOC(=O)C,PPAR gamma,-,0.9336
CCCCOC(=O)C,Honey bee toxicity,-,0.9902
CCCCOC(=O)C,Biodegradation,+,1
CCCCOC(=O)C,Crustacea aquatic toxicity,-,0.52
CCCCOC(=O)C,Fish aquatic toxicity,+,0.7179
CCCCOC(=O)C,ADMET predicted profile --- Regressions,Value,Unit
CCCCOC(=O)C,Water solubility,-1.085,logS
CCCCOC(=O)C,Plasma protein binding,0.236,100%
CCCCOC(=O)C,Acute Oral Toxicity,1.405,log(1/(mol/kg))
CCCCOC(=O)C,Tetrahymena pyriformis,-0.572,pIGC50 (ug/L)
,  ,,
CC1=CC(=O)CC(C1)(C)C,Human Intestinal Absorption,+,0.9951
CC1=CC(=O)CC(C1)(C)C,Caco-2,+,0.955
CC1=CC(=O)CC(C1)(C)C,Blood Brain Barrier,+,0.725
CC1=CC(=O)CC(C1)(C)C,Human oral bioavailability,+,0.8429
CC1=CC(=O)CC(C1)(C)C,Subcellular localzation,Mitochondria,0.5982
CC1=CC(=O)CC(C1)(C)C,OATP2B1 inhibitior,-,0.8628
CC1=CC(=O)CC(C1)(C)C,OATP1B1 inhibitior,+,0.956
CC1=CC(=O)CC(C1)(C)C,OATP1B3 inhibitior,+,0.9506
CC1=CC(=O)CC(C1)(C)C,MATE1 inhibitior,-,0.9
CC1=CC(=O)CC(C1)(C)C,OCT2 inhibitior,-,0.85
CC1=CC(=O)CC(C1)(C)C,BSEP inhibitior,-,0.8513
CC1=CC(=O)CC(C1)(C)C,P-glycoprotein inhibitior,-,0.9827
CC1=CC(=O)CC(C1)(C)C,P-glycoprotein substrate,-,0.9791
CC1=CC(=O)CC(C1)(C)C,CYP3A4 substrate,-,0.5908
CC1=CC(=O)CC(C1)(C)C,CYP2C9 substrate,-,0.8078
CC1=CC(=O)CC(C1)(C)C,CYP2D6 substrate,-,0.8705
CC1=CC(=O)CC(C1)(C)C,CYP3A4 inhibition,-,0.8979
CC1=CC(=O)CC(C1)(C)C,CYP2C9 inhibition,-,0.8195
CC1=CC(=O)CC(C1)(C)C,CYP2C19 inhibition,-,0.7521
CC1=CC(=O)CC(C1)(C)C,CYP2D6 inhibition,-,0.9439
CC1=CC(=O)CC(C1)(C)C,CYP1A2 inhibition,-,0.876
CC1=CC(=O)CC(C1)(C)C,CYP2C8 inhibition,-,0.9881
CC1=CC(=O)CC(C1)(C)C,CYP inhibitory promiscuity,-,0.8593
CC1=CC(=O)CC(C1)(C)C,UGT catelyzed,-,0
CC1=CC(=O)CC(C1)(C)C,Carcinogenicity (binary),-,0.6336
CC1=CC(=O)CC(C1)(C)C,Carcinogenicity (trinary),Warning,0.5339
CC1=CC(=O)CC(C1)(C)C,Eye corrosion,-,0.6292
CC1=CC(=O)CC(C1)(C)C,Eye irritation,+,0.9717
CC1=CC(=O)CC(C1)(C)C,Skin irritation,+,0.6706
CC1=CC(=O)CC(C1)(C)C,Skin corrosion,-,0.9562
CC1=CC(=O)CC(C1)(C)C,Ames mutagenesis,-,0.86
CC1=CC(=O)CC(C1)(C)C,Human Ether-a-go-go-Related Gene inhibition,-,0.7635
CC1=CC(=O)CC(C1)(C)C,Micronuclear,-,0.97
CC1=CC(=O)CC(C1)(C)C,Hepatotoxicity,+,0.6212
CC1=CC(=O)CC(C1)(C)C,skin sensitisation,+,0.9559
CC1=CC(=O)CC(C1)(C)C,Respiratory toxicity,-,0.7667
CC1=CC(=O)CC(C1)(C)C,Reproductive toxicity,-,0.6667
CC1=CC(=O)CC(C1)(C)C,Mitochondrial toxicity,-,0.9875
CC1=CC(=O)CC(C1)(C)C,Nephrotoxicity,+,0.7839
CC1=CC(=O)CC(C1)(C)C,Acute Oral Toxicity (c),III,0.8109
CC1=CC(=O)CC(C1)(C)C,Estrogen receptor binding,-,0.9833
CC1=CC(=O)CC(C1)(C)C,Androgen receptor binding,-,0.8233
CC1=CC(=O)CC(C1)(C)C,Thyroid receptor binding,-,0.909
CC1=CC(=O)CC(C1)(C)C,Glucocorticoid receptor binding,-,0.8943
CC1=CC(=O)CC(C1)(C)C,Aromatase binding,-,0.9255
CC1=CC(=O)CC(C1)(C)C,PPAR gamma,-,0.9056
CC1=CC(=O)CC(C1)(C)C,Honey bee toxicity,-,0.9575
CC1=CC(=O)CC(C1)(C)C,Biodegradation,+,0.6
CC1=CC(=O)CC(C1)(C)C,Crustacea aquatic toxicity,+,0.51
CC1=CC(=O)CC(C1)(C)C,Fish aquatic toxicity,+,0.8808
CC1=CC(=O)CC(C1)(C)C,ADMET predicted profile --- Regressions,Value,Unit
CC1=CC(=O)CC(C1)(C)C,Water solubility,-1.515,logS
CC1=CC(=O)CC(C1)(C)C,Plasma protein binding,0.086,100%
CC1=CC(=O)CC(C1)(C)C,Acute Oral Toxicity,1.864,log(1/(mol/kg))
CC1=CC(=O)CC(C1)(C)C,Tetrahymena pyriformis,-0.51,pIGC50 (ug/L)
,  ,,
COS(=O)(=O)C  ,Human Intestinal Absorption,+,0.9076
COS(=O)(=O)C  ,Caco-2,-,0.5742
COS(=O)(=O)C  ,Blood Brain Barrier,+,0.85
COS(=O)(=O)C  ,Human oral bioavailability,+,0.8857
COS(=O)(=O)C  ,Subcellular localzation,Mitochondria,0.5268
COS(=O)(=O)C  ,OATP2B1 inhibitior,-,1
COS(=O)(=O)C  ,OATP1B1 inhibitior,+,0.969
COS(=O)(=O)C  ,OATP1B3 inhibitior,+,0.948
COS(=O)(=O)C  ,MATE1 inhibitior,-,1
COS(=O)(=O)C  ,OCT2 inhibitior,-,1
COS(=O)(=O)C  ,BSEP inhibitior,-,0.941
COS(=O)(=O)C  ,P-glycoprotein inhibitior,-,0.9847
COS(=O)(=O)C  ,P-glycoprotein substrate,-,0.995
COS(=O)(=O)C  ,CYP3A4 substrate,-,0.7081
COS(=O)(=O)C  ,CYP2C9 substrate,-,0.8426
COS(=O)(=O)C  ,CYP2D6 substrate,-,0.8039
COS(=O)(=O)C  ,CYP3A4 inhibition,-,0.9887
COS(=O)(=O)C  ,CYP2C9 inhibition,-,0.8351
COS(=O)(=O)C  ,CYP2C19 inhibition,-,0.7607
COS(=O)(=O)C  ,CYP2D6 inhibition,-,0.9289
COS(=O)(=O)C  ,CYP1A2 inhibition,-,0.7946
COS(=O)(=O)C  ,CYP2C8 inhibition,-,0.9941
COS(=O)(=O)C  ,CYP inhibitory promiscuity,-,0.9328
COS(=O)(=O)C  ,UGT catelyzed,-,0
COS(=O)(=O)C  ,Carcinogenicity (binary),+,0.8596
COS(=O)(=O)C  ,Carcinogenicity (trinary),Non-required,0.6287
COS(=O)(=O)C  ,Eye corrosion,+,0.9784
COS(=O)(=O)C  ,Eye irritation,+,0.9357
COS(=O)(=O)C  ,Skin irritation,+,0.868
COS(=O)(=O)C  ,Skin corrosion,+,0.9639
COS(=O)(=O)C  ,Ames mutagenesis,+,0.6446
COS(=O)(=O)C  ,Human Ether-a-go-go-Related Gene inhibition,-,0.7072
COS(=O)(=O)C  ,Micronuclear,+,0.82
COS(=O)(=O)C  ,Hepatotoxicity,+,0.5733
COS(=O)(=O)C  ,skin sensitisation,+,0.9333
COS(=O)(=O)C  ,Respiratory toxicity,-,0.9
COS(=O)(=O)C  ,Reproductive toxicity,-,0.6556
COS(=O)(=O)C  ,Mitochondrial toxicity,-,0.7375
COS(=O)(=O)C  ,Nephrotoxicity,+,0.8329
COS(=O)(=O)C  ,Acute Oral Toxicity (c),II,0.7586
COS(=O)(=O)C  ,Estrogen receptor binding,-,0.9034
COS(=O)(=O)C  ,Androgen receptor binding,-,0.9153
COS(=O)(=O)C  ,Thyroid receptor binding,-,0.8639
COS(=O)(=O)C  ,Glucocorticoid receptor binding,-,0.9366
COS(=O)(=O)C  ,Aromatase binding,-,0.8526
COS(=O)(=O)C  ,PPAR gamma,-,0.9317
COS(=O)(=O)C  ,Honey bee toxicity,-,0.5414
COS(=O)(=O)C  ,Biodegradation,+,0.775
COS(=O)(=O)C  ,Crustacea aquatic toxicity,-,0.72
COS(=O)(=O)C  ,Fish aquatic toxicity,+,0.7356
COS(=O)(=O)C  ,ADMET predicted profile --- Regressions,Value,Unit
COS(=O)(=O)C  ,Water solubility,-1.231,logS
COS(=O)(=O)C  ,Plasma protein binding,0.071,100%
COS(=O)(=O)C  ,Acute Oral Toxicity,2.506,log(1/(mol/kg))
COS(=O)(=O)C  ,Tetrahymena pyriformis,-1.289,pIGC50 (ug/L)
,  ,,
CCN1CCCC1=O  ,Human Intestinal Absorption,+,0.9893
CCN1CCCC1=O  ,Caco-2,+,0.9455
CCN1CCCC1=O  ,Blood Brain Barrier,+,0.975
CCN1CCCC1=O  ,Human oral bioavailability,+,0.7857
CCN1CCCC1=O  ,Subcellular localzation,Lysosomes,0.6053
CCN1CCCC1=O  ,OATP2B1 inhibitior,-,0.8476
CCN1CCCC1=O  ,OATP1B1 inhibitior,+,0.9739
CCN1CCCC1=O  ,OATP1B3 inhibitior,+,0.9458
CCN1CCCC1=O  ,MATE1 inhibitior,-,1
CCN1CCCC1=O  ,OCT2 inhibitior,+,0.55
CCN1CCCC1=O  ,BSEP inhibitior,-,0.9192
CCN1CCCC1=O  ,P-glycoprotein inhibitior,-,0.9915
CCN1CCCC1=O  ,P-glycoprotein substrate,-,0.9642
CCN1CCCC1=O  ,CYP3A4 substrate,-,0.7155
CCN1CCCC1=O  ,CYP2C9 substrate,-,0.8117
CCN1CCCC1=O  ,CYP2D6 substrate,-,0.8612
CCN1CCCC1=O  ,CYP3A4 inhibition,-,0.9614
CCN1CCCC1=O  ,CYP2C9 inhibition,-,0.5801
CCN1CCCC1=O  ,CYP2C19 inhibition,+,0.5616
CCN1CCCC1=O  ,CYP2D6 inhibition,-,0.5739
CCN1CCCC1=O  ,CYP1A2 inhibition,-,0.7379
CCN1CCCC1=O  ,CYP2C8 inhibition,-,0.9974
CCN1CCCC1=O  ,CYP inhibitory promiscuity,-,0.899
CCN1CCCC1=O  ,UGT catelyzed,-,0
CCN1CCCC1=O  ,Carcinogenicity (binary),-,0.87
CCN1CCCC1=O  ,Carcinogenicity (trinary),Non-required,0.6132
CCN1CCCC1=O  ,Eye corrosion,-,0.7975
CCN1CCCC1=O  ,Eye irritation,+,0.9807
CCN1CCCC1=O  ,Skin irritation,-,0.6903
CCN1CCCC1=O  ,Skin corrosion,-,0.7365
CCN1CCCC1=O  ,Ames mutagenesis,-,0.8
CCN1CCCC1=O  ,Human Ether-a-go-go-Related Gene inhibition,-,0.757
CCN1CCCC1=O  ,Micronuclear,-,0.93
CCN1CCCC1=O  ,Hepatotoxicity,+,0.7981
CCN1CCCC1=O  ,skin sensitisation,-,0.9436
CCN1CCCC1=O  ,Respiratory toxicity,-,0.6333
CCN1CCCC1=O  ,Reproductive toxicity,+,0.7222
CCN1CCCC1=O  ,Mitochondrial toxicity,-,0.6125
CCN1CCCC1=O  ,Nephrotoxicity,-,0.6057
CCN1CCCC1=O  ,Acute Oral Toxicity (c),III,0.79
CCN1CCCC1=O  ,Estrogen receptor binding,-,0.9728
CCN1CCCC1=O  ,Androgen receptor binding,-,0.9016
CCN1CCCC1=O  ,Thyroid receptor binding,-,0.9371
CCN1CCCC1=O  ,Glucocorticoid receptor binding,-,0.9111
CCN1CCCC1=O  ,Aromatase binding,-,0.8707
CCN1CCCC1=O  ,PPAR gamma,-,0.9234
CCN1CCCC1=O  ,Honey bee toxicity,-,0.9842
CCN1CCCC1=O  ,Biodegradation,+,0.675
CCN1CCCC1=O  ,Crustacea aquatic toxicity,-,0.59
CCN1CCCC1=O  ,Fish aquatic toxicity,-,0.7663
CCN1CCCC1=O  ,Water solubility,-0.78,logS
CCN1CCCC1=O  ,Plasma protein binding,-0.033,100%
CCN1CCCC1=O  ,Acute Oral Toxicity,1.463,log(1/(mol/kg))
CCN1CCCC1=O  ,Tetrahymena pyriformis,-0.421,pIGC50 (ug/L)
,  ,,
C(CCl)Cl,Human Intestinal Absorption,+,0.975
C(CCl)Cl,Caco-2,+,0.6468
C(CCl)Cl,Blood Brain Barrier,+,0.975
C(CCl)Cl,Human oral bioavailability,+,0.9
C(CCl)Cl,Subcellular localzation,Mitochondria,0.4687
C(CCl)Cl,OATP2B1 inhibitior,-,0.8723
C(CCl)Cl,OATP1B1 inhibitior,+,0.9739
C(CCl)Cl,OATP1B3 inhibitior,+,0.9544
C(CCl)Cl,MATE1 inhibitior,-,0.88
C(CCl)Cl,OCT2 inhibitior,-,0.95
C(CCl)Cl,BSEP inhibitior,-,0.9402
C(CCl)Cl,P-glycoprotein inhibitior,-,0.9843
C(CCl)Cl,P-glycoprotein substrate,-,0.9953
C(CCl)Cl,CYP3A4 substrate,-,0.7806
C(CCl)Cl,CYP2C9 substrate,-,0.512
C(CCl)Cl,CYP2D6 substrate,-,0.7632
C(CCl)Cl,CYP3A4 inhibition,-,0.9739
C(CCl)Cl,CYP2C9 inhibition,-,0.8725
C(CCl)Cl,CYP2C19 inhibition,-,0.8067
C(CCl)Cl,CYP2D6 inhibition,-,0.9541
C(CCl)Cl,CYP1A2 inhibition,-,0.7103
C(CCl)Cl,CYP2C8 inhibition,-,0.9908
C(CCl)Cl,CYP inhibitory promiscuity,-,0.8115
C(CCl)Cl,UGT catelyzed,-,0
C(CCl)Cl,Carcinogenicity (binary),+,0.57
C(CCl)Cl,Carcinogenicity (trinary),Danger,0.5411
C(CCl)Cl,Eye corrosion,+,1
C(CCl)Cl,Eye irritation,+,0.9834
C(CCl)Cl,Skin irritation,+,0.9076
C(CCl)Cl,Skin corrosion,-,0.7112
C(CCl)Cl,Ames mutagenesis,+,0.85
C(CCl)Cl,Human Ether-a-go-go-Related Gene inhibition,-,0.742
C(CCl)Cl,Micronuclear,-,1
C(CCl)Cl,Hepatotoxicity,+,0.9625
C(CCl)Cl,skin sensitisation,-,0.8596
C(CCl)Cl,Respiratory toxicity,-,0.7778
C(CCl)Cl,Reproductive toxicity,-,0.5444
C(CCl)Cl,Mitochondrial toxicity,-,0.6625
C(CCl)Cl,Nephrotoxicity,+,0.7701
C(CCl)Cl,Acute Oral Toxicity (c),III,0.7089
C(CCl)Cl,Estrogen receptor binding,-,0.8194
C(CCl)Cl,Androgen receptor binding,-,0.9351
C(CCl)Cl,Thyroid receptor binding,-,0.8359
C(CCl)Cl,Glucocorticoid receptor binding,-,0.9118
C(CCl)Cl,Aromatase binding,-,0.8852
C(CCl)Cl,PPAR gamma,-,0.8283
C(CCl)Cl,Honey bee toxicity,-,0.71
C(CCl)Cl,Biodegradation,-,0.925
C(CCl)Cl,Crustacea aquatic toxicity,-,0.87
C(CCl)Cl,Fish aquatic toxicity,-,0.6865
C(CCl)Cl,ADMET predicted profile --- Regressions,Value,Unit
C(CCl)Cl,Water solubility,-1.558,logS
C(CCl)Cl,Plasma protein binding,0.757,100%
C(CCl)Cl,Acute Oral Toxicity,2.209,log(1/(mol/kg))
C(CCl)Cl,Tetrahymena pyriformis,-0.614,pIGC50 (ug/L)
,  ,,
CC(C)(C)O,Human Intestinal Absorption,+,0.9825
CC(C)(C)O,Caco-2,+,0.5947
CC(C)(C)O,Blood Brain Barrier,+,1
CC(C)(C)O,Human oral bioavailability,+,0.5714
CC(C)(C)O,Subcellular localzation,Mitochondria,0.5311
CC(C)(C)O,OATP2B1 inhibitior,-,1
CC(C)(C)O,OATP1B1 inhibitior,+,0.9731
CC(C)(C)O,OATP1B3 inhibitior,+,0.9657
CC(C)(C)O,MATE1 inhibitior,-,1
CC(C)(C)O,OCT2 inhibitior,-,0.95
CC(C)(C)O,BSEP inhibitior,-,0.9401
CC(C)(C)O,P-glycoprotein inhibitior,-,0.9843
CC(C)(C)O,P-glycoprotein substrate,-,0.9946
CC(C)(C)O,CYP3A4 substrate,-,0.8063
CC(C)(C)O,CYP2C9 substrate,-,1
CC(C)(C)O,CYP2D6 substrate,-,0.7954
CC(C)(C)O,CYP3A4 inhibition,-,0.9391
CC(C)(C)O,CYP2C9 inhibition,-,0.9071
CC(C)(C)O,CYP2C19 inhibition,-,0.9231
CC(C)(C)O,CYP2D6 inhibition,-,0.9568
CC(C)(C)O,CYP1A2 inhibition,-,0.9045
CC(C)(C)O,CYP2C8 inhibition,-,0.9959
CC(C)(C)O,CYP inhibitory promiscuity,-,0.9253
CC(C)(C)O,UGT catelyzed,+,0.9
CC(C)(C)O,Carcinogenicity (binary),+,0.6083
CC(C)(C)O,Carcinogenicity (trinary),Non-required,0.5809
CC(C)(C)O,Eye corrosion,+,0.9809
CC(C)(C)O,Eye irritation,+,0.9839
CC(C)(C)O,Skin irritation,+,0.9043
CC(C)(C)O,Skin corrosion,+,0.6369
CC(C)(C)O,Ames mutagenesis,-,0.97
CC(C)(C)O,Human Ether-a-go-go-Related Gene inhibition,-,0.7618
CC(C)(C)O,Micronuclear,-,0.96
CC(C)(C)O,Hepatotoxicity,+,0.8177
CC(C)(C)O,skin sensitisation,-,0.9321
CC(C)(C)O,Respiratory toxicity,-,0.9333
CC(C)(C)O,Reproductive toxicity,-,0.9889
CC(C)(C)O,Mitochondrial toxicity,-,0.9577
CC(C)(C)O,Nephrotoxicity,+,0.6517
CC(C)(C)O,Acute Oral Toxicity (c),III,0.8522
CC(C)(C)O,Estrogen receptor binding,-,0.9161
CC(C)(C)O,Androgen receptor binding,-,0.9514
CC(C)(C)O,Thyroid receptor binding,-,0.8504
CC(C)(C)O,Glucocorticoid receptor binding,-,0.9107
CC(C)(C)O,Aromatase binding,-,0.9343
CC(C)(C)O,PPAR gamma,-,0.9054
CC(C)(C)O,Honey bee toxicity,-,0.9618
CC(C)(C)O,Biodegradation,-,0.625
CC(C)(C)O,Crustacea aquatic toxicity,-,0.56
CC(C)(C)O,Fish aquatic toxicity,-,0.8223
CC(C)(C)O,ADMET predicted profile --- Regressions,Value,Unit
CC(C)(C)O,Water solubility,-0.558,logS
CC(C)(C)O,Plasma protein binding,0.687,100%
CC(C)(C)O,Acute Oral Toxicity,1.226,log(1/(mol/kg))
CC(C)(C)O,Tetrahymena pyriformis,-1.755,pIGC50 (ug/L)
,  ,,
C1COCO2,Human Intestinal Absorption,+,0.9777
C1COCO3,Caco-2,+,0.784
C1COCO4,Blood Brain Barrier,+,0.95
C1COCO5,Human oral bioavailability,+,0.7286
C1COCO6,Subcellular localzation,Mitochondria,0.4956
C1COCO7,OATP2B1 inhibitior,-,0.8702
C1COCO8,OATP1B1 inhibitior,+,0.9827
C1COCO9,OATP1B3 inhibitior,+,0.949
C1COCO10,MATE1 inhibitior,-,0.98
C1COCO11,OCT2 inhibitior,-,0.85
C1COCO12,BSEP inhibitior,-,0.9518
C1COCO13,P-glycoprotein inhibitior,-,0.987
C1COCO14,P-glycoprotein substrate,-,0.9961
C1COCO15,CYP3A4 substrate,-,0.8034
C1COCO16,CYP2C9 substrate,-,0.8046
C1COCO17,CYP2D6 substrate,-,0.805
C1COCO18,CYP3A4 inhibition,-,0.943
C1COCO19,CYP2C9 inhibition,-,0.8406
C1COCO20,CYP2C19 inhibition,-,0.7797
C1COCO21,CYP2D6 inhibition,-,0.8661
C1COCO22,CYP1A2 inhibition,-,0.743
C1COCO23,CYP2C8 inhibition,-,0.9916
C1COCO24,CYP inhibitory promiscuity,-,0.8763
C1COCO25,UGT catelyzed,-,0
C1COCO26,Carcinogenicity (binary),-,0.86
C1COCO27,Carcinogenicity (trinary),Warning,0.4799
C1COCO28,Eye corrosion,+,0.8882
C1COCO29,Eye irritation,+,0.994
C1COCO30,Skin irritation,+,0.697
C1COCO31,Skin corrosion,-,0.5994
C1COCO32,Ames mutagenesis,-,0.95
C1COCO33,Human Ether-a-go-go-Related Gene inhibition,-,0.7841
C1COCO34,Micronuclear,-,0.98
C1COCO35,Hepatotoxicity,+,0.8875
C1COCO36,skin sensitisation,-,0.9436
C1COCO37,Respiratory toxicity,-,0.9333
C1COCO38,Reproductive toxicity,+,0.7444
C1COCO39,Mitochondrial toxicity,-,0.9625
C1COCO40,Nephrotoxicity,+,0.7926
C1COCO41,Acute Oral Toxicity (c),III,0.7968
C1COCO42,Estrogen receptor binding,-,0.9145
C1COCO43,Androgen receptor binding,-,0.9471
C1COCO44,Thyroid receptor binding,-,0.8618
C1COCO45,Glucocorticoid receptor binding,-,0.876
C1COCO46,Aromatase binding,-,0.8825
C1COCO47,PPAR gamma,-,0.8909
C1COCO48,Honey bee toxicity,-,0.796
C1COCO49,Biodegradation,+,0.775
C1COCO50,Crustacea aquatic toxicity,-,0.88
C1COCO51,Fish aquatic toxicity,-,0.9137
C1COCO52,ADMET predicted profile --- Regressions,Value,Unit
C1COCO53,Water solubility,0.128,logS
C1COCO54,Plasma protein binding,0.262,100%
C1COCO55,Acute Oral Toxicity,1.45,log(1/(mol/kg))
C1COCO56,Tetrahymena pyriformis,-0.951,pIGC50 (ug/L)
,  ,,
C(=C(Cl)Cl)Cl,Human Intestinal Absorption,+,0.991
C(=C(Cl)Cl)Cl,Caco-2,+,0.7881
C(=C(Cl)Cl)Cl,Blood Brain Barrier,+,1
C(=C(Cl)Cl)Cl,Human oral bioavailability,+,0.6714
C(=C(Cl)Cl)Cl,Subcellular localzation,Lysosomes,0.4668
C(=C(Cl)Cl)Cl,OATP2B1 inhibitior,-,0.8733
C(=C(Cl)Cl)Cl,OATP1B1 inhibitior,+,0.9646
C(=C(Cl)Cl)Cl,OATP1B3 inhibitior,+,0.9555
C(=C(Cl)Cl)Cl,MATE1 inhibitior,-,1
C(=C(Cl)Cl)Cl,OCT2 inhibitior,-,1
C(=C(Cl)Cl)Cl,BSEP inhibitior,-,0.9205
C(=C(Cl)Cl)Cl,P-glycoprotein inhibitior,-,0.9868
C(=C(Cl)Cl)Cl,P-glycoprotein substrate,-,0.9969
C(=C(Cl)Cl)Cl,CYP3A4 substrate,-,0.7879
C(=C(Cl)Cl)Cl,CYP2C9 substrate,-,0.7594
C(=C(Cl)Cl)Cl,CYP2D6 substrate,-,0.7902
C(=C(Cl)Cl)Cl,CYP3A4 inhibition,-,0.8826
C(=C(Cl)Cl)Cl,CYP2C9 inhibition,-,0.8139
C(=C(Cl)Cl)Cl,CYP2C19 inhibition,-,0.7217
C(=C(Cl)Cl)Cl,CYP2D6 inhibition,-,0.9331
C(=C(Cl)Cl)Cl,CYP1A2 inhibition,-,0.632
C(=C(Cl)Cl)Cl,CYP2C8 inhibition,-,0.9714
C(=C(Cl)Cl)Cl,CYP inhibitory promiscuity,-,0.706
C(=C(Cl)Cl)Cl,UGT catelyzed,-,0
C(=C(Cl)Cl)Cl,Carcinogenicity (binary),+,0.7639
C(=C(Cl)Cl)Cl,Carcinogenicity (trinary),Non-required,0.5111
C(=C(Cl)Cl)Cl,Eye corrosion,+,0.8156
C(=C(Cl)Cl)Cl,Eye irritation,+,0.9807
C(=C(Cl)Cl)Cl,Skin irritation,+,0.8698
C(=C(Cl)Cl)Cl,Skin corrosion,+,0.8485
C(=C(Cl)Cl)Cl,Ames mutagenesis,-,0.62
C(=C(Cl)Cl)Cl,Human Ether-a-go-go-Related Gene inhibition,-,0.7708
C(=C(Cl)Cl)Cl,Micronuclear,-,0.97
C(=C(Cl)Cl)Cl,Hepatotoxicity,+,1
C(=C(Cl)Cl)Cl,skin sensitisation,+,0.7322
C(=C(Cl)Cl)Cl,Respiratory toxicity,-,0.7889
C(=C(Cl)Cl)Cl,Reproductive toxicity,-,0.8556
C(=C(Cl)Cl)Cl,Mitochondrial toxicity,-,0.925
C(=C(Cl)Cl)Cl,Nephrotoxicity,+,0.7127
C(=C(Cl)Cl)Cl,Acute Oral Toxicity (c),III,0.6495
C(=C(Cl)Cl)Cl,Estrogen receptor binding,-,0.8703
C(=C(Cl)Cl)Cl,Androgen receptor binding,-,0.949
C(=C(Cl)Cl)Cl,Thyroid receptor binding,-,0.7734
C(=C(Cl)Cl)Cl,Glucocorticoid receptor binding,-,0.7977
C(=C(Cl)Cl)Cl,Aromatase binding,-,0.8661
C(=C(Cl)Cl)Cl,PPAR gamma,-,0.7948
C(=C(Cl)Cl)Cl,Honey bee toxicity,-,0.5089
C(=C(Cl)Cl)Cl,Biodegradation,-,0.95
C(=C(Cl)Cl)Cl,Crustacea aquatic toxicity,+,0.76
C(=C(Cl)Cl)Cl,Fish aquatic toxicity,+,0.906
C(=C(Cl)Cl)Cl,ADMET predicted profile --- Regressions,Value,Unit
C(=C(Cl)Cl)Cl,Water solubility,-2.603,logS
C(=C(Cl)Cl)Cl,Plasma protein binding,0.35,100%
C(=C(Cl)Cl)Cl,Acute Oral Toxicity,1.274,log(1/(mol/kg))
C(=C(Cl)Cl)Cl,Tetrahymena pyriformis,1.477,pIGC50 (ug/L)
,  ,,
CCCOC(=O)C,Human Intestinal Absorption,+,0.9965
CCCOC(=O)C,Caco-2,+,0.7992
CCCOC(=O)C,Blood Brain Barrier,+,0.95
CCCOC(=O)C,Human oral bioavailability,+,0.5714
CCCOC(=O)C,Subcellular localzation,Mitochondria,0.6303
CCCOC(=O)C,OATP2B1 inhibitior,-,0.8445
CCCOC(=O)C,OATP1B1 inhibitior,+,0.9569
CCCOC(=O)C,OATP1B3 inhibitior,+,0.9246
CCCOC(=O)C,MATE1 inhibitior,-,0.88
CCCOC(=O)C,OCT2 inhibitior,-,0.975
CCCOC(=O)C,BSEP inhibitior,-,0.8922
CCCOC(=O)C,P-glycoprotein inhibitior,-,0.9837
CCCOC(=O)C,P-glycoprotein substrate,-,0.984
CCCOC(=O)C,CYP3A4 substrate,-,0.7099
CCCOC(=O)C,CYP2C9 substrate,-,0.7977
CCCOC(=O)C,CYP2D6 substrate,-,0.8679
CCCOC(=O)C,CYP3A4 inhibition,-,0.9688
CCCOC(=O)C,CYP2C9 inhibition,-,0.9411
CCCOC(=O)C,CYP2C19 inhibition,-,0.9213
CCCOC(=O)C,CYP2D6 inhibition,-,0.9408
CCCOC(=O)C,CYP1A2 inhibition,+,0.5111
CCCOC(=O)C,CYP2C8 inhibition,-,0.9766
CCCOC(=O)C,CYP inhibitory promiscuity,-,0.8855
CCCOC(=O)C,UGT catelyzed,-,0
CCCOC(=O)C,Carcinogenicity (binary),-,0.6
CCCOC(=O)C,Carcinogenicity (trinary),Non-required,0.6127
CCCOC(=O)C,Eye corrosion,+,0.9901
CCCOC(=O)C,Eye irritation,+,0.9807
CCCOC(=O)C,Skin irritation,+,0.7942
CCCOC(=O)C,Skin corrosion,-,0.89
CCCOC(=O)C,Ames mutagenesis,-,0.84
CCCOC(=O)C,Human Ether-a-go-go-Related Gene inhibition,-,0.7911
CCCOC(=O)C,Micronuclear,-,1
CCCOC(=O)C,Hepatotoxicity,+,0.6
CCCOC(=O)C,skin sensitisation,+,0.6907
CCCOC(=O)C,Respiratory toxicity,-,0.9444
CCCOC(=O)C,Reproductive toxicity,-,0.9778
CCCOC(=O)C,Mitochondrial toxicity,-,1
CCCOC(=O)C,Nephrotoxicity,+,0.7701
CCCOC(=O)C,Acute Oral Toxicity (c),III,0.5153
CCCOC(=O)C,Estrogen receptor binding,-,0.9328
CCCOC(=O)C,Androgen receptor binding,-,0.8712
CCCOC(=O)C,Thyroid receptor binding,-,0.9362
CCCOC(=O)C,Glucocorticoid receptor binding,-,0.9593
CCCOC(=O)C,Aromatase binding,-,0.9212
CCCOC(=O)C,PPAR gamma,-,0.9075
CCCOC(=O)C,Honey bee toxicity,-,0.9754
CCCOC(=O)C,Biodegradation,+,1
CCCOC(=O)C,Crustacea aquatic toxicity,-,0.7632
CCCOC(=O)C,Fish aquatic toxicity,+,0.7179
CCCOC(=O)C,ADMET predicted profile --- Regressions,Value,Unit
CCCOC(=O)C,Water solubility,-1.085,logS
CCCOC(=O)C,Plasma protein binding,0.055,100%
CCCOC(=O)C,Acute Oral Toxicity,1.15,log(1/(mol/kg))
CCCOC(=O)C,Tetrahymena pyriformis,-1.303,pIGC50 (ug/L)
,  ,,
CC=C(C)C,Human Intestinal Absorption,+,0.9911
CC=C(C)C,Caco-2,+,0.6801
CC=C(C)C,Blood Brain Barrier,+,0.975
CC=C(C)C,Human oral bioavailability,+,0.5571
CC=C(C)C,Subcellular localzation,Lysosomes,0.4504
CC=C(C)C,OATP2B1 inhibitior,-,1
CC=C(C)C,OATP1B1 inhibitior,+,0.9466
CC=C(C)C,OATP1B3 inhibitior,+,0.9568
CC=C(C)C,MATE1 inhibitior,-,0.98
CC=C(C)C,OCT2 inhibitior,-,0.95
CC=C(C)C,BSEP inhibitior,-,0.8776
CC=C(C)C,P-glycoprotein inhibitior,-,0.9853
CC=C(C)C,P-glycoprotein substrate,-,0.9934
CC=C(C)C,CYP3A4 substrate,-,0.8118
CC=C(C)C,CYP2C9 substrate,-,0.7983
CC=C(C)C,CYP2D6 substrate,-,0.7996
CC=C(C)C,CYP3A4 inhibition,-,0.9436
CC=C(C)C,CYP2C9 inhibition,-,0.8927
CC=C(C)C,CYP2C19 inhibition,-,0.9075
CC=C(C)C,CYP2D6 inhibition,-,0.9281
CC=C(C)C,CYP1A2 inhibition,-,0.8718
CC=C(C)C,CYP2C8 inhibition,-,0.9979
CC=C(C)C,CYP inhibitory promiscuity,-,0.6843
CC=C(C)C,UGT catelyzed,-,0
CC=C(C)C,Carcinogenicity (binary),+,0.6683
CC=C(C)C,Carcinogenicity (trinary),Warning,0.61
CC=C(C)C,Eye corrosion,+,0.945
CC=C(C)C,Eye irritation,+,0.9932
CC=C(C)C,Skin irritation,+,0.8007
CC=C(C)C,Skin corrosion,-,0.7896
CC=C(C)C,Ames mutagenesis,-,0.88
CC=C(C)C,Human Ether-a-go-go-Related Gene inhibition,-,0.7777
CC=C(C)C,Micronuclear,-,0.97
CC=C(C)C,Hepatotoxicity,+,0.7
CC=C(C)C,skin sensitisation,+,0.8752
CC=C(C)C,Respiratory toxicity,-,0.9333
CC=C(C)C,Reproductive toxicity,-,0.9778
CC=C(C)C,Mitochondrial toxicity,-,0.5839
CC=C(C)C,Nephrotoxicity,+,0.6595
CC=C(C)C,Acute Oral Toxicity (c),III,0.8122
CC=C(C)C,Estrogen receptor binding,-,0.9398
CC=C(C)C,Androgen receptor binding,-,0.9455
CC=C(C)C,Thyroid receptor binding,-,0.8482
CC=C(C)C,Glucocorticoid receptor binding,-,0.8976
CC=C(C)C,Aromatase binding,-,0.8585
CC=C(C)C,PPAR gamma,-,0.8793
CC=C(C)C,Honey bee toxicity,-,0.8752
CC=C(C)C,Biodegradation,+,0.625
CC=C(C)C,Crustacea aquatic toxicity,-,0.71
CC=C(C)C,Fish aquatic toxicity,+,0.8634
CC=C(C)C,ADMET predicted profile --- Regressions,Value,Unit
CC=C(C)C,Water solubility,-2.622,logS
CC=C(C)C,Plasma protein binding,0.549,100%
CC=C(C)C,Acute Oral Toxicity,1.446,log(1/(mol/kg))
CC=C(C)C,Tetrahymena pyriformis,-0.673,pIGC50 (ug/L)
,  ,,
COC(=O)C=C,Human Intestinal Absorption,+,0.9944
COC(=O)C=C,Caco-2,+,0.8336
COC(=O)C=C,Blood Brain Barrier,+,0.925
COC(=O)C=C,Human oral bioavailability,-,0.5429
COC(=O)C=C,Subcellular localzation,Mitochondria,0.5194
COC(=O)C=C,OATP2B1 inhibitior,-,1
COC(=O)C=C,OATP1B1 inhibitior,+,0.9618
COC(=O)C=C,OATP1B3 inhibitior,+,0.9632
COC(=O)C=C,MATE1 inhibitior,-,0.8
COC(=O)C=C,OCT2 inhibitior,-,0.975
COC(=O)C=C,BSEP inhibitior,-,0.9378
COC(=O)C=C,P-glycoprotein inhibitior,-,0.9862
COC(=O)C=C,P-glycoprotein substrate,-,0.9912
COC(=O)C=C,CYP3A4 substrate,-,0.6781
COC(=O)C=C,CYP2C9 substrate,-,1
COC(=O)C=C,CYP2D6 substrate,-,0.879
COC(=O)C=C,CYP3A4 inhibition,-,0.9618
COC(=O)C=C,CYP2C9 inhibition,-,0.9376
COC(=O)C=C,CYP2C19 inhibition,-,0.9189
COC(=O)C=C,CYP2D6 inhibition,-,0.9735
COC(=O)C=C,CYP1A2 inhibition,-,0.8252
COC(=O)C=C,CYP2C8 inhibition,-,0.9789
COC(=O)C=C,CYP inhibitory promiscuity,-,0.937
COC(=O)C=C,UGT catelyzed,-,0
COC(=O)C=C,Carcinogenicity (binary),+,0.7027
COC(=O)C=C,Carcinogenicity (trinary),Non-required,0.618
COC(=O)C=C,Eye corrosion,+,0.9906
COC(=O)C=C,Eye irritation,+,0.9805
COC(=O)C=C,Skin irritation,+,0.8536
COC(=O)C=C,Skin corrosion,+,0.6524
COC(=O)C=C,Ames mutagenesis,-,0.96
COC(=O)C=C,Human Ether-a-go-go-Related Gene inhibition,-,0.7676
COC(=O)C=C,Micronuclear,-,0.83
COC(=O)C=C,Hepatotoxicity,+,0.5034
COC(=O)C=C,skin sensitisation,+,0.9333
COC(=O)C=C,Respiratory toxicity,-,0.9222
COC(=O)C=C,Reproductive toxicity,-,1
COC(=O)C=C,Mitochondrial toxicity,-,0.9625
COC(=O)C=C,Nephrotoxicity,+,0.7225
COC(=O)C=C,Acute Oral Toxicity (c),II,0.5547
COC(=O)C=C,Estrogen receptor binding,-,0.9139
COC(=O)C=C,Androgen receptor binding,-,0.7773
COC(=O)C=C,Thyroid receptor binding,-,0.8739
COC(=O)C=C,Glucocorticoid receptor binding,-,0.8139
COC(=O)C=C,Aromatase binding,-,0.8552
COC(=O)C=C,PPAR gamma,-,0.8946
COC(=O)C=C,Honey bee toxicity,-,0.7789
COC(=O)C=C,Biodegradation,+,0.8
COC(=O)C=C,Crustacea aquatic toxicity,-,0.78
COC(=O)C=C,Fish aquatic toxicity,+,0.7487
COC(=O)C=C,ADMET predicted profile --- Regressions,Value,Unit
COC(=O)C=C,Water solubility,-0.283,logS
COC(=O)C=C,Plasma protein binding,0.239,100%
COC(=O)C=C,Acute Oral Toxicity,2.279,log(1/(mol/kg))
COC(=O)C=C,Tetrahymena pyriformis,0.52,pIGC50 (ug/L)
,  ,,
CCCCOC(=O)CC,Human Intestinal Absorption,+,0.997
CCCCOC(=O)CC,Caco-2,+,0.9462
CCCCOC(=O)CC,Blood Brain Barrier,+,0.95
CCCCOC(=O)CC,Human oral bioavailability,-,0.5714
CCCCOC(=O)CC,Subcellular localzation,Mitochondria,0.609
CCCCOC(=O)CC,OATP2B1 inhibitior,-,0.8416
CCCCOC(=O)CC,OATP1B1 inhibitior,+,0.9361
CCCCOC(=O)CC,OATP1B3 inhibitior,+,0.9171
CCCCOC(=O)CC,MATE1 inhibitior,-,0.88
CCCCOC(=O)CC,OCT2 inhibitior,-,0.85
CCCCOC(=O)CC,BSEP inhibitior,-,0.8889
CCCCOC(=O)CC,P-glycoprotein inhibitior,-,0.987
CCCCOC(=O)CC,P-glycoprotein substrate,-,0.9624
CCCCOC(=O)CC,CYP3A4 substrate,-,0.5917
CCCCOC(=O)CC,CYP2C9 substrate,-,0.7977
CCCCOC(=O)CC,CYP2D6 substrate,-,0.8679
CCCCOC(=O)CC,CYP3A4 inhibition,-,0.9513
CCCCOC(=O)CC,CYP2C9 inhibition,-,0.9277
CCCCOC(=O)CC,CYP2C19 inhibition,-,0.9391
CCCCOC(=O)CC,CYP2D6 inhibition,-,0.9225
CCCCOC(=O)CC,CYP1A2 inhibition,-,0.5
CCCCOC(=O)CC,CYP2C8 inhibition,-,0.873
CCCCOC(=O)CC,CYP inhibitory promiscuity,-,0.8517
CCCCOC(=O)CC,UGT catelyzed,-,0
CCCCOC(=O)CC,Carcinogenicity (binary),-,0.64
CCCCOC(=O)CC,Carcinogenicity (trinary),Non-required,0.6625
CCCCOC(=O)CC,Eye corrosion,+,0.987
CCCCOC(=O)CC,Eye irritation,+,0.9828
CCCCOC(=O)CC,Skin irritation,-,0.6447
CCCCOC(=O)CC,Skin corrosion,-,0.9941
CCCCOC(=O)CC,Ames mutagenesis,-,0.95
CCCCOC(=O)CC,Human Ether-a-go-go-Related Gene inhibition,-,0.6719
CCCCOC(=O)CC,Micronuclear,-,1
CCCCOC(=O)CC,Hepatotoxicity,-,0.6625
CCCCOC(=O)CC,skin sensitisation,+,0.7184
CCCCOC(=O)CC,Respiratory toxicity,-,0.9
CCCCOC(=O)CC,Reproductive toxicity,-,1
CCCCOC(=O)CC,Mitochondrial toxicity,-,1
CCCCOC(=O)CC,Nephrotoxicity,+,0.624
CCCCOC(=O)CC,Acute Oral Toxicity (c),III,0.8356
CCCCOC(=O)CC,Estrogen receptor binding,-,0.9567
CCCCOC(=O)CC,Androgen receptor binding,-,0.8679
CCCCOC(=O)CC,Thyroid receptor binding,-,0.9112
CCCCOC(=O)CC,Glucocorticoid receptor binding,-,0.9404
CCCCOC(=O)CC,Aromatase binding,-,0.9286
CCCCOC(=O)CC,PPAR gamma,-,0.8954
CCCCOC(=O)CC,Honey bee toxicity,-,0.9914
CCCCOC(=O)CC,Biodegradation,+,0.975
CCCCOC(=O)CC,Crustacea aquatic toxicity,-,0.51
CCCCOC(=O)CC,Fish aquatic toxicity,+,0.9484
CCCCOC(=O)CC,ADMET predicted profile --- Regressions,Value,Unit
CCCCOC(=O)CC,Water solubility,-2.773,logS
CCCCOC(=O)CC,Plasma protein binding,0.326,100%
CCCCOC(=O)CC,Acute Oral Toxicity,1.383,log(1/(mol/kg))
CCCCOC(=O)CC,Tetrahymena pyriformis,0.079,pIGC50 (ug/L)
,  ,,
CCOCCCC,Human Intestinal Absorption,+,0.994
CCOCCCC,Caco-2,+,0.9616
CCOCCCC,Blood Brain Barrier,+,0.975
CCOCCCC,Human oral bioavailability,+,0.7286
CCOCCCC,Subcellular localzation,Lysosomes,0.4731
CCOCCCC,OATP2B1 inhibitior,-,0.8439
CCOCCCC,OATP1B1 inhibitior,+,0.9316
CCOCCCC,OATP1B3 inhibitior,+,0.9426
CCOCCCC,MATE1 inhibitior,-,0.96
CCOCCCC,OCT2 inhibitior,-,0.8
CCOCCCC,BSEP inhibitior,-,0.9506
CCOCCCC,P-glycoprotein inhibitior,-,0.9778
CCOCCCC,P-glycoprotein substrate,-,0.9623
CCOCCCC,CYP3A4 substrate,-,0.6666
CCOCCCC,CYP2C9 substrate,-,1
CCOCCCC,CYP2D6 substrate,-,0.7019
CCOCCCC,CYP3A4 inhibition,-,0.9781
CCOCCCC,CYP2C9 inhibition,-,0.919
CCOCCCC,CYP2C19 inhibition,-,0.9024
CCOCCCC,CYP2D6 inhibition,-,0.9426
CCOCCCC,CYP1A2 inhibition,-,0.7012
CCOCCCC,CYP2C8 inhibition,-,0.942
CCOCCCC,CYP inhibitory promiscuity,-,0.9061
CCOCCCC,UGT catelyzed,-,0
CCOCCCC,Carcinogenicity (binary),-,0.6
CCOCCCC,Carcinogenicity (trinary),Non-required,0.5995
CCOCCCC,Eye corrosion,+,0.9662
CCOCCCC,Eye irritation,+,1
CCOCCCC,Skin irritation,-,0.7817
CCOCCCC,Skin corrosion,-,0.9842
CCOCCCC,Ames mutagenesis,-,1
CCOCCCC,Human Ether-a-go-go-Related Gene inhibition,-,0.6709
CCOCCCC,Micronuclear,-,1
CCOCCCC,Hepatotoxicity,-,0.55
CCOCCCC,skin sensitisation,+,0.7982
CCOCCCC,Respiratory toxicity,-,0.9889
CCOCCCC,Reproductive toxicity,-,0.8622
CCOCCCC,Mitochondrial toxicity,-,1
CCOCCCC,Nephrotoxicity,+,0.7486
CCOCCCC,Acute Oral Toxicity (c),III,0.5429
CCOCCCC,Estrogen receptor binding,-,0.9316
CCOCCCC,Androgen receptor binding,-,0.9037
CCOCCCC,Thyroid receptor binding,-,0.7953
CCOCCCC,Glucocorticoid receptor binding,-,0.9219
CCOCCCC,Aromatase binding,-,0.9171
CCOCCCC,PPAR gamma,-,0.9142
CCOCCCC,Honey bee toxicity,-,0.9874
CCOCCCC,Biodegradation,-,0.7
CCOCCCC,Crustacea aquatic toxicity,-,0.6952
CCOCCCC,Fish aquatic toxicity,+,0.7627
CCOCCCC,ADMET predicted profile --- Regressions,Value,Unit
CCOCCCC,Water solubility,-1.912,logS
CCOCCCC,Plasma protein binding,0.673,100%
CCOCCCC,Acute Oral Toxicity,1.341,log(1/(mol/kg))
CCOCCCC,Tetrahymena pyriformis,-0.139,pIGC50 (ug/L)
,  ,,
CCOC(=O)CC(=O)OCC  ,Human Intestinal Absorption,+,0.9586
CCOC(=O)CC(=O)OCC  ,Caco-2,+,0.6836
CCOC(=O)CC(=O)OCC  ,Blood Brain Barrier,+,0.85
CCOC(=O)CC(=O)OCC  ,Human oral bioavailability,+,0.7
CCOC(=O)CC(=O)OCC  ,Subcellular localzation,Mitochondria,0.8085
CCOC(=O)CC(=O)OCC  ,OATP2B1 inhibitior,-,0.8499
CCOC(=O)CC(=O)OCC  ,OATP1B1 inhibitior,+,0.9696
CCOC(=O)CC(=O)OCC  ,OATP1B3 inhibitior,+,0.9604
CCOC(=O)CC(=O)OCC  ,MATE1 inhibitior,-,0.88
CCOC(=O)CC(=O)OCC  ,OCT2 inhibitior,-,0.9
CCOC(=O)CC(=O)OCC  ,BSEP inhibitior,-,0.897
CCOC(=O)CC(=O)OCC  ,P-glycoprotein inhibitior,-,0.9724
CCOC(=O)CC(=O)OCC  ,P-glycoprotein substrate,-,0.9941
CCOC(=O)CC(=O)OCC  ,CYP3A4 substrate,-,0.6841
CCOC(=O)CC(=O)OCC  ,CYP2C9 substrate,-,0.5886
CCOC(=O)CC(=O)OCC  ,CYP2D6 substrate,-,0.8689
CCOC(=O)CC(=O)OCC  ,CYP3A4 inhibition,-,0.9068
CCOC(=O)CC(=O)OCC  ,CYP2C9 inhibition,-,0.9025
CCOC(=O)CC(=O)OCC  ,CYP2C19 inhibition,-,0.8669
CCOC(=O)CC(=O)OCC  ,CYP2D6 inhibition,-,0.9199
CCOC(=O)CC(=O)OCC  ,CYP1A2 inhibition,-,0.8868
CCOC(=O)CC(=O)OCC  ,CYP2C8 inhibition,-,0.9775
CCOC(=O)CC(=O)OCC  ,CYP inhibitory promiscuity,-,0.8125
CCOC(=O)CC(=O)OCC  ,UGT catelyzed,-,0
CCOC(=O)CC(=O)OCC  ,Carcinogenicity (binary),-,0.5166
CCOC(=O)CC(=O)OCC  ,Carcinogenicity (trinary),Non-required,0.6261
CCOC(=O)CC(=O)OCC  ,Eye corrosion,+,0.9544
CCOC(=O)CC(=O)OCC  ,Eye irritation,+,0.992
CCOC(=O)CC(=O)OCC  ,Skin irritation,-,0.5959
CCOC(=O)CC(=O)OCC  ,Skin corrosion,-,0.7345
CCOC(=O)CC(=O)OCC  ,Ames mutagenesis,-,0.99
CCOC(=O)CC(=O)OCC  ,Human Ether-a-go-go-Related Gene inhibition,-,0.7694
CCOC(=O)CC(=O)OCC  ,Micronuclear,-,0.93
CCOC(=O)CC(=O)OCC  ,Hepatotoxicity,+,0.542
CCOC(=O)CC(=O)OCC  ,skin sensitisation,-,0.8239
CCOC(=O)CC(=O)OCC  ,Respiratory toxicity,-,0.9333
CCOC(=O)CC(=O)OCC  ,Reproductive toxicity,-,0.7889
CCOC(=O)CC(=O)OCC  ,Mitochondrial toxicity,-,0.9375
CCOC(=O)CC(=O)OCC  ,Nephrotoxicity,+,0.6491
CCOC(=O)CC(=O)OCC  ,Acute Oral Toxicity (c),IV,0.6271
CCOC(=O)CC(=O)OCC  ,Estrogen receptor binding,-,0.7862
CCOC(=O)CC(=O)OCC  ,Androgen receptor binding,-,0.9659
CCOC(=O)CC(=O)OCC  ,Thyroid receptor binding,-,0.9127
CCOC(=O)CC(=O)OCC  ,Glucocorticoid receptor binding,-,0.8719
CCOC(=O)CC(=O)OCC  ,Aromatase binding,-,0.9185
CCOC(=O)CC(=O)OCC  ,PPAR gamma,-,0.8884
CCOC(=O)CC(=O)OCC  ,Honey bee toxicity,-,0.955
CCOC(=O)CC(=O)OCC  ,Biodegradation,+,0.85
CCOC(=O)CC(=O)OCC  ,Crustacea aquatic toxicity,-,0.62
CCOC(=O)CC(=O)OCC  ,Fish aquatic toxicity,+,0.8572
CCOC(=O)CC(=O)OCC  ,ADMET predicted profile --- Regressions,Value,Unit
CCOC(=O)CC(=O)OCC  ,Water solubility,-0.757,logS
CCOC(=O)CC(=O)OCC  ,Plasma protein binding,-0.058,100%
CCOC(=O)CC(=O)OCC  ,Acute Oral Toxicity,1.658,log(1/(mol/kg))
CCOC(=O)CC(=O)OCC  ,Tetrahymena pyriformis,-0.851,pIGC50 (ug/L)
,  ,,
CC[Pb](CC)(CC)CC,Human Intestinal Absorption,+,0.8579
CC[Pb](CC)(CC)CC,Caco-2,+,0.7426
CC[Pb](CC)(CC)CC,Blood Brain Barrier,+,0.875
CC[Pb](CC)(CC)CC,Human oral bioavailability,+,0.7571
CC[Pb](CC)(CC)CC,Subcellular localzation,Lysosomes,0.6641
CC[Pb](CC)(CC)CC,OATP2B1 inhibitior,-,0.861
CC[Pb](CC)(CC)CC,OATP1B1 inhibitior,+,0.9548
CC[Pb](CC)(CC)CC,OATP1B3 inhibitior,+,0.9466
CC[Pb](CC)(CC)CC,MATE1 inhibitior,-,0.98
CC[Pb](CC)(CC)CC,OCT2 inhibitior,-,0.775
CC[Pb](CC)(CC)CC,BSEP inhibitior,-,0.9425
CC[Pb](CC)(CC)CC,P-glycoprotein inhibitior,-,0.985
CC[Pb](CC)(CC)CC,P-glycoprotein substrate,-,0.9802
CC[Pb](CC)(CC)CC,CYP3A4 substrate,-,0.7948
CC[Pb](CC)(CC)CC,CYP2C9 substrate,-,0.8078
CC[Pb](CC)(CC)CC,CYP2D6 substrate,-,0.781
CC[Pb](CC)(CC)CC,CYP3A4 inhibition,-,0.9683
CC[Pb](CC)(CC)CC,CYP2C9 inhibition,-,0.8673
CC[Pb](CC)(CC)CC,CYP2C19 inhibition,-,0.8731
CC[Pb](CC)(CC)CC,CYP2D6 inhibition,-,0.9463
CC[Pb](CC)(CC)CC,CYP1A2 inhibition,-,0.8262
CC[Pb](CC)(CC)CC,CYP2C8 inhibition,-,0.9926
CC[Pb](CC)(CC)CC,CYP inhibitory promiscuity,-,0.9012
CC[Pb](CC)(CC)CC,UGT catelyzed,-,0
CC[Pb](CC)(CC)CC,Carcinogenicity (binary),+,0.57
CC[Pb](CC)(CC)CC,Carcinogenicity (trinary),Non-required,0.5685
CC[Pb](CC)(CC)CC,Eye corrosion,+,0.9594
CC[Pb](CC)(CC)CC,Eye irritation,+,1
CC[Pb](CC)(CC)CC,Skin irritation,+,0.7602
CC[Pb](CC)(CC)CC,Skin corrosion,+,0.8218
CC[Pb](CC)(CC)CC,Ames mutagenesis,-,0.95
CC[Pb](CC)(CC)CC,Human Ether-a-go-go-Related Gene inhibition,-,0.8027
CC[Pb](CC)(CC)CC,Micronuclear,-,0.93
CC[Pb](CC)(CC)CC,Hepatotoxicity,+,0.7002
CC[Pb](CC)(CC)CC,skin sensitisation,-,0.5788
CC[Pb](CC)(CC)CC,Respiratory toxicity,-,0.7889
CC[Pb](CC)(CC)CC,Reproductive toxicity,-,0.8333
CC[Pb](CC)(CC)CC,Mitochondrial toxicity,+,0.5336
CC[Pb](CC)(CC)CC,Nephrotoxicity,+,0.5339
CC[Pb](CC)(CC)CC,Acute Oral Toxicity (c),III,0.7112
CC[Pb](CC)(CC)CC,Estrogen receptor binding,-,0.8982
CC[Pb](CC)(CC)CC,Androgen receptor binding,-,0.9108
CC[Pb](CC)(CC)CC,Thyroid receptor binding,-,0.8788
CC[Pb](CC)(CC)CC,Glucocorticoid receptor binding,-,0.9215
CC[Pb](CC)(CC)CC,Aromatase binding,-,0.8079
CC[Pb](CC)(CC)CC,PPAR gamma,-,0.8596
CC[Pb](CC)(CC)CC,Honey bee toxicity,-,0.9494
CC[Pb](CC)(CC)CC,Biodegradation,-,0.625
CC[Pb](CC)(CC)CC,Crustacea aquatic toxicity,-,0.67
CC[Pb](CC)(CC)CC,Fish aquatic toxicity,-,0.3767
CC[Pb](CC)(CC)CC,ADMET predicted profile --- Regressions,Value,Unit
CC[Pb](CC)(CC)CC,Water solubility,-2.393,logS
CC[Pb](CC)(CC)CC,Plasma protein binding,0.349,100%
CC[Pb](CC)(CC)CC,Acute Oral Toxicity,2.812,log(1/(mol/kg))
CC[Pb](CC)(CC)CC,Tetrahymena pyriformis,-0.66,pIGC50 (ug/L)
,  ,,
CCCC(C)C,Human Intestinal Absorption,+,0.9926
CCCC(C)C,Caco-2,+,0.7315
CCCC(C)C,Blood Brain Barrier,+,1
CCCC(C)C,Human oral bioavailability,+,0.8571
CCCC(C)C,Subcellular localzation,Lysosomes,0.3807
CCCC(C)C,OATP2B1 inhibitior,-,0.8589
CCCC(C)C,OATP1B1 inhibitior,+,0.9666
CCCC(C)C,OATP1B3 inhibitior,+,0.9477
CCCC(C)C,MATE1 inhibitior,-,0.9
CCCC(C)C,OCT2 inhibitior,-,0.85
CCCC(C)C,BSEP inhibitior,-,0.9613
CCCC(C)C,P-glycoprotein inhibitior,-,0.9852
CCCC(C)C,P-glycoprotein substrate,-,0.9361
CCCC(C)C,CYP3A4 substrate,-,0.8039
CCCC(C)C,CYP2C9 substrate,-,0.8153
CCCC(C)C,CYP2D6 substrate,-,0.7243
CCCC(C)C,CYP3A4 inhibition,-,0.9891
CCCC(C)C,CYP2C9 inhibition,-,0.9473
CCCC(C)C,CYP2C19 inhibition,-,0.955
CCCC(C)C,CYP2D6 inhibition,-,0.9521
CCCC(C)C,CYP1A2 inhibition,-,0.7912
CCCC(C)C,CYP2C8 inhibition,-,0.9971
CCCC(C)C,CYP inhibitory promiscuity,-,0.8572
CCCC(C)C,UGT catelyzed,-,0
CCCC(C)C,Carcinogenicity (binary),-,0.53
CCCC(C)C,Carcinogenicity (trinary),Non-required,0.5691
CCCC(C)C,Eye corrosion,+,0.9927
CCCC(C)C,Eye irritation,+,0.9968
CCCC(C)C,Skin irritation,+,0.8701
CCCC(C)C,Skin corrosion,-,0.9554
CCCC(C)C,Ames mutagenesis,-,0.94
CCCC(C)C,Human Ether-a-go-go-Related Gene inhibition,-,0.752
CCCC(C)C,Micronuclear,-,1
CCCC(C)C,Hepatotoxicity,+,0.8016
CCCC(C)C,skin sensitisation,+,0.9037
CCCC(C)C,Respiratory toxicity,+,0.6222
CCCC(C)C,Reproductive toxicity,-,0.7333
CCCC(C)C,Mitochondrial toxicity,+,0.9
CCCC(C)C,Nephrotoxicity,+,0.5099
CCCC(C)C,Acute Oral Toxicity (c),III,0.5296
CCCC(C)C,Estrogen receptor binding,-,0.9352
CCCC(C)C,Androgen receptor binding,-,0.9469
CCCC(C)C,Thyroid receptor binding,-,0.8749
CCCC(C)C,Glucocorticoid receptor binding,-,0.9504
CCCC(C)C,Aromatase binding,-,0.8984
CCCC(C)C,PPAR gamma,-,0.9233
CCCC(C)C,Honey bee toxicity,-,0.9645
CCCC(C)C,Biodegradation,+,0.975
CCCC(C)C,Crustacea aquatic toxicity,-,0.62
CCCC(C)C,Fish aquatic toxicity,+,0.8565
CCCC(C)C,ADMET predicted profile --- Regressions,Value,Unit
CCCC(C)C,Water solubility,-3.973,logS
CCCC(C)C,Plasma protein binding,1.138,100%
CCCC(C)C,Acute Oral Toxicity,0.95,log(1/(mol/kg))
CCCC(C)C,Tetrahymena pyriformis,-0.595,pIGC50 (ug/L)
,  ,,
CCCN,Human Intestinal Absorption,+,0.992
CCCN,Caco-2,+,0.8255
CCCN,Blood Brain Barrier,+,1
CCCN,Human oral bioavailability,+,0.8857
CCCN,Subcellular localzation,Lysosomes,0.9477
CCCN,OATP2B1 inhibitior,-,0.8695
CCCN,OATP1B1 inhibitior,+,0.9703
CCCN,OATP1B3 inhibitior,+,0.9504
CCCN,MATE1 inhibitior,-,0.88
CCCN,OCT2 inhibitior,-,0.7
CCCN,BSEP inhibitior,-,0.9491
CCCN,P-glycoprotein inhibitior,-,0.986
CCCN,P-glycoprotein substrate,-,0.9557
CCCN,CYP3A4 substrate,-,0.8596
CCCN,CYP2C9 substrate,-,1
CCCN,CYP2D6 substrate,+,0.5
CCCN,CYP3A4 inhibition,-,0.9421
CCCN,CYP2C9 inhibition,-,0.9092
CCCN,CYP2C19 inhibition,-,0.9101
CCCN,CYP2D6 inhibition,-,0.8129
CCCN,CYP1A2 inhibition,-,0.7175
CCCN,CYP2C8 inhibition,-,0.9812
CCCN,CYP inhibitory promiscuity,-,0.8682
CCCN,UGT catelyzed,-,0
CCCN,Carcinogenicity (binary),+,0.53
CCCN,Carcinogenicity (trinary),Non-required,0.6854
CCCN,Eye corrosion,+,1
CCCN,Eye irritation,+,0.9699
CCCN,Skin irritation,+,0.9021
CCCN,Skin corrosion,+,0.9851
CCCN,Ames mutagenesis,-,0.9025
CCCN,Human Ether-a-go-go-Related Gene inhibition,-,0.7713
CCCN,Micronuclear,-,0.91
CCCN,Hepatotoxicity,+,0.6199
CCCN,skin sensitisation,-,0.5682
CCCN,Respiratory toxicity,+,0.6444
CCCN,Reproductive toxicity,-,0.6667
CCCN,Mitochondrial toxicity,+,0.6625
CCCN,Nephrotoxicity,+,0.5466
CCCN,Acute Oral Toxicity (c),II,0.7849
CCCN,Estrogen receptor binding,-,0.891
CCCN,Androgen receptor binding,-,0.9404
CCCN,Thyroid receptor binding,-,0.8615
CCCN,Glucocorticoid receptor binding,-,0.9194
CCCN,Aromatase binding,-,0.9196
CCCN,PPAR gamma,-,0.8915
CCCN,Honey bee toxicity,-,0.9821
CCCN,Biodegradation,+,0.9
CCCN,Crustacea aquatic toxicity,-,0.87
CCCN,Fish aquatic toxicity,-,0.914
CCCN,Water solubility,0.184,logS
CCCN,Plasma protein binding,0.379,1
CCCN,Acute Oral Toxicity,2.15,log(1/(mol/kg))
CCCN,Tetrahymena pyriformis,-0.681,pIGC50 (ug/L)
,,,
CCC(=O)OCC(C)C,Human Intestinal Absorption,+,0.9954
CCC(=O)OCC(C)C,Caco-2,+,0.7787
CCC(=O)OCC(C)C,Blood Brain Barrier,+,0.95
CCC(=O)OCC(C)C,Human oral bioavailability,+,0.5857
CCC(=O)OCC(C)C,Subcellular localzation,Mitochondria,0.7148
CCC(=O)OCC(C)C,OATP2B1 inhibitior,-,0.8379
CCC(=O)OCC(C)C,OATP1B1 inhibitior,+,0.9498
CCC(=O)OCC(C)C,OATP1B3 inhibitior,+,0.9413
CCC(=O)OCC(C)C,MATE1 inhibitior,-,0.86
CCC(=O)OCC(C)C,OCT2 inhibitior,-,0.925
CCC(=O)OCC(C)C,BSEP inhibitior,-,0.857
CCC(=O)OCC(C)C,P-glycoprotein inhibitior,-,0.9734
CCC(=O)OCC(C)C,P-glycoprotein substrate,-,0.9667
CCC(=O)OCC(C)C,CYP3A4 substrate,-,0.6723
CCC(=O)OCC(C)C,CYP2C9 substrate,+,0.5942
CCC(=O)OCC(C)C,CYP2D6 substrate,-,0.8718
CCC(=O)OCC(C)C,CYP3A4 inhibition,-,0.9569
CCC(=O)OCC(C)C,CYP2C9 inhibition,-,0.9157
CCC(=O)OCC(C)C,CYP2C19 inhibition,-,0.9333
CCC(=O)OCC(C)C,CYP2D6 inhibition,-,0.9388
CCC(=O)OCC(C)C,CYP1A2 inhibition,-,0.7339
CCC(=O)OCC(C)C,CYP2C8 inhibition,-,0.988
CCC(=O)OCC(C)C,CYP inhibitory promiscuity,-,0.8492
CCC(=O)OCC(C)C,UGT catelyzed,-,0
CCC(=O)OCC(C)C,Carcinogenicity (binary),+,0.56
CCC(=O)OCC(C)C,Carcinogenicity (trinary),Warning,0.5386
CCC(=O)OCC(C)C,Eye corrosion,+,0.9748
CCC(=O)OCC(C)C,Eye irritation,+,0.9864
CCC(=O)OCC(C)C,Skin irritation,-,0.6793
CCC(=O)OCC(C)C,Skin corrosion,-,0.9856
CCC(=O)OCC(C)C,Ames mutagenesis,-,0.96
CCC(=O)OCC(C)C,Human Ether-a-go-go-Related Gene inhibition,-,0.7062
CCC(=O)OCC(C)C,Micronuclear,-,0.97
CCC(=O)OCC(C)C,Hepatotoxicity,-,0.5875
CCC(=O)OCC(C)C,skin sensitisation,+,0.7223
CCC(=O)OCC(C)C,Respiratory toxicity,-,0.7889
CCC(=O)OCC(C)C,Reproductive toxicity,-,0.9667
CCC(=O)OCC(C)C,Mitochondrial toxicity,-,1
CCC(=O)OCC(C)C,Nephrotoxicity,-,0.6981
CCC(=O)OCC(C)C,Acute Oral Toxicity (c),III,0.8141
CCC(=O)OCC(C)C,Estrogen receptor binding,-,0.9682
CCC(=O)OCC(C)C,Androgen receptor binding,-,0.9223
CCC(=O)OCC(C)C,Thyroid receptor binding,-,0.9255
CCC(=O)OCC(C)C,Glucocorticoid receptor binding,-,0.9331
CCC(=O)OCC(C)C,Aromatase binding,-,0.8907
CCC(=O)OCC(C)C,PPAR gamma,-,0.9237
CCC(=O)OCC(C)C,Honey bee toxicity,-,0.953
CCC(=O)OCC(C)C,Biodegradation,+,0.875
CCC(=O)OCC(C)C,Crustacea aquatic toxicity,-,0.7255
CCC(=O)OCC(C)C,Fish aquatic toxicity,+,0.8741
CCC(=O)OCC(C)C,ADMET predicted profile --- Regressions,Value,Unit
CCC(=O)OCC(C)C,Water solubility,-1.827,logS
CCC(=O)OCC(C)C,Plasma protein binding,0.453,100%
CCC(=O)OCC(C)C,Acute Oral Toxicity,1.244,log(1/(mol/kg))
CCC(=O)OCC(C)C,Tetrahymena pyriformis,-0.663,pIGC50 (ug/L)
,  ,,
CCSC#N,Human Intestinal Absorption,+,0.9891
CCSC#N,Caco-2,+,0.5666
CCSC#N,Blood Brain Barrier,+,0.95
CCSC#N,Human oral bioavailability,+,0.7857
CCSC#N,Subcellular localzation,Lysosomes,0.556
CCSC#N,OATP2B1 inhibitior,-,0.8697
CCSC#N,OATP1B1 inhibitior,+,0.9492
CCSC#N,OATP1B3 inhibitior,+,0.9539
CCSC#N,MATE1 inhibitior,-,0.98
CCSC#N,OCT2 inhibitior,-,0.925
CCSC#N,BSEP inhibitior,-,0.8884
CCSC#N,P-glycoprotein inhibitior,-,0.9862
CCSC#N,P-glycoprotein substrate,-,0.9659
CCSC#N,CYP3A4 substrate,-,0.7518
CCSC#N,CYP2C9 substrate,-,0.8
CCSC#N,CYP2D6 substrate,-,0.7695
CCSC#N,CYP3A4 inhibition,-,0.9667
CCSC#N,CYP2C9 inhibition,-,0.7978
CCSC#N,CYP2C19 inhibition,-,0.8005
CCSC#N,CYP2D6 inhibition,-,0.9165
CCSC#N,CYP1A2 inhibition,-,0.5375
CCSC#N,CYP2C8 inhibition,-,0.9717
CCSC#N,CYP inhibitory promiscuity,-,0.6095
CCSC#N,UGT catelyzed,-,0
CCSC#N,Carcinogenicity (binary),+,0.64
CCSC#N,Carcinogenicity (trinary),Non-required,0.7069
CCSC#N,Eye corrosion,+,0.9944
CCSC#N,Eye irritation,+,0.9904
CCSC#N,Skin irritation,+,0.8676
CCSC#N,Skin corrosion,+,0.637
CCSC#N,Ames mutagenesis,-,0.88
CCSC#N,Human Ether-a-go-go-Related Gene inhibition,-,0.7332
CCSC#N,Micronuclear,-,0.74
CCSC#N,Hepatotoxicity,+,0.8324
CCSC#N,skin sensitisation,+,0.7894
CCSC#N,Respiratory toxicity,-,0.5556
CCSC#N,Reproductive toxicity,-,0.6444
CCSC#N,Mitochondrial toxicity,-,0.85
CCSC#N,Nephrotoxicity,+,0.7558
CCSC#N,Acute Oral Toxicity (c),III,0.4243
CCSC#N,Estrogen receptor binding,-,0.9062
CCSC#N,Androgen receptor binding,-,0.9426
CCSC#N,Thyroid receptor binding,-,0.8509
CCSC#N,Glucocorticoid receptor binding,-,0.8381
CCSC#N,Aromatase binding,-,0.863
CCSC#N,PPAR gamma,-,0.848
CCSC#N,Honey bee toxicity,-,0.7311
CCSC#N,Biodegradation,-,0.525
CCSC#N,Crustacea aquatic toxicity,+,0.64
CCSC#N,Fish aquatic toxicity,-,0.529
CCSC#N,ADMET predicted profile --- Regressions,Value,Unit
CCSC#N,Water solubility,-0.188,logS
CCSC#N,Plasma protein binding,0.365,100%
CCSC#N,Acute Oral Toxicity,2.922,log(1/(mol/kg))
CCSC#N,Tetrahymena pyriformis,0.569,pIGC50 (ug/L)
,  ,,
C(CBr)Br,Human Intestinal Absorption,+,0.9716
C(CBr)Br,Caco-2,+,0.6466
C(CBr)Br,Blood Brain Barrier,+,0.975
C(CBr)Br,Human oral bioavailability,+,0.7714
C(CBr)Br,Subcellular localzation,Lysosomes,0.5048
C(CBr)Br,OATP2B1 inhibitior,-,0.8723
C(CBr)Br,OATP1B1 inhibitior,+,0.9712
C(CBr)Br,OATP1B3 inhibitior,+,0.9544
C(CBr)Br,MATE1 inhibitior,-,1
C(CBr)Br,OCT2 inhibitior,-,0.925
C(CBr)Br,BSEP inhibitior,-,0.9514
C(CBr)Br,P-glycoprotein inhibitior,-,0.9862
C(CBr)Br,P-glycoprotein substrate,-,0.994
C(CBr)Br,CYP3A4 substrate,-,0.8431
C(CBr)Br,CYP2C9 substrate,-,0.5774
C(CBr)Br,CYP2D6 substrate,-,0.7501
C(CBr)Br,CYP3A4 inhibition,-,0.9705
C(CBr)Br,CYP2C9 inhibition,-,0.8624
C(CBr)Br,CYP2C19 inhibition,-,0.8449
C(CBr)Br,CYP2D6 inhibition,-,0.9592
C(CBr)Br,CYP1A2 inhibition,-,0.7368
C(CBr)Br,CYP2C8 inhibition,-,0.9928
C(CBr)Br,CYP inhibitory promiscuity,-,0.8243
C(CBr)Br,UGT catelyzed,-,0
C(CBr)Br,Carcinogenicity (binary),+,0.5378
C(CBr)Br,Carcinogenicity (trinary),Danger,0.5843
C(CBr)Br,Eye corrosion,+,1
C(CBr)Br,Eye irritation,+,0.9795
C(CBr)Br,Skin irritation,+,0.911
C(CBr)Br,Skin corrosion,-,0.6647
C(CBr)Br,Ames mutagenesis,+,0.91
C(CBr)Br,Human Ether-a-go-go-Related Gene inhibition,-,0.7509
C(CBr)Br,Micronuclear,-,0.96
C(CBr)Br,Hepatotoxicity,+,0.975
C(CBr)Br,skin sensitisation,-,0.6449
C(CBr)Br,Respiratory toxicity,-,0.9556
C(CBr)Br,Reproductive toxicity,-,0.5556
C(CBr)Br,Mitochondrial toxicity,-,0.9125
C(CBr)Br,Nephrotoxicity,+,0.5997
C(CBr)Br,Acute Oral Toxicity (c),II,0.7429
C(CBr)Br,Estrogen receptor binding,-,0.9358
C(CBr)Br,Androgen receptor binding,-,0.9627
C(CBr)Br,Thyroid receptor binding,-,0.8795
C(CBr)Br,Glucocorticoid receptor binding,-,0.9187
C(CBr)Br,Aromatase binding,-,0.9038
C(CBr)Br,PPAR gamma,-,0.9353
C(CBr)Br,Honey bee toxicity,-,0.7749
C(CBr)Br,Biodegradation,-,0.925
C(CBr)Br,Crustacea aquatic toxicity,-,0.52
C(CBr)Br,Fish aquatic toxicity,-,0.6396
C(CBr)Br,ADMET predicted profile --- Regressions,Value,Unit
C(CBr)Br,Water solubility,-1.742,logS
C(CBr)Br,Plasma protein binding,0.769,100%
C(CBr)Br,Acute Oral Toxicity,3.06,log(1/(mol/kg))
C(CBr)Br,Tetrahymena pyriformis,-0.208,pIGC50 (ug/L)
,  ,,
CC[Pb](CC)(CC)CC,Human Intestinal Absorption,+,0.8579
CC[Pb](CC)(CC)CC,Caco-2,+,0.7426
CC[Pb](CC)(CC)CC,Blood Brain Barrier,+,0.875
CC[Pb](CC)(CC)CC,Human oral bioavailability,+,0.7571
CC[Pb](CC)(CC)CC,Subcellular localzation,Lysosomes,0.6641
CC[Pb](CC)(CC)CC,OATP2B1 inhibitior,-,0.861
CC[Pb](CC)(CC)CC,OATP1B1 inhibitior,+,0.9548
CC[Pb](CC)(CC)CC,OATP1B3 inhibitior,+,0.9466
CC[Pb](CC)(CC)CC,MATE1 inhibitior,-,0.98
CC[Pb](CC)(CC)CC,OCT2 inhibitior,-,0.775
CC[Pb](CC)(CC)CC,BSEP inhibitior,-,0.9425
CC[Pb](CC)(CC)CC,P-glycoprotein inhibitior,-,0.985
CC[Pb](CC)(CC)CC,P-glycoprotein substrate,-,0.9802
CC[Pb](CC)(CC)CC,CYP3A4 substrate,-,0.7948
CC[Pb](CC)(CC)CC,CYP2C9 substrate,-,0.8078
CC[Pb](CC)(CC)CC,CYP2D6 substrate,-,0.781
CC[Pb](CC)(CC)CC,CYP3A4 inhibition,-,0.9683
CC[Pb](CC)(CC)CC,CYP2C9 inhibition,-,0.8673
CC[Pb](CC)(CC)CC,CYP2C19 inhibition,-,0.8731
CC[Pb](CC)(CC)CC,CYP2D6 inhibition,-,0.9463
CC[Pb](CC)(CC)CC,CYP1A2 inhibition,-,0.8262
CC[Pb](CC)(CC)CC,CYP2C8 inhibition,-,0.9926
CC[Pb](CC)(CC)CC,CYP inhibitory promiscuity,-,0.9012
CC[Pb](CC)(CC)CC,UGT catelyzed,-,0
CC[Pb](CC)(CC)CC,Carcinogenicity (binary),+,0.57
CC[Pb](CC)(CC)CC,Carcinogenicity (trinary),Non-required,0.5685
CC[Pb](CC)(CC)CC,Eye corrosion,+,0.9594
CC[Pb](CC)(CC)CC,Eye irritation,+,1
CC[Pb](CC)(CC)CC,Skin irritation,+,0.7602
CC[Pb](CC)(CC)CC,Skin corrosion,+,0.8218
CC[Pb](CC)(CC)CC,Ames mutagenesis,-,0.95
CC[Pb](CC)(CC)CC,Human Ether-a-go-go-Related Gene inhibition,-,0.8027
CC[Pb](CC)(CC)CC,Micronuclear,-,0.93
CC[Pb](CC)(CC)CC,Hepatotoxicity,+,0.7002
CC[Pb](CC)(CC)CC,skin sensitisation,-,0.5788
CC[Pb](CC)(CC)CC,Respiratory toxicity,-,0.7889
CC[Pb](CC)(CC)CC,Reproductive toxicity,-,0.8333
CC[Pb](CC)(CC)CC,Mitochondrial toxicity,+,0.5336
CC[Pb](CC)(CC)CC,Nephrotoxicity,+,0.5339
CC[Pb](CC)(CC)CC,Acute Oral Toxicity (c),III,0.7112
CC[Pb](CC)(CC)CC,Estrogen receptor binding,-,0.8982
CC[Pb](CC)(CC)CC,Androgen receptor binding,-,0.9108
CC[Pb](CC)(CC)CC,Thyroid receptor binding,-,0.8788
CC[Pb](CC)(CC)CC,Glucocorticoid receptor binding,-,0.9215
CC[Pb](CC)(CC)CC,Aromatase binding,-,0.8079
CC[Pb](CC)(CC)CC,PPAR gamma,-,0.8596
CC[Pb](CC)(CC)CC,Honey bee toxicity,-,0.9494
CC[Pb](CC)(CC)CC,Biodegradation,-,0.625
CC[Pb](CC)(CC)CC,Crustacea aquatic toxicity,-,0.67
CC[Pb](CC)(CC)CC,Fish aquatic toxicity,-,0.3767
CC[Pb](CC)(CC)CC,ADMET predicted profile --- Regressions,Value,Unit
CC[Pb](CC)(CC)CC,Water solubility,-2.393,logS
CC[Pb](CC)(CC)CC,Plasma protein binding,0.349,100%
CC[Pb](CC)(CC)CC,Acute Oral Toxicity,2.812,log(1/(mol/kg))
CC[Pb](CC)(CC)CC,Tetrahymena pyriformis,-0.66,pIGC50 (ug/L)
,  ,,
C(CBr)Br,Human Intestinal Absorption,+,0.9716
C(CBr)Br,Caco-2,+,0.6466
C(CBr)Br,Blood Brain Barrier,+,0.975
C(CBr)Br,Human oral bioavailability,+,0.7714
C(CBr)Br,Subcellular localzation,Lysosomes,0.5048
C(CBr)Br,OATP2B1 inhibitior,-,0.8723
C(CBr)Br,OATP1B1 inhibitior,+,0.9712
C(CBr)Br,OATP1B3 inhibitior,+,0.9544
C(CBr)Br,MATE1 inhibitior,-,1
C(CBr)Br,OCT2 inhibitior,-,0.925
C(CBr)Br,BSEP inhibitior,-,0.9514
C(CBr)Br,P-glycoprotein inhibitior,-,0.9862
C(CBr)Br,P-glycoprotein substrate,-,0.994
C(CBr)Br,CYP3A4 substrate,-,0.8431
C(CBr)Br,CYP2C9 substrate,-,0.5774
C(CBr)Br,CYP2D6 substrate,-,0.7501
C(CBr)Br,CYP3A4 inhibition,-,0.9705
C(CBr)Br,CYP2C9 inhibition,-,0.8624
C(CBr)Br,CYP2C19 inhibition,-,0.8449
C(CBr)Br,CYP2D6 inhibition,-,0.9592
C(CBr)Br,CYP1A2 inhibition,-,0.7368
C(CBr)Br,CYP2C8 inhibition,-,0.9928
C(CBr)Br,CYP inhibitory promiscuity,-,0.8243
C(CBr)Br,UGT catelyzed,-,0
C(CBr)Br,Carcinogenicity (binary),+,0.5378
C(CBr)Br,Carcinogenicity (trinary),Danger,0.5843
C(CBr)Br,Eye corrosion,+,1
C(CBr)Br,Eye irritation,+,0.9795
C(CBr)Br,Skin irritation,+,0.911
C(CBr)Br,Skin corrosion,-,0.6647
C(CBr)Br,Ames mutagenesis,+,0.91
C(CBr)Br,Human Ether-a-go-go-Related Gene inhibition,-,0.7509
C(CBr)Br,Micronuclear,-,0.96
C(CBr)Br,Hepatotoxicity,+,0.975
C(CBr)Br,skin sensitisation,-,0.6449
C(CBr)Br,Respiratory toxicity,-,0.9556
C(CBr)Br,Reproductive toxicity,-,0.5556
C(CBr)Br,Mitochondrial toxicity,-,0.9125
C(CBr)Br,Nephrotoxicity,+,0.5997
C(CBr)Br,Acute Oral Toxicity (c),II,0.7429
C(CBr)Br,Estrogen receptor binding,-,0.9358
C(CBr)Br,Androgen receptor binding,-,0.9627
C(CBr)Br,Thyroid receptor binding,-,0.8795
C(CBr)Br,Glucocorticoid receptor binding,-,0.9187
C(CBr)Br,Aromatase binding,-,0.9038
C(CBr)Br,PPAR gamma,-,0.9353
C(CBr)Br,Honey bee toxicity,-,0.7749
C(CBr)Br,Biodegradation,-,0.925
C(CBr)Br,Crustacea aquatic toxicity,-,0.52
C(CBr)Br,Fish aquatic toxicity,-,0.6396
C(CBr)Br,ADMET predicted profile --- Regressions,Value,Unit
C(CBr)Br,Water solubility,-1.742,logS
C(CBr)Br,Plasma protein binding,0.769,100%
C(CBr)Br,Acute Oral Toxicity,3.06,log(1/(mol/kg))
C(CBr)Br,Tetrahymena pyriformis,-0.208,pIGC50 (ug/L)
,  ,,
CCl,ADMET predicted profile --- Classifications,Value,Probability
CCl,Human Intestinal Absorption,+,0.9902
CCl,Caco-2,+,0.5695
CCl,Blood Brain Barrier,+,1
CCl,Human oral bioavailability,+,0.8286
CCl,Subcellular localzation,Lysosomes,0.5239
CCl,OATP2B1 inhibitior,-,0.8765
CCl,OATP1B1 inhibitior,+,0.974
CCl,OATP1B3 inhibitior,+,0.9632
CCl,MATE1 inhibitior,-,0.9
CCl,OCT2 inhibitior,-,0.975
CCl,BSEP inhibitior,-,0.9386
CCl,P-glycoprotein inhibitior,-,0.9867
CCl,P-glycoprotein substrate,-,0.9964
CCl,CYP3A4 substrate,-,0.8021
CCl,CYP2C9 substrate,+,1
CCl,CYP2D6 substrate,-,0.7862
CCl,CYP3A4 inhibition,-,0.9799
CCl,CYP2C9 inhibition,-,0.9258
CCl,CYP2C19 inhibition,-,0.8822
CCl,CYP2D6 inhibition,-,0.9553
CCl,CYP1A2 inhibition,-,0.8097
CCl,CYP2C8 inhibition,-,0.9963
CCl,CYP inhibitory promiscuity,-,0.9273
CCl,UGT catelyzed,-,0
CCl,Carcinogenicity (binary),+,0.7073
CCl,Carcinogenicity (trinary),Non-required,0.6316
CCl,Eye corrosion,+,0.9743
CCl,Eye irritation,+,0.9847
CCl,Skin irritation,+,0.8974
CCl,Skin corrosion,+,0.8517
CCl,Ames mutagenesis,-,0.81
CCl,Human Ether-a-go-go-Related Gene inhibition,-,0.799
CCl,Micronuclear,-,0.87
CCl,Hepatotoxicity,+,0.95
CCl,skin sensitisation,+,0.5768
CCl,Respiratory toxicity,-,0.9889
CCl,Reproductive toxicity,-,0.6556
CCl,Mitochondrial toxicity,-,0.9875
CCl,Nephrotoxicity,+,0.7852
CCl,Acute Oral Toxicity (c),III,0.8029
CCl,Estrogen receptor binding,-,0.9257
CCl,Androgen receptor binding,-,0.9514
CCl,Thyroid receptor binding,-,0.8617
CCl,Glucocorticoid receptor binding,-,0.8944
CCl,Aromatase binding,-,0.8923
CCl,PPAR gamma,-,0.9113
CCl,Honey bee toxicity,-,0.8421
CCl,Biodegradation,+,0.65
CCl,Crustacea aquatic toxicity,-,0.5
CCl,Fish aquatic toxicity,-,0.6366
CCl,ADMET predicted profile --- Regressions,Value,Unit
CCl,Water solubility,-0.448,logS
CCl,Plasma protein binding,0.225,100%
CCl,Acute Oral Toxicity,1.678,log(1/(mol/kg))
CCl,Tetrahymena pyriformis,-1.707,pIGC50 (ug/L)
,  ,,
CCC(=O)OCC(C)C,Human Intestinal Absorption,+,0.9954
CCC(=O)OCC(C)C,Caco-2,+,0.7787
CCC(=O)OCC(C)C,Blood Brain Barrier,+,0.95
CCC(=O)OCC(C)C,Human oral bioavailability,+,0.5857
CCC(=O)OCC(C)C,Subcellular localzation,Mitochondria,0.7148
CCC(=O)OCC(C)C,OATP2B1 inhibitior,-,0.8379
CCC(=O)OCC(C)C,OATP1B1 inhibitior,+,0.9498
CCC(=O)OCC(C)C,OATP1B3 inhibitior,+,0.9413
CCC(=O)OCC(C)C,MATE1 inhibitior,-,0.86
CCC(=O)OCC(C)C,OCT2 inhibitior,-,0.925
CCC(=O)OCC(C)C,BSEP inhibitior,-,0.857
CCC(=O)OCC(C)C,P-glycoprotein inhibitior,-,0.9734
CCC(=O)OCC(C)C,P-glycoprotein substrate,-,0.9667
CCC(=O)OCC(C)C,CYP3A4 substrate,-,0.6723
CCC(=O)OCC(C)C,CYP2C9 substrate,+,0.5942
CCC(=O)OCC(C)C,CYP2D6 substrate,-,0.8718
CCC(=O)OCC(C)C,CYP3A4 inhibition,-,0.9569
CCC(=O)OCC(C)C,CYP2C9 inhibition,-,0.9157
CCC(=O)OCC(C)C,CYP2C19 inhibition,-,0.9333
CCC(=O)OCC(C)C,CYP2D6 inhibition,-,0.9388
CCC(=O)OCC(C)C,CYP1A2 inhibition,-,0.7339
CCC(=O)OCC(C)C,CYP2C8 inhibition,-,0.988
CCC(=O)OCC(C)C,CYP inhibitory promiscuity,-,0.8492
CCC(=O)OCC(C)C,UGT catelyzed,-,0
CCC(=O)OCC(C)C,Carcinogenicity (binary),+,0.56
CCC(=O)OCC(C)C,Carcinogenicity (trinary),Warning,0.5386
CCC(=O)OCC(C)C,Eye corrosion,+,0.9748
CCC(=O)OCC(C)C,Eye irritation,+,0.9864
CCC(=O)OCC(C)C,Skin irritation,-,0.6793
CCC(=O)OCC(C)C,Skin corrosion,-,0.9856
CCC(=O)OCC(C)C,Ames mutagenesis,-,0.96
CCC(=O)OCC(C)C,Human Ether-a-go-go-Related Gene inhibition,-,0.7062
CCC(=O)OCC(C)C,Micronuclear,-,0.97
CCC(=O)OCC(C)C,Hepatotoxicity,-,0.5875
CCC(=O)OCC(C)C,skin sensitisation,+,0.7223
CCC(=O)OCC(C)C,Respiratory toxicity,-,0.7889
CCC(=O)OCC(C)C,Reproductive toxicity,-,0.9667
CCC(=O)OCC(C)C,Mitochondrial toxicity,-,1
CCC(=O)OCC(C)C,Nephrotoxicity,-,0.6981
CCC(=O)OCC(C)C,Acute Oral Toxicity (c),III,0.8141
CCC(=O)OCC(C)C,Estrogen receptor binding,-,0.9682
CCC(=O)OCC(C)C,Androgen receptor binding,-,0.9223
CCC(=O)OCC(C)C,Thyroid receptor binding,-,0.9255
CCC(=O)OCC(C)C,Glucocorticoid receptor binding,-,0.9331
CCC(=O)OCC(C)C,Aromatase binding,-,0.8907
CCC(=O)OCC(C)C,PPAR gamma,-,0.9237
CCC(=O)OCC(C)C,Honey bee toxicity,-,0.953
CCC(=O)OCC(C)C,Biodegradation,+,0.875
CCC(=O)OCC(C)C,Crustacea aquatic toxicity,-,0.7255
CCC(=O)OCC(C)C,Fish aquatic toxicity,+,0.8741
CCC(=O)OCC(C)C,ADMET predicted profile --- Regressions,Value,Unit
CCC(=O)OCC(C)C,Water solubility,-1.827,logS
CCC(=O)OCC(C)C,Plasma protein binding,0.453,100%
CCC(=O)OCC(C)C,Acute Oral Toxicity,1.244,log(1/(mol/kg))
CCC(=O)OCC(C)C,Tetrahymena pyriformis,-0.663,pIGC50 (ug/L)
,  ,,
CCCN,Human Intestinal Absorption,+,0.992
CCCN,Caco-2,+,0.8255
CCCN,Blood Brain Barrier,+,1
CCCN,Human oral bioavailability,+,0.8857
CCCN,Subcellular localzation,Lysosomes,0.9477
CCCN,OATP2B1 inhibitior,-,0.8695
CCCN,OATP1B1 inhibitior,+,0.9703
CCCN,OATP1B3 inhibitior,+,0.9504
CCCN,MATE1 inhibitior,-,0.88
CCCN,OCT2 inhibitior,-,0.7
CCCN,BSEP inhibitior,-,0.9491
CCCN,P-glycoprotein inhibitior,-,0.986
CCCN,P-glycoprotein substrate,-,0.9557
CCCN,CYP3A4 substrate,-,0.8596
CCCN,CYP2C9 substrate,-,1
CCCN,CYP2D6 substrate,+,0.5
CCCN,CYP3A4 inhibition,-,0.9421
CCCN,CYP2C9 inhibition,-,0.9092
CCCN,CYP2C19 inhibition,-,0.9101
CCCN,CYP2D6 inhibition,-,0.8129
CCCN,CYP1A2 inhibition,-,0.7175
CCCN,CYP2C8 inhibition,-,0.9812
CCCN,CYP inhibitory promiscuity,-,0.8682
CCCN,UGT catelyzed,-,0
CCCN,Carcinogenicity (binary),+,0.53
CCCN,Carcinogenicity (trinary),Non-required,0.6854
CCCN,Eye corrosion,+,1
CCCN,Eye irritation,+,0.9699
CCCN,Skin irritation,+,0.9021
CCCN,Skin corrosion,+,0.9851
CCCN,Ames mutagenesis,-,0.9025
CCCN,Human Ether-a-go-go-Related Gene inhibition,-,0.7713
CCCN,Micronuclear,-,0.91
CCCN,Hepatotoxicity,+,0.6199
CCCN,skin sensitisation,-,0.5682
CCCN,Respiratory toxicity,+,0.6444
CCCN,Reproductive toxicity,-,0.6667
CCCN,Mitochondrial toxicity,+,0.6625
CCCN,Nephrotoxicity,+,0.5466
CCCN,Acute Oral Toxicity (c),II,0.7849
CCCN,Estrogen receptor binding,-,0.891
CCCN,Androgen receptor binding,-,0.9404
CCCN,Thyroid receptor binding,-,0.8615
CCCN,Glucocorticoid receptor binding,-,0.9194
CCCN,Aromatase binding,-,0.9196
CCCN,PPAR gamma,-,0.8915
CCCN,Honey bee toxicity,-,0.9821
CCCN,Biodegradation,+,0.9
CCCN,Crustacea aquatic toxicity,-,0.87
CCCN,Fish aquatic toxicity,-,0.914
CCCN,ADMET predicted profile --- Regressions,Value,Unit
CCCN,Water solubility,0.184,logS
CCCN,Plasma protein binding,0.379,100%
CCCN,Acute Oral Toxicity,2.15,log(1/(mol/kg))
CCCN,Tetrahymena pyriformis,-0.681,pIGC50 (ug/L)
,  ,,
CCNCC,Human Intestinal Absorption,+,0.9861
CCNCC,Caco-2,+,0.7951
CCNCC,Blood Brain Barrier,+,0.925
CCNCC,Human oral bioavailability,+,0.8429
CCNCC,Subcellular localzation,Lysosomes,0.9326
CCNCC,OATP2B1 inhibitior,-,0.8662
CCNCC,OATP1B1 inhibitior,+,0.9427
CCNCC,OATP1B3 inhibitior,+,0.9518
CCNCC,MATE1 inhibitior,-,0.94
CCNCC,OCT2 inhibitior,-,0.7
CCNCC,BSEP inhibitior,-,0.9413
CCNCC,P-glycoprotein inhibitior,-,0.9865
CCNCC,P-glycoprotein substrate,-,0.9433
CCNCC,CYP3A4 substrate,-,0.8177
CCNCC,CYP2C9 substrate,-,0.7927
CCNCC,CYP2D6 substrate,+,0.4648
CCNCC,CYP3A4 inhibition,-,0.9765
CCNCC,CYP2C9 inhibition,-,0.8768
CCNCC,CYP2C19 inhibition,-,0.9128
CCNCC,CYP2D6 inhibition,-,0.9131
CCNCC,CYP1A2 inhibition,-,0.7056
CCNCC,CYP2C8 inhibition,-,0.9873
CCNCC,CYP inhibitory promiscuity,-,0.8932
CCNCC,UGT catelyzed,-,0
CCNCC,Carcinogenicity (binary),+,0.55
CCNCC,Carcinogenicity (trinary),Non-required,0.6828
CCNCC,Eye corrosion,+,1
CCNCC,Eye irritation,+,0.9907
CCNCC,Skin irritation,+,0.8598
CCNCC,Skin corrosion,+,0.9671
CCNCC,Ames mutagenesis,-,0.98
CCNCC,Human Ether-a-go-go-Related Gene inhibition,-,0.829
CCNCC,Micronuclear,-,0.96
CCNCC,Hepatotoxicity,+,0.7752
CCNCC,skin sensitisation,+,0.581
CCNCC,Respiratory toxicity,-,0.9
CCNCC,Reproductive toxicity,-,0.9556
CCNCC,Mitochondrial toxicity,-,0.7375
CCNCC,Nephrotoxicity,+,0.6738
CCNCC,Acute Oral Toxicity (c),III,0.8473
CCNCC,Estrogen receptor binding,-,0.9457
CCNCC,Androgen receptor binding,-,0.9388
CCNCC,Thyroid receptor binding,-,0.8421
CCNCC,Glucocorticoid receptor binding,-,0.9454
CCNCC,Aromatase binding,-,0.9134
CCNCC,PPAR gamma,-,0.8979
CCNCC,Honey bee toxicity,-,0.9592
CCNCC,Biodegradation,+,0.75
CCNCC,Crustacea aquatic toxicity,-,0.72
CCNCC,Fish aquatic toxicity,-,0.8095
CCNCC,ADMET predicted profile --- Regressions,Value,Unit
CCNCC,Water solubility,0.391,logS
CCNCC,Plasma protein binding,0.244,100%
CCNCC,Acute Oral Toxicity,2.145,log(1/(mol/kg))
CCNCC,Tetrahymena pyriformis,-0.756,pIGC50 (ug/L)
,,,
CCCOC(=O)C,Human Intestinal Absorption,+,0.9965
CCCOC(=O)C,Caco-2,+,0.7992
CCCOC(=O)C,Blood Brain Barrier,+,0.95
CCCOC(=O)C,Human oral bioavailability,+,0.5714
CCCOC(=O)C,Subcellular localzation,Mitochondria,0.6303
CCCOC(=O)C,OATP2B1 inhibitior,-,0.8445
CCCOC(=O)C,OATP1B1 inhibitior,+,0.9569
CCCOC(=O)C,OATP1B3 inhibitior,+,0.9246
CCCOC(=O)C,MATE1 inhibitior,-,0.88
CCCOC(=O)C,OCT2 inhibitior,-,0.975
CCCOC(=O)C,BSEP inhibitior,-,0.8922
CCCOC(=O)C,P-glycoprotein inhibitior,-,0.9837
CCCOC(=O)C,P-glycoprotein substrate,-,0.984
CCCOC(=O)C,CYP3A4 substrate,-,0.7099
CCCOC(=O)C,CYP2C9 substrate,-,0.7977
CCCOC(=O)C,CYP2D6 substrate,-,0.8679
CCCOC(=O)C,CYP3A4 inhibition,-,0.9688
CCCOC(=O)C,CYP2C9 inhibition,-,0.9411
CCCOC(=O)C,CYP2C19 inhibition,-,0.9213
CCCOC(=O)C,CYP2D6 inhibition,-,0.9408
CCCOC(=O)C,CYP1A2 inhibition,+,0.5111
CCCOC(=O)C,CYP2C8 inhibition,-,0.9766
CCCOC(=O)C,CYP inhibitory promiscuity,-,0.8855
CCCOC(=O)C,UGT catelyzed,-,0
CCCOC(=O)C,Carcinogenicity (binary),-,0.6
CCCOC(=O)C,Carcinogenicity (trinary),Non-required,0.6127
CCCOC(=O)C,Eye corrosion,+,0.9901
CCCOC(=O)C,Eye irritation,+,0.9807
CCCOC(=O)C,Skin irritation,+,0.7942
CCCOC(=O)C,Skin corrosion,-,0.89
CCCOC(=O)C,Ames mutagenesis,-,0.84
CCCOC(=O)C,Human Ether-a-go-go-Related Gene inhibition,-,0.7911
CCCOC(=O)C,Micronuclear,-,1
CCCOC(=O)C,Hepatotoxicity,+,0.6
CCCOC(=O)C,skin sensitisation,+,0.6907
CCCOC(=O)C,Respiratory toxicity,-,0.9444
CCCOC(=O)C,Reproductive toxicity,-,0.9778
CCCOC(=O)C,Mitochondrial toxicity,-,1
CCCOC(=O)C,Nephrotoxicity,+,0.7701
CCCOC(=O)C,Acute Oral Toxicity (c),III,0.5153
CCCOC(=O)C,Estrogen receptor binding,-,0.9328
CCCOC(=O)C,Androgen receptor binding,-,0.8712
CCCOC(=O)C,Thyroid receptor binding,-,0.9362
CCCOC(=O)C,Glucocorticoid receptor binding,-,0.9593
CCCOC(=O)C,Aromatase binding,-,0.9212
CCCOC(=O)C,PPAR gamma,-,0.9075
CCCOC(=O)C,Honey bee toxicity,-,0.9754
CCCOC(=O)C,Biodegradation,+,1
CCCOC(=O)C,Crustacea aquatic toxicity,-,0.7632
CCCOC(=O)C,Fish aquatic toxicity,+,0.7179
CCCOC(=O)C,Water solubility,-1.085,logS
CCCOC(=O)C,Plasma protein binding,0.055,100%
CCCOC(=O)C,Acute Oral Toxicity,1.15,log(1/(mol/kg))
CCCOC(=O)C,Tetrahymena pyriformis,-1.303,pIGC50 (ug/L)
,,,
CC=C(C)C,Human Intestinal Absorption,+,0.9911
CC=C(C)C,Caco-2,+,0.6801
CC=C(C)C,Blood Brain Barrier,+,0.975
CC=C(C)C,Human oral bioavailability,+,0.5571
CC=C(C)C,Subcellular localzation,Lysosomes,0.4504
CC=C(C)C,OATP2B1 inhibitior,-,1
CC=C(C)C,OATP1B1 inhibitior,+,0.9466
CC=C(C)C,OATP1B3 inhibitior,+,0.9568
CC=C(C)C,MATE1 inhibitior,-,0.98
CC=C(C)C,OCT2 inhibitior,-,0.95
CC=C(C)C,BSEP inhibitior,-,0.8776
CC=C(C)C,P-glycoprotein inhibitior,-,0.9853
CC=C(C)C,P-glycoprotein substrate,-,0.9934
CC=C(C)C,CYP3A4 substrate,-,0.8118
CC=C(C)C,CYP2C9 substrate,-,0.7983
CC=C(C)C,CYP2D6 substrate,-,0.7996
CC=C(C)C,CYP3A4 inhibition,-,0.9436
CC=C(C)C,CYP2C9 inhibition,-,0.8927
CC=C(C)C,CYP2C19 inhibition,-,0.9075
CC=C(C)C,CYP2D6 inhibition,-,0.9281
CC=C(C)C,CYP1A2 inhibition,-,0.8718
CC=C(C)C,CYP2C8 inhibition,-,0.9979
CC=C(C)C,CYP inhibitory promiscuity,-,0.6843
CC=C(C)C,UGT catelyzed,-,0
CC=C(C)C,Carcinogenicity (binary),+,0.6683
CC=C(C)C,Carcinogenicity (trinary),Warning,0.61
CC=C(C)C,Eye corrosion,+,0.945
CC=C(C)C,Eye irritation,+,0.9932
CC=C(C)C,Skin irritation,+,0.8007
CC=C(C)C,Skin corrosion,-,0.7896
CC=C(C)C,Ames mutagenesis,-,0.88
CC=C(C)C,Human Ether-a-go-go-Related Gene inhibition,-,0.7777
CC=C(C)C,Micronuclear,-,0.97
CC=C(C)C,Hepatotoxicity,+,0.7
CC=C(C)C,skin sensitisation,+,0.8752
CC=C(C)C,Respiratory toxicity,-,0.9333
CC=C(C)C,Reproductive toxicity,-,0.9778
CC=C(C)C,Mitochondrial toxicity,-,0.5839
CC=C(C)C,Nephrotoxicity,+,0.6595
CC=C(C)C,Acute Oral Toxicity (c),III,0.8122
CC=C(C)C,Estrogen receptor binding,-,0.9398
CC=C(C)C,Androgen receptor binding,-,0.9455
CC=C(C)C,Thyroid receptor binding,-,0.8482
CC=C(C)C,Glucocorticoid receptor binding,-,0.8976
CC=C(C)C,Aromatase binding,-,0.8585
CC=C(C)C,PPAR gamma,-,0.8793
CC=C(C)C,Honey bee toxicity,-,0.8752
CC=C(C)C,Biodegradation,+,0.625
CC=C(C)C,Crustacea aquatic toxicity,-,0.71
CC=C(C)C,Fish aquatic toxicity,+,0.8634
CC=C(C)C,ADMET predicted profile --- Regressions,Value,Unit
CC=C(C)C,Water solubility,-2.622,logS
CC=C(C)C,Plasma protein binding,0.549,100%
CC=C(C)C,Acute Oral Toxicity,1.446,log(1/(mol/kg))
CC=C(C)C,Tetrahymena pyriformis,-0.673,pIGC50 (ug/L)
,,,
COC(=O)C=C,Human Intestinal Absorption,+,0.9944
COC(=O)C=C,Caco-2,+,0.8336
COC(=O)C=C,Blood Brain Barrier,+,0.925
COC(=O)C=C,Human oral bioavailability,-,0.5429
COC(=O)C=C,Subcellular localzation,Mitochondria,0.5194
COC(=O)C=C,OATP2B1 inhibitior,-,1
COC(=O)C=C,OATP1B1 inhibitior,+,0.9618
COC(=O)C=C,OATP1B3 inhibitior,+,0.9632
COC(=O)C=C,MATE1 inhibitior,-,0.8
COC(=O)C=C,OCT2 inhibitior,-,0.975
COC(=O)C=C,BSEP inhibitior,-,0.9378
COC(=O)C=C,P-glycoprotein inhibitior,-,0.9862
COC(=O)C=C,P-glycoprotein substrate,-,0.9912
COC(=O)C=C,CYP3A4 substrate,-,0.6781
COC(=O)C=C,CYP2C9 substrate,-,1
COC(=O)C=C,CYP2D6 substrate,-,0.879
COC(=O)C=C,CYP3A4 inhibition,-,0.9618
COC(=O)C=C,CYP2C9 inhibition,-,0.9376
COC(=O)C=C,CYP2C19 inhibition,-,0.9189
COC(=O)C=C,CYP2D6 inhibition,-,0.9735
COC(=O)C=C,CYP1A2 inhibition,-,0.8252
COC(=O)C=C,CYP2C8 inhibition,-,0.9789
COC(=O)C=C,CYP inhibitory promiscuity,-,0.937
COC(=O)C=C,UGT catelyzed,-,0
COC(=O)C=C,Carcinogenicity (binary),+,0.7027
COC(=O)C=C,Carcinogenicity (trinary),Non-required,0.618
COC(=O)C=C,Eye corrosion,+,0.9906
COC(=O)C=C,Eye irritation,+,0.9805
COC(=O)C=C,Skin irritation,+,0.8536
COC(=O)C=C,Skin corrosion,+,0.6524
COC(=O)C=C,Ames mutagenesis,-,0.96
COC(=O)C=C,Human Ether-a-go-go-Related Gene inhibition,-,0.7676
COC(=O)C=C,Micronuclear,-,0.83
COC(=O)C=C,Hepatotoxicity,+,0.5034
COC(=O)C=C,skin sensitisation,+,0.9333
COC(=O)C=C,Respiratory toxicity,-,0.9222
COC(=O)C=C,Reproductive toxicity,-,1
COC(=O)C=C,Mitochondrial toxicity,-,0.9625
COC(=O)C=C,Nephrotoxicity,+,0.7225
COC(=O)C=C,Acute Oral Toxicity (c),II,0.5547
COC(=O)C=C,Estrogen receptor binding,-,0.9139
COC(=O)C=C,Androgen receptor binding,-,0.7773
COC(=O)C=C,Thyroid receptor binding,-,0.8739
COC(=O)C=C,Glucocorticoid receptor binding,-,0.8139
COC(=O)C=C,Aromatase binding,-,0.8552
COC(=O)C=C,PPAR gamma,-,0.8946
COC(=O)C=C,Honey bee toxicity,-,0.7789
COC(=O)C=C,Biodegradation,+,0.8
COC(=O)C=C,Crustacea aquatic toxicity,-,0.78
COC(=O)C=C,Fish aquatic toxicity,+,0.7487
COC(=O)C=C,Water solubility,-0.283,logS
COC(=O)C=C,Plasma protein binding,0.239,1
COC(=O)C=C,Acute Oral Toxicity,2.279,log(1/(mol/kg))
COC(=O)C=C,Tetrahymena pyriformis,0.52,pIGC50 (ug/L)
,,,
CCOC(=O)CC(=O)OCC,Human Intestinal Absorption,+,0.9586
CCOC(=O)CC(=O)OCC,Caco-2,+,0.6836
CCOC(=O)CC(=O)OCC,Blood Brain Barrier,+,0.85
CCOC(=O)CC(=O)OCC,Human oral bioavailability,+,0.7
CCOC(=O)CC(=O)OCC,Subcellular localzation,Mitochondria,0.8085
CCOC(=O)CC(=O)OCC,OATP2B1 inhibitior,-,0.8499
CCOC(=O)CC(=O)OCC,OATP1B1 inhibitior,+,0.9696
CCOC(=O)CC(=O)OCC,OATP1B3 inhibitior,+,0.9604
CCOC(=O)CC(=O)OCC,MATE1 inhibitior,-,0.88
CCOC(=O)CC(=O)OCC,OCT2 inhibitior,-,0.9
CCOC(=O)CC(=O)OCC,BSEP inhibitior,-,0.897
CCOC(=O)CC(=O)OCC,P-glycoprotein inhibitior,-,0.9724
CCOC(=O)CC(=O)OCC,P-glycoprotein substrate,-,0.9941
CCOC(=O)CC(=O)OCC,CYP3A4 substrate,-,0.6841
CCOC(=O)CC(=O)OCC,CYP2C9 substrate,-,0.5886
CCOC(=O)CC(=O)OCC,CYP2D6 substrate,-,0.8689
CCOC(=O)CC(=O)OCC,CYP3A4 inhibition,-,0.9068
CCOC(=O)CC(=O)OCC,CYP2C9 inhibition,-,0.9025
CCOC(=O)CC(=O)OCC,CYP2C19 inhibition,-,0.8669
CCOC(=O)CC(=O)OCC,CYP2D6 inhibition,-,0.9199
CCOC(=O)CC(=O)OCC,CYP1A2 inhibition,-,0.8868
CCOC(=O)CC(=O)OCC,CYP2C8 inhibition,-,0.9775
CCOC(=O)CC(=O)OCC,CYP inhibitory promiscuity,-,0.8125
CCOC(=O)CC(=O)OCC,UGT catelyzed,-,0
CCOC(=O)CC(=O)OCC,Carcinogenicity (binary),-,0.5166
CCOC(=O)CC(=O)OCC,Carcinogenicity (trinary),Non-required,0.6261
CCOC(=O)CC(=O)OCC,Eye corrosion,+,0.9544
CCOC(=O)CC(=O)OCC,Eye irritation,+,0.992
CCOC(=O)CC(=O)OCC,Skin irritation,-,0.5959
CCOC(=O)CC(=O)OCC,Skin corrosion,-,0.7345
CCOC(=O)CC(=O)OCC,Ames mutagenesis,-,0.99
CCOC(=O)CC(=O)OCC,Human Ether-a-go-go-Related Gene inhibition,-,0.7694
CCOC(=O)CC(=O)OCC,Micronuclear,-,0.93
CCOC(=O)CC(=O)OCC,Hepatotoxicity,+,0.542
CCOC(=O)CC(=O)OCC,skin sensitisation,-,0.8239
CCOC(=O)CC(=O)OCC,Respiratory toxicity,-,0.9333
CCOC(=O)CC(=O)OCC,Reproductive toxicity,-,0.7889
CCOC(=O)CC(=O)OCC,Mitochondrial toxicity,-,0.9375
CCOC(=O)CC(=O)OCC,Nephrotoxicity,+,0.6491
CCOC(=O)CC(=O)OCC,Acute Oral Toxicity (c),IV,0.6271
CCOC(=O)CC(=O)OCC,Estrogen receptor binding,-,0.7862
CCOC(=O)CC(=O)OCC,Androgen receptor binding,-,0.9659
CCOC(=O)CC(=O)OCC,Thyroid receptor binding,-,0.9127
CCOC(=O)CC(=O)OCC,Glucocorticoid receptor binding,-,0.8719
CCOC(=O)CC(=O)OCC,Aromatase binding,-,0.9185
CCOC(=O)CC(=O)OCC,PPAR gamma,-,0.8884
CCOC(=O)CC(=O)OCC,Honey bee toxicity,-,0.955
CCOC(=O)CC(=O)OCC,Biodegradation,+,0.85
CCOC(=O)CC(=O)OCC,Crustacea aquatic toxicity,-,0.62
CCOC(=O)CC(=O)OCC,Fish aquatic toxicity,+,0.8572
CCOC(=O)CC(=O)OCC,Water solubility,-0.757,logS
CCOC(=O)CC(=O)OCC,Plasma protein binding,-0.058,100%
CCOC(=O)CC(=O)OCC,Acute Oral Toxicity,1.658,log(1/(mol/kg))
CCOC(=O)CC(=O)OCC,Tetrahymena pyriformis,-0.851,pIGC50 (ug/L)
,,,
CCCC(C)C,Human Intestinal Absorption,+,0.9926
CCCC(C)C,Caco-2,+,0.7315
CCCC(C)C,Blood Brain Barrier,+,1
CCCC(C)C,Human oral bioavailability,+,0.8571
CCCC(C)C,Subcellular localzation,Lysosomes,0.3807
CCCC(C)C,OATP2B1 inhibitior,-,0.8589
CCCC(C)C,OATP1B1 inhibitior,+,0.9666
CCCC(C)C,OATP1B3 inhibitior,+,0.9477
CCCC(C)C,MATE1 inhibitior,-,0.9
CCCC(C)C,OCT2 inhibitior,-,0.85
CCCC(C)C,BSEP inhibitior,-,0.9613
CCCC(C)C,P-glycoprotein inhibitior,-,0.9852
CCCC(C)C,P-glycoprotein substrate,-,0.9361
CCCC(C)C,CYP3A4 substrate,-,0.8039
CCCC(C)C,CYP2C9 substrate,-,0.8153
CCCC(C)C,CYP2D6 substrate,-,0.7243
CCCC(C)C,CYP3A4 inhibition,-,0.9891
CCCC(C)C,CYP2C9 inhibition,-,0.9473
CCCC(C)C,CYP2C19 inhibition,-,0.955
CCCC(C)C,CYP2D6 inhibition,-,0.9521
CCCC(C)C,CYP1A2 inhibition,-,0.7912
CCCC(C)C,CYP2C8 inhibition,-,0.9971
CCCC(C)C,CYP inhibitory promiscuity,-,0.8572
CCCC(C)C,UGT catelyzed,-,0
CCCC(C)C,Carcinogenicity (binary),-,0.53
CCCC(C)C,Carcinogenicity (trinary),Non-required,0.5691
CCCC(C)C,Eye corrosion,+,0.9927
CCCC(C)C,Eye irritation,+,0.9968
CCCC(C)C,Skin irritation,+,0.8701
CCCC(C)C,Skin corrosion,-,0.9554
CCCC(C)C,Ames mutagenesis,-,0.94
CCCC(C)C,Human Ether-a-go-go-Related Gene inhibition,-,0.752
CCCC(C)C,Micronuclear,-,1
CCCC(C)C,Hepatotoxicity,+,0.8016
CCCC(C)C,skin sensitisation,+,0.9037
CCCC(C)C,Respiratory toxicity,+,0.6222
CCCC(C)C,Reproductive toxicity,-,0.7333
CCCC(C)C,Mitochondrial toxicity,+,0.9
CCCC(C)C,Nephrotoxicity,+,0.5099
CCCC(C)C,Acute Oral Toxicity (c),III,0.5296
CCCC(C)C,Estrogen receptor binding,-,0.9352
CCCC(C)C,Androgen receptor binding,-,0.9469
CCCC(C)C,Thyroid receptor binding,-,0.8749
CCCC(C)C,Glucocorticoid receptor binding,-,0.9504
CCCC(C)C,Aromatase binding,-,0.8984
CCCC(C)C,PPAR gamma,-,0.9233
CCCC(C)C,Honey bee toxicity,-,0.9645
CCCC(C)C,Biodegradation,+,0.975
CCCC(C)C,Crustacea aquatic toxicity,-,0.62
CCCC(C)C,Fish aquatic toxicity,+,0.8565
CCCC(C)C,Water solubility,-3.973,logS
CCCC(C)C,Plasma protein binding,1.138,1
CCCC(C)C,Acute Oral Toxicity,0.95,log(1/(mol/kg))
CCCC(C)C,Tetrahymena pyriformis,-0.595,pIGC50 (ug/L)
,,,
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Human Intestinal Absorption,+,0.8529
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Caco-2,-,0.9373
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Blood Brain Barrier,+,0.625
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Human oral bioavailability,+,0.5571
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Subcellular localzation,Mitochondria,0.7995
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,OATP2B1 inhibitior,+,1
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,OATP1B1 inhibitior,-,0.5088
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,OATP1B3 inhibitior,+,0.8067
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,MATE1 inhibitior,-,0.9
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,OCT2 inhibitior,-,0.8859
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,BSEP inhibitior,+,0.9919
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,P-glycoprotein inhibitior,+,0.8392
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,P-glycoprotein substrate,+,0.9343
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CYP3A4 substrate,+,0.7664
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CYP2C9 substrate,+,0.6006
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CYP2D6 substrate,-,0.8925
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CYP3A4 inhibition,-,0.6675
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CYP2C9 inhibition,-,0.719
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CYP2C19 inhibition,-,0.6191
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CYP2D6 inhibition,-,0.9042
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CYP1A2 inhibition,-,0.8551
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CYP2C8 inhibition,-,0.9882
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CYP inhibitory promiscuity,+,0.6894
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,UGT catelyzed,+,0.8
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Carcinogenicity (binary),-,0.81
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Carcinogenicity (trinary),Non-required,0.5886
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Eye corrosion,-,0.989
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Eye irritation,-,0.966
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Skin irritation,-,0.8222
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Skin corrosion,-,0.9463
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Ames mutagenesis,-,0.65
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Human Ether-a-go-go-Related Gene inhibition,+,0.8274
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Micronuclear,+,0.87
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Hepatotoxicity,+,0.8125
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,skin sensitisation,-,0.8858
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Respiratory toxicity,+,0.9333
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Reproductive toxicity,+,0.9889
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Mitochondrial toxicity,+,0.925
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Nephrotoxicity,+,0.4504
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Acute Oral Toxicity (c),III,0.5957
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Estrogen receptor binding,+,0.7577
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Androgen receptor binding,+,0.8696
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Thyroid receptor binding,+,0.6186
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Glucocorticoid receptor binding,+,0.8971
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Aromatase binding,+,0.5612
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,PPAR gamma,+,0.8083
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Honey bee toxicity,-,0.8712
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Biodegradation,-,0.875
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Crustacea aquatic toxicity,-,0.55
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Fish aquatic toxicity,+,0.9893
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,ADMET predicted profile --- Regressions,Value,Unit
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Water solubility,-3.842,logS
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Plasma protein binding,0.891,100%
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Acute Oral Toxicity,2.045,log(1/(mol/kg))
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,Tetrahymena pyriformis,0.841,pIGC50 (ug/L)
,,,
CC(=O)OC1=CC=CC=C1C(=O)O,Human Intestinal Absorption,+,0.9859
CC(=O)OC1=CC=CC=C1C(=O)O,Caco-2,-,0.7353
CC(=O)OC1=CC=CC=C1C(=O)O,Blood Brain Barrier,-,0.7
CC(=O)OC1=CC=CC=C1C(=O)O,Human oral bioavailability,+,0.6714
CC(=O)OC1=CC=CC=C1C(=O)O,Subcellular localzation,Mitochondria,0.9369
CC(=O)OC1=CC=CC=C1C(=O)O,OATP2B1 inhibitior,-,1
CC(=O)OC1=CC=CC=C1C(=O)O,OATP1B1 inhibitior,+,0.9774
CC(=O)OC1=CC=CC=C1C(=O)O,OATP1B3 inhibitior,+,0.9823
CC(=O)OC1=CC=CC=C1C(=O)O,MATE1 inhibitior,-,0.98
CC(=O)OC1=CC=CC=C1C(=O)O,OCT2 inhibitior,-,0.975
CC(=O)OC1=CC=CC=C1C(=O)O,BSEP inhibitior,-,0.9074
CC(=O)OC1=CC=CC=C1C(=O)O,P-glycoprotein inhibitior,-,0.9802
CC(=O)OC1=CC=CC=C1C(=O)O,P-glycoprotein substrate,-,0.9748
CC(=O)OC1=CC=CC=C1C(=O)O,CYP3A4 substrate,-,0.7931
CC(=O)OC1=CC=CC=C1C(=O)O,CYP2C9 substrate,+,1
CC(=O)OC1=CC=CC=C1C(=O)O,CYP2D6 substrate,-,0.9005
CC(=O)OC1=CC=CC=C1C(=O)O,CYP3A4 inhibition,-,0.9611
CC(=O)OC1=CC=CC=C1C(=O)O,CYP2C9 inhibition,-,0.9071
CC(=O)OC1=CC=CC=C1C(=O)O,CYP2C19 inhibition,-,0.9445
CC(=O)OC1=CC=CC=C1C(=O)O,CYP2D6 inhibition,-,0.9576
CC(=O)OC1=CC=CC=C1C(=O)O,CYP1A2 inhibition,-,0.9046
CC(=O)OC1=CC=CC=C1C(=O)O,CYP2C8 inhibition,-,0.8286
CC(=O)OC1=CC=CC=C1C(=O)O,CYP inhibitory promiscuity,-,0.9557
CC(=O)OC1=CC=CC=C1C(=O)O,UGT catelyzed,-,0
CC(=O)OC1=CC=CC=C1C(=O)O,Carcinogenicity (binary),-,0.6325
CC(=O)OC1=CC=CC=C1C(=O)O,Carcinogenicity (trinary),Non-required,0.7139
CC(=O)OC1=CC=CC=C1C(=O)O,Eye corrosion,-,0.6035
CC(=O)OC1=CC=CC=C1C(=O)O,Eye irritation,+,1
CC(=O)OC1=CC=CC=C1C(=O)O,Skin irritation,+,0.7176
CC(=O)OC1=CC=CC=C1C(=O)O,Skin corrosion,-,0.8598
CC(=O)OC1=CC=CC=C1C(=O)O,Ames mutagenesis,-,0.97
CC(=O)OC1=CC=CC=C1C(=O)O,Human Ether-a-go-go-Related Gene inhibition,-,0.877
CC(=O)OC1=CC=CC=C1C(=O)O,Micronuclear,+,0.6966
CC(=O)OC1=CC=CC=C1C(=O)O,Hepatotoxicity,+,0.775
CC(=O)OC1=CC=CC=C1C(=O)O,skin sensitisation,-,0.8431
CC(=O)OC1=CC=CC=C1C(=O)O,Respiratory toxicity,+,0.7111
CC(=O)OC1=CC=CC=C1C(=O)O,Reproductive toxicity,+,0.7778
CC(=O)OC1=CC=CC=C1C(=O)O,Mitochondrial toxicity,+,0.625
CC(=O)OC1=CC=CC=C1C(=O)O,Nephrotoxicity,+,0.7839
CC(=O)OC1=CC=CC=C1C(=O)O,Acute Oral Toxicity (c),II,0.726
CC(=O)OC1=CC=CC=C1C(=O)O,Estrogen receptor binding,-,0.7113
CC(=O)OC1=CC=CC=C1C(=O)O,Androgen receptor binding,-,0.749
CC(=O)OC1=CC=CC=C1C(=O)O,Thyroid receptor binding,-,0.8815
CC(=O)OC1=CC=CC=C1C(=O)O,Glucocorticoid receptor binding,-,0.8524
CC(=O)OC1=CC=CC=C1C(=O)O,Aromatase binding,-,0.8352
CC(=O)OC1=CC=CC=C1C(=O)O,PPAR gamma,-,0.8031
CC(=O)OC1=CC=CC=C1C(=O)O,Honey bee toxicity,-,0.8649
CC(=O)OC1=CC=CC=C1C(=O)O,Biodegradation,+,0.85
CC(=O)OC1=CC=CC=C1C(=O)O,Crustacea aquatic toxicity,-,0.89
CC(=O)OC1=CC=CC=C1C(=O)O,Fish aquatic toxicity,+,0.9702
CC(=O)OC1=CC=CC=C1C(=O)O,ADMET predicted profile --- Regressions,Value,Unit
CC(=O)OC1=CC=CC=C1C(=O)O,Water solubility,-1.783,logS
CC(=O)OC1=CC=CC=C1C(=O)O,Plasma protein binding,0.583,100%
CC(=O)OC1=CC=CC=C1C(=O)O,Acute Oral Toxicity,2.451,log(1/(mol/kg))
CC(=O)OC1=CC=CC=C1C(=O)O,Tetrahymena pyriformis,-0.637,pIGC50 (ug/L)
,,,
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Human Intestinal Absorption,+,0.9805
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Caco-2,+,0.9313
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Blood Brain Barrier,+,0.975
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Human oral bioavailability,-,0.9
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Subcellular localzation,Mitochondria,0.4895
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,OATP2B1 inhibitior,-,1
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,OATP1B1 inhibitior,+,0.9376
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,OATP1B3 inhibitior,+,0.9475
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,MATE1 inhibitior,-,1
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,OCT2 inhibitior,-,0.65
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,BSEP inhibitior,-,0.7619
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,P-glycoprotein inhibitior,-,0.9008
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,P-glycoprotein substrate,+,0.7055
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,CYP3A4 substrate,+,0.798
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,CYP2C9 substrate,-,1
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,CYP2D6 substrate,+,0.7047
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,CYP3A4 inhibition,-,0.8899
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,CYP2C9 inhibition,-,0.8866
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,CYP2C19 inhibition,-,0.8256
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,CYP2D6 inhibition,+,0.6978
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,CYP1A2 inhibition,-,0.6494
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,CYP2C8 inhibition,-,0.9882
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,CYP inhibitory promiscuity,-,0.747
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,UGT catelyzed,+,1
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Carcinogenicity (binary),-,0.97
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Carcinogenicity (trinary),Non-required,0.7141
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Eye corrosion,-,0.9899
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Eye irritation,-,0.9922
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Skin irritation,-,0.7803
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Skin corrosion,-,0.9366
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Ames mutagenesis,-,0.96
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Human Ether-a-go-go-Related Gene inhibition,-,0.7261
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Micronuclear,-,0.57
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Hepatotoxicity,-,0.825
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,skin sensitisation,-,0.8156
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Respiratory toxicity,+,0.9556
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Reproductive toxicity,+,0.9667
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Mitochondrial toxicity,+,0.9875
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Nephrotoxicity,-,0.7982
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Acute Oral Toxicity (c),II,0.745
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Estrogen receptor binding,-,0.7985
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Androgen receptor binding,-,0.8512
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Thyroid receptor binding,-,0.5174
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Glucocorticoid receptor binding,-,0.5
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Aromatase binding,-,0.8513
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,PPAR gamma,-,0.6877
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Honey bee toxicity,-,0.7525
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Biodegradation,-,0.925
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Crustacea aquatic toxicity,+,0.59
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Fish aquatic toxicity,+,0.8787
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,ADMET predicted profile --- Regressions,Value,Unit
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Water solubility,-2.034,logS
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Plasma protein binding,0.328,100%
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Acute Oral Toxicity,2.556,log(1/(mol/kg))
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,Tetrahymena pyriformis,1.318,pIGC50 (ug/L)
,,,
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Human Intestinal Absorption,+,0.9817
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Caco-2,+,0.7523
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Blood Brain Barrier,+,0.975
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Human oral bioavailability,-,0.9143
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Subcellular localzation,Mitochondria,0.5027
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,OATP2B1 inhibitior,-,1
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,OATP1B1 inhibitior,+,0.9362
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,OATP1B3 inhibitior,+,0.953
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,MATE1 inhibitior,-,1
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,OCT2 inhibitior,-,0.65
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,BSEP inhibitior,-,0.9409
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,P-glycoprotein inhibitior,-,0.9467
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,P-glycoprotein substrate,+,0.9191
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,CYP3A4 substrate,+,0.7738
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,CYP2C9 substrate,-,1
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,CYP2D6 substrate,+,0.6295
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,CYP3A4 inhibition,-,0.9176
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,CYP2C9 inhibition,-,0.9046
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,CYP2C19 inhibition,-,0.8155
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,CYP2D6 inhibition,-,0.647
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,CYP1A2 inhibition,-,0.5191
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,CYP2C8 inhibition,-,0.9882
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,CYP inhibitory promiscuity,-,0.7503
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,UGT catelyzed,+,1
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Carcinogenicity (binary),-,0.97
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Carcinogenicity (trinary),Non-required,0.6614
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Eye corrosion,-,0.9893
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Eye irritation,-,0.9848
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Skin irritation,-,0.7543
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Skin corrosion,-,0.9195
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Ames mutagenesis,-,0.92
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Human Ether-a-go-go-Related Gene inhibition,-,0.7261
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Micronuclear,-,0.53
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Hepatotoxicity,-,0.8125
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,skin sensitisation,-,0.7856
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Respiratory toxicity,+,0.9444
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Reproductive toxicity,+,0.9444
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Mitochondrial toxicity,+,1
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Nephrotoxicity,-,0.7323
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Acute Oral Toxicity (c),II,0.7376
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Estrogen receptor binding,-,0.7548
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Androgen receptor binding,-,0.8408
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Thyroid receptor binding,+,0.5816
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Glucocorticoid receptor binding,-,0.4687
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Aromatase binding,-,0.8148
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,PPAR gamma,-,0.5784
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Honey bee toxicity,-,0.8174
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Biodegradation,-,0.95
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Crustacea aquatic toxicity,+,0.58
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Fish aquatic toxicity,+,0.855
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,ADMET predicted profile --- Regressions,Value,Unit
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Water solubility,-2.993,logS
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Plasma protein binding,0.383,100%
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Acute Oral Toxicity,2.891,log(1/(mol/kg))
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,Tetrahymena pyriformis,1.222,pIGC50 (ug/L)
,,,
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Human Intestinal Absorption,+,0.9596
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Caco-2,+,0.9618
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Blood Brain Barrier,-,0.65
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Human oral bioavailability,-,0.7143
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Subcellular localzation,Mitochondria,0.5275
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,OATP2B1 inhibitior,-,1
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,OATP1B1 inhibitior,+,0.9412
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,OATP1B3 inhibitior,+,0.9432
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,MATE1 inhibitior,-,0.94
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,OCT2 inhibitior,-,0.975
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,BSEP inhibitior,-,0.8385
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,P-glycoprotein inhibitior,-,0.9289
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,P-glycoprotein substrate,-,0.7231
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,CYP3A4 substrate,-,0.5282
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,CYP2C9 substrate,+,1
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,CYP2D6 substrate,+,0.4069
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,CYP3A4 inhibition,-,0.9394
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,CYP2C9 inhibition,-,0.9231
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,CYP2C19 inhibition,-,0.9026
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,CYP2D6 inhibition,-,0.9231
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,CYP1A2 inhibition,-,0.9046
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,CYP2C8 inhibition,-,0.8888
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,CYP inhibitory promiscuity,+,0.577
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,UGT catelyzed,-,0
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Carcinogenicity (binary),-,0.63
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Carcinogenicity (trinary),Non-required,0.7165
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Eye corrosion,-,0.9846
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Eye irritation,-,0.5364
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Skin irritation,+,0.6689
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Skin corrosion,-,0.9428
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Ames mutagenesis,-,0.56
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Human Ether-a-go-go-Related Gene inhibition,-,0.5905
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Micronuclear,+,0.65
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Hepatotoxicity,-,0.525
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,skin sensitisation,-,0.7481
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Respiratory toxicity,+,0.9333
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Reproductive toxicity,+,0.6
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Mitochondrial toxicity,+,0.925
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Nephrotoxicity,-,0.7443
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Acute Oral Toxicity (c),II,0.7397
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Estrogen receptor binding,-,0.88
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Androgen receptor binding,-,0.8909
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Thyroid receptor binding,-,0.5
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Glucocorticoid receptor binding,-,0.7868
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Aromatase binding,-,0.586
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,PPAR gamma,-,0.5385
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Honey bee toxicity,-,0.9926
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Biodegradation,-,0.65
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Crustacea aquatic toxicity,-,0.72
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Fish aquatic toxicity,-,0.3841
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,ADMET predicted profile --- Regressions,Value,Unit
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Water solubility,-1.822,logS
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Plasma protein binding,0.558,100%
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Acute Oral Toxicity,2.598,log(1/(mol/kg))
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,Tetrahymena pyriformis,-0.123,pIGC50 (ug/L)
,,,
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Human Intestinal Absorption,+,0.9329
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Caco-2,+,0.8795
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Blood Brain Barrier,+,0.875
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Human oral bioavailability,+,0.7571
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Subcellular localzation,Mitochondria,0.4796
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,OATP2B1 inhibitior,-,1
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,OATP1B1 inhibitior,+,0.926
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,OATP1B3 inhibitior,+,0.9407
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,MATE1 inhibitior,-,0.72
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,OCT2 inhibitior,+,0.575
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,BSEP inhibitior,-,0.8304
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,P-glycoprotein inhibitior,-,0.6269
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,P-glycoprotein substrate,+,0.8809
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,CYP3A4 substrate,+,0.696
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,CYP2C9 substrate,-,1
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,CYP2D6 substrate,+,0.3826
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,CYP3A4 inhibition,-,0.9237
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,CYP2C9 inhibition,-,0.9341
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,CYP2C19 inhibition,-,0.9383
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,CYP2D6 inhibition,-,0.5614
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,CYP1A2 inhibition,-,0.8627
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,CYP2C8 inhibition,-,0.8121
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,CYP inhibitory promiscuity,-,0.9408
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,UGT catelyzed,-,0
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Carcinogenicity (binary),-,0.97
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Carcinogenicity (trinary),Non-required,0.6582
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Eye corrosion,-,0.99
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Eye irritation,-,0.9541
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Skin irritation,-,0.8227
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Skin corrosion,-,0.9533
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Ames mutagenesis,-,0.61
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Human Ether-a-go-go-Related Gene inhibition,+,0.6986
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Micronuclear,-,0.55
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Hepatotoxicity,+,0.875
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,skin sensitisation,-,0.9307
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Respiratory toxicity,+,0.8
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Reproductive toxicity,+,0.9111
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Mitochondrial toxicity,+,0.775
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Nephrotoxicity,+,0.7839
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Acute Oral Toxicity (c),III,0.6875
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Estrogen receptor binding,-,0.6148
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Androgen receptor binding,-,0.8511
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Thyroid receptor binding,-,0.6822
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Glucocorticoid receptor binding,-,0.7607
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Aromatase binding,-,0.6159
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,PPAR gamma,-,0.671
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Honey bee toxicity,-,0.9251
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Biodegradation,-,0.625
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Crustacea aquatic toxicity,+,0.54
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Fish aquatic toxicity,+,0.8803
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,ADMET predicted profile --- Regressions,Value,Unit
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Water solubility,-2.194,logS
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Plasma protein binding,0.417,100%
CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,Acute Oral Toxicity,2.297,log(1/(mol/kg))
,Tetrahymena pyriformis,0.275,pIGC50 (ug/L)
,,,
CC(CC1=CC=CC=C1)NC,Human Intestinal Absorption,+,0.9975
CC(CC1=CC=CC=C1)NC,Caco-2,+,0.9571
CC(CC1=CC=CC=C1)NC,Blood Brain Barrier,+,0.975
CC(CC1=CC=CC=C1)NC,Human oral bioavailability,+,0.8857
CC(CC1=CC=CC=C1)NC,Subcellular localzation,Lysosomes,0.8644
CC(CC1=CC=CC=C1)NC,OATP2B1 inhibitior,-,1
CC(CC1=CC=CC=C1)NC,OATP1B1 inhibitior,+,0.9467
CC(CC1=CC=CC=C1)NC,OATP1B3 inhibitior,+,0.955
CC(CC1=CC=CC=C1)NC,MATE1 inhibitior,-,0.94
CC(CC1=CC=CC=C1)NC,OCT2 inhibitior,-,0.55
CC(CC1=CC=CC=C1)NC,BSEP inhibitior,-,0.9106
CC(CC1=CC=CC=C1)NC,P-glycoprotein inhibitior,-,0.9868
CC(CC1=CC=CC=C1)NC,P-glycoprotein substrate,-,0.8682
CC(CC1=CC=CC=C1)NC,CYP3A4 substrate,-,0.7728
CC(CC1=CC=CC=C1)NC,CYP2C9 substrate,-,1
CC(CC1=CC=CC=C1)NC,CYP2D6 substrate,+,0.6672
CC(CC1=CC=CC=C1)NC,CYP3A4 inhibition,-,0.9536
CC(CC1=CC=CC=C1)NC,CYP2C9 inhibition,-,0.957
CC(CC1=CC=CC=C1)NC,CYP2C19 inhibition,-,0.7754
CC(CC1=CC=CC=C1)NC,CYP2D6 inhibition,+,0.8695
CC(CC1=CC=CC=C1)NC,CYP1A2 inhibition,-,0.6771
CC(CC1=CC=CC=C1)NC,CYP2C8 inhibition,-,0.9684
CC(CC1=CC=CC=C1)NC,CYP inhibitory promiscuity,-,0.9095
CC(CC1=CC=CC=C1)NC,UGT catelyzed,-,0
CC(CC1=CC=CC=C1)NC,Carcinogenicity (binary),-,0.721
CC(CC1=CC=CC=C1)NC,Carcinogenicity (trinary),Non-required,0.7799
CC(CC1=CC=CC=C1)NC,Eye corrosion,-,0.9905
CC(CC1=CC=CC=C1)NC,Eye irritation,-,0.9541
CC(CC1=CC=CC=C1)NC,Skin irritation,+,0.823
CC(CC1=CC=CC=C1)NC,Skin corrosion,+,0.9121
CC(CC1=CC=CC=C1)NC,Ames mutagenesis,-,0.98
CC(CC1=CC=CC=C1)NC,Human Ether-a-go-go-Related Gene inhibition,-,0.6539
CC(CC1=CC=CC=C1)NC,Micronuclear,+,0.54
CC(CC1=CC=CC=C1)NC,Hepatotoxicity,-,0.8518
CC(CC1=CC=CC=C1)NC,skin sensitisation,+,0.6156
CC(CC1=CC=CC=C1)NC,Respiratory toxicity,+,0.9333
CC(CC1=CC=CC=C1)NC,Reproductive toxicity,-,0.6
CC(CC1=CC=CC=C1)NC,Mitochondrial toxicity,+,0.9
CC(CC1=CC=CC=C1)NC,Nephrotoxicity,-,0.6451
CC(CC1=CC=CC=C1)NC,Acute Oral Toxicity (c),II,0.7678
CC(CC1=CC=CC=C1)NC,Estrogen receptor binding,-,0.9335
CC(CC1=CC=CC=C1)NC,Androgen receptor binding,-,0.845
CC(CC1=CC=CC=C1)NC,Thyroid receptor binding,-,0.9029
CC(CC1=CC=CC=C1)NC,Glucocorticoid receptor binding,-,0.9308
CC(CC1=CC=CC=C1)NC,Aromatase binding,-,0.8469
CC(CC1=CC=CC=C1)NC,PPAR gamma,-,0.9388
CC(CC1=CC=CC=C1)NC,Honey bee toxicity,-,0.9036
CC(CC1=CC=CC=C1)NC,Biodegradation,-,0.9
CC(CC1=CC=CC=C1)NC,Crustacea aquatic toxicity,+,0.64
CC(CC1=CC=CC=C1)NC,Fish aquatic toxicity,+,0.74
CC(CC1=CC=CC=C1)NC,ADMET predicted profile --- Regressions,Value,Unit
CC(CC1=CC=CC=C1)NC,Water solubility,-2.218,logS
CC(CC1=CC=CC=C1)NC,Plasma protein binding,0.264,100%
CC(CC1=CC=CC=C1)NC,Acute Oral Toxicity,3.497,log(1/(mol/kg))
CC(CC1=CC=CC=C1)NC,Tetrahymena pyriformis,0.145,pIGC50 (ug/L)
,,,
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Human Intestinal Absorption,+,0.9704
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Caco-2,+,0.6402
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Blood Brain Barrier,+,1
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Human oral bioavailability,-,0.9571
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Subcellular localzation,Mitochondria,0.4401
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,OATP2B1 inhibitior,-,1
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,OATP1B1 inhibitior,+,0.9224
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,OATP1B3 inhibitior,+,0.9285
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,MATE1 inhibitior,-,0.82
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,OCT2 inhibitior,-,0.775
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,BSEP inhibitior,-,0.536
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,P-glycoprotein inhibitior,+,0.6187
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,P-glycoprotein substrate,+,0.6963
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,CYP3A4 substrate,+,0.7438
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,CYP2C9 substrate,-,1
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,CYP2D6 substrate,+,0.3642
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,CYP3A4 inhibition,-,0.8072
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,CYP2C9 inhibition,-,0.8162
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,CYP2C19 inhibition,-,0.8059
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,CYP2D6 inhibition,-,0.6335
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,CYP1A2 inhibition,-,0.7994
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,CYP2C8 inhibition,-,0.9265
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,CYP inhibitory promiscuity,-,0.8335
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,UGT catelyzed,-,0
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Carcinogenicity (binary),-,0.94
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Carcinogenicity (trinary),Non-required,0.581
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Eye corrosion,-,0.99
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Eye irritation,-,0.9721
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Skin irritation,-,0.8024
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Skin corrosion,-,0.9452
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Ames mutagenesis,-,0.7254
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Human Ether-a-go-go-Related Gene inhibition,-,0.726
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Micronuclear,-,0.53
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Hepatotoxicity,-,0.6875
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,skin sensitisation,-,0.8478
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Respiratory toxicity,+,0.9556
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Reproductive toxicity,+,0.9111
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Mitochondrial toxicity,+,0.95
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Nephrotoxicity,-,0.6375
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Acute Oral Toxicity (c),III,0.7187
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Estrogen receptor binding,+,0.5939
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Androgen receptor binding,-,0.6642
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Thyroid receptor binding,-,0.5614
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Glucocorticoid receptor binding,+,0.7398
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Aromatase binding,-,0.661
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,PPAR gamma,+,0.6508
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Honey bee toxicity,-,0.6304
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Biodegradation,-,0.75
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Crustacea aquatic toxicity,-,0.555
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Fish aquatic toxicity,+,0.9758
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,ADMET predicted profile --- Regressions,Value,Unit
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Water solubility,-3.04,logS
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Plasma protein binding,0.531,100%
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Acute Oral Toxicity,2.083,log(1/(mol/kg))
CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,Tetrahymena pyriformis,1.291,pIGC50 (ug/L)
,,,
CC(CC1=CC=CC=C1)N,Human Intestinal Absorption,+,1
CC(CC1=CC=CC=C1)N,Caco-2,+,0.9594
CC(CC1=CC=CC=C1)N,Blood Brain Barrier,+,1
CC(CC1=CC=CC=C1)N,Human oral bioavailability,+,0.9286
CC(CC1=CC=CC=C1)N,Subcellular localzation,Lysosomes,0.9263
CC(CC1=CC=CC=C1)N,OATP2B1 inhibitior,-,1
CC(CC1=CC=CC=C1)N,OATP1B1 inhibitior,+,0.9743
CC(CC1=CC=CC=C1)N,OATP1B3 inhibitior,+,0.958
CC(CC1=CC=CC=C1)N,MATE1 inhibitior,-,0.9
CC(CC1=CC=CC=C1)N,OCT2 inhibitior,-,0.775
CC(CC1=CC=CC=C1)N,BSEP inhibitior,-,0.9034
CC(CC1=CC=CC=C1)N,P-glycoprotein inhibitior,-,0.9935
CC(CC1=CC=CC=C1)N,P-glycoprotein substrate,-,0.8754
CC(CC1=CC=CC=C1)N,CYP3A4 substrate,-,0.8047
CC(CC1=CC=CC=C1)N,CYP2C9 substrate,-,1
CC(CC1=CC=CC=C1)N,CYP2D6 substrate,+,0.6122
CC(CC1=CC=CC=C1)N,CYP3A4 inhibition,-,0.8709
CC(CC1=CC=CC=C1)N,CYP2C9 inhibition,-,0.9313
CC(CC1=CC=CC=C1)N,CYP2C19 inhibition,-,0.8445
CC(CC1=CC=CC=C1)N,CYP2D6 inhibition,+,0.657
CC(CC1=CC=CC=C1)N,CYP1A2 inhibition,-,0.5697
CC(CC1=CC=CC=C1)N,CYP2C8 inhibition,-,0.9882
CC(CC1=CC=CC=C1)N,CYP inhibitory promiscuity,-,0.8732
CC(CC1=CC=CC=C1)N,UGT catelyzed,-,0
CC(CC1=CC=CC=C1)N,Carcinogenicity (binary),-,0.53
CC(CC1=CC=CC=C1)N,Carcinogenicity (trinary),Non-required,0.7287
CC(CC1=CC=CC=C1)N,Eye corrosion,-,0.9593
CC(CC1=CC=CC=C1)N,Eye irritation,-,0.9541
CC(CC1=CC=CC=C1)N,Skin irritation,+,0.8532
CC(CC1=CC=CC=C1)N,Skin corrosion,+,0.974
CC(CC1=CC=CC=C1)N,Ames mutagenesis,-,0.97
CC(CC1=CC=CC=C1)N,Human Ether-a-go-go-Related Gene inhibition,-,0.7106
CC(CC1=CC=CC=C1)N,Micronuclear,+,0.85
CC(CC1=CC=CC=C1)N,Hepatotoxicity,+,0.5068
CC(CC1=CC=CC=C1)N,skin sensitisation,+,0.6957
CC(CC1=CC=CC=C1)N,Respiratory toxicity,+,0.8222
CC(CC1=CC=CC=C1)N,Reproductive toxicity,-,0.7
CC(CC1=CC=CC=C1)N,Mitochondrial toxicity,+,0.55
CC(CC1=CC=CC=C1)N,Nephrotoxicity,-,0.7394
CC(CC1=CC=CC=C1)N,Acute Oral Toxicity (c),I,0.7687
CC(CC1=CC=CC=C1)N,Estrogen receptor binding,-,0.9577
CC(CC1=CC=CC=C1)N,Androgen receptor binding,-,0.8437
CC(CC1=CC=CC=C1)N,Thyroid receptor binding,-,0.8907
CC(CC1=CC=CC=C1)N,Glucocorticoid receptor binding,-,0.8554
CC(CC1=CC=CC=C1)N,Aromatase binding,-,0.8997
CC(CC1=CC=CC=C1)N,PPAR gamma,-,0.9201
CC(CC1=CC=CC=C1)N,Honey bee toxicity,-,0.9686
CC(CC1=CC=CC=C1)N,Biodegradation,-,0.9
CC(CC1=CC=CC=C1)N,Crustacea aquatic toxicity,+,0.59
CC(CC1=CC=CC=C1)N,Fish aquatic toxicity,-,0.4224
CC(CC1=CC=CC=C1)N,ADMET predicted profile --- Regressions,Value,Unit
CC(CC1=CC=CC=C1)N,Water solubility,-1.356,logS
CC(CC1=CC=CC=C1)N,Plasma protein binding,0.504,1
CC(CC1=CC=CC=C1)N,Acute Oral Toxicity,3.319,log(1/(mol/kg))
CC(CC1=CC=CC=C1)N,Tetrahymena pyriformis,-0.049,pIGC50 (ug/L)
,,,
CC(CC1=CC=CC=C1)N,Human Intestinal Absorption,+,1
CC(CC1=CC=CC=C1)N,Caco-2,+,0.9594
CC(CC1=CC=CC=C1)N,Blood Brain Barrier,+,1
CC(CC1=CC=CC=C1)N,Human oral bioavailability,+,0.9286
CC(CC1=CC=CC=C1)N,Subcellular localzation,Lysosomes,0.9263
CC(CC1=CC=CC=C1)N,OATP2B1 inhibitior,-,1
CC(CC1=CC=CC=C1)N,OATP1B1 inhibitior,+,0.9743
CC(CC1=CC=CC=C1)N,OATP1B3 inhibitior,+,0.958
CC(CC1=CC=CC=C1)N,MATE1 inhibitior,-,0.9
CC(CC1=CC=CC=C1)N,OCT2 inhibitior,-,0.775
CC(CC1=CC=CC=C1)N,BSEP inhibitior,-,0.9034
CC(CC1=CC=CC=C1)N,P-glycoprotein inhibitior,-,0.9935
CC(CC1=CC=CC=C1)N,P-glycoprotein substrate,-,0.8754
CC(CC1=CC=CC=C1)N,CYP3A4 substrate,-,0.8047
CC(CC1=CC=CC=C1)N,CYP2C9 substrate,-,1
CC(CC1=CC=CC=C1)N,CYP2D6 substrate,+,0.6122
CC(CC1=CC=CC=C1)N,CYP3A4 inhibition,-,0.8709
CC(CC1=CC=CC=C1)N,CYP2C9 inhibition,-,0.9313
CC(CC1=CC=CC=C1)N,CYP2C19 inhibition,-,0.8445
CC(CC1=CC=CC=C1)N,CYP2D6 inhibition,+,0.657
CC(CC1=CC=CC=C1)N,CYP1A2 inhibition,-,0.5697
CC(CC1=CC=CC=C1)N,CYP2C8 inhibition,-,0.9882
CC(CC1=CC=CC=C1)N,CYP inhibitory promiscuity,-,0.8732
CC(CC1=CC=CC=C1)N,UGT catelyzed,-,0
CC(CC1=CC=CC=C1)N,Carcinogenicity (binary),-,0.53
CC(CC1=CC=CC=C1)N,Carcinogenicity (trinary),Non-required,0.7287
CC(CC1=CC=CC=C1)N,Eye corrosion,-,0.9593
CC(CC1=CC=CC=C1)N,Eye irritation,-,0.9541
CC(CC1=CC=CC=C1)N,Skin irritation,+,0.8532
CC(CC1=CC=CC=C1)N,Skin corrosion,+,0.974
CC(CC1=CC=CC=C1)N,Ames mutagenesis,-,0.97
CC(CC1=CC=CC=C1)N,Human Ether-a-go-go-Related Gene inhibition,-,0.7106
CC(CC1=CC=CC=C1)N,Micronuclear,+,0.85
CC(CC1=CC=CC=C1)N,Hepatotoxicity,+,0.5068
CC(CC1=CC=CC=C1)N,skin sensitisation,+,0.6957
CC(CC1=CC=CC=C1)N,Respiratory toxicity,+,0.8222
CC(CC1=CC=CC=C1)N,Reproductive toxicity,-,0.7
CC(CC1=CC=CC=C1)N,Mitochondrial toxicity,+,0.55
CC(CC1=CC=CC=C1)N,Nephrotoxicity,-,0.7394
CC(CC1=CC=CC=C1)N,Acute Oral Toxicity (c),I,0.7687
CC(CC1=CC=CC=C1)N,Estrogen receptor binding,-,0.9577
CC(CC1=CC=CC=C1)N,Androgen receptor binding,-,0.8437
CC(CC1=CC=CC=C1)N,Thyroid receptor binding,-,0.8907
CC(CC1=CC=CC=C1)N,Glucocorticoid receptor binding,-,0.8554
CC(CC1=CC=CC=C1)N,Aromatase binding,-,0.8997
CC(CC1=CC=CC=C1)N,PPAR gamma,-,0.9201
CC(CC1=CC=CC=C1)N,Honey bee toxicity,-,0.9686
CC(CC1=CC=CC=C1)N,Biodegradation,-,0.9
CC(CC1=CC=CC=C1)N,Crustacea aquatic toxicity,+,0.59
CC(CC1=CC=CC=C1)N,Fish aquatic toxicity,-,0.4224
CC(CC1=CC=CC=C1)N,ADMET predicted profile --- Regressions,Value,Unit
CC(CC1=CC=CC=C1)N,Water solubility,-1.356,logS
CC(CC1=CC=CC=C1)N,Plasma protein binding,0.504,100%
CC(CC1=CC=CC=C1)N,Acute Oral Toxicity,3.319,log(1/(mol/kg))
CC(CC1=CC=CC=C1)N,Tetrahymena pyriformis,-0.049,pIGC50 (ug/L)
,,,
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Human Intestinal Absorption,+,0.9761
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Caco-2,+,0.8403
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Blood Brain Barrier,+,0.975
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Human oral bioavailability,-,0.9286
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Subcellular localzation,Lysosomes,0.574
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,OATP2B1 inhibitior,-,0.8613
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,OATP1B1 inhibitior,+,0.9417
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,OATP1B3 inhibitior,+,0.9358
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,MATE1 inhibitior,-,0.96
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,OCT2 inhibitior,-,0.6599
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,BSEP inhibitior,-,0.7469
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,P-glycoprotein inhibitior,-,0.9313
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,P-glycoprotein substrate,-,0.8677
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,CYP3A4 substrate,+,0.566
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,CYP2C9 substrate,-,0.8055
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,CYP2D6 substrate,+,0.63
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,CYP3A4 inhibition,-,0.8714
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,CYP2C9 inhibition,-,0.9431
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,CYP2C19 inhibition,-,0.882
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,CYP2D6 inhibition,-,0.5131
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,CYP1A2 inhibition,-,0.9327
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,CYP2C8 inhibition,-,0.9882
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,CYP inhibitory promiscuity,-,0.9691
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,UGT catelyzed,-,0.5
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Carcinogenicity (binary),-,0.99
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Carcinogenicity (trinary),Non-required,0.6523
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Eye corrosion,-,0.9908
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Eye irritation,-,0.9781
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Skin irritation,-,0.8113
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Skin corrosion,-,0.9459
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Ames mutagenesis,-,0.7354
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Human Ether-a-go-go-Related Gene inhibition,-,0.4506
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Micronuclear,-,0.59
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Hepatotoxicity,-,0.9625
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,skin sensitisation,-,0.8287
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Respiratory toxicity,+,1
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Reproductive toxicity,+,0.9556
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Mitochondrial toxicity,+,0.9875
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Nephrotoxicity,-,0.8535
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Acute Oral Toxicity (c),II,0.4762
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Estrogen receptor binding,-,0.7016
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Androgen receptor binding,-,0.5481
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Thyroid receptor binding,-,0.5694
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Glucocorticoid receptor binding,+,0.5496
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Aromatase binding,-,0.5886
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,PPAR gamma,+,0.6215
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Honey bee toxicity,-,0.8169
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Biodegradation,-,0.825
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Crustacea aquatic toxicity,+,0.5426
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Fish aquatic toxicity,-,0.3808
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,ADMET predicted profile --- Regressions,Value,Unit
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Water solubility,-2.085,logS
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Plasma protein binding,0.492,100%
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Acute Oral Toxicity,2.575,log(1/(mol/kg))
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,Tetrahymena pyriformis,1.029,pIGC50 (ug/L)
,,,
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Human Intestinal Absorption,+,0.9904
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Caco-2,+,0.8977
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Blood Brain Barrier,+,0.975
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Human oral bioavailability,+,0.7429
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Subcellular localzation,Lysosomes,0.4837
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,OATP2B1 inhibitior,-,0.8591
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,OATP1B1 inhibitior,+,0.9241
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,OATP1B3 inhibitior,+,0.9505
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,MATE1 inhibitior,-,0.92
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,OCT2 inhibitior,-,0.625
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,BSEP inhibitior,-,0.7028
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,P-glycoprotein inhibitior,-,0.9166
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,P-glycoprotein substrate,+,0.8175
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,CYP3A4 substrate,+,0.7328
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,CYP2C9 substrate,-,1
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,CYP2D6 substrate,+,0.7047
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,CYP3A4 inhibition,-,0.7625
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,CYP2C9 inhibition,-,0.9412
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,CYP2C19 inhibition,-,0.8402
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,CYP2D6 inhibition,+,0.6629
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,CYP1A2 inhibition,-,0.8207
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,CYP2C8 inhibition,-,0.9882
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,CYP inhibitory promiscuity,-,0.8675
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,UGT catelyzed,-,0
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Carcinogenicity (binary),-,0.95
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Carcinogenicity (trinary),Non-required,0.6651
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Eye corrosion,-,0.9918
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Eye irritation,-,0.9827
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Skin irritation,-,0.8307
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Skin corrosion,-,0.9438
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Ames mutagenesis,-,0.76
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Human Ether-a-go-go-Related Gene inhibition,+,0.6483
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Micronuclear,-,0.66
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Hepatotoxicity,-,0.925
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,skin sensitisation,-,0.8395
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Respiratory toxicity,+,0.9778
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Reproductive toxicity,+,0.8667
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Mitochondrial toxicity,+,1
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Nephrotoxicity,-,0.853
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Acute Oral Toxicity (c),II,0.509
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Estrogen receptor binding,-,0.8071
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Androgen receptor binding,-,0.8512
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Thyroid receptor binding,-,0.6643
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Glucocorticoid receptor binding,+,0.6335
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Aromatase binding,-,0.7422
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,PPAR gamma,-,0.4863
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Honey bee toxicity,-,0.7362
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Biodegradation,-,0.825
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Crustacea aquatic toxicity,+,0.59
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Fish aquatic toxicity,+,0.7529
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,ADMET predicted profile --- Regressions,Value,Unit
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Water solubility,-2.243,logS
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Plasma protein binding,0.366,100%
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Acute Oral Toxicity,3.071,log(1/(mol/kg))
CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,Tetrahymena pyriformis,1.182,pIGC50 (ug/L)
,,,
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Human Intestinal Absorption,+,0.9964
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Caco-2,+,0.9132
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Blood Brain Barrier,+,0.925
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Human oral bioavailability,-,0.7571
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Subcellular localzation,Mitochondria,0.703
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,OATP2B1 inhibitior,-,0.8609
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,OATP1B1 inhibitior,+,0.9121
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,OATP1B3 inhibitior,+,0.947
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,MATE1 inhibitior,-,0.96
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,OCT2 inhibitior,-,0.625
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,BSEP inhibitior,-,0.8209
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,P-glycoprotein inhibitior,-,0.9867
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,P-glycoprotein substrate,-,0.9613
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CYP3A4 substrate,+,0.5304
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CYP2C9 substrate,-,0.6147
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CYP2D6 substrate,+,0.5197
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CYP3A4 inhibition,-,0.8253
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CYP2C9 inhibition,-,0.7985
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CYP2C19 inhibition,-,0.5347
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CYP2D6 inhibition,-,0.6912
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CYP1A2 inhibition,-,0.7323
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CYP2C8 inhibition,-,0.8326
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CYP inhibitory promiscuity,+,0.5426
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,UGT catelyzed,-,0
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Carcinogenicity (binary),-,0.74
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Carcinogenicity (trinary),Non-required,0.5898
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Eye corrosion,-,0.9886
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Eye irritation,-,0.8923
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Skin irritation,+,0.6778
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Skin corrosion,-,0.8983
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Ames mutagenesis,-,0.69
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Human Ether-a-go-go-Related Gene inhibition,-,0.513
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Micronuclear,-,0.65
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Hepatotoxicity,+,0.5719
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,skin sensitisation,-,0.8095
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Respiratory toxicity,+,0.6222
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Reproductive toxicity,+,0.7222
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Mitochondrial toxicity,+,0.775
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Nephrotoxicity,+,0.5
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Acute Oral Toxicity (c),III,0.58
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Estrogen receptor binding,-,0.7153
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Androgen receptor binding,-,0.5937
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Thyroid receptor binding,-,0.5911
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Glucocorticoid receptor binding,-,0.7028
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Aromatase binding,-,0.7164
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,PPAR gamma,+,0.5428
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Honey bee toxicity,-,0.9571
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Biodegradation,-,0.775
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Crustacea aquatic toxicity,+,0.78
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Fish aquatic toxicity,+,0.9419
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,ADMET predicted profile --- Regressions,Value,Unit
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Water solubility,-4.54,logS
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Plasma protein binding,0.495,1
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Acute Oral Toxicity,2.101,log(1/(mol/kg))
CNC1(CCCCC1=O)C2=CC=CC=C2Cl,Tetrahymena pyriformis,0.769,pIGC50 (ug/L)
,,,
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Human Intestinal Absorption,+,0.9759
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Caco-2,+,0.7405
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Blood Brain Barrier,+,1
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Human oral bioavailability,-,0.7714
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Subcellular localzation,Mitochondria,0.4978
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,OATP2B1 inhibitior,-,1
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,OATP1B1 inhibitior,+,0.9377
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,OATP1B3 inhibitior,+,0.9494
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,MATE1 inhibitior,-,0.86
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,OCT2 inhibitior,-,0.525
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,BSEP inhibitior,+,0.8864
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,P-glycoprotein inhibitior,+,0.9511
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,P-glycoprotein substrate,-,0.8435
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CYP3A4 substrate,+,0.6851
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CYP2C9 substrate,-,1
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CYP2D6 substrate,+,0.4032
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CYP3A4 inhibition,-,0.8218
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CYP2C9 inhibition,-,0.873
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CYP2C19 inhibition,-,0.5724
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CYP2D6 inhibition,-,0.6327
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CYP1A2 inhibition,-,0.7715
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CYP2C8 inhibition,-,0.8255
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CYP inhibitory promiscuity,+,0.7346
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,UGT catelyzed,-,0
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Carcinogenicity (binary),-,0.9
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Carcinogenicity (trinary),Non-required,0.6125
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Eye corrosion,-,0.9886
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Eye irritation,-,0.9857
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Skin irritation,-,0.794
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Skin corrosion,-,0.9649
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Ames mutagenesis,-,0.82
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Human Ether-a-go-go-Related Gene inhibition,+,0.9131
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Micronuclear,+,0.69
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Hepatotoxicity,-,0.775
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,skin sensitisation,-,0.8775
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Respiratory toxicity,+,0.9889
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Reproductive toxicity,+,0.6333
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Mitochondrial toxicity,+,1
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Nephrotoxicity,-,0.884
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Acute Oral Toxicity (c),I,0.7896
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Estrogen receptor binding,+,0.9084
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Androgen receptor binding,+,0.8696
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Thyroid receptor binding,-,0.5729
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Glucocorticoid receptor binding,-,0.6789
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Aromatase binding,-,0.771
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,PPAR gamma,-,0.7344
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Honey bee toxicity,-,0.9538
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Biodegradation,-,0.775
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Crustacea aquatic toxicity,+,0.64
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Fish aquatic toxicity,-,0.4128
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,ADMET predicted profile --- Regressions,Value,Unit
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Water solubility,-2.544,logS
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Plasma protein binding,0.715,100%
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Acute Oral Toxicity,3.665,log(1/(mol/kg))
CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,Tetrahymena pyriformis,0.761,pIGC50 (ug/L)
,,,
COC1=CC(=CC(=C1OC)OC)CCN,Human Intestinal Absorption,+,0.9975
COC1=CC(=CC(=C1OC)OC)CCN,Caco-2,+,0.8997
COC1=CC(=CC(=C1OC)OC)CCN,Blood Brain Barrier,+,0.575
COC1=CC(=CC(=C1OC)OC)CCN,Human oral bioavailability,+,0.7714
COC1=CC(=CC(=C1OC)OC)CCN,Subcellular localzation,Mitochondria,0.5399
COC1=CC(=CC(=C1OC)OC)CCN,OATP2B1 inhibitior,-,1
COC1=CC(=CC(=C1OC)OC)CCN,OATP1B1 inhibitior,+,0.9491
COC1=CC(=CC(=C1OC)OC)CCN,OATP1B3 inhibitior,+,0.9608
COC1=CC(=CC(=C1OC)OC)CCN,MATE1 inhibitior,-,0.96
COC1=CC(=CC(=C1OC)OC)CCN,OCT2 inhibitior,-,0.775
COC1=CC(=CC(=C1OC)OC)CCN,BSEP inhibitior,-,0.9127
COC1=CC(=CC(=C1OC)OC)CCN,P-glycoprotein inhibitior,-,0.9663
COC1=CC(=CC(=C1OC)OC)CCN,P-glycoprotein substrate,-,0.7778
COC1=CC(=CC(=C1OC)OC)CCN,CYP3A4 substrate,-,0.6357
COC1=CC(=CC(=C1OC)OC)CCN,CYP2C9 substrate,-,0.8305
COC1=CC(=CC(=C1OC)OC)CCN,CYP2D6 substrate,+,0.6999
COC1=CC(=CC(=C1OC)OC)CCN,CYP3A4 inhibition,-,0.8266
COC1=CC(=CC(=C1OC)OC)CCN,CYP2C9 inhibition,-,0.9512
COC1=CC(=CC(=C1OC)OC)CCN,CYP2C19 inhibition,-,0.9021
COC1=CC(=CC(=C1OC)OC)CCN,CYP2D6 inhibition,-,0.918
COC1=CC(=CC(=C1OC)OC)CCN,CYP1A2 inhibition,+,0.876
COC1=CC(=CC(=C1OC)OC)CCN,CYP2C8 inhibition,+,0.7162
COC1=CC(=CC(=C1OC)OC)CCN,CYP inhibitory promiscuity,-,0.8734
COC1=CC(=CC(=C1OC)OC)CCN,UGT catelyzed,-,0
COC1=CC(=CC(=C1OC)OC)CCN,Carcinogenicity (binary),-,0.73
COC1=CC(=CC(=C1OC)OC)CCN,Carcinogenicity (trinary),Non-required,0.6507
COC1=CC(=CC(=C1OC)OC)CCN,Eye corrosion,+,0.7575
COC1=CC(=CC(=C1OC)OC)CCN,Eye irritation,-,0.5
COC1=CC(=CC(=C1OC)OC)CCN,Skin irritation,+,0.6682
COC1=CC(=CC(=C1OC)OC)CCN,Skin corrosion,-,0.7148
COC1=CC(=CC(=C1OC)OC)CCN,Ames mutagenesis,-,0.63
COC1=CC(=CC(=C1OC)OC)CCN,Human Ether-a-go-go-Related Gene inhibition,+,0.641
COC1=CC(=CC(=C1OC)OC)CCN,Micronuclear,-,0.76
COC1=CC(=CC(=C1OC)OC)CCN,Hepatotoxicity,-,0.5966
COC1=CC(=CC(=C1OC)OC)CCN,skin sensitisation,-,0.8157
COC1=CC(=CC(=C1OC)OC)CCN,Respiratory toxicity,+,0.6111
COC1=CC(=CC(=C1OC)OC)CCN,Reproductive toxicity,+,0.6778
COC1=CC(=CC(=C1OC)OC)CCN,Mitochondrial toxicity,+,0.8625
COC1=CC(=CC(=C1OC)OC)CCN,Nephrotoxicity,-,0.8381
COC1=CC(=CC(=C1OC)OC)CCN,Acute Oral Toxicity (c),III,0.5087
COC1=CC(=CC(=C1OC)OC)CCN,Estrogen receptor binding,-,0.8249
COC1=CC(=CC(=C1OC)OC)CCN,Androgen receptor binding,-,0.8513
COC1=CC(=CC(=C1OC)OC)CCN,Thyroid receptor binding,-,0.6238
COC1=CC(=CC(=C1OC)OC)CCN,Glucocorticoid receptor binding,-,0.8149
COC1=CC(=CC(=C1OC)OC)CCN,Aromatase binding,-,0.6568
COC1=CC(=CC(=C1OC)OC)CCN,PPAR gamma,-,0.8592
COC1=CC(=CC(=C1OC)OC)CCN,Honey bee toxicity,-,0.9028
COC1=CC(=CC(=C1OC)OC)CCN,Biodegradation,-,0.8
COC1=CC(=CC(=C1OC)OC)CCN,Crustacea aquatic toxicity,+,0.56
COC1=CC(=CC(=C1OC)OC)CCN,Fish aquatic toxicity,-,0.9071
COC1=CC(=CC(=C1OC)OC)CCN,ADMET predicted profile --- Regressions,Value,Unit
COC1=CC(=CC(=C1OC)OC)CCN,Water solubility,-2.065,logS
COC1=CC(=CC(=C1OC)OC)CCN,Plasma protein binding,0.46,100%
COC1=CC(=CC(=C1OC)OC)CCN,Acute Oral Toxicity,1.983,log(1/(mol/kg))
COC1=CC(=CC(=C1OC)OC)CCN,Tetrahymena pyriformis,-0.172,pIGC50 (ug/L)
,,,
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Human Intestinal Absorption,+,0.8915
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Caco-2,+,0.7708
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Blood Brain Barrier,+,0.875
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Human oral bioavailability,-,0.8
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Subcellular localzation,Mitochondria,0.6594
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,OATP2B1 inhibitior,-,1
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,OATP1B1 inhibitior,+,0.9169
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,OATP1B3 inhibitior,+,0.939
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,MATE1 inhibitior,-,0.92
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,OCT2 inhibitior,-,0.8
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,BSEP inhibitior,-,0.958
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,P-glycoprotein inhibitior,-,0.904
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,P-glycoprotein substrate,-,0.6516
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,CYP3A4 substrate,+,0.6604
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,CYP2C9 substrate,+,0.5716
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,CYP2D6 substrate,+,0.5768
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,CYP3A4 inhibition,-,0.8303
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,CYP2C9 inhibition,-,0.8028
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,CYP2C19 inhibition,-,0.7766
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,CYP2D6 inhibition,-,0.8238
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,CYP1A2 inhibition,-,0.6897
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,CYP2C8 inhibition,-,0.8749
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,CYP inhibitory promiscuity,-,0.7735
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,UGT catelyzed,-,0
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Carcinogenicity (binary),-,0.79
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Carcinogenicity (trinary),Non-required,0.6098
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Eye corrosion,-,0.9785
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Eye irritation,-,0.8092
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Skin irritation,-,0.7535
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Skin corrosion,-,0.9089
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Ames mutagenesis,+,0.59
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Human Ether-a-go-go-Related Gene inhibition,+,0.6995
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Micronuclear,+,0.74
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Hepatotoxicity,-,0.625
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,skin sensitisation,-,0.8548
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Respiratory toxicity,+,0.8667
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Reproductive toxicity,+,0.7889
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Mitochondrial toxicity,+,0.9375
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Nephrotoxicity,-,0.6402
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Acute Oral Toxicity (c),III,0.5527
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Estrogen receptor binding,-,0.6822
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Androgen receptor binding,-,0.5825
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Thyroid receptor binding,-,0.5153
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Glucocorticoid receptor binding,-,0.6024
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Aromatase binding,+,0.6018
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,PPAR gamma,+,0.5876
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Honey bee toxicity,-,0.5834
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Biodegradation,-,0.65
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Crustacea aquatic toxicity,-,0.5655
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Fish aquatic toxicity,+,0.8239
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,ADMET predicted profile --- Regressions,Value,Unit
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Water solubility,-3.009,logS
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Plasma protein binding,0.66,100%
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Acute Oral Toxicity,2.661,log(1/(mol/kg))
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,Tetrahymena pyriformis,0.942,pIGC50 (ug/L)
,,,
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Human Intestinal Absorption,+,0.9906
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Caco-2,+,0.9091
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Blood Brain Barrier,+,1
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Human oral bioavailability,+,0.9143
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Subcellular localzation,Mitochondria,0.4577
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,OATP2B1 inhibitior,-,0.8626
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,OATP1B1 inhibitior,+,0.8798
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,OATP1B3 inhibitior,+,0.9472
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,MATE1 inhibitior,-,0.82
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,OCT2 inhibitior,+,0.55
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,BSEP inhibitior,+,0.7711
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,P-glycoprotein inhibitior,-,0.6818
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,P-glycoprotein substrate,+,0.6187
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP3A4 substrate,-,0.654
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP2C9 substrate,-,1
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP2D6 substrate,+,0.5523
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP3A4 inhibition,-,0.5507
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP2C9 inhibition,-,0.864
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP2C19 inhibition,-,0.8177
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP2D6 inhibition,+,0.5449
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP1A2 inhibition,+,0.5312
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP2C8 inhibition,-,0.9188
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP inhibitory promiscuity,-,0.6586
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,UGT catelyzed,-,0
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Carcinogenicity (binary),+,0.56
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Carcinogenicity (trinary),Non-required,0.6933
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Eye corrosion,-,0.9901
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Eye irritation,-,0.9697
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Skin irritation,-,0.6117
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Skin corrosion,-,0.5125
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Ames mutagenesis,-,0.67
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Human Ether-a-go-go-Related Gene inhibition,+,0.7601
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Micronuclear,-,0.76
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Hepatotoxicity,-,0.8625
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,skin sensitisation,-,0.6548
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Respiratory toxicity,+,0.9222
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Reproductive toxicity,-,0.5667
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Mitochondrial toxicity,+,0.8875
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Nephrotoxicity,-,0.7797
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Acute Oral Toxicity (c),II,0.7449
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Estrogen receptor binding,+,0.6361
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Androgen receptor binding,-,0.5793
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Thyroid receptor binding,+,0.5263
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Glucocorticoid receptor binding,-,0.6823
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Aromatase binding,-,0.8127
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,PPAR gamma,+,0.6455
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Honey bee toxicity,-,0.9621
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Biodegradation,-,0.875
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Crustacea aquatic toxicity,-,0.56
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Fish aquatic toxicity,+,0.9205
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,ADMET predicted profile --- Regressions,Value,Unit
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Water solubility,-3.224,logS
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Plasma protein binding,0.772,100%
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Acute Oral Toxicity,3.225,log(1/(mol/kg))
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,Tetrahymena pyriformis,0.485,pIGC50 (ug/L)
,,,
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Human Intestinal Absorption,+,0.9821
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Caco-2,+,0.9313
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Blood Brain Barrier,-,0.523
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Human oral bioavailability,+,0.7857
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Subcellular localzation,Mitochondria,0.7501
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,OATP2B1 inhibitior,-,1
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,OATP1B1 inhibitior,+,0.9541
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,OATP1B3 inhibitior,+,0.9529
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,MATE1 inhibitior,-,0.7805
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,OCT2 inhibitior,+,0.975
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,BSEP inhibitior,+,0.8817
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,P-glycoprotein inhibitior,+,0.8509
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,P-glycoprotein substrate,+,0.8755
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,CYP3A4 substrate,+,0.6949
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,CYP2C9 substrate,-,1
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,CYP2D6 substrate,+,0.5188
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,CYP3A4 inhibition,-,0.8309
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,CYP2C9 inhibition,-,0.9071
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,CYP2C19 inhibition,-,0.9026
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,CYP2D6 inhibition,+,0.8931
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,CYP1A2 inhibition,-,0.9045
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,CYP2C8 inhibition,-,0.9882
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,CYP inhibitory promiscuity,-,0.7225
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,UGT catelyzed,+,0.9
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Carcinogenicity (binary),-,0.97
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Carcinogenicity (trinary),Non-required,0.6553
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Eye corrosion,-,0.9886
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Eye irritation,-,0.9837
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Skin irritation,+,0.667
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Skin corrosion,-,0.9034
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Ames mutagenesis,-,1
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Human Ether-a-go-go-Related Gene inhibition,+,0.8917
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Micronuclear,+,0.62
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Hepatotoxicity,+,0.9875
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,skin sensitisation,-,0.866
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Respiratory toxicity,+,0.7889
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Reproductive toxicity,+,0.8778
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Mitochondrial toxicity,+,0.925
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Nephrotoxicity,-,0.824
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Acute Oral Toxicity (c),II,0.746
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Estrogen receptor binding,-,0.5092
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Androgen receptor binding,+,0.8037
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Thyroid receptor binding,-,0.5568
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Glucocorticoid receptor binding,+,0.5838
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Aromatase binding,-,0.4938
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,PPAR gamma,-,0.8546
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Honey bee toxicity,-,0.7392
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Biodegradation,-,0.825
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Crustacea aquatic toxicity,-,0.56
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Fish aquatic toxicity,-,0.5605
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,ADMET predicted profile --- Regressions,Value,Unit
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Water solubility,-2.761,logS
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Plasma protein binding,0.764,100%
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Acute Oral Toxicity,2.706,log(1/(mol/kg))
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,Tetrahymena pyriformis,0.691,pIGC50 (ug/L)
,,,
CC(C(C1=CC=CC=C1)O)NC,Human Intestinal Absorption,+,0.9845
CC(C(C1=CC=CC=C1)O)NC,Caco-2,+,0.9313
CC(C(C1=CC=CC=C1)O)NC,Blood Brain Barrier,-,0.85
CC(C(C1=CC=CC=C1)O)NC,Human oral bioavailability,+,0.7714
CC(C(C1=CC=CC=C1)O)NC,Subcellular localzation,Lysosomes,0.5451
CC(C(C1=CC=CC=C1)O)NC,OATP2B1 inhibitior,-,1
CC(C(C1=CC=CC=C1)O)NC,OATP1B1 inhibitior,+,0.9566
CC(C(C1=CC=CC=C1)O)NC,OATP1B3 inhibitior,+,0.9659
CC(C(C1=CC=CC=C1)O)NC,MATE1 inhibitior,-,1
CC(C(C1=CC=CC=C1)O)NC,OCT2 inhibitior,-,0.975
CC(C(C1=CC=CC=C1)O)NC,BSEP inhibitior,-,0.9237
CC(C(C1=CC=CC=C1)O)NC,P-glycoprotein inhibitior,-,0.9741
CC(C(C1=CC=CC=C1)O)NC,P-glycoprotein substrate,-,0.9308
CC(C(C1=CC=CC=C1)O)NC,CYP3A4 substrate,-,0.7817
CC(C(C1=CC=CC=C1)O)NC,CYP2C9 substrate,-,1
CC(C(C1=CC=CC=C1)O)NC,CYP2D6 substrate,+,0.6099
CC(C(C1=CC=CC=C1)O)NC,CYP3A4 inhibition,-,0.9431
CC(C(C1=CC=CC=C1)O)NC,CYP2C9 inhibition,-,0.7209
CC(C(C1=CC=CC=C1)O)NC,CYP2C19 inhibition,-,0.5737
CC(C(C1=CC=CC=C1)O)NC,CYP2D6 inhibition,+,0.5846
CC(C(C1=CC=CC=C1)O)NC,CYP1A2 inhibition,-,0.5595
CC(C(C1=CC=CC=C1)O)NC,CYP2C8 inhibition,-,0.9882
CC(C(C1=CC=CC=C1)O)NC,CYP inhibitory promiscuity,-,0.907
CC(C(C1=CC=CC=C1)O)NC,UGT catelyzed,+,0.8
CC(C(C1=CC=CC=C1)O)NC,Carcinogenicity (binary),-,0.6242
CC(C(C1=CC=CC=C1)O)NC,Carcinogenicity (trinary),Non-required,0.7401
CC(C(C1=CC=CC=C1)O)NC,Eye corrosion,-,0.9886
CC(C(C1=CC=CC=C1)O)NC,Eye irritation,-,0.9696
CC(C(C1=CC=CC=C1)O)NC,Skin irritation,-,0.5871
CC(C(C1=CC=CC=C1)O)NC,Skin corrosion,-,0.5499
CC(C(C1=CC=CC=C1)O)NC,Ames mutagenesis,-,0.99
CC(C(C1=CC=CC=C1)O)NC,Human Ether-a-go-go-Related Gene inhibition,-,0.764
CC(C(C1=CC=CC=C1)O)NC,Micronuclear,+,0.56
CC(C(C1=CC=CC=C1)O)NC,Hepatotoxicity,+,0.6651
CC(C(C1=CC=CC=C1)O)NC,skin sensitisation,-,0.7718
CC(C(C1=CC=CC=C1)O)NC,Respiratory toxicity,+,0.9222
CC(C(C1=CC=CC=C1)O)NC,Reproductive toxicity,-,0.5778
CC(C(C1=CC=CC=C1)O)NC,Mitochondrial toxicity,+,0.9
CC(C(C1=CC=CC=C1)O)NC,Nephrotoxicity,-,0.6496
CC(C(C1=CC=CC=C1)O)NC,Acute Oral Toxicity (c),III,0.894
CC(C(C1=CC=CC=C1)O)NC,Estrogen receptor binding,-,0.9205
CC(C(C1=CC=CC=C1)O)NC,Androgen receptor binding,-,0.8448
CC(C(C1=CC=CC=C1)O)NC,Thyroid receptor binding,-,0.8826
CC(C(C1=CC=CC=C1)O)NC,Glucocorticoid receptor binding,-,0.912
CC(C(C1=CC=CC=C1)O)NC,Aromatase binding,-,0.8514
CC(C(C1=CC=CC=C1)O)NC,PPAR gamma,-,0.9004
CC(C(C1=CC=CC=C1)O)NC,Honey bee toxicity,-,0.9411
CC(C(C1=CC=CC=C1)O)NC,Biodegradation,-,0.95
CC(C(C1=CC=CC=C1)O)NC,Crustacea aquatic toxicity,-,0.52
CC(C(C1=CC=CC=C1)O)NC,Fish aquatic toxicity,-,0.8469
CC(C(C1=CC=CC=C1)O)NC,ADMET predicted profile --- Regressions,Value,Unit
CC(C(C1=CC=CC=C1)O)NC,Water solubility,-0.482,logS
CC(C(C1=CC=CC=C1)O)NC,Plasma protein binding,0.265,100%
CC(C(C1=CC=CC=C1)O)NC,Acute Oral Toxicity,2.171,log(1/(mol/kg))
CC(C(C1=CC=CC=C1)O)NC,Tetrahymena pyriformis,-0.666,pIGC50 (ug/L)
,,,
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Human Intestinal Absorption,+,0.9914
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Caco-2,+,0.8611
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Blood Brain Barrier,+,0.75
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Human oral bioavailability,+,0.9571
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Subcellular localzation,Mitochondria,0.9091
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,OATP2B1 inhibitior,-,1
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,OATP1B1 inhibitior,+,0.9413
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,OATP1B3 inhibitior,+,0.948
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,MATE1 inhibitior,-,1
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,OCT2 inhibitior,-,1
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,BSEP inhibitior,-,0.752
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,P-glycoprotein inhibitior,-,0.9361
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,P-glycoprotein substrate,-,0.9361
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,CYP3A4 substrate,-,0.7914
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,CYP2C9 substrate,-,1
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,CYP2D6 substrate,-,0.8993
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,CYP3A4 inhibition,-,0.9598
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,CYP2C9 inhibition,-,0.907
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,CYP2C19 inhibition,-,0.9465
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,CYP2D6 inhibition,-,0.9604
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,CYP1A2 inhibition,-,0.9046
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,CYP2C8 inhibition,-,0.9434
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,CYP inhibitory promiscuity,-,0.9438
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,UGT catelyzed,-,0
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Carcinogenicity (binary),+,0.5332
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Carcinogenicity (trinary),Non-required,0.7238
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Eye corrosion,-,0.9606
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Eye irritation,+,0.8397
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Skin irritation,+,0.5639
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Skin corrosion,-,0.8284
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Ames mutagenesis,-,0.94
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Human Ether-a-go-go-Related Gene inhibition,-,0.7077
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Micronuclear,-,0.76
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Hepatotoxicity,+,0.9625
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,skin sensitisation,-,0.7151
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Respiratory toxicity,+,0.9111
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Reproductive toxicity,-,0.7889
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Mitochondrial toxicity,+,0.825
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Nephrotoxicity,-,0.7882
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Acute Oral Toxicity (c),II,0.7719
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Estrogen receptor binding,+,0.8128
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Androgen receptor binding,+,0.5749
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Thyroid receptor binding,-,0.5
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Glucocorticoid receptor binding,-,0.8661
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Aromatase binding,+,0.7255
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,PPAR gamma,+,0.6192
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Honey bee toxicity,-,0.9547
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Biodegradation,-,0.8
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Crustacea aquatic toxicity,-,0.56
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Fish aquatic toxicity,+,0.9689
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,ADMET predicted profile --- Regressions,Value,Unit
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Water solubility,-3.637,logS
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Plasma protein binding,0.988,100%
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Acute Oral Toxicity,2.876,log(1/(mol/kg))
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,Tetrahymena pyriformis,0.165,pIGC50 (ug/L)
,,,
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Human Intestinal Absorption,+,0.9761
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Caco-2,+,0.5706
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Blood Brain Barrier,+,1
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Human oral bioavailability,-,0.9857
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Subcellular localzation,Mitochondria,0.58
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,OATP2B1 inhibitior,-,1
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,OATP1B1 inhibitior,+,0.9398
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,OATP1B3 inhibitior,+,0.9492
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,MATE1 inhibitior,-,0.98
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,OCT2 inhibitior,-,0.9099
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,BSEP inhibitior,-,0.9231
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,P-glycoprotein inhibitior,-,0.9215
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,P-glycoprotein substrate,-,0.8666
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,CYP3A4 substrate,+,0.5846
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,CYP2C9 substrate,-,0.8108
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,CYP2D6 substrate,+,0.535
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,CYP3A4 inhibition,-,0.9153
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,CYP2C9 inhibition,-,0.9303
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,CYP2C19 inhibition,-,0.9025
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,CYP2D6 inhibition,-,0.7886
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,CYP1A2 inhibition,-,0.9046
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,CYP2C8 inhibition,-,0.877
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,CYP inhibitory promiscuity,-,0.9523
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,UGT catelyzed,+,0.8
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Carcinogenicity (binary),-,0.98
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Carcinogenicity (trinary),Non-required,0.5181
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Eye corrosion,-,0.9904
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Eye irritation,-,0.9683
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Skin irritation,-,0.7669
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Skin corrosion,-,0.9262
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Ames mutagenesis,-,0.6654
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Human Ether-a-go-go-Related Gene inhibition,-,0.5888
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Micronuclear,+,0.64
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Hepatotoxicity,-,1
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,skin sensitisation,-,0.6975
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Respiratory toxicity,+,0.9778
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Reproductive toxicity,+,0.9444
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Mitochondrial toxicity,+,1
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Nephrotoxicity,-,0.8242
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Acute Oral Toxicity (c),III,0.6217
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Estrogen receptor binding,-,0.8681
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Androgen receptor binding,+,0.5299
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Thyroid receptor binding,-,0.5341
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Glucocorticoid receptor binding,+,0.6619
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Aromatase binding,+,0.5635
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,PPAR gamma,+,0.6057
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Honey bee toxicity,-,0.7932
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Biodegradation,-,0.775
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Crustacea aquatic toxicity,-,0.51
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Fish aquatic toxicity,+,0.6627
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,ADMET predicted profile --- Regressions,Value,Unit
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Water solubility,-2.563,logS
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Plasma protein binding,0.547,100%
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Acute Oral Toxicity,2.691,log(1/(mol/kg))
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,Tetrahymena pyriformis,1.315,pIGC50 (ug/L)
,,,
CC(C(C1=CC=CC=C1)O)NC,Human Intestinal Absorption,+,0.9845
CC(C(C1=CC=CC=C1)O)NC,Caco-2,+,0.9313
CC(C(C1=CC=CC=C1)O)NC,Blood Brain Barrier,-,0.85
CC(C(C1=CC=CC=C1)O)NC,Human oral bioavailability,+,0.7714
CC(C(C1=CC=CC=C1)O)NC,Subcellular localzation,Lysosomes,0.5451
CC(C(C1=CC=CC=C1)O)NC,OATP2B1 inhibitior,-,1
CC(C(C1=CC=CC=C1)O)NC,OATP1B1 inhibitior,+,0.9566
CC(C(C1=CC=CC=C1)O)NC,OATP1B3 inhibitior,+,0.9659
CC(C(C1=CC=CC=C1)O)NC,MATE1 inhibitior,-,1
CC(C(C1=CC=CC=C1)O)NC,OCT2 inhibitior,-,0.975
CC(C(C1=CC=CC=C1)O)NC,BSEP inhibitior,-,0.9237
CC(C(C1=CC=CC=C1)O)NC,P-glycoprotein inhibitior,-,0.9741
CC(C(C1=CC=CC=C1)O)NC,P-glycoprotein substrate,-,0.9308
CC(C(C1=CC=CC=C1)O)NC,CYP3A4 substrate,-,0.7817
CC(C(C1=CC=CC=C1)O)NC,CYP2C9 substrate,-,1
CC(C(C1=CC=CC=C1)O)NC,CYP2D6 substrate,+,0.6099
CC(C(C1=CC=CC=C1)O)NC,CYP3A4 inhibition,-,0.9431
CC(C(C1=CC=CC=C1)O)NC,CYP2C9 inhibition,-,0.7209
CC(C(C1=CC=CC=C1)O)NC,CYP2C19 inhibition,-,0.5737
CC(C(C1=CC=CC=C1)O)NC,CYP2D6 inhibition,+,0.5846
CC(C(C1=CC=CC=C1)O)NC,CYP1A2 inhibition,-,0.5595
CC(C(C1=CC=CC=C1)O)NC,CYP2C8 inhibition,-,0.9882
CC(C(C1=CC=CC=C1)O)NC,CYP inhibitory promiscuity,-,0.907
CC(C(C1=CC=CC=C1)O)NC,UGT catelyzed,+,0.8
CC(C(C1=CC=CC=C1)O)NC,Carcinogenicity (binary),-,0.6242
CC(C(C1=CC=CC=C1)O)NC,Carcinogenicity (trinary),Non-required,0.7401
CC(C(C1=CC=CC=C1)O)NC,Eye corrosion,-,0.9886
CC(C(C1=CC=CC=C1)O)NC,Eye irritation,-,0.9696
CC(C(C1=CC=CC=C1)O)NC,Skin irritation,-,0.5871
CC(C(C1=CC=CC=C1)O)NC,Skin corrosion,-,0.5499
CC(C(C1=CC=CC=C1)O)NC,Ames mutagenesis,-,0.99
CC(C(C1=CC=CC=C1)O)NC,Human Ether-a-go-go-Related Gene inhibition,-,0.764
CC(C(C1=CC=CC=C1)O)NC,Micronuclear,+,0.56
CC(C(C1=CC=CC=C1)O)NC,Hepatotoxicity,+,0.6651
CC(C(C1=CC=CC=C1)O)NC,skin sensitisation,-,0.7718
CC(C(C1=CC=CC=C1)O)NC,Respiratory toxicity,+,0.9222
CC(C(C1=CC=CC=C1)O)NC,Reproductive toxicity,-,0.5778
CC(C(C1=CC=CC=C1)O)NC,Mitochondrial toxicity,+,0.9
CC(C(C1=CC=CC=C1)O)NC,Nephrotoxicity,-,0.6496
CC(C(C1=CC=CC=C1)O)NC,Acute Oral Toxicity (c),III,0.894
CC(C(C1=CC=CC=C1)O)NC,Estrogen receptor binding,-,0.9205
CC(C(C1=CC=CC=C1)O)NC,Androgen receptor binding,-,0.8448
CC(C(C1=CC=CC=C1)O)NC,Thyroid receptor binding,-,0.8826
CC(C(C1=CC=CC=C1)O)NC,Glucocorticoid receptor binding,-,0.912
CC(C(C1=CC=CC=C1)O)NC,Aromatase binding,-,0.8514
CC(C(C1=CC=CC=C1)O)NC,PPAR gamma,-,0.9004
CC(C(C1=CC=CC=C1)O)NC,Honey bee toxicity,-,0.9411
CC(C(C1=CC=CC=C1)O)NC,Biodegradation,-,0.95
CC(C(C1=CC=CC=C1)O)NC,Crustacea aquatic toxicity,-,0.52
CC(C(C1=CC=CC=C1)O)NC,Fish aquatic toxicity,-,0.8469
CC(C(C1=CC=CC=C1)O)NC,ADMET predicted profile --- Regressions,Value,Unit
CC(C(C1=CC=CC=C1)O)NC,Water solubility,-0.482,logS
CC(C(C1=CC=CC=C1)O)NC,Plasma protein binding,0.265,100%
CC(C(C1=CC=CC=C1)O)NC,Acute Oral Toxicity,2.171,log(1/(mol/kg))
CC(C(C1=CC=CC=C1)O)NC,Tetrahymena pyriformis,-0.666,pIGC50 (ug/L)
,,,
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Human Intestinal Absorption,+,0.9769
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Caco-2,+,0.9369
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Blood Brain Barrier,+,0.975
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Human oral bioavailability,-,0.9571
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Subcellular localzation,Mitochondria,0.5489
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,OATP2B1 inhibitior,-,0.8654
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,OATP1B1 inhibitior,+,0.949
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,OATP1B3 inhibitior,+,0.9472
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,MATE1 inhibitior,-,0.98
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,OCT2 inhibitior,-,0.7
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,BSEP inhibitior,+,0.8637
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,P-glycoprotein inhibitior,-,0.7546
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,P-glycoprotein substrate,-,0.6507
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CYP3A4 substrate,-,0.697
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CYP2C9 substrate,-,1
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CYP2D6 substrate,+,0.6212
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CYP3A4 inhibition,-,0.8308
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CYP2C9 inhibition,-,0.9341
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CYP2C19 inhibition,-,0.9025
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CYP2D6 inhibition,+,0.8931
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CYP1A2 inhibition,+,0.9107
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CYP2C8 inhibition,-,0.9882
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CYP inhibitory promiscuity,-,0.567
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,UGT catelyzed,-,0
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Carcinogenicity (binary),-,0.96
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Carcinogenicity (trinary),Non-required,0.7046
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Eye corrosion,-,0.9894
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Eye irritation,-,0.9668
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Skin irritation,-,0.6384
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Skin corrosion,-,0.8278
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Ames mutagenesis,-,0.95
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Human Ether-a-go-go-Related Gene inhibition,+,0.8786
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Micronuclear,+,0.54
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Hepatotoxicity,+,0.775
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,skin sensitisation,-,0.8189
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Respiratory toxicity,+,0.9556
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Reproductive toxicity,+,0.6444
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Mitochondrial toxicity,+,1
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Nephrotoxicity,-,0.8449
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Acute Oral Toxicity (c),II,0.4964
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Estrogen receptor binding,+,0.7328
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Androgen receptor binding,-,0.6583
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Thyroid receptor binding,+,0.7391
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Glucocorticoid receptor binding,+,0.5641
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Aromatase binding,+,0.7899
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,PPAR gamma,+,0.771
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Honey bee toxicity,-,0.9531
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Biodegradation,-,0.9
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Crustacea aquatic toxicity,+,0.64
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Fish aquatic toxicity,+,0.9312
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,ADMET predicted profile --- Regressions,Value,Unit
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Water solubility,-4.197,logS
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Plasma protein binding,0.855,1
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Acute Oral Toxicity,2.325,log(1/(mol/kg))
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,Tetrahymena pyriformis,0.885,pIGC50 (ug/L)
,,,
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Human Intestinal Absorption,+,0.8019
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Caco-2,-,0.8183
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Blood Brain Barrier,+,0.875
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Human oral bioavailability,+,0.8857
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Subcellular localzation,Mitochondria,0.6162
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,OATP2B1 inhibitior,-,1
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,OATP1B1 inhibitior,+,0.9729
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,OATP1B3 inhibitior,+,0.9479
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,MATE1 inhibitior,-,0.96
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,OCT2 inhibitior,-,0.9
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,BSEP inhibitior,-,0.9395
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,P-glycoprotein inhibitior,-,0.9603
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,P-glycoprotein substrate,-,0.9154
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CYP3A4 substrate,-,0.6335
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CYP2C9 substrate,-,1
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CYP2D6 substrate,-,0.9106
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CYP3A4 inhibition,-,0.9037
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CYP2C9 inhibition,-,0.9071
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CYP2C19 inhibition,-,0.9026
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CYP2D6 inhibition,-,0.9625
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CYP1A2 inhibition,-,0.9259
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CYP2C8 inhibition,-,0.9673
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CYP inhibitory promiscuity,-,0.8798
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,UGT catelyzed,-,0
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Carcinogenicity (binary),-,0.6713
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Carcinogenicity (trinary),Non-required,0.572
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Eye corrosion,-,0.9831
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Eye irritation,-,0.971
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Skin irritation,-,0.685
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Skin corrosion,-,0.9398
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Ames mutagenesis,+,0.57
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Human Ether-a-go-go-Related Gene inhibition,-,0.657
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Micronuclear,+,0.92
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Hepatotoxicity,+,0.9125
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,skin sensitisation,-,0.8832
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Respiratory toxicity,+,0.8778
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Reproductive toxicity,+,0.8222
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Mitochondrial toxicity,+,0.9
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Nephrotoxicity,+,0.7551
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Acute Oral Toxicity (c),III,0.6485
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Estrogen receptor binding,-,0.9629
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Androgen receptor binding,-,0.8187
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Thyroid receptor binding,-,0.6945
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Glucocorticoid receptor binding,-,0.8662
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Aromatase binding,-,0.714
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,PPAR gamma,-,0.825
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Honey bee toxicity,-,0.9722
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Biodegradation,-,0.7
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Crustacea aquatic toxicity,-,0.7
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Fish aquatic toxicity,+,0.7153
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,ADMET predicted profile --- Regressions,Value,Unit
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Water solubility,-2.297,logS
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Plasma protein binding,0.526,100%
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Acute Oral Toxicity,1.531,log(1/(mol/kg))
CC(=O)NC1=NN=C(S1)S(=O)(=O)N,Tetrahymena pyriformis,-0.357,pIGC50 (ug/L)
,,,
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Human Intestinal Absorption,+,0.9803
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Caco-2,+,0.8079
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Blood Brain Barrier,+,1
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Human oral bioavailability,+,0.9857
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Subcellular localzation,Mitochondria,0.8624
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,OATP2B1 inhibitior,-,1
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,OATP1B1 inhibitior,+,0.9423
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,OATP1B3 inhibitior,+,0.949
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,MATE1 inhibitior,-,0.98
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,OCT2 inhibitior,-,0.95
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,BSEP inhibitior,-,0.8281
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,P-glycoprotein inhibitior,-,0.9829
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,P-glycoprotein substrate,-,0.9188
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CYP3A4 substrate,-,0.7986
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CYP2C9 substrate,-,0.5
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CYP2D6 substrate,-,0.8437
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CYP3A4 inhibition,-,0.9236
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CYP2C9 inhibition,-,0.9023
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CYP2C19 inhibition,-,0.8664
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CYP2D6 inhibition,-,0.9593
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CYP1A2 inhibition,-,0.84
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CYP2C8 inhibition,-,0.9415
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CYP inhibitory promiscuity,-,0.9164
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,UGT catelyzed,-,0
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Carcinogenicity (binary),-,0.58
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Carcinogenicity (trinary),Non-required,0.7028
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Eye corrosion,-,0.992
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Eye irritation,-,0.9647
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Skin irritation,-,0.8286
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Skin corrosion,-,0.9499
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Ames mutagenesis,+,0.95
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Human Ether-a-go-go-Related Gene inhibition,-,0.8202
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Micronuclear,+,0.93
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Hepatotoxicity,+,0.7689
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,skin sensitisation,-,0.8716
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Respiratory toxicity,+,0.9667
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Reproductive toxicity,+,0.9
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Mitochondrial toxicity,+,0.95
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Nephrotoxicity,+,0.5178
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Acute Oral Toxicity (c),II,0.7243
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Estrogen receptor binding,-,0.6929
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Androgen receptor binding,-,0.6322
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Thyroid receptor binding,-,0.8272
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Glucocorticoid receptor binding,-,0.7815
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Aromatase binding,-,0.5
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,PPAR gamma,-,0.8026
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Honey bee toxicity,-,0.9598
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Biodegradation,-,0.9
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Crustacea aquatic toxicity,+,0.51
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Fish aquatic toxicity,-,0.661
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,ADMET predicted profile --- Regressions,Value,Unit
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Water solubility,-2.257,logS
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Plasma protein binding,0.342,100%
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Acute Oral Toxicity,2.518,log(1/(mol/kg))
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Tetrahymena pyriformis,-0.544,pIGC50 (ug/L)
,,,
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Human Intestinal Absorption,+,0.9963
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Caco-2,+,0.7604
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Blood Brain Barrier,+,1
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Human oral bioavailability,+,0.6714
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Subcellular localzation,Mitochondria,0.7344
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,OATP2B1 inhibitior,-,1
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,OATP1B1 inhibitior,+,0.9723
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,OATP1B3 inhibitior,+,0.9506
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,MATE1 inhibitior,-,0.86
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,OCT2 inhibitior,+,0.7
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,BSEP inhibitior,-,0.8659
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,P-glycoprotein inhibitior,-,0.9462
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,P-glycoprotein substrate,-,0.7375
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CYP3A4 substrate,+,0.5683
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CYP2C9 substrate,-,1
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CYP2D6 substrate,+,0.3624
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CYP3A4 inhibition,-,0.8539
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CYP2C9 inhibition,-,0.897
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CYP2C19 inhibition,-,0.9265
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CYP2D6 inhibition,-,0.5245
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CYP1A2 inhibition,-,0.592
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CYP2C8 inhibition,-,0.9153
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CYP inhibitory promiscuity,-,0.9328
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,UGT catelyzed,-,0
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Carcinogenicity (binary),-,0.92
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Carcinogenicity (trinary),Non-required,0.7319
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Eye corrosion,-,0.9886
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Eye irritation,-,0.9541
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Skin irritation,-,0.5921
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Skin corrosion,-,0.8907
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Ames mutagenesis,-,0.97
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Human Ether-a-go-go-Related Gene inhibition,-,0.4565
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Micronuclear,-,0.68
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Hepatotoxicity,+,0.7159
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,skin sensitisation,-,0.9172
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Respiratory toxicity,+,0.9333
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Reproductive toxicity,+,0.6889
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Mitochondrial toxicity,+,0.8625
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Nephrotoxicity,-,0.8119
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Acute Oral Toxicity (c),II,0.7519
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Estrogen receptor binding,-,0.8633
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Androgen receptor binding,+,0.6898
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Thyroid receptor binding,-,0.7438
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Glucocorticoid receptor binding,-,0.7662
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Aromatase binding,-,0.7496
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,PPAR gamma,-,0.8183
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Honey bee toxicity,-,0.951
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Biodegradation,-,0.8
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Crustacea aquatic toxicity,-,0.55
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Fish aquatic toxicity,-,0.694
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,ADMET predicted profile --- Regressions,Value,Unit
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Water solubility,-1.991,logS
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Plasma protein binding,0.328,100%
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Acute Oral Toxicity,2.534,log(1/(mol/kg))
COC(=O)C(C1CCCCN1)C2=CC=CC=C2,Tetrahymena pyriformis,0.626,pIGC50 (ug/L)
,,,
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Human Intestinal Absorption,+,0.9761
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Caco-2,+,0.9313
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Blood Brain Barrier,+,1
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Human oral bioavailability,-,0.9571
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Subcellular localzation,Lysosomes,0.7009
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,OATP2B1 inhibitior,-,1
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,OATP1B1 inhibitior,+,0.9099
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,OATP1B3 inhibitior,+,0.9482
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,MATE1 inhibitior,-,1
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,OCT2 inhibitior,+,0.925
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,BSEP inhibitior,+,0.9071
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,P-glycoprotein inhibitior,+,0.7781
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,P-glycoprotein substrate,+,0.7457
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CYP3A4 substrate,+,0.7557
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CYP2C9 substrate,-,1
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CYP2D6 substrate,+,0.7085
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CYP3A4 inhibition,-,0.9375
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CYP2C9 inhibition,-,0.9071
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CYP2C19 inhibition,+,0.5512
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CYP2D6 inhibition,+,0.9422
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CYP1A2 inhibition,+,0.9305
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CYP2C8 inhibition,-,0.9341
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CYP inhibitory promiscuity,+,0.6601
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,UGT catelyzed,-,0
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Carcinogenicity (binary),-,0.89
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Carcinogenicity (trinary),Non-required,0.7297
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Eye corrosion,-,0.9912
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Eye irritation,-,0.9679
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Skin irritation,-,0.7013
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Skin corrosion,-,0.8812
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Ames mutagenesis,-,0.84
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Human Ether-a-go-go-Related Gene inhibition,+,0.8134
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Micronuclear,-,0.78
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Hepatotoxicity,+,0.9875
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,skin sensitisation,-,0.7823
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Respiratory toxicity,+,0.9778
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Reproductive toxicity,+,0.6556
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Mitochondrial toxicity,+,1
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Nephrotoxicity,-,0.8389
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Acute Oral Toxicity (c),II,0.7472
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Estrogen receptor binding,+,0.8757
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Androgen receptor binding,-,0.5727
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Thyroid receptor binding,+,0.8357
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Glucocorticoid receptor binding,-,0.5315
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Aromatase binding,+,0.7473
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,PPAR gamma,+,0.8931
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Honey bee toxicity,-,0.9062
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Biodegradation,-,0.9
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Crustacea aquatic toxicity,+,0.72
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Fish aquatic toxicity,+,0.9641
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,ADMET predicted profile --- Regressions,Value,Unit
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Water solubility,-4.947,logS
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Plasma protein binding,0.931,100%
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Acute Oral Toxicity,2.262,log(1/(mol/kg))
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,Tetrahymena pyriformis,1.39,pIGC50 (ug/L)
,,,
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Human Intestinal Absorption,+,0.9969
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Caco-2,+,0.4894
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Blood Brain Barrier,+,0.975
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Human oral bioavailability,+,0.7
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Subcellular localzation,Mitochondria,0.9339
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,OATP2B1 inhibitior,-,1
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,OATP1B1 inhibitior,+,0.9517
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,OATP1B3 inhibitior,+,0.9479
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,MATE1 inhibitior,-,0.98
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,OCT2 inhibitior,-,0.85
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,BSEP inhibitior,+,0.9072
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,P-glycoprotein inhibitior,+,0.8807
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,P-glycoprotein substrate,-,0.7472
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CYP3A4 substrate,+,0.742
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CYP2C9 substrate,-,1
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CYP2D6 substrate,+,0.5101
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CYP3A4 inhibition,+,0.6899
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CYP2C9 inhibition,-,0.9207
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CYP2C19 inhibition,-,0.9248
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CYP2D6 inhibition,+,0.9197
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CYP1A2 inhibition,-,0.9045
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CYP2C8 inhibition,-,0.66
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CYP inhibitory promiscuity,-,0.7933
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,UGT catelyzed,-,0.5
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Carcinogenicity (binary),-,0.77
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Carcinogenicity (trinary),Non-required,0.5065
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Eye corrosion,-,0.9922
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Eye irritation,-,0.9646
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Skin irritation,-,0.6608
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Skin corrosion,-,0.9089
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Ames mutagenesis,-,0.97
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Human Ether-a-go-go-Related Gene inhibition,-,0.5
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Micronuclear,+,0.78
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Hepatotoxicity,+,0.5274
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,skin sensitisation,-,0.8059
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Respiratory toxicity,+,0.9667
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Reproductive toxicity,+,0.9333
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Mitochondrial toxicity,+,0.9875
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Nephrotoxicity,-,0.8067
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Acute Oral Toxicity (c),II,0.7338
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Estrogen receptor binding,-,0.6952
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Androgen receptor binding,+,0.8696
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Thyroid receptor binding,+,0.6706
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Glucocorticoid receptor binding,-,0.5275
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Aromatase binding,+,0.6573
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,PPAR gamma,-,0.6179
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Honey bee toxicity,-,0.9419
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Biodegradation,-,0.7
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Crustacea aquatic toxicity,-,0.53
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Fish aquatic toxicity,-,0.5213
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,ADMET predicted profile --- Regressions,Value,Unit
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Water solubility,-4.367,logS
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Plasma protein binding,0.897,100%
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Acute Oral Toxicity,2.553,log(1/(mol/kg))
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,Tetrahymena pyriformis,1.795,pIGC50 (ug/L)
,,,
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Human Intestinal Absorption,+,0.9762
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Caco-2,+,0.9313
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Blood Brain Barrier,+,0.975
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Human oral bioavailability,+,0.9571
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Subcellular localzation,Mitochondria,0.5892
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,OATP2B1 inhibitior,-,0.8421
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,OATP1B1 inhibitior,+,0.9177
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,OATP1B3 inhibitior,+,0.9402
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,MATE1 inhibitior,-,0.94
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,OCT2 inhibitior,-,0.925
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,BSEP inhibitior,+,0.8717
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,P-glycoprotein inhibitior,-,0.8832
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,P-glycoprotein substrate,-,0.9374
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,CYP3A4 substrate,+,0.702
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,CYP2C9 substrate,-,0.6481
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,CYP2D6 substrate,-,0.8871
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,CYP3A4 inhibition,-,0.6563
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,CYP2C9 inhibition,-,0.5063
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,CYP2C19 inhibition,+,0.5065
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,CYP2D6 inhibition,-,0.8445
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,CYP1A2 inhibition,+,0.8262
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,CYP2C8 inhibition,-,0.9882
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,CYP inhibitory promiscuity,-,0.6407
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,UGT catelyzed,+,0.6
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Carcinogenicity (binary),-,0.6278
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Carcinogenicity (trinary),Non-required,0.7136
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Eye corrosion,-,0.9886
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Eye irritation,-,0.9568
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Skin irritation,+,0.6075
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Skin corrosion,-,0.9508
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Ames mutagenesis,-,0.79
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Human Ether-a-go-go-Related Gene inhibition,-,0.8264
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Micronuclear,+,0.78
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Hepatotoxicity,-,0.925
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,skin sensitisation,-,0.8429
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Respiratory toxicity,+,0.8556
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Reproductive toxicity,+,0.9444
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Mitochondrial toxicity,+,0.8125
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Nephrotoxicity,+,0.7981
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Acute Oral Toxicity (c),III,0.7272
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Estrogen receptor binding,+,0.9052
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Androgen receptor binding,+,0.8754
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Thyroid receptor binding,+,0.8269
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Glucocorticoid receptor binding,+,0.9436
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Aromatase binding,+,0.8388
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,PPAR gamma,+,0.9662
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Honey bee toxicity,-,0.8837
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Biodegradation,-,0.85
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Crustacea aquatic toxicity,+,0.77
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Fish aquatic toxicity,+,0.9039
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,ADMET predicted profile --- Regressions,Value,Unit
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Water solubility,-3.887,logS
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Plasma protein binding,0.931,1
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Acute Oral Toxicity,1.347,log(1/(mol/kg))
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,Tetrahymena pyriformis,1.546,pIGC50 (ug/L)
,,,
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Human Intestinal Absorption,+,0.9968
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Caco-2,+,0.9126
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Blood Brain Barrier,+,0.95
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Human oral bioavailability,+,0.8571
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Subcellular localzation,Mitochondria,0.8441
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,OATP2B1 inhibitior,-,0.8413
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,OATP1B1 inhibitior,+,0.9414
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,OATP1B3 inhibitior,+,0.9479
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,MATE1 inhibitior,-,1
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,OCT2 inhibitior,+,0.7402
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,BSEP inhibitior,+,0.8954
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,P-glycoprotein inhibitior,-,0.602
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,P-glycoprotein substrate,-,0.9362
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,CYP3A4 substrate,+,0.6762
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,CYP2C9 substrate,+,1
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,CYP2D6 substrate,-,0.8694
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,CYP3A4 inhibition,-,0.8309
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,CYP2C9 inhibition,-,0.8331
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,CYP2C19 inhibition,-,0.9119
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,CYP2D6 inhibition,-,0.8754
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,CYP1A2 inhibition,+,0.624
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,CYP2C8 inhibition,-,0.9882
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,CYP inhibitory promiscuity,-,0.5265
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,UGT catelyzed,-,0
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Carcinogenicity (binary),-,0.93
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Carcinogenicity (trinary),Non-required,0.6465
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Eye corrosion,-,0.9898
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Eye irritation,-,0.9569
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Skin irritation,-,0.7649
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Skin corrosion,-,0.9349
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Ames mutagenesis,+,0.62
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Human Ether-a-go-go-Related Gene inhibition,-,0.4351
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Micronuclear,+,0.71
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Hepatotoxicity,+,0.8533
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,skin sensitisation,-,0.877
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Respiratory toxicity,+,0.8556
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Reproductive toxicity,+,0.8111
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Mitochondrial toxicity,+,0.925
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Nephrotoxicity,+,0.4716
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Acute Oral Toxicity (c),III,0.8022
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Estrogen receptor binding,+,0.7744
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Androgen receptor binding,+,0.8696
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Thyroid receptor binding,+,0.6791
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Glucocorticoid receptor binding,+,0.897
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Aromatase binding,+,0.8685
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,PPAR gamma,+,0.7053
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Honey bee toxicity,-,0.9493
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Biodegradation,-,0.95
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Crustacea aquatic toxicity,-,0.63
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Fish aquatic toxicity,-,0.6428
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,ADMET predicted profile --- Regressions,Value,Unit
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Water solubility,-2.585,logS
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Plasma protein binding,1.014,100%
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Acute Oral Toxicity,2.615,log(1/(mol/kg))
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,Tetrahymena pyriformis,1.291,pIGC50 (ug/L)
,,,
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Human Intestinal Absorption,+,0.9863
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Caco-2,+,0.9548
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Blood Brain Barrier,+,1
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Human oral bioavailability,-,0.8
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Subcellular localzation,Mitochondria,0.5052
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,OATP2B1 inhibitior,-,0.8581
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,OATP1B1 inhibitior,-,0.7307
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,OATP1B3 inhibitior,+,0.9549
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,MATE1 inhibitior,-,0.92
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,OCT2 inhibitior,+,0.75
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,BSEP inhibitior,+,0.6065
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,P-glycoprotein inhibitior,-,0.9165
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,P-glycoprotein substrate,+,0.5818
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,CYP3A4 substrate,+,0.7356
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,CYP2C9 substrate,+,1
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,CYP2D6 substrate,+,0.8031
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,CYP3A4 inhibition,-,0.8308
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,CYP2C9 inhibition,-,0.9071
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,CYP2C19 inhibition,-,0.9025
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,CYP2D6 inhibition,+,0.8932
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,CYP1A2 inhibition,-,0.9046
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,CYP2C8 inhibition,-,0.9116
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,CYP inhibitory promiscuity,-,0.8673
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,UGT catelyzed,-,0
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Carcinogenicity (binary),-,0.97
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Carcinogenicity (trinary),Non-required,0.6932
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Eye corrosion,-,0.9886
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Eye irritation,-,0.9851
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Skin irritation,-,0.6884
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Skin corrosion,-,0.8079
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Ames mutagenesis,-,0.7
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Human Ether-a-go-go-Related Gene inhibition,+,0.9101
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Micronuclear,-,0.77
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Hepatotoxicity,-,0.975
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,skin sensitisation,-,0.8497
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Respiratory toxicity,+,0.9222
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Reproductive toxicity,+,0.8556
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Mitochondrial toxicity,+,0.975
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Nephrotoxicity,-,0.8939
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Acute Oral Toxicity (c),II,0.79
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Estrogen receptor binding,-,0.688
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Androgen receptor binding,+,0.8405
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Thyroid receptor binding,-,0.5412
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Glucocorticoid receptor binding,-,0.7503
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Aromatase binding,-,0.6872
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,PPAR gamma,-,0.7065
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Honey bee toxicity,-,0.838
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Biodegradation,-,0.9
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Crustacea aquatic toxicity,+,0.83
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Fish aquatic toxicity,+,0.7561
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,ADMET predicted profile --- Regressions,Value,Unit
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Water solubility,-2.272,logS
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Plasma protein binding,0.582,100%
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Acute Oral Toxicity,3.325,log(1/(mol/kg))
CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,Tetrahymena pyriformis,2.052,pIGC50 (ug/L)
,,,
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Human Intestinal Absorption,+,0.9153
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Caco-2,+,0.5387
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Blood Brain Barrier,+,0.95
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Human oral bioavailability,-,0.9143
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Subcellular localzation,Mitochondria,0.4709
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),OATP2B1 inhibitior,-,1
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),OATP1B1 inhibitior,+,0.8936
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),OATP1B3 inhibitior,+,0.9293
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),MATE1 inhibitior,-,0.94
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),OCT2 inhibitior,-,0.675
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),BSEP inhibitior,+,0.7668
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),P-glycoprotein inhibitior,-,0.5787
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),P-glycoprotein substrate,+,0.9344
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),CYP3A4 substrate,+,0.6928
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),CYP2C9 substrate,-,1
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),CYP2D6 substrate,+,0.6173
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),CYP3A4 inhibition,-,0.8322
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),CYP2C9 inhibition,-,0.8692
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),CYP2C19 inhibition,-,0.7801
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),CYP2D6 inhibition,-,0.6721
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),CYP1A2 inhibition,-,0.9153
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),CYP2C8 inhibition,+,0.5508
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),CYP inhibitory promiscuity,-,0.9212
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),UGT catelyzed,+,0.8
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Carcinogenicity (binary),-,0.95
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Carcinogenicity (trinary),Non-required,0.594
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Eye corrosion,-,0.99
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Eye irritation,-,0.9541
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Skin irritation,-,0.8654
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Skin corrosion,-,0.9629
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Ames mutagenesis,-,0.58
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Human Ether-a-go-go-Related Gene inhibition,+,0.8917
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Micronuclear,-,0.52
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Hepatotoxicity,-,0.5752
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),skin sensitisation,-,0.855
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Respiratory toxicity,+,0.9667
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Reproductive toxicity,+,0.9667
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Mitochondrial toxicity,+,0.975
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Nephrotoxicity,-,0.7827
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Acute Oral Toxicity (c),III,0.5506
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Estrogen receptor binding,+,0.8588
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Androgen receptor binding,+,0.7023
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Thyroid receptor binding,+,0.6833
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Glucocorticoid receptor binding,+,0.7558
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Aromatase binding,+,0.7712
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),PPAR gamma,+,0.5932
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Honey bee toxicity,-,0.8085
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Biodegradation,-,0.85
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Crustacea aquatic toxicity,+,0.59
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Fish aquatic toxicity,+,0.6827
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),ADMET predicted profile --- Regressions,Value,Unit
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Water solubility,-2.395,logS
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Plasma protein binding,0.405,100%
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Acute Oral Toxicity,3.256,log(1/(mol/kg))
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O),Tetrahymena pyriformis,1.878,pIGC50 (ug/L)
,,,
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Human Intestinal Absorption,+,0.9783
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Caco-2,+,0.9313
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Blood Brain Barrier,+,0.925
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Human oral bioavailability,+,0.8429
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Subcellular localzation,Mitochondria,0.8985
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,OATP2B1 inhibitior,-,0.851
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,OATP1B1 inhibitior,+,0.8995
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,OATP1B3 inhibitior,+,0.9266
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,MATE1 inhibitior,-,1
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,OCT2 inhibitior,-,0.825
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,BSEP inhibitior,-,0.8428
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,P-glycoprotein inhibitior,-,0.9266
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,P-glycoprotein substrate,-,0.6402
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,CYP3A4 substrate,+,0.6112
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,CYP2C9 substrate,-,0.5
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,CYP2D6 substrate,+,0.7047
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,CYP3A4 inhibition,-,0.6256
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,CYP2C9 inhibition,-,0.704
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,CYP2C19 inhibition,-,0.6841
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,CYP2D6 inhibition,+,0.6566
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,CYP1A2 inhibition,-,0.7136
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,CYP2C8 inhibition,-,0.801
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,CYP inhibitory promiscuity,-,0.7832
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,UGT catelyzed,+,0.7
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Carcinogenicity (binary),-,0.75
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Carcinogenicity (trinary),Non-required,0.6384
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Eye corrosion,-,0.9886
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Eye irritation,-,0.9541
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Skin irritation,-,0.7478
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Skin corrosion,-,0.8532
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Ames mutagenesis,-,0.677
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Human Ether-a-go-go-Related Gene inhibition,+,0.8086
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Micronuclear,-,0.7
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Hepatotoxicity,-,0.6036
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,skin sensitisation,-,0.7911
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Respiratory toxicity,+,0.9778
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Reproductive toxicity,+,0.6556
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Mitochondrial toxicity,+,0.975
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Nephrotoxicity,-,0.9404
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Acute Oral Toxicity (c),II,0.7306
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Estrogen receptor binding,-,0.5194
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Androgen receptor binding,-,0.6806
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Thyroid receptor binding,+,0.5783
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Glucocorticoid receptor binding,-,0.6018
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Aromatase binding,-,0.5537
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,PPAR gamma,-,0.7346
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Honey bee toxicity,-,0.9385
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Biodegradation,-,0.775
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Crustacea aquatic toxicity,+,0.52
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Fish aquatic toxicity,+,0.8471
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,ADMET predicted profile --- Regressions,Value,Unit
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Water solubility,-3.781,logS
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Plasma protein binding,0.455,100%
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Acute Oral Toxicity,2.883,log(1/(mol/kg))
CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,Tetrahymena pyriformis,0.932,pIGC50 (ug/L)
,,,
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Human Intestinal Absorption,+,0.9958
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Caco-2,+,0.9338
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Blood Brain Barrier,+,0.975
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Human oral bioavailability,+,0.9143
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Subcellular localzation,Mitochondria,0.3675
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,OATP2B1 inhibitior,-,1
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,OATP1B1 inhibitior,+,0.9726
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,OATP1B3 inhibitior,+,0.948
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,MATE1 inhibitior,-,0.98
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,OCT2 inhibitior,-,0.95
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,BSEP inhibitior,-,0.4811
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,P-glycoprotein inhibitior,-,0.9424
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,P-glycoprotein substrate,-,0.9653
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CYP3A4 substrate,-,0.6583
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CYP2C9 substrate,+,1
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CYP2D6 substrate,-,0.7387
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CYP3A4 inhibition,-,0.8222
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CYP2C9 inhibition,-,0.907
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CYP2C19 inhibition,-,0.9025
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CYP2D6 inhibition,-,0.9232
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CYP1A2 inhibition,-,0.9045
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CYP2C8 inhibition,-,0.9882
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CYP inhibitory promiscuity,+,0.7358
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,UGT catelyzed,-,0
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Carcinogenicity (binary),-,0.77
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Carcinogenicity (trinary),Non-required,0.5064
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Eye corrosion,-,0.9886
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Eye irritation,-,0.7086
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Skin irritation,-,0.6505
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Skin corrosion,-,0.9517
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Ames mutagenesis,-,0.83
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Human Ether-a-go-go-Related Gene inhibition,-,0.8225
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Micronuclear,+,0.82
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Hepatotoxicity,+,0.95
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,skin sensitisation,-,0.8665
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Respiratory toxicity,+,0.8778
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Reproductive toxicity,+,0.8222
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Mitochondrial toxicity,+,0.9875
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Nephrotoxicity,-,0.5893
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Acute Oral Toxicity (c),III,0.7753
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Estrogen receptor binding,+,0.8191
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Androgen receptor binding,+,0.6094
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Thyroid receptor binding,+,0.7424
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Glucocorticoid receptor binding,+,0.8275
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Aromatase binding,+,0.8036
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,PPAR gamma,+,0.6697
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Honey bee toxicity,-,0.9803
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Biodegradation,-,0.875
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Crustacea aquatic toxicity,-,0.83
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Fish aquatic toxicity,+,0.8501
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,ADMET predicted profile --- Regressions,Value,Unit
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Water solubility,-4.2,logS
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Plasma protein binding,0.774,100%
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Acute Oral Toxicity,1.757,log(1/(mol/kg))
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,Tetrahymena pyriformis,0.557,pIGC50 (ug/L)
,,,
C1CCC(CC1)(CC(=O)O)CN,Human Intestinal Absorption,+,0.9788
C1CCC(CC1)(CC(=O)O)CN,Caco-2,-,0.6546
C1CCC(CC1)(CC(=O)O)CN,Blood Brain Barrier,+,0.875
C1CCC(CC1)(CC(=O)O)CN,Human oral bioavailability,+,0.7286
C1CCC(CC1)(CC(=O)O)CN,Subcellular localzation,Mitochondria,0.5525
C1CCC(CC1)(CC(=O)O)CN,OATP2B1 inhibitior,-,0.8514
C1CCC(CC1)(CC(=O)O)CN,OATP1B1 inhibitior,+,0.9582
C1CCC(CC1)(CC(=O)O)CN,OATP1B3 inhibitior,+,0.9488
C1CCC(CC1)(CC(=O)O)CN,MATE1 inhibitior,-,0.98
C1CCC(CC1)(CC(=O)O)CN,OCT2 inhibitior,-,0.725
C1CCC(CC1)(CC(=O)O)CN,BSEP inhibitior,-,0.8728
C1CCC(CC1)(CC(=O)O)CN,P-glycoprotein inhibitior,-,0.9779
C1CCC(CC1)(CC(=O)O)CN,P-glycoprotein substrate,-,0.98
C1CCC(CC1)(CC(=O)O)CN,CYP3A4 substrate,-,0.7123
C1CCC(CC1)(CC(=O)O)CN,CYP2C9 substrate,-,0.5856
C1CCC(CC1)(CC(=O)O)CN,CYP2D6 substrate,-,0.7742
C1CCC(CC1)(CC(=O)O)CN,CYP3A4 inhibition,-,0.8438
C1CCC(CC1)(CC(=O)O)CN,CYP2C9 inhibition,-,0.9273
C1CCC(CC1)(CC(=O)O)CN,CYP2C19 inhibition,-,0.9547
C1CCC(CC1)(CC(=O)O)CN,CYP2D6 inhibition,-,0.9418
C1CCC(CC1)(CC(=O)O)CN,CYP1A2 inhibition,-,0.9409
C1CCC(CC1)(CC(=O)O)CN,CYP2C8 inhibition,-,0.9882
C1CCC(CC1)(CC(=O)O)CN,CYP inhibitory promiscuity,-,0.9706
C1CCC(CC1)(CC(=O)O)CN,UGT catelyzed,-,0
C1CCC(CC1)(CC(=O)O)CN,Carcinogenicity (binary),-,0.7635
C1CCC(CC1)(CC(=O)O)CN,Carcinogenicity (trinary),Warning,0.5375
C1CCC(CC1)(CC(=O)O)CN,Eye corrosion,-,0.9739
C1CCC(CC1)(CC(=O)O)CN,Eye irritation,+,0.8743
C1CCC(CC1)(CC(=O)O)CN,Skin irritation,-,0.646
C1CCC(CC1)(CC(=O)O)CN,Skin corrosion,-,0.8801
C1CCC(CC1)(CC(=O)O)CN,Ames mutagenesis,-,0.87
C1CCC(CC1)(CC(=O)O)CN,Human Ether-a-go-go-Related Gene inhibition,-,0.6966
C1CCC(CC1)(CC(=O)O)CN,Micronuclear,-,0.89
C1CCC(CC1)(CC(=O)O)CN,Hepatotoxicity,+,0.85
C1CCC(CC1)(CC(=O)O)CN,skin sensitisation,-,0.7641
C1CCC(CC1)(CC(=O)O)CN,Respiratory toxicity,+,0.8222
C1CCC(CC1)(CC(=O)O)CN,Reproductive toxicity,+,0.7667
C1CCC(CC1)(CC(=O)O)CN,Mitochondrial toxicity,+,0.925
C1CCC(CC1)(CC(=O)O)CN,Nephrotoxicity,-,0.885
C1CCC(CC1)(CC(=O)O)CN,Acute Oral Toxicity (c),III,0.4759
C1CCC(CC1)(CC(=O)O)CN,Estrogen receptor binding,-,0.9406
C1CCC(CC1)(CC(=O)O)CN,Androgen receptor binding,-,0.7824
C1CCC(CC1)(CC(=O)O)CN,Thyroid receptor binding,-,0.8228
C1CCC(CC1)(CC(=O)O)CN,Glucocorticoid receptor binding,-,0.7723
C1CCC(CC1)(CC(=O)O)CN,Aromatase binding,-,0.7572
C1CCC(CC1)(CC(=O)O)CN,PPAR gamma,-,0.6444
C1CCC(CC1)(CC(=O)O)CN,Honey bee toxicity,-,0.9651
C1CCC(CC1)(CC(=O)O)CN,Biodegradation,-,0.525
C1CCC(CC1)(CC(=O)O)CN,Crustacea aquatic toxicity,-,0.9
C1CCC(CC1)(CC(=O)O)CN,Fish aquatic toxicity,-,0.7952
C1CCC(CC1)(CC(=O)O)CN,ADMET predicted profile --- Regressions,Value,Unit
C1CCC(CC1)(CC(=O)O)CN,Water solubility,-2.13,logS
C1CCC(CC1)(CC(=O)O)CN,Plasma protein binding,0.439,1
C1CCC(CC1)(CC(=O)O)CN,Acute Oral Toxicity,1.45,log(1/(mol/kg))
C1CCC(CC1)(CC(=O)O)CN,Tetrahymena pyriformis,0.551,pIGC50 (ug/L)
,,,
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Human Intestinal Absorption,+,1
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Caco-2,-,0.5545
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Blood Brain Barrier,+,1
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Human oral bioavailability,+,0.7571
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Subcellular localzation,Mitochondria,0.6421
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,OATP2B1 inhibitior,-,1
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,OATP1B1 inhibitior,+,0.9085
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,OATP1B3 inhibitior,+,0.9401
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,MATE1 inhibitior,-,0.64
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,OCT2 inhibitior,-,0.5
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,BSEP inhibitior,+,0.9072
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,P-glycoprotein inhibitior,+,0.9112
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,P-glycoprotein substrate,+,0.9343
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP3A4 substrate,+,0.7981
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2C9 substrate,-,1
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2D6 substrate,-,0.7439
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP3A4 inhibition,-,0.82
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2C9 inhibition,-,0.9071
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2C19 inhibition,-,0.9026
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2D6 inhibition,+,0.8931
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP1A2 inhibition,-,0.9046
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2C8 inhibition,-,0.9882
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP inhibitory promiscuity,+,0.8459
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,UGT catelyzed,-,0
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Carcinogenicity (binary),-,0.74
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Carcinogenicity (trinary),Non-required,0.5555
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Eye corrosion,-,0.9886
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Eye irritation,-,0.9796
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Skin irritation,-,0.7859
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Skin corrosion,-,0.9307
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Ames mutagenesis,+,0.51
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Human Ether-a-go-go-Related Gene inhibition,+,0.8917
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Micronuclear,+,0.72
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Hepatotoxicity,+,0.7875
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,skin sensitisation,-,0.8181
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Respiratory toxicity,+,0.9667
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Reproductive toxicity,+,0.9556
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Mitochondrial toxicity,+,1
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Nephrotoxicity,-,0.8944
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Acute Oral Toxicity (c),II,0.7383
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Estrogen receptor binding,+,0.8905
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Androgen receptor binding,-,0.8513
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Thyroid receptor binding,+,0.6295
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Glucocorticoid receptor binding,+,0.5982
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Aromatase binding,+,0.6264
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,PPAR gamma,+,0.6463
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Honey bee toxicity,-,0.8562
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Biodegradation,-,0.7
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Crustacea aquatic toxicity,+,0.56
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Fish aquatic toxicity,+,0.9134
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,ADMET predicted profile --- Regressions,Value,Unit
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Water solubility,-3.305,logS
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Plasma protein binding,0.855,100%
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Acute Oral Toxicity,3.572,log(1/(mol/kg))
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Tetrahymena pyriformis,1.014,pIGC50 (ug/L)
,,,
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Human Intestinal Absorption,+,0.9836
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Caco-2,+,0.9595
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Blood Brain Barrier,+,1
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Human oral bioavailability,+,0.7714
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Subcellular localzation,Lysosomes,0.4218
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,OATP2B1 inhibitior,-,1
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,OATP1B1 inhibitior,+,0.9385
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,OATP1B3 inhibitior,+,0.9465
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,MATE1 inhibitior,-,0.98
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,OCT2 inhibitior,+,1
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,BSEP inhibitior,+,0.8755
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,P-glycoprotein inhibitior,+,0.9077
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,P-glycoprotein substrate,-,0.9137
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP3A4 substrate,+,0.7121
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2C9 substrate,+,1
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 substrate,+,0.7661
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP3A4 inhibition,-,0.9158
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2C9 inhibition,-,0.9071
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2C19 inhibition,-,0.9025
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 inhibition,+,0.8933
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP1A2 inhibition,+,0.7324
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2C8 inhibition,-,0.9865
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP inhibitory promiscuity,-,0.6955
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,UGT catelyzed,-,0
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Carcinogenicity (binary),-,0.85
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Carcinogenicity (trinary),Non-required,0.7209
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Eye corrosion,-,0.9886
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Eye irritation,-,0.9709
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Skin irritation,-,0.5548
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Skin corrosion,-,0.5
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Ames mutagenesis,-,0.96
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Human Ether-a-go-go-Related Gene inhibition,+,0.8917
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Micronuclear,-,0.77
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Hepatotoxicity,+,0.7569
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,skin sensitisation,-,0.6588
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Respiratory toxicity,+,1
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Reproductive toxicity,+,0.5444
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Mitochondrial toxicity,+,0.9875
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Nephrotoxicity,-,0.7567
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Acute Oral Toxicity (c),II,0.7507
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Estrogen receptor binding,-,0.474
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Androgen receptor binding,+,0.7744
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Thyroid receptor binding,+,0.605
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Glucocorticoid receptor binding,-,0.749
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Aromatase binding,+,0.5714
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,PPAR gamma,+,0.7292
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Honey bee toxicity,-,0.9333
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Biodegradation,-,0.95
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Crustacea aquatic toxicity,+,0.72
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Fish aquatic toxicity,+,0.986
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,ADMET predicted profile --- Regressions,Value,Unit
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Water solubility,-4.398,logS
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Plasma protein binding,0.987,100%
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Acute Oral Toxicity,2.59,log(1/(mol/kg))
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,Tetrahymena pyriformis,0.412,pIGC50 (ug/L)
,,,
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Human Intestinal Absorption,+,0.9761
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Caco-2,+,0.8075
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Blood Brain Barrier,+,0.975
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Human oral bioavailability,-,0.8429
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Subcellular localzation,Mitochondria,0.8533
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,OATP2B1 inhibitior,-,0.8517
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,OATP1B1 inhibitior,+,0.9228
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,OATP1B3 inhibitior,+,0.9345
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,MATE1 inhibitior,-,1
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,OCT2 inhibitior,-,0.8
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,BSEP inhibitior,-,0.8346
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,P-glycoprotein inhibitior,-,0.6765
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,P-glycoprotein substrate,+,0.5729
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP3A4 substrate,+,0.5
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2C9 substrate,-,0.5
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2D6 substrate,+,0.7047
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP3A4 inhibition,-,0.8308
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2C9 inhibition,-,0.6876
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2C19 inhibition,-,0.7199
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2D6 inhibition,+,0.7287
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP1A2 inhibition,-,0.7664
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2C8 inhibition,-,0.9882
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP inhibitory promiscuity,-,0.8666
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,UGT catelyzed,+,0.6
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Carcinogenicity (binary),-,0.74
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Carcinogenicity (trinary),Non-required,0.6563
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Eye corrosion,-,0.9886
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Eye irritation,-,0.9729
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Skin irritation,-,0.7263
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Skin corrosion,-,0.7847
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Ames mutagenesis,-,0.8
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Human Ether-a-go-go-Related Gene inhibition,+,0.8793
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Micronuclear,-,0.69
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Hepatotoxicity,+,0.8297
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,skin sensitisation,-,0.7582
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Respiratory toxicity,+,0.9222
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Reproductive toxicity,+,0.6111
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Mitochondrial toxicity,+,0.975
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Nephrotoxicity,-,0.9352
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Acute Oral Toxicity (c),III,0.47
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Estrogen receptor binding,+,0.7128
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Androgen receptor binding,+,0.5947
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Thyroid receptor binding,+,0.538
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Glucocorticoid receptor binding,-,0.6614
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Aromatase binding,+,0.5685
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,PPAR gamma,-,0.5519
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Honey bee toxicity,-,0.9611
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Biodegradation,-,0.8
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Crustacea aquatic toxicity,-,0.81
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Fish aquatic toxicity,+,0.6836
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,ADMET predicted profile --- Regressions,Value,Unit
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Water solubility,-3.453,logS
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Plasma protein binding,0.453,100%
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Acute Oral Toxicity,2.81,log(1/(mol/kg))
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,Tetrahymena pyriformis,1.503,pIGC50 (ug/L)
,,,
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Human Intestinal Absorption,+,0.9835
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Caco-2,+,0.9313
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Blood Brain Barrier,+,0.775
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Human oral bioavailability,+,0.8286
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Subcellular localzation,Mitochondria,0.6315
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,OATP2B1 inhibitior,-,1
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,OATP1B1 inhibitior,+,0.9564
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,OATP1B3 inhibitior,+,0.9449
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,MATE1 inhibitior,+,0.58
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,OCT2 inhibitior,-,0.55
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,BSEP inhibitior,-,0.6489
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,P-glycoprotein inhibitior,-,0.9783
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,P-glycoprotein substrate,-,0.9361
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,CYP3A4 substrate,-,0.5436
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,CYP2C9 substrate,-,0.756
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,CYP2D6 substrate,-,0.9031
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,CYP3A4 inhibition,-,0.7678
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,CYP2C9 inhibition,-,0.9071
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,CYP2C19 inhibition,-,0.8594
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,CYP2D6 inhibition,+,0.7007
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,CYP1A2 inhibition,-,0.611
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,CYP2C8 inhibition,-,0.664
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,CYP inhibitory promiscuity,-,0.5515
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,UGT catelyzed,-,0
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Carcinogenicity (binary),-,0.7919
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Carcinogenicity (trinary),Non-required,0.5755
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Eye corrosion,-,0.9895
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Eye irritation,-,0.9784
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Skin irritation,-,0.593
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Skin corrosion,-,0.9577
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Ames mutagenesis,+,0.54
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Human Ether-a-go-go-Related Gene inhibition,-,0.726
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Micronuclear,+,0.82
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Hepatotoxicity,+,0.6375
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,skin sensitisation,-,0.8897
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Respiratory toxicity,+,0.7889
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Reproductive toxicity,+,0.8444
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Mitochondrial toxicity,+,0.8125
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Nephrotoxicity,+,0.8331
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Acute Oral Toxicity (c),II,0.6525
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Estrogen receptor binding,+,0.8802
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Androgen receptor binding,-,0.8475
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Thyroid receptor binding,+,0.864
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Glucocorticoid receptor binding,+,0.9184
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Aromatase binding,+,0.8048
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,PPAR gamma,+,0.8895
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Honey bee toxicity,-,0.9583
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Biodegradation,-,0.925
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Crustacea aquatic toxicity,+,0.9
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Fish aquatic toxicity,+,0.7747
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,ADMET predicted profile --- Regressions,Value,Unit
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Water solubility,-2.825,logS
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Plasma protein binding,0.628,100%
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Acute Oral Toxicity,2.584,log(1/(mol/kg))
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Tetrahymena pyriformis,0.831,pIGC50 (ug/L)
,,,
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Human Intestinal Absorption,+,0.9851
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Caco-2,+,0.8798
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Blood Brain Barrier,+,1
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Human oral bioavailability,+,0.8857
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Subcellular localzation,Lysosomes,0.6876
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,OATP2B1 inhibitior,-,0.8582
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,OATP1B1 inhibitior,+,0.9414
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,OATP1B3 inhibitior,+,0.9479
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,MATE1 inhibitior,-,1
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,OCT2 inhibitior,+,0.65
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,BSEP inhibitior,+,0.9071
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,P-glycoprotein inhibitior,+,0.9361
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,P-glycoprotein substrate,-,0.8369
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CYP3A4 substrate,+,0.7628
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CYP2C9 substrate,-,0.8125
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CYP2D6 substrate,+,0.3654
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CYP3A4 inhibition,-,0.9137
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CYP2C9 inhibition,-,0.9432
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CYP2C19 inhibition,-,0.9026
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CYP2D6 inhibition,+,0.8932
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CYP1A2 inhibition,+,0.5722
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CYP2C8 inhibition,-,0.9882
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CYP inhibitory promiscuity,-,0.571
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,UGT catelyzed,-,0
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Carcinogenicity (binary),-,0.8518
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Carcinogenicity (trinary),Non-required,0.7243
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Eye corrosion,-,0.9874
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Eye irritation,-,0.9629
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Skin irritation,+,0.6651
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Skin corrosion,-,0.8871
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Ames mutagenesis,-,0.89
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Human Ether-a-go-go-Related Gene inhibition,+,0.8503
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Micronuclear,+,0.75
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Hepatotoxicity,+,0.75
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,skin sensitisation,-,0.8427
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Respiratory toxicity,+,0.9889
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Reproductive toxicity,+,0.8222
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Mitochondrial toxicity,+,1
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Nephrotoxicity,+,0.5325
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Acute Oral Toxicity (c),II,0.7428
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Estrogen receptor binding,-,0.5901
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Androgen receptor binding,+,0.8696
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Thyroid receptor binding,+,0.8163
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Glucocorticoid receptor binding,-,0.5748
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Aromatase binding,+,0.6832
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,PPAR gamma,+,0.8708
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Honey bee toxicity,-,0.8997
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Biodegradation,-,0.975
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Crustacea aquatic toxicity,+,0.71
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Fish aquatic toxicity,+,0.9708
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,ADMET predicted profile --- Regressions,Value,Unit
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Water solubility,-3.409,logS
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Plasma protein binding,1.037,100%
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Acute Oral Toxicity,2.011,log(1/(mol/kg))
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,Tetrahymena pyriformis,1.569,pIGC50 (ug/L)
,,,
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Human Intestinal Absorption,+,0.9847
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Caco-2,+,0.8586
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Blood Brain Barrier,+,1
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Human oral bioavailability,+,0.8857
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Subcellular localzation,Lysosomes,0.5443
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,OATP2B1 inhibitior,-,0.8617
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,OATP1B1 inhibitior,+,0.9557
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,OATP1B3 inhibitior,+,0.9407
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,MATE1 inhibitior,-,0.98
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,OCT2 inhibitior,+,0.9
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,BSEP inhibitior,+,0.9072
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,P-glycoprotein inhibitior,+,0.8323
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,P-glycoprotein substrate,-,0.6501
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,CYP3A4 substrate,+,0.5105
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,CYP2C9 substrate,-,1
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,CYP2D6 substrate,-,0.7007
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,CYP3A4 inhibition,-,0.9526
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,CYP2C9 inhibition,-,0.6914
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,CYP2C19 inhibition,+,0.572
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,CYP2D6 inhibition,+,0.608
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,CYP1A2 inhibition,+,0.6454
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,CYP2C8 inhibition,-,0.9882
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,CYP inhibitory promiscuity,+,0.707
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,UGT catelyzed,-,0
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Carcinogenicity (binary),-,0.98
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Carcinogenicity (trinary),Non-required,0.7335
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Eye corrosion,-,0.9881
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Eye irritation,-,0.9691
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Skin irritation,-,0.6686
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Skin corrosion,-,0.8914
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Ames mutagenesis,-,0.75
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Human Ether-a-go-go-Related Gene inhibition,+,0.9242
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Micronuclear,+,0.74
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Hepatotoxicity,+,0.9625
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,skin sensitisation,-,0.8593
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Respiratory toxicity,+,0.9778
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Reproductive toxicity,+,0.9333
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Mitochondrial toxicity,+,1
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Nephrotoxicity,-,0.759
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Acute Oral Toxicity (c),III,0.5711
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Estrogen receptor binding,-,0.5325
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Androgen receptor binding,+,0.7285
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Thyroid receptor binding,+,0.6705
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Glucocorticoid receptor binding,-,0.5214
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Aromatase binding,+,0.7859
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,PPAR gamma,-,0.5955
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Honey bee toxicity,-,0.9032
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Biodegradation,-,0.95
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Crustacea aquatic toxicity,+,0.68
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Fish aquatic toxicity,+,0.9784
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,ADMET predicted profile --- Regressions,Value,Unit
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Water solubility,-3.393,logS
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Plasma protein binding,1.07,100%
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Acute Oral Toxicity,2.828,log(1/(mol/kg))
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Tetrahymena pyriformis,1.253,pIGC50 (ug/L)
,,,
CC(C)CC(CC(=O)O)CN,Human Intestinal Absorption,+,0.9753
CC(C)CC(CC(=O)O)CN,Caco-2,-,0.5365
CC(C)CC(CC(=O)O)CN,Blood Brain Barrier,+,0.9
CC(C)CC(CC(=O)O)CN,Human oral bioavailability,+,0.8571
CC(C)CC(CC(=O)O)CN,Subcellular localzation,Lysosomes,0.7086
CC(C)CC(CC(=O)O)CN,OATP2B1 inhibitior,-,0.85
CC(C)CC(CC(=O)O)CN,OATP1B1 inhibitior,+,0.9608
CC(C)CC(CC(=O)O)CN,OATP1B3 inhibitior,+,0.948
CC(C)CC(CC(=O)O)CN,MATE1 inhibitior,-,0.96
CC(C)CC(CC(=O)O)CN,OCT2 inhibitior,-,0.875
CC(C)CC(CC(=O)O)CN,BSEP inhibitior,-,0.9316
CC(C)CC(CC(=O)O)CN,P-glycoprotein inhibitior,-,0.985
CC(C)CC(CC(=O)O)CN,P-glycoprotein substrate,-,0.8534
CC(C)CC(CC(=O)O)CN,CYP3A4 substrate,-,0.6995
CC(C)CC(CC(=O)O)CN,CYP2C9 substrate,+,0.6594
CC(C)CC(CC(=O)O)CN,CYP2D6 substrate,-,0.7987
CC(C)CC(CC(=O)O)CN,CYP3A4 inhibition,-,0.9352
CC(C)CC(CC(=O)O)CN,CYP2C9 inhibition,-,0.9425
CC(C)CC(CC(=O)O)CN,CYP2C19 inhibition,-,0.9629
CC(C)CC(CC(=O)O)CN,CYP2D6 inhibition,-,0.9539
CC(C)CC(CC(=O)O)CN,CYP1A2 inhibition,-,0.9385
CC(C)CC(CC(=O)O)CN,CYP2C8 inhibition,-,0.9892
CC(C)CC(CC(=O)O)CN,CYP inhibitory promiscuity,-,0.9784
CC(C)CC(CC(=O)O)CN,UGT catelyzed,-,0
CC(C)CC(CC(=O)O)CN,Carcinogenicity (binary),-,0.5815
CC(C)CC(CC(=O)O)CN,Carcinogenicity (trinary),Non-required,0.5627
CC(C)CC(CC(=O)O)CN,Eye corrosion,+,0.4894
CC(C)CC(CC(=O)O)CN,Eye irritation,+,0.9619
CC(C)CC(CC(=O)O)CN,Skin irritation,-,0.7264
CC(C)CC(CC(=O)O)CN,Skin corrosion,+,0.5196
CC(C)CC(CC(=O)O)CN,Ames mutagenesis,-,0.8755
CC(C)CC(CC(=O)O)CN,Human Ether-a-go-go-Related Gene inhibition,-,0.7695
CC(C)CC(CC(=O)O)CN,Micronuclear,-,0.91
CC(C)CC(CC(=O)O)CN,Hepatotoxicity,+,0.875
CC(C)CC(CC(=O)O)CN,skin sensitisation,-,0.7926
CC(C)CC(CC(=O)O)CN,Respiratory toxicity,+,0.7889
CC(C)CC(CC(=O)O)CN,Reproductive toxicity,-,0.7768
CC(C)CC(CC(=O)O)CN,Mitochondrial toxicity,+,0.9
CC(C)CC(CC(=O)O)CN,Nephrotoxicity,-,0.6833
CC(C)CC(CC(=O)O)CN,Acute Oral Toxicity (c),III,0.5319
CC(C)CC(CC(=O)O)CN,Estrogen receptor binding,-,0.8962
CC(C)CC(CC(=O)O)CN,Androgen receptor binding,-,0.8513
CC(C)CC(CC(=O)O)CN,Thyroid receptor binding,-,0.838
CC(C)CC(CC(=O)O)CN,Glucocorticoid receptor binding,-,0.6892
CC(C)CC(CC(=O)O)CN,Aromatase binding,-,0.7896
CC(C)CC(CC(=O)O)CN,PPAR gamma,-,0.7756
CC(C)CC(CC(=O)O)CN,Honey bee toxicity,-,0.9744
CC(C)CC(CC(=O)O)CN,Biodegradation,+,0.625
CC(C)CC(CC(=O)O)CN,Crustacea aquatic toxicity,-,0.89
CC(C)CC(CC(=O)O)CN,Fish aquatic toxicity,-,0.8558
CC(C)CC(CC(=O)O)CN,ADMET predicted profile --- Regressions,Value,Unit
CC(C)CC(CC(=O)O)CN,Water solubility,-0.257,logS
CC(C)CC(CC(=O)O)CN,Plasma protein binding,0.605,1
CC(C)CC(CC(=O)O)CN,Acute Oral Toxicity,1.526,log(1/(mol/kg))
CC(C)CC(CC(=O)O)CN,Tetrahymena pyriformis,-0.617,pIGC50 (ug/L)
,,,
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Human Intestinal Absorption,+,0.9898
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Caco-2,+,0.8634
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Blood Brain Barrier,+,1
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Human oral bioavailability,-,0.9143
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Subcellular localzation,Lysosomes,0.486
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,OATP2B1 inhibitior,-,0.8653
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,OATP1B1 inhibitior,+,0.9414
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,OATP1B3 inhibitior,+,0.9506
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,MATE1 inhibitior,-,0.98
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,OCT2 inhibitior,+,0.525
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,BSEP inhibitior,+,0.7207
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,P-glycoprotein inhibitior,-,0.9285
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,P-glycoprotein substrate,+,0.5452
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CYP3A4 substrate,+,0.6569
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CYP2C9 substrate,+,0.6409
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CYP2D6 substrate,+,0.6286
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CYP3A4 inhibition,-,0.8309
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CYP2C9 inhibition,-,0.6675
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CYP2C19 inhibition,-,0.6206
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CYP2D6 inhibition,+,0.7222
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CYP1A2 inhibition,+,0.8503
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CYP2C8 inhibition,-,0.9882
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CYP inhibitory promiscuity,-,0.6031
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,UGT catelyzed,-,0
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Carcinogenicity (binary),-,0.96
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Carcinogenicity (trinary),Non-required,0.7321
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Eye corrosion,-,0.9888
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Eye irritation,-,0.9989
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Skin irritation,-,0.512
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Skin corrosion,-,0.8461
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Ames mutagenesis,-,0.51
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Human Ether-a-go-go-Related Gene inhibition,+,0.8554
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Micronuclear,+,0.58
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Hepatotoxicity,+,0.95
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,skin sensitisation,-,0.8918
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Respiratory toxicity,+,0.9667
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Reproductive toxicity,+,0.7667
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Mitochondrial toxicity,+,1
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Nephrotoxicity,-,0.879
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Acute Oral Toxicity (c),III,0.8137
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Estrogen receptor binding,-,0.7566
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Androgen receptor binding,-,0.7137
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Thyroid receptor binding,-,0.5888
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Glucocorticoid receptor binding,-,0.8661
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Aromatase binding,-,0.6602
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,PPAR gamma,-,0.5265
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Honey bee toxicity,-,0.9392
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Biodegradation,-,0.875
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Crustacea aquatic toxicity,+,0.67
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Fish aquatic toxicity,+,0.764
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,ADMET predicted profile --- Regressions,Value,Unit
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Water solubility,-2.676,logS
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Plasma protein binding,0.858,100%
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Acute Oral Toxicity,2.016,log(1/(mol/kg))
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,Tetrahymena pyriformis,0.528,pIGC50 (ug/L)
,,,
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Human Intestinal Absorption,+,0.9958
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Caco-2,+,0.9313
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Blood Brain Barrier,+,0.975
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Human oral bioavailability,+,0.7143
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Subcellular localzation,Mitochondria,0.5662
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,OATP2B1 inhibitior,-,1
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,OATP1B1 inhibitior,+,0.949
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,OATP1B3 inhibitior,+,0.9607
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,MATE1 inhibitior,-,0.92
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,OCT2 inhibitior,+,0.55
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,BSEP inhibitior,-,0.8667
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,P-glycoprotein inhibitior,-,0.9395
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,P-glycoprotein substrate,-,0.7675
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CYP3A4 substrate,+,0.5418
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CYP2C9 substrate,-,1
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CYP2D6 substrate,-,0.678
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CYP3A4 inhibition,-,0.7743
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CYP2C9 inhibition,-,0.907
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CYP2C19 inhibition,+,0.8993
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CYP2D6 inhibition,+,0.8932
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CYP1A2 inhibition,-,0.7499
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CYP2C8 inhibition,-,0.9882
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CYP inhibitory promiscuity,+,0.5141
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,UGT catelyzed,-,0
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Carcinogenicity (binary),-,0.5685
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Carcinogenicity (trinary),Non-required,0.6441
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Eye corrosion,-,0.9886
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Eye irritation,-,0.954
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Skin irritation,+,0.5955
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Skin corrosion,-,0.707
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Ames mutagenesis,-,0.76
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Human Ether-a-go-go-Related Gene inhibition,-,0.7261
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Micronuclear,-,0.61
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Hepatotoxicity,+,0.8875
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,skin sensitisation,+,0.5601
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Respiratory toxicity,+,0.5667
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Reproductive toxicity,-,0.7222
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Mitochondrial toxicity,+,0.5625
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Nephrotoxicity,-,0.679
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Acute Oral Toxicity (c),III,0.7824
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Estrogen receptor binding,+,0.6347
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Androgen receptor binding,-,0.8907
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Thyroid receptor binding,-,0.7499
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Glucocorticoid receptor binding,-,0.8738
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Aromatase binding,-,0.5924
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,PPAR gamma,-,0.7561
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Honey bee toxicity,-,0.919
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Biodegradation,-,0.825
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Crustacea aquatic toxicity,+,0.5918
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Fish aquatic toxicity,+,0.7576
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,ADMET predicted profile --- Regressions,Value,Unit
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Water solubility,-3.618,logS
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Plasma protein binding,0.96,100%
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Acute Oral Toxicity,1.429,log(1/(mol/kg))
CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,Tetrahymena pyriformis,0.612,pIGC50 (ug/L)
,,,
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Human Intestinal Absorption,+,1
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Caco-2,+,0.8134
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Blood Brain Barrier,+,0.975
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Human oral bioavailability,-,0.7429
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Subcellular localzation,Lysosomes,0.6606
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,OATP2B1 inhibitior,-,1
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,OATP1B1 inhibitior,+,0.933
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,OATP1B3 inhibitior,+,0.9455
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,MATE1 inhibitior,-,0.88
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,OCT2 inhibitior,+,0.675
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,BSEP inhibitior,+,0.6683
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,P-glycoprotein inhibitior,-,0.7704
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,P-glycoprotein substrate,-,0.6047
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CYP3A4 substrate,+,0.6352
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CYP2C9 substrate,-,1
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CYP2D6 substrate,+,0.6844
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CYP3A4 inhibition,+,0.5108
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CYP2C9 inhibition,-,0.7721
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CYP2C19 inhibition,-,0.572
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CYP2D6 inhibition,+,0.6977
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CYP1A2 inhibition,+,0.839
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CYP2C8 inhibition,-,0.9882
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CYP inhibitory promiscuity,+,0.6689
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,UGT catelyzed,-,0
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Carcinogenicity (binary),-,0.88
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Carcinogenicity (trinary),Non-required,0.6257
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Eye corrosion,-,0.9886
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Eye irritation,-,0.9844
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Skin irritation,-,0.665
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Skin corrosion,-,0.8324
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Ames mutagenesis,+,0.52
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Human Ether-a-go-go-Related Gene inhibition,+,0.8548
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Micronuclear,-,0.61
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Hepatotoxicity,+,0.85
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,skin sensitisation,-,0.7965
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Respiratory toxicity,+,0.9
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Reproductive toxicity,+,0.8444
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Mitochondrial toxicity,+,1
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Nephrotoxicity,-,0.7348
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Acute Oral Toxicity (c),III,0.6028
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Estrogen receptor binding,+,0.7295
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Androgen receptor binding,+,0.5989
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Thyroid receptor binding,-,0.5859
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Glucocorticoid receptor binding,-,0.8063
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Aromatase binding,+,0.6935
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,PPAR gamma,+,0.5786
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Honey bee toxicity,-,0.8646
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Biodegradation,-,0.875
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Crustacea aquatic toxicity,+,0.62
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Fish aquatic toxicity,-,0.4519
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,ADMET predicted profile --- Regressions,Value,Unit
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Water solubility,-3.362,logS
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Plasma protein binding,1.101,1
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Acute Oral Toxicity,2.679,log(1/(mol/kg))
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,Tetrahymena pyriformis,0.577,pIGC50 (ug/L)
,,,
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Human Intestinal Absorption,+,1
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Caco-2,+,0.5086
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Blood Brain Barrier,+,1
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Human oral bioavailability,+,0.8857
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Subcellular localzation,Mitochondria,0.7775
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,OATP2B1 inhibitior,-,1
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,OATP1B1 inhibitior,+,0.9414
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,OATP1B3 inhibitior,+,0.9458
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,MATE1 inhibitior,-,0.74
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,OCT2 inhibitior,+,0.925
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,BSEP inhibitior,+,0.9045
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,P-glycoprotein inhibitior,+,0.9512
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,P-glycoprotein substrate,-,0.842
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,CYP3A4 substrate,+,0.798
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,CYP2C9 substrate,+,0.6091
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,CYP2D6 substrate,+,0.4561
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,CYP3A4 inhibition,-,0.6613
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,CYP2C9 inhibition,-,0.9071
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,CYP2C19 inhibition,-,0.9026
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,CYP2D6 inhibition,-,0.9231
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,CYP1A2 inhibition,-,0.9045
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,CYP2C8 inhibition,-,0.9882
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,CYP inhibitory promiscuity,+,0.83
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,UGT catelyzed,-,0
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Carcinogenicity (binary),-,0.79
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Carcinogenicity (trinary),Non-required,0.6083
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Eye corrosion,-,0.9886
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Eye irritation,-,0.9784
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Skin irritation,-,0.7179
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Skin corrosion,-,0.9431
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Ames mutagenesis,-,0.74
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Human Ether-a-go-go-Related Gene inhibition,+,0.8916
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Micronuclear,+,0.89
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Hepatotoxicity,+,0.875
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,skin sensitisation,-,0.8545
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Respiratory toxicity,+,0.9778
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Reproductive toxicity,+,0.9333
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Mitochondrial toxicity,+,0.9875
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Nephrotoxicity,-,0.8377
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Acute Oral Toxicity (c),III,0.7919
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Estrogen receptor binding,+,0.7394
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Androgen receptor binding,+,0.5363
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Thyroid receptor binding,+,0.6947
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Glucocorticoid receptor binding,-,0.5772
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Aromatase binding,+,0.6368
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,PPAR gamma,-,0.5155
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Honey bee toxicity,-,0.94
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Biodegradation,-,0.825
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Crustacea aquatic toxicity,+,0.71
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Fish aquatic toxicity,+,0.9313
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,ADMET predicted profile --- Regressions,Value,Unit
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Water solubility,-3.69,logS
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Plasma protein binding,0.915,1
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Acute Oral Toxicity,2.454,log(1/(mol/kg))
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,Tetrahymena pyriformis,1.001,pIGC50 (ug/L)
,,,
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Human Intestinal Absorption,+,1
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Caco-2,+,0.9421
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Blood Brain Barrier,+,0.975
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Human oral bioavailability,+,0.9
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Subcellular localzation,Mitochondria,0.6013
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,OATP2B1 inhibitior,-,1
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,OATP1B1 inhibitior,+,0.9521
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,OATP1B3 inhibitior,+,0.949
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,MATE1 inhibitior,-,0.98
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,OCT2 inhibitior,+,0.775
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,BSEP inhibitior,-,0.7292
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,P-glycoprotein inhibitior,-,0.9169
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,P-glycoprotein substrate,-,0.6685
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,CYP3A4 substrate,+,0.6001
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,CYP2C9 substrate,+,1
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,CYP2D6 substrate,+,0.7159
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,CYP3A4 inhibition,-,0.8122
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,CYP2C9 inhibition,-,0.957
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,CYP2C19 inhibition,-,0.9025
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,CYP2D6 inhibition,+,0.9037
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,CYP1A2 inhibition,+,0.9324
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,CYP2C8 inhibition,-,0.982
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,CYP inhibitory promiscuity,-,0.7371
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,UGT catelyzed,-,0
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Carcinogenicity (binary),-,0.75
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Carcinogenicity (trinary),Non-required,0.7056
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Eye corrosion,-,0.9381
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Eye irritation,-,0.9874
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Skin irritation,-,0.5692
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Skin corrosion,-,0.6601
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Ames mutagenesis,-,0.7737
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Human Ether-a-go-go-Related Gene inhibition,+,0.8917
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Micronuclear,-,0.7
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Hepatotoxicity,+,0.9
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,skin sensitisation,-,0.8084
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Respiratory toxicity,+,0.9111
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Reproductive toxicity,+,0.7222
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Mitochondrial toxicity,+,0.9625
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Nephrotoxicity,-,0.6396
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Acute Oral Toxicity (c),III,0.5784
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Estrogen receptor binding,-,0.5945
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Androgen receptor binding,-,0.7769
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Thyroid receptor binding,+,0.5258
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Glucocorticoid receptor binding,-,0.8859
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Aromatase binding,+,0.5227
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,PPAR gamma,-,0.5616
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Honey bee toxicity,-,0.8593
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Biodegradation,-,0.85
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Crustacea aquatic toxicity,+,0.7
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Fish aquatic toxicity,-,0.407
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,ADMET predicted profile --- Regressions,Value,Unit
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Water solubility,-3.041,logS
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Plasma protein binding,1.146,100%
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Acute Oral Toxicity,2.795,log(1/(mol/kg))
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,Tetrahymena pyriformis,0.182,pIGC50 (ug/L)
,,,
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Human Intestinal Absorption,+,0.9713
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Caco-2,+,0.6731
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Blood Brain Barrier,+,0.775
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Human oral bioavailability,-,0.8143
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Subcellular localzation,Mitochondria,0.855
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,OATP2B1 inhibitior,-,0.8486
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,OATP1B1 inhibitior,+,0.8316
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,OATP1B3 inhibitior,+,0.939
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,MATE1 inhibitior,-,0.94
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,OCT2 inhibitior,-,0.7792
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,BSEP inhibitior,-,0.9626
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,P-glycoprotein inhibitior,-,0.9167
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,P-glycoprotein substrate,+,0.5323
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,CYP3A4 substrate,-,0.5389
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,CYP2C9 substrate,-,0.5629
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,CYP2D6 substrate,+,0.6454
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,CYP3A4 inhibition,-,0.8646
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,CYP2C9 inhibition,-,0.757
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,CYP2C19 inhibition,-,0.7811
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,CYP2D6 inhibition,+,0.6334
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,CYP1A2 inhibition,-,0.6816
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,CYP2C8 inhibition,-,0.963
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,CYP inhibitory promiscuity,-,0.8888
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,UGT catelyzed,+,0.6
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Carcinogenicity (binary),-,0.75
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Carcinogenicity (trinary),Non-required,0.6632
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Eye corrosion,-,0.9886
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Eye irritation,-,0.9542
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Skin irritation,-,0.7318
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Skin corrosion,-,0.789
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Ames mutagenesis,-,0.8237
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Human Ether-a-go-go-Related Gene inhibition,+,0.6617
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Micronuclear,-,0.66
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Hepatotoxicity,+,0.8375
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,skin sensitisation,-,0.7435
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Respiratory toxicity,+,0.9333
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Reproductive toxicity,+,0.6333
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Mitochondrial toxicity,+,0.95
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Nephrotoxicity,-,0.8993
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Acute Oral Toxicity (c),III,0.643
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Estrogen receptor binding,+,0.6161
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Androgen receptor binding,+,0.5927
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Thyroid receptor binding,+,0.5565
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Glucocorticoid receptor binding,-,0.7151
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Aromatase binding,-,0.6186
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,PPAR gamma,+,0.6324
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Honey bee toxicity,-,0.9544
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Biodegradation,-,0.775
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Crustacea aquatic toxicity,-,0.73
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Fish aquatic toxicity,+,0.6808
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,ADMET predicted profile --- Regressions,Value,Unit
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Water solubility,-2.841,logS
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Plasma protein binding,0.503,100%
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Acute Oral Toxicity,2.638,log(1/(mol/kg))
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,Tetrahymena pyriformis,1.197,pIGC50 (ug/L)
,,,
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Human Intestinal Absorption,+,0.9913
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Caco-2,+,0.7437
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Blood Brain Barrier,+,0.975
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Human oral bioavailability,+,0.5286
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Subcellular localzation,Mitochondria,0.5342
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,OATP2B1 inhibitior,-,1
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,OATP1B1 inhibitior,+,0.9356
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,OATP1B3 inhibitior,+,0.9471
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,MATE1 inhibitior,-,0.98
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,OCT2 inhibitior,-,0.9
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,BSEP inhibitior,+,0.7647
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,P-glycoprotein inhibitior,-,0.7377
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,P-glycoprotein substrate,+,0.9277
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CYP3A4 substrate,+,0.7916
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CYP2C9 substrate,-,1
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CYP2D6 substrate,+,0.6913
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CYP3A4 inhibition,-,0.8309
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CYP2C9 inhibition,+,0.8949
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CYP2C19 inhibition,+,0.8994
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CYP2D6 inhibition,-,0.5054
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CYP1A2 inhibition,-,0.9045
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CYP2C8 inhibition,-,0.9882
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CYP inhibitory promiscuity,+,0.5223
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,UGT catelyzed,-,0
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Carcinogenicity (binary),-,0.81
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Carcinogenicity (trinary),Non-required,0.6567
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Eye corrosion,-,0.9886
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Eye irritation,-,0.9541
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Skin irritation,-,0.8082
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Skin corrosion,-,0.896
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Ames mutagenesis,-,0.53
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Human Ether-a-go-go-Related Gene inhibition,+,0.9264
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Micronuclear,-,0.61
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Hepatotoxicity,+,0.825
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,skin sensitisation,-,0.7765
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Respiratory toxicity,+,0.9333
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Reproductive toxicity,+,0.6889
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Mitochondrial toxicity,+,0.975
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Nephrotoxicity,-,0.8449
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Acute Oral Toxicity (c),III,0.6012
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Estrogen receptor binding,-,0.5
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Androgen receptor binding,-,0.8512
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Thyroid receptor binding,+,0.8272
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Glucocorticoid receptor binding,-,0.5315
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Aromatase binding,+,0.5919
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,PPAR gamma,+,0.6342
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Honey bee toxicity,-,0.7927
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Biodegradation,-,0.875
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Crustacea aquatic toxicity,-,0.83
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Fish aquatic toxicity,+,0.9638
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,ADMET predicted profile --- Regressions,Value,Unit
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Water solubility,-3.777,logS
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Plasma protein binding,0.575,100%
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Acute Oral Toxicity,3.301,log(1/(mol/kg))
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,Tetrahymena pyriformis,1.482,pIGC50 (ug/L)
,,,
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Human Intestinal Absorption,+,1
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Caco-2,+,0.9313
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Blood Brain Barrier,+,1
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Human oral bioavailability,+,0.9286
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Subcellular localzation,Mitochondria,0.5725
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,OATP2B1 inhibitior,-,1
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,OATP1B1 inhibitior,+,0.9291
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,OATP1B3 inhibitior,+,0.948
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,MATE1 inhibitior,-,1
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,OCT2 inhibitior,+,0.875
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,BSEP inhibitior,+,0.8441
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,P-glycoprotein inhibitior,-,0.7443
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,P-glycoprotein substrate,-,0.8446
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CYP3A4 substrate,+,0.634
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CYP2C9 substrate,+,1
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CYP2D6 substrate,+,0.6779
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CYP3A4 inhibition,+,0.7959
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CYP2C9 inhibition,-,0.907
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CYP2C19 inhibition,+,0.8993
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CYP2D6 inhibition,+,0.8932
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CYP1A2 inhibition,+,0.9107
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CYP2C8 inhibition,-,0.9882
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CYP inhibitory promiscuity,+,0.7149
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,UGT catelyzed,-,0
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Carcinogenicity (binary),-,0.6756
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Carcinogenicity (trinary),Non-required,0.7114
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Eye corrosion,-,0.9886
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Eye irritation,-,0.9541
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Skin irritation,-,0.652
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Skin corrosion,-,0.7758
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Ames mutagenesis,-,0.76
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Human Ether-a-go-go-Related Gene inhibition,+,0.9161
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Micronuclear,-,0.63
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Hepatotoxicity,+,0.875
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,skin sensitisation,-,0.8401
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Respiratory toxicity,+,0.9667
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Reproductive toxicity,+,0.7444
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Mitochondrial toxicity,+,0.9625
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Nephrotoxicity,+,0.5092
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Acute Oral Toxicity (c),III,0.7805
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Estrogen receptor binding,+,0.8906
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Androgen receptor binding,+,0.6307
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Thyroid receptor binding,+,0.6494
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Glucocorticoid receptor binding,-,0.7332
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Aromatase binding,-,0.5099
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,PPAR gamma,+,0.7852
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Honey bee toxicity,-,0.8641
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Biodegradation,-,0.875
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Crustacea aquatic toxicity,+,0.74
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Fish aquatic toxicity,+,0.6474
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,ADMET predicted profile --- Regressions,Value,Unit
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Water solubility,-3.918,logS
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Plasma protein binding,1.006,100%
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Acute Oral Toxicity,2.53,log(1/(mol/kg))
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,Tetrahymena pyriformis,0.684,pIGC50 (ug/L)
,,,
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Human Intestinal Absorption,+,0.9954
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Caco-2,+,0.6463
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Blood Brain Barrier,+,0.825
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Human oral bioavailability,-,0.8429
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Subcellular localzation,Lysosomes,0.4829
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,OATP2B1 inhibitior,-,1
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,OATP1B1 inhibitior,+,0.921
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,OATP1B3 inhibitior,+,0.9475
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,MATE1 inhibitior,-,0.96
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,OCT2 inhibitior,+,0.8
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,BSEP inhibitior,+,0.9071
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,P-glycoprotein inhibitior,+,0.7146
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,P-glycoprotein substrate,-,0.9362
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP3A4 substrate,-,0.5961
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2C9 substrate,-,1
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 substrate,+,0.6248
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP3A4 inhibition,+,0.8298
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2C9 inhibition,+,0.8948
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2C19 inhibition,-,0.9025
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 inhibition,-,0.9231
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP1A2 inhibition,+,0.9107
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2C8 inhibition,-,0.9882
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP inhibitory promiscuity,+,0.8649
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,UGT catelyzed,-,0
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Carcinogenicity (binary),-,0.88
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Carcinogenicity (trinary),Non-required,0.6188
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Eye corrosion,-,0.9886
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Eye irritation,-,0.9541
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Skin irritation,+,0.6588
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Skin corrosion,-,0.9275
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Ames mutagenesis,-,0.67
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Human Ether-a-go-go-Related Gene inhibition,+,0.9254
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Micronuclear,+,0.58
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Hepatotoxicity,+,0.775
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,skin sensitisation,-,0.8354
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Respiratory toxicity,+,0.8889
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Reproductive toxicity,+,0.9778
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Mitochondrial toxicity,+,0.9375
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Nephrotoxicity,-,0.7051
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Acute Oral Toxicity (c),III,0.5586
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Estrogen receptor binding,+,0.6247
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Androgen receptor binding,+,0.7201
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Thyroid receptor binding,+,0.5649
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Glucocorticoid receptor binding,-,0.6353
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Aromatase binding,-,0.5423
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,PPAR gamma,-,0.5
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Honey bee toxicity,-,0.8672
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Biodegradation,-,0.8
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Crustacea aquatic toxicity,+,0.61
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Fish aquatic toxicity,+,0.8519
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,ADMET predicted profile --- Regressions,Value,Unit
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Water solubility,-3.385,logS
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Plasma protein binding,1.003,100%
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Acute Oral Toxicity,2.486,log(1/(mol/kg))
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Tetrahymena pyriformis,1.067,pIGC50 (ug/L)
,,,
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Human Intestinal Absorption,+,0.9965
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Caco-2,+,0.7735
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Blood Brain Barrier,+,0.975
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Human oral bioavailability,-,0.7714
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Subcellular localzation,Lysosomes,0.787
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,OATP2B1 inhibitior,-,0.8618
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,OATP1B1 inhibitior,+,0.9377
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,OATP1B3 inhibitior,+,0.9491
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,MATE1 inhibitior,-,0.86
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,OCT2 inhibitior,-,0.75
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,BSEP inhibitior,+,0.9072
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,P-glycoprotein inhibitior,-,0.8545
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,P-glycoprotein substrate,-,0.9363
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CYP3A4 substrate,+,0.6689
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CYP2C9 substrate,-,1
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CYP2D6 substrate,+,0.694
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CYP3A4 inhibition,-,0.5442
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CYP2C9 inhibition,-,0.9307
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CYP2C19 inhibition,+,0.6839
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CYP2D6 inhibition,-,0.6469
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CYP1A2 inhibition,+,0.7909
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CYP2C8 inhibition,+,0.9818
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CYP inhibitory promiscuity,+,0.6633
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,UGT catelyzed,-,0
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Carcinogenicity (binary),-,0.7518
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Carcinogenicity (trinary),Non-required,0.7805
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Eye corrosion,-,0.9886
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Eye irritation,-,0.9937
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Skin irritation,-,0.656
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Skin corrosion,-,0.9023
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Ames mutagenesis,-,0.6
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Human Ether-a-go-go-Related Gene inhibition,+,0.8916
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Micronuclear,-,0.64
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Hepatotoxicity,+,0.8625
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,skin sensitisation,-,0.7452
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Respiratory toxicity,+,0.8111
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Reproductive toxicity,+,0.5974
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Mitochondrial toxicity,+,0.9
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Nephrotoxicity,+,0.6567
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Acute Oral Toxicity (c),III,0.4808
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Estrogen receptor binding,+,0.9659
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Androgen receptor binding,+,0.7918
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Thyroid receptor binding,+,0.7814
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Glucocorticoid receptor binding,+,0.6843
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Aromatase binding,+,0.659
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,PPAR gamma,+,0.8709
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Honey bee toxicity,-,0.9174
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Biodegradation,-,0.775
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Crustacea aquatic toxicity,+,0.97
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Fish aquatic toxicity,+,0.9879
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,ADMET predicted profile --- Regressions,Value,Unit
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Water solubility,-4.945,logS
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Plasma protein binding,0.987,100%
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Acute Oral Toxicity,2.208,log(1/(mol/kg))
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,Tetrahymena pyriformis,1.61,pIGC50 (ug/L)
,,,
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Human Intestinal Absorption,+,0.9729
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Caco-2,+,0.7508
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Blood Brain Barrier,+,0.925
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Human oral bioavailability,+,0.6429
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Subcellular localzation,Lysosomes,0.5392
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,OATP2B1 inhibitior,-,1
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,OATP1B1 inhibitior,+,0.949
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,OATP1B3 inhibitior,+,0.9446
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,MATE1 inhibitior,-,0.94
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,OCT2 inhibitior,-,0.575
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,BSEP inhibitior,+,0.8865
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,P-glycoprotein inhibitior,+,0.574
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,P-glycoprotein substrate,-,0.6497
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,CYP3A4 substrate,-,0.6158
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,CYP2C9 substrate,-,0.6381
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,CYP2D6 substrate,+,0.4598
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,CYP3A4 inhibition,-,0.5913
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,CYP2C9 inhibition,-,0.8627
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,CYP2C19 inhibition,-,0.6703
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,CYP2D6 inhibition,+,0.6235
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,CYP1A2 inhibition,+,0.758
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,CYP2C8 inhibition,-,0.9239
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,CYP inhibitory promiscuity,+,0.8015
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,UGT catelyzed,-,0
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Carcinogenicity (binary),-,0.95
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Carcinogenicity (trinary),Non-required,0.564
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Eye corrosion,-,0.8056
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Eye irritation,-,0.9773
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Skin irritation,-,0.7499
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Skin corrosion,-,0.8051
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Ames mutagenesis,-,0.68
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Human Ether-a-go-go-Related Gene inhibition,+,0.9586
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Micronuclear,+,0.68
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Hepatotoxicity,+,0.6
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,skin sensitisation,-,0.8721
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Respiratory toxicity,+,0.8889
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Reproductive toxicity,+,0.6111
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Mitochondrial toxicity,+,0.9625
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Nephrotoxicity,-,0.6123
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Acute Oral Toxicity (c),III,0.5202
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Estrogen receptor binding,+,0.6358
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Androgen receptor binding,-,0.5909
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Thyroid receptor binding,+,0.6384
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Glucocorticoid receptor binding,-,0.7461
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Aromatase binding,+,0.673
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,PPAR gamma,+,0.6989
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Honey bee toxicity,-,0.9428
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Biodegradation,-,0.925
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Crustacea aquatic toxicity,+,0.71
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Fish aquatic toxicity,+,0.9374
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,ADMET predicted profile --- Regressions,Value,Unit
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Water solubility,-2.566,logS
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Plasma protein binding,0.895,1
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Acute Oral Toxicity,2.232,log(1/(mol/kg))
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,Tetrahymena pyriformis,1.308,pIGC50 (ug/L)
,,,
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Human Intestinal Absorption,+,0.9924
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Caco-2,-,0.6396
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Blood Brain Barrier,+,1
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Human oral bioavailability,+,0.7429
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Subcellular localzation,Mitochondria,0.6127
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,OATP2B1 inhibitior,-,1
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,OATP1B1 inhibitior,+,0.9152
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,OATP1B3 inhibitior,+,0.9354
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,MATE1 inhibitior,+,0.76
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,OCT2 inhibitior,+,0.85
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,BSEP inhibitior,+,0.9581
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,P-glycoprotein inhibitior,+,0.7901
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,P-glycoprotein substrate,+,0.5369
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,CYP3A4 substrate,+,0.6614
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,CYP2C9 substrate,-,1
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,CYP2D6 substrate,+,0.4196
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,CYP3A4 inhibition,-,0.7835
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,CYP2C9 inhibition,+,0.6714
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,CYP2C19 inhibition,+,0.7439
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,CYP2D6 inhibition,-,0.8292
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,CYP1A2 inhibition,-,0.677
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,CYP2C8 inhibition,-,0.7431
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,CYP inhibitory promiscuity,+,0.8126
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,UGT catelyzed,-,0
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Carcinogenicity (binary),-,0.81
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Carcinogenicity (trinary),Non-required,0.5626
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Eye corrosion,-,0.9833
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Eye irritation,-,0.9541
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Skin irritation,-,0.666
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Skin corrosion,-,0.894
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Ames mutagenesis,-,0.55
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Human Ether-a-go-go-Related Gene inhibition,+,0.9078
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Micronuclear,+,0.81
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Hepatotoxicity,-,0.6499
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,skin sensitisation,-,0.8345
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Respiratory toxicity,+,0.8778
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Reproductive toxicity,+,0.7556
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Mitochondrial toxicity,+,0.9625
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Nephrotoxicity,-,0.7407
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Acute Oral Toxicity (c),III,0.6296
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Estrogen receptor binding,-,0.5274
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Androgen receptor binding,+,0.7889
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Thyroid receptor binding,-,0.5454
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Glucocorticoid receptor binding,-,0.6568
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Aromatase binding,-,0.6239
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,PPAR gamma,-,0.6163
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Honey bee toxicity,-,0.7957
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Biodegradation,-,0.875
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Crustacea aquatic toxicity,+,0.58
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Fish aquatic toxicity,+,0.9001
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,ADMET predicted profile --- Regressions,Value,Unit
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Water solubility,-3.768,logS
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Plasma protein binding,0.9,100%
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Acute Oral Toxicity,2.377,log(1/(mol/kg))
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,Tetrahymena pyriformis,1.231,pIGC50 (ug/L)
,,,
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Human Intestinal Absorption,+,0.9974
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Caco-2,-,0.6579
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Blood Brain Barrier,+,0.8
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Human oral bioavailability,-,0.6714
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Subcellular localzation,Mitochondria,0.6854
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,OATP2B1 inhibitior,-,1
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,OATP1B1 inhibitior,+,0.8956
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,OATP1B3 inhibitior,+,0.9364
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,MATE1 inhibitior,-,0.64
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,OCT2 inhibitior,-,0.625
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,BSEP inhibitior,+,0.7093
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,P-glycoprotein inhibitior,+,0.8257
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,P-glycoprotein substrate,+,0.8453
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP3A4 substrate,+,0.7551
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2C9 substrate,-,1
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2D6 substrate,-,0.7478
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP3A4 inhibition,-,0.6468
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2C9 inhibition,-,0.7395
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2C19 inhibition,-,0.7815
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2D6 inhibition,-,0.5326
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP1A2 inhibition,-,0.7379
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2C8 inhibition,-,0.9015
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP inhibitory promiscuity,+,0.7558
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,UGT catelyzed,+,0.8
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Carcinogenicity (binary),-,0.76
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Carcinogenicity (trinary),Non-required,0.5561
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Eye corrosion,-,0.9886
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Eye irritation,-,0.98
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Skin irritation,-,0.7723
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Skin corrosion,-,0.9323
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Ames mutagenesis,+,0.5463
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Human Ether-a-go-go-Related Gene inhibition,+,0.8826
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Micronuclear,+,0.75
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Hepatotoxicity,-,0.8375
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,skin sensitisation,-,0.8321
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Respiratory toxicity,+,0.9667
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Reproductive toxicity,+,0.9444
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Mitochondrial toxicity,+,0.9875
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Nephrotoxicity,-,0.873
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Acute Oral Toxicity (c),II,0.7377
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Estrogen receptor binding,-,0.6164
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Androgen receptor binding,-,0.6318
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Thyroid receptor binding,+,0.6009
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Glucocorticoid receptor binding,+,0.598
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Aromatase binding,+,0.6474
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,PPAR gamma,+,0.6196
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Honey bee toxicity,-,0.8823
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Biodegradation,-,0.8
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Crustacea aquatic toxicity,+,0.55
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Fish aquatic toxicity,+,0.8692
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,ADMET predicted profile --- Regressions,Value,Unit
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Water solubility,-3.16,logS
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Plasma protein binding,0.769,100%
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Acute Oral Toxicity,3.622,log(1/(mol/kg))
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Tetrahymena pyriformis,0.865,pIGC50 (ug/L)
,,,
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Human Intestinal Absorption,+,0.9972
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Caco-2,+,0.9312
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Blood Brain Barrier,+,0.975
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Human oral bioavailability,+,0.9143
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Subcellular localzation,Mitochondria,0.5141
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,OATP2B1 inhibitior,-,1
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,OATP1B1 inhibitior,+,0.9118
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,OATP1B3 inhibitior,+,0.9389
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,MATE1 inhibitior,-,0.6009
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,OCT2 inhibitior,+,0.6891
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,BSEP inhibitior,+,0.8461
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,P-glycoprotein inhibitior,+,0.8137
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,P-glycoprotein substrate,-,0.5207
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,CYP3A4 substrate,+,0.7529
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,CYP2C9 substrate,-,1
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,CYP2D6 substrate,-,0.659
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,CYP3A4 inhibition,-,0.7723
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,CYP2C9 inhibition,+,0.6329
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,CYP2C19 inhibition,+,0.8086
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,CYP2D6 inhibition,-,0.7151
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,CYP1A2 inhibition,+,0.6576
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,CYP2C8 inhibition,-,0.7946
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,CYP inhibitory promiscuity,+,0.9567
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,UGT catelyzed,-,0
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Carcinogenicity (binary),-,0.75
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Carcinogenicity (trinary),Non-required,0.5959
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Eye corrosion,-,0.9886
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Eye irritation,-,0.9904
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Skin irritation,+,0.7009
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Skin corrosion,-,0.9024
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Ames mutagenesis,-,0.557
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Human Ether-a-go-go-Related Gene inhibition,+,0.8604
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Micronuclear,+,0.84
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Hepatotoxicity,+,0.7875
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,skin sensitisation,-,0.821
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Respiratory toxicity,+,0.9667
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Reproductive toxicity,+,0.8667
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Mitochondrial toxicity,+,1
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Nephrotoxicity,-,0.8812
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Acute Oral Toxicity (c),III,0.5756
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Estrogen receptor binding,-,0.5
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Androgen receptor binding,+,0.8697
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Thyroid receptor binding,-,0.5217
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Glucocorticoid receptor binding,+,0.897
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Aromatase binding,+,0.5438
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,PPAR gamma,+,0.5803
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Honey bee toxicity,-,0.7731
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Biodegradation,-,0.775
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Crustacea aquatic toxicity,+,0.63
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Fish aquatic toxicity,+,0.9286
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,ADMET predicted profile --- Regressions,Value,Unit
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Water solubility,-4.001,logS
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Plasma protein binding,1.004,100%
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Acute Oral Toxicity,2.224,log(1/(mol/kg))
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,Tetrahymena pyriformis,1.326,pIGC50 (ug/L)
,,,
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Human Intestinal Absorption,+,0.9962
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Caco-2,-,0.6566
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Blood Brain Barrier,+,0.975
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Human oral bioavailability,+,0.6286
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Subcellular localzation,Mitochondria,0.7214
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,OATP2B1 inhibitior,-,1
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,OATP1B1 inhibitior,+,0.9102
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,OATP1B3 inhibitior,+,0.936
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,MATE1 inhibitior,-,0.94
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,OCT2 inhibitior,+,0.625
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,BSEP inhibitior,+,0.9677
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,P-glycoprotein inhibitior,+,0.8563
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,P-glycoprotein substrate,-,0.5662
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CYP3A4 substrate,+,0.7981
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CYP2C9 substrate,-,1
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CYP2D6 substrate,+,0.5405
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CYP3A4 inhibition,+,0.5256
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CYP2C9 inhibition,+,0.6682
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CYP2C19 inhibition,+,0.8934
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CYP2D6 inhibition,+,0.6633
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CYP1A2 inhibition,+,0.6581
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CYP2C8 inhibition,-,0.6587
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,CYP inhibitory promiscuity,+,0.9104
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,UGT catelyzed,-,0
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Carcinogenicity (binary),-,0.78
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Carcinogenicity (trinary),Non-required,0.6167
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Eye corrosion,-,0.9899
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Eye irritation,-,0.9595
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Skin irritation,+,0.6669
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Skin corrosion,-,0.942
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Ames mutagenesis,-,0.79
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Human Ether-a-go-go-Related Gene inhibition,+,0.9385
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Micronuclear,+,0.88
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Hepatotoxicity,-,0.7625
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,skin sensitisation,-,0.8701
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Respiratory toxicity,+,0.9889
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Reproductive toxicity,+,0.9222
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Mitochondrial toxicity,+,0.975
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Nephrotoxicity,-,0.8082
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Acute Oral Toxicity (c),II,0.4776
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Estrogen receptor binding,+,0.8054
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Androgen receptor binding,+,0.7956
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Thyroid receptor binding,+,0.6045
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Glucocorticoid receptor binding,+,0.641
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Aromatase binding,+,0.6909
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,PPAR gamma,+,0.6726
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Honey bee toxicity,-,0.9141
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Biodegradation,-,0.775
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Crustacea aquatic toxicity,+,0.63
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Fish aquatic toxicity,+,0.8732
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,ADMET predicted profile --- Regressions,Value,Unit
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Water solubility,-4.568,logS
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Plasma protein binding,1.112,1
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Acute Oral Toxicity,2.522,log(1/(mol/kg))
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Tetrahymena pyriformis,1.06,pIGC50 (ug/L)
,,,
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Human Intestinal Absorption,+,0.9963
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Caco-2,-,0.5963
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Blood Brain Barrier,+,1
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Human oral bioavailability,+,0.5857
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Subcellular localzation,Mitochondria,0.7401
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,OATP2B1 inhibitior,-,1
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,OATP1B1 inhibitior,+,0.9226
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,OATP1B3 inhibitior,+,0.9384
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,MATE1 inhibitior,-,0.7
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,OCT2 inhibitior,+,0.7074
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,BSEP inhibitior,+,0.9412
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,P-glycoprotein inhibitior,+,0.9126
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,P-glycoprotein substrate,+,0.5809
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,CYP3A4 substrate,+,0.6845
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,CYP2C9 substrate,-,1
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,CYP2D6 substrate,+,0.347
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,CYP3A4 inhibition,+,0.7493
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,CYP2C9 inhibition,+,0.8842
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,CYP2C19 inhibition,+,0.8304
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,CYP2D6 inhibition,-,0.6722
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,CYP1A2 inhibition,-,0.6217
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,CYP2C8 inhibition,-,0.6662
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,CYP inhibitory promiscuity,+,0.9181
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,UGT catelyzed,-,0
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Carcinogenicity (binary),-,0.92
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Carcinogenicity (trinary),Non-required,0.5973
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Eye corrosion,-,0.9896
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Eye irritation,-,0.9297
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Skin irritation,-,0.7371
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Skin corrosion,-,0.939
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Ames mutagenesis,-,0.54
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Human Ether-a-go-go-Related Gene inhibition,+,0.9448
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Micronuclear,+,0.86
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Hepatotoxicity,-,0.7375
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,skin sensitisation,-,0.8765
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Respiratory toxicity,+,0.9111
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Reproductive toxicity,+,0.8667
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Mitochondrial toxicity,+,0.9625
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Nephrotoxicity,-,0.9097
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Acute Oral Toxicity (c),III,0.7237
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Estrogen receptor binding,+,0.8372
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Androgen receptor binding,+,0.8135
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Thyroid receptor binding,+,0.6331
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Glucocorticoid receptor binding,+,0.5429
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Aromatase binding,+,0.6304
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,PPAR gamma,+,0.5892
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Honey bee toxicity,-,0.9037
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Biodegradation,-,0.8
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Crustacea aquatic toxicity,+,0.52
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Fish aquatic toxicity,+,0.7698
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,ADMET predicted profile --- Regressions,Value,Unit
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Water solubility,-4.084,logS
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Plasma protein binding,0.936,100%
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Acute Oral Toxicity,2.497,log(1/(mol/kg))
C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,Tetrahymena pyriformis,0.935,pIGC50 (ug/L)
,,,
[Li+].[Li+].C(=O)([O-])[O-],Human Intestinal Absorption,+,0.9683
[Li+].[Li+].C(=O)([O-])[O-],Caco-2,-,0.6085
[Li+].[Li+].C(=O)([O-])[O-],Blood Brain Barrier,+,0.875
[Li+].[Li+].C(=O)([O-])[O-],Human oral bioavailability,+,0.6571
[Li+].[Li+].C(=O)([O-])[O-],Subcellular localzation,Mitochondria,0.7744
[Li+].[Li+].C(=O)([O-])[O-],OATP2B1 inhibitior,-,0.8682
[Li+].[Li+].C(=O)([O-])[O-],OATP1B1 inhibitior,+,0.9745
[Li+].[Li+].C(=O)([O-])[O-],OATP1B3 inhibitior,+,0.9526
[Li+].[Li+].C(=O)([O-])[O-],MATE1 inhibitior,-,1
[Li+].[Li+].C(=O)([O-])[O-],OCT2 inhibitior,-,1
[Li+].[Li+].C(=O)([O-])[O-],BSEP inhibitior,-,0.9573
[Li+].[Li+].C(=O)([O-])[O-],P-glycoprotein inhibitior,-,0.9881
[Li+].[Li+].C(=O)([O-])[O-],P-glycoprotein substrate,-,0.998
[Li+].[Li+].C(=O)([O-])[O-],CYP3A4 substrate,-,0.8266
[Li+].[Li+].C(=O)([O-])[O-],CYP2C9 substrate,-,0.8191
[Li+].[Li+].C(=O)([O-])[O-],CYP2D6 substrate,-,0.8196
[Li+].[Li+].C(=O)([O-])[O-],CYP3A4 inhibition,-,0.9789
[Li+].[Li+].C(=O)([O-])[O-],CYP2C9 inhibition,-,0.8949
[Li+].[Li+].C(=O)([O-])[O-],CYP2C19 inhibition,-,0.9078
[Li+].[Li+].C(=O)([O-])[O-],CYP2D6 inhibition,-,0.9381
[Li+].[Li+].C(=O)([O-])[O-],CYP1A2 inhibition,-,0.8426
[Li+].[Li+].C(=O)([O-])[O-],CYP2C8 inhibition,-,0.997
[Li+].[Li+].C(=O)([O-])[O-],CYP inhibitory promiscuity,-,0.9717
[Li+].[Li+].C(=O)([O-])[O-],UGT catelyzed,-,0
[Li+].[Li+].C(=O)([O-])[O-],Carcinogenicity (binary),+,0.6114
[Li+].[Li+].C(=O)([O-])[O-],Carcinogenicity (trinary),Non-required,0.6398
[Li+].[Li+].C(=O)([O-])[O-],Eye corrosion,+,0.7427
[Li+].[Li+].C(=O)([O-])[O-],Eye irritation,+,0.9437
[Li+].[Li+].C(=O)([O-])[O-],Skin irritation,+,0.7833
[Li+].[Li+].C(=O)([O-])[O-],Skin corrosion,+,0.5343
[Li+].[Li+].C(=O)([O-])[O-],Ames mutagenesis,-,0.73
[Li+].[Li+].C(=O)([O-])[O-],Human Ether-a-go-go-Related Gene inhibition,-,0.8465
[Li+].[Li+].C(=O)([O-])[O-],Micronuclear,-,0.52
[Li+].[Li+].C(=O)([O-])[O-],Hepatotoxicity,+,0.875
[Li+].[Li+].C(=O)([O-])[O-],skin sensitisation,-,0.7351
[Li+].[Li+].C(=O)([O-])[O-],Respiratory toxicity,-,0.8
[Li+].[Li+].C(=O)([O-])[O-],Reproductive toxicity,+,0.6091
[Li+].[Li+].C(=O)([O-])[O-],Mitochondrial toxicity,-,0.675
[Li+].[Li+].C(=O)([O-])[O-],Nephrotoxicity,+,0.6442
[Li+].[Li+].C(=O)([O-])[O-],Acute Oral Toxicity (c),III,0.4137
[Li+].[Li+].C(=O)([O-])[O-],Estrogen receptor binding,-,0.9457
[Li+].[Li+].C(=O)([O-])[O-],Androgen receptor binding,-,0.9514
[Li+].[Li+].C(=O)([O-])[O-],Thyroid receptor binding,-,0.8735
[Li+].[Li+].C(=O)([O-])[O-],Glucocorticoid receptor binding,-,0.8993
[Li+].[Li+].C(=O)([O-])[O-],Aromatase binding,-,0.9269
[Li+].[Li+].C(=O)([O-])[O-],PPAR gamma,-,0.882
[Li+].[Li+].C(=O)([O-])[O-],Honey bee toxicity,-,0.9081
[Li+].[Li+].C(=O)([O-])[O-],Biodegradation,+,0.825
[Li+].[Li+].C(=O)([O-])[O-],Crustacea aquatic toxicity,-,0.85
[Li+].[Li+].C(=O)([O-])[O-],Fish aquatic toxicity,+,0.6573
[Li+].[Li+].C(=O)([O-])[O-],ADMET predicted profile --- Regressions,Value,Unit
[Li+].[Li+].C(=O)([O-])[O-],Water solubility,-0.673,logS
[Li+].[Li+].C(=O)([O-])[O-],Plasma protein binding,0.043,100%
[Li+].[Li+].C(=O)([O-])[O-],Acute Oral Toxicity,1.175,log(1/(mol/kg))
[Li+].[Li+].C(=O)([O-])[O-],Tetrahymena pyriformis,-0.814,pIGC50 (ug/L)
,,,
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Human Intestinal Absorption,+,0.9124
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Caco-2,+,0.5
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Blood Brain Barrier,+,1
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Human oral bioavailability,+,0.8571
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Subcellular localzation,Lysosomes,0.4793
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,OATP2B1 inhibitior,-,0.8571
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,OATP1B1 inhibitior,+,0.9466
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,OATP1B3 inhibitior,+,0.9363
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,MATE1 inhibitior,-,0.96
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,OCT2 inhibitior,-,0.85
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,BSEP inhibitior,-,0.8667
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,P-glycoprotein inhibitior,-,0.6949
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,P-glycoprotein substrate,+,0.799
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,CYP3A4 substrate,-,0.561
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,CYP2C9 substrate,-,1
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,CYP2D6 substrate,-,0.8425
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,CYP3A4 inhibition,-,0.8469
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,CYP2C9 inhibition,-,0.7259
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,CYP2C19 inhibition,-,0.6539
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,CYP2D6 inhibition,-,0.8674
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,CYP1A2 inhibition,-,0.6623
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,CYP2C8 inhibition,-,0.7345
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,CYP inhibitory promiscuity,-,0.7952
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,UGT catelyzed,-,0
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Carcinogenicity (binary),-,0.54
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Carcinogenicity (trinary),Non-required,0.564
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Eye corrosion,-,0.9886
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Eye irritation,-,0.9205
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Skin irritation,-,0.776
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Skin corrosion,-,0.9028
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Ames mutagenesis,+,0.73
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Human Ether-a-go-go-Related Gene inhibition,-,0.4755
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Micronuclear,+,0.82
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Hepatotoxicity,-,0.5625
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,skin sensitisation,-,0.8245
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Respiratory toxicity,+,0.8444
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Reproductive toxicity,+,0.8111
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Mitochondrial toxicity,+,0.85
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Nephrotoxicity,+,0.7838
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Acute Oral Toxicity (c),III,0.5739
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Estrogen receptor binding,-,0.491
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Androgen receptor binding,-,0.5446
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Thyroid receptor binding,+,0.5606
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Glucocorticoid receptor binding,-,0.6227
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Aromatase binding,-,0.5083
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,PPAR gamma,+,0.6393
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Honey bee toxicity,-,0.5067
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Biodegradation,-,0.775
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Crustacea aquatic toxicity,-,0.62
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Fish aquatic toxicity,+,0.8179
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,ADMET predicted profile --- Regressions,Value,Unit
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Water solubility,-3.047,logS
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Plasma protein binding,0.303,1
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Acute Oral Toxicity,2.715,log(1/(mol/kg))
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,Tetrahymena pyriformis,-0.02,pIGC50 (ug/L)
,,,
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Human Intestinal Absorption,+,0.969
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Caco-2,-,0.8053
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Blood Brain Barrier,+,0.875
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Human oral bioavailability,+,0.8857
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Subcellular localzation,Mitochondria,0.5543
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,OATP2B1 inhibitior,-,1
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,OATP1B1 inhibitior,+,0.9596
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,OATP1B3 inhibitior,+,0.9435
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,MATE1 inhibitior,-,1
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,OCT2 inhibitior,-,0.95
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,BSEP inhibitior,-,0.9723
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,P-glycoprotein inhibitior,-,0.9753
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,P-glycoprotein substrate,-,0.909
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,CYP3A4 substrate,-,0.6201
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,CYP2C9 substrate,-,0.8
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,CYP2D6 substrate,-,0.8944
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,CYP3A4 inhibition,-,0.831
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,CYP2C9 inhibition,-,0.7933
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,CYP2C19 inhibition,-,0.8282
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,CYP2D6 inhibition,-,0.9206
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,CYP1A2 inhibition,-,0.8687
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,CYP2C8 inhibition,-,0.9882
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,CYP inhibitory promiscuity,-,0.887
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,UGT catelyzed,-,0.6
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Carcinogenicity (binary),-,0.88
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Carcinogenicity (trinary),Non-required,0.4774
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Eye corrosion,-,0.9886
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Eye irritation,-,0.9541
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Skin irritation,-,0.7813
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Skin corrosion,-,0.9357
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Ames mutagenesis,-,0.7204
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Human Ether-a-go-go-Related Gene inhibition,-,0.6026
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Micronuclear,+,0.98
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Hepatotoxicity,+,0.9501
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,skin sensitisation,-,0.8609
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Respiratory toxicity,+,0.9556
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Reproductive toxicity,+,0.9111
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Mitochondrial toxicity,+,0.9625
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Nephrotoxicity,+,0.7066
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Acute Oral Toxicity (c),III,0.6225
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Estrogen receptor binding,-,0.6319
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Androgen receptor binding,+,0.6979
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Thyroid receptor binding,+,0.832
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Glucocorticoid receptor binding,-,0.6052
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Aromatase binding,+,0.5489
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,PPAR gamma,+,0.7722
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Honey bee toxicity,-,0.9499
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Biodegradation,-,0.85
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Crustacea aquatic toxicity,-,0.58
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Fish aquatic toxicity,-,0.4465
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,ADMET predicted profile --- Regressions,Value,Unit
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Water solubility,-2.404,logS
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Plasma protein binding,0.387,100%
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Acute Oral Toxicity,1.601,log(1/(mol/kg))
C1C(OC(S1)CO)N2C=CC(=NC2=O)N,Tetrahymena pyriformis,-0.487,pIGC50 (ug/L)
,,,
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Human Intestinal Absorption,+,0.988
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Caco-2,-,0.8434
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Blood Brain Barrier,+,0.775
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Human oral bioavailability,+,0.7857
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Subcellular localzation,Mitochondria,0.4058
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,OATP2B1 inhibitior,-,1
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,OATP1B1 inhibitior,+,0.9547
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,OATP1B3 inhibitior,+,0.9422
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,MATE1 inhibitior,-,1
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,OCT2 inhibitior,-,0.95
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,BSEP inhibitior,-,0.9604
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,P-glycoprotein inhibitior,-,0.9648
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,P-glycoprotein substrate,-,0.8019
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,CYP3A4 substrate,-,0.6048
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,CYP2C9 substrate,-,0.8021
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,CYP2D6 substrate,-,0.8894
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,CYP3A4 inhibition,-,0.6915
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,CYP2C9 inhibition,-,0.7384
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,CYP2C19 inhibition,-,0.7947
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,CYP2D6 inhibition,-,0.8666
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,CYP1A2 inhibition,-,0.7748
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,CYP2C8 inhibition,-,0.9581
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,CYP inhibitory promiscuity,-,0.7653
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,UGT catelyzed,-,0.6
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Carcinogenicity (binary),-,0.82
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Carcinogenicity (trinary),Non-required,0.501
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Eye corrosion,-,0.9886
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Eye irritation,-,0.9788
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Skin irritation,-,0.7778
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Skin corrosion,-,0.9314
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Ames mutagenesis,-,0.7116
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Human Ether-a-go-go-Related Gene inhibition,-,0.5369
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Micronuclear,+,0.98
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Hepatotoxicity,-,0.541
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,skin sensitisation,-,0.838
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Respiratory toxicity,+,0.9556
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Reproductive toxicity,+,0.9222
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Mitochondrial toxicity,+,0.975
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Nephrotoxicity,+,0.6687
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Acute Oral Toxicity (c),III,0.5829
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Estrogen receptor binding,-,0.6456
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Androgen receptor binding,-,0.5233
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Thyroid receptor binding,+,0.7536
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Glucocorticoid receptor binding,-,0.8661
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Aromatase binding,+,0.604
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,PPAR gamma,+,0.8269
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Honey bee toxicity,-,0.9348
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Biodegradation,-,0.675
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Crustacea aquatic toxicity,-,0.57
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Fish aquatic toxicity,+,0.781
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,ADMET predicted profile --- Regressions,Value,Unit
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Water solubility,-2.827,logS
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Plasma protein binding,0.188,100%
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Acute Oral Toxicity,1.249,log(1/(mol/kg))
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,Tetrahymena pyriformis,-0.411,pIGC50 (ug/L)
,,,
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Human Intestinal Absorption,+,0.9259
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Caco-2,+,0.6802
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Blood Brain Barrier,-,0.575
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Human oral bioavailability,-,0.7286
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Subcellular localzation,Lysosomes,0.4282
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,OATP2B1 inhibitior,-,0.757
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,OATP1B1 inhibitior,+,0.9125
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,OATP1B3 inhibitior,+,0.9335
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,MATE1 inhibitior,-,0.98
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,OCT2 inhibitior,-,0.875
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,BSEP inhibitior,+,0.8447
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,P-glycoprotein inhibitior,+,0.7947
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,P-glycoprotein substrate,+,0.8733
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,CYP3A4 substrate,+,0.7197
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,CYP2C9 substrate,+,0.8343
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,CYP2D6 substrate,-,0.7393
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,CYP3A4 inhibition,-,0.5076
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,CYP2C9 inhibition,-,0.6999
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,CYP2C19 inhibition,-,0.6587
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,CYP2D6 inhibition,-,0.8784
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,CYP1A2 inhibition,-,0.7328
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,CYP2C8 inhibition,+,0.5409
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,CYP inhibitory promiscuity,-,0.7132
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,UGT catelyzed,+,0.6
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Carcinogenicity (binary),-,0.71
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Carcinogenicity (trinary),Non-required,0.5712
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Eye corrosion,-,0.9886
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Eye irritation,-,0.963
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Skin irritation,-,0.7668
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Skin corrosion,-,0.9173
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Ames mutagenesis,-,0.5791
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Human Ether-a-go-go-Related Gene inhibition,-,0.385
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Micronuclear,+,0.9
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Hepatotoxicity,+,0.8625
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,skin sensitisation,-,0.8762
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Respiratory toxicity,+,0.9111
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Reproductive toxicity,+,0.7111
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Mitochondrial toxicity,+,0.875
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Nephrotoxicity,-,0.8386
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Acute Oral Toxicity (c),III,0.5771
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Estrogen receptor binding,+,0.6619
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Androgen receptor binding,+,0.6403
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Thyroid receptor binding,-,0.8319
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Glucocorticoid receptor binding,+,0.5723
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Aromatase binding,-,0.8514
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,PPAR gamma,+,0.7037
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Honey bee toxicity,-,0.7702
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Biodegradation,-,0.775
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Crustacea aquatic toxicity,-,0.57
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Fish aquatic toxicity,+,0.9959
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,ADMET predicted profile --- Regressions,Value,Unit
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Water solubility,-3.536,logS
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Plasma protein binding,0.749,100%
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Acute Oral Toxicity,2.781,log(1/(mol/kg))
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,Tetrahymena pyriformis,0.306,pIGC50 (ug/L)
,,,
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Human Intestinal Absorption,+,0.6354
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Caco-2,-,0.9373
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Blood Brain Barrier,-,0.9
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Human oral bioavailability,-,0.6714
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Subcellular localzation,Lysosomes,0.4687
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,OATP2B1 inhibitior,+,1
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,OATP1B1 inhibitior,+,0.8461
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,OATP1B3 inhibitior,+,0.9341
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,MATE1 inhibitior,-,0.78
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,OCT2 inhibitior,-,0.95
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,BSEP inhibitior,+,0.91
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,P-glycoprotein inhibitior,+,0.81
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,P-glycoprotein substrate,+,0.6697
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CYP3A4 substrate,+,0.798
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CYP2C9 substrate,+,1
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CYP2D6 substrate,-,0.8328
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CYP3A4 inhibition,+,0.5843
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CYP2C9 inhibition,-,0.6229
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CYP2C19 inhibition,+,0.5399
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CYP2D6 inhibition,-,0.8424
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CYP1A2 inhibition,-,0.67
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CYP2C8 inhibition,+,0.651
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CYP inhibitory promiscuity,+,0.5946
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,UGT catelyzed,-,0.6
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Carcinogenicity (binary),-,0.76
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Carcinogenicity (trinary),Non-required,0.5824
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Eye corrosion,-,0.9886
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Eye irritation,-,0.9541
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Skin irritation,-,0.7871
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Skin corrosion,-,0.9324
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Ames mutagenesis,-,0.54
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Human Ether-a-go-go-Related Gene inhibition,+,0.8916
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Micronuclear,+,0.81
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Hepatotoxicity,+,0.9625
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,skin sensitisation,-,0.8543
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Respiratory toxicity,+,0.9444
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Reproductive toxicity,+,0.9
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Mitochondrial toxicity,+,0.9375
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Nephrotoxicity,+,0.5899
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Acute Oral Toxicity (c),III,0.5962
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Estrogen receptor binding,+,0.8015
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Androgen receptor binding,+,0.6779
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Thyroid receptor binding,+,0.6172
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Glucocorticoid receptor binding,+,0.7014
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Aromatase binding,+,0.5186
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,PPAR gamma,+,0.8707
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Honey bee toxicity,-,0.7149
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Biodegradation,-,0.825
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Crustacea aquatic toxicity,-,0.55
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Fish aquatic toxicity,+,0.8897
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,ADMET predicted profile --- Regressions,Value,Unit
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Water solubility,-3.225,logS
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Plasma protein binding,0.978,100%
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Acute Oral Toxicity,2.986,log(1/(mol/kg))
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Tetrahymena pyriformis,0.436,pIGC50 (ug/L)
,,,
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Human Intestinal Absorption,-,0.5613
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Caco-2,-,0.8387
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Blood Brain Barrier,-,0.575
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Human oral bioavailability,+,0.7714
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Subcellular localzation,Mitochondria,0.8099
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,OATP2B1 inhibitior,+,1
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,OATP1B1 inhibitior,+,0.9101
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,OATP1B3 inhibitior,+,0.9358
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,MATE1 inhibitior,-,0.78
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,OCT2 inhibitior,-,0.875
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,BSEP inhibitior,+,0.9885
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,P-glycoprotein inhibitior,+,0.8091
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,P-glycoprotein substrate,+,0.7602
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CYP3A4 substrate,-,0.5
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CYP2C9 substrate,-,1
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CYP2D6 substrate,-,0.8134
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CYP3A4 inhibition,-,0.8425
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CYP2C9 inhibition,-,0.7041
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CYP2C19 inhibition,-,0.5948
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CYP2D6 inhibition,-,0.848
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CYP1A2 inhibition,-,0.7553
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CYP2C8 inhibition,+,0.7933
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CYP inhibitory promiscuity,-,0.7718
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,UGT catelyzed,-,0.5
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Carcinogenicity (binary),-,0.67
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Carcinogenicity (trinary),Non-required,0.5815
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Eye corrosion,-,0.9886
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Eye irritation,-,0.9541
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Skin irritation,-,0.8497
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Skin corrosion,-,0.9555
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Ames mutagenesis,-,0.6
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Human Ether-a-go-go-Related Gene inhibition,+,0.8576
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Micronuclear,+,0.78
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Hepatotoxicity,+,0.8625
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,skin sensitisation,-,0.8602
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Respiratory toxicity,+,0.9333
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Reproductive toxicity,+,0.8
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Mitochondrial toxicity,+,0.925
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Nephrotoxicity,-,0.8932
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Acute Oral Toxicity (c),III,0.5912
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Estrogen receptor binding,+,0.7801
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Androgen receptor binding,+,0.8695
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Thyroid receptor binding,+,0.8461
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Glucocorticoid receptor binding,+,0.74
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Aromatase binding,+,0.5824
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,PPAR gamma,+,0.7855
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Honey bee toxicity,-,0.7914
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Biodegradation,-,0.8
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Crustacea aquatic toxicity,+,0.51
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Fish aquatic toxicity,+,0.7476
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,ADMET predicted profile --- Regressions,Value,Unit
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Water solubility,-2.903,logS
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Plasma protein binding,1,100%
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Acute Oral Toxicity,3.265,log(1/(mol/kg))
CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,Tetrahymena pyriformis,-0.186,pIGC50 (ug/L)
,,,
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Human Intestinal Absorption,+,0.9949
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Caco-2,+,0.9313
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Blood Brain Barrier,+,0.95
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Human oral bioavailability,+,0.9
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Subcellular localzation,Mitochondria,0.6901
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,OATP2B1 inhibitior,-,0.8577
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,OATP1B1 inhibitior,+,0.9549
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,OATP1B3 inhibitior,+,0.946
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,MATE1 inhibitior,-,0.9
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,OCT2 inhibitior,-,0.5635
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,BSEP inhibitior,+,0.7537
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,P-glycoprotein inhibitior,-,0.8232
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,P-glycoprotein substrate,-,0.8555
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,CYP3A4 substrate,+,0.6538
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,CYP2C9 substrate,+,1
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,CYP2D6 substrate,-,0.8866
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,CYP3A4 inhibition,-,0.8309
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,CYP2C9 inhibition,-,0.8009
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,CYP2C19 inhibition,-,0.7971
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,CYP2D6 inhibition,-,0.9451
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,CYP1A2 inhibition,+,0.6175
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,CYP2C8 inhibition,-,0.9883
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,CYP inhibitory promiscuity,-,0.5443
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,UGT catelyzed,-,0
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Carcinogenicity (binary),-,0.88
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Carcinogenicity (trinary),Non-required,0.6209
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Eye corrosion,-,0.9889
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Eye irritation,-,0.9948
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Skin irritation,-,0.7587
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Skin corrosion,-,0.9557
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Ames mutagenesis,-,0.68
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Human Ether-a-go-go-Related Gene inhibition,-,0.6167
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Micronuclear,+,0.88
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Hepatotoxicity,+,0.925
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,skin sensitisation,-,0.8988
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Respiratory toxicity,+,0.9444
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Reproductive toxicity,+,0.7444
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Mitochondrial toxicity,+,0.925
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Nephrotoxicity,+,0.4536
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Acute Oral Toxicity (c),II,0.525
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Estrogen receptor binding,+,0.8167
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Androgen receptor binding,-,0.4838
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Thyroid receptor binding,+,0.6969
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Glucocorticoid receptor binding,+,0.6464
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Aromatase binding,+,0.6711
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,PPAR gamma,+,0.622
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Honey bee toxicity,-,0.9343
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Biodegradation,-,0.9
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Crustacea aquatic toxicity,-,0.54
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Fish aquatic toxicity,-,0.6466
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,ADMET predicted profile --- Regressions,Value,Unit
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Water solubility,-3.253,logS
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Plasma protein binding,0.662,100%
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Acute Oral Toxicity,2.089,log(1/(mol/kg))
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Tetrahymena pyriformis,0.532,pIGC50 (ug/L)
,,,
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Human Intestinal Absorption,+,0.9966
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Caco-2,+,0.7162
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Blood Brain Barrier,-,0.625
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Human oral bioavailability,-,0.7714
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Subcellular localzation,Mitochondria,0.4831
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,OATP2B1 inhibitior,-,1
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,OATP1B1 inhibitior,+,0.907
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,OATP1B3 inhibitior,+,0.948
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,MATE1 inhibitior,-,0.94
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,OCT2 inhibitior,-,0.925
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,BSEP inhibitior,-,0.6111
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,P-glycoprotein inhibitior,-,0.8757
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,P-glycoprotein substrate,-,0.9363
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,CYP3A4 substrate,+,0.7672
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,CYP2C9 substrate,-,0.8075
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,CYP2D6 substrate,-,0.7056
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,CYP3A4 inhibition,-,0.7577
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,CYP2C9 inhibition,-,0.6975
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,CYP2C19 inhibition,-,0.5291
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,CYP2D6 inhibition,-,0.8699
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,CYP1A2 inhibition,+,0.6996
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,CYP2C8 inhibition,+,0.9818
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,CYP inhibitory promiscuity,-,0.6705
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,UGT catelyzed,-,0
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Carcinogenicity (binary),-,0.7057
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Carcinogenicity (trinary),Danger,0.5069
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Eye corrosion,-,0.9794
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Eye irritation,-,0.9541
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Skin irritation,-,0.7501
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Skin corrosion,-,0.9422
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Ames mutagenesis,-,0.7
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Human Ether-a-go-go-Related Gene inhibition,-,0.5
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Micronuclear,+,0.73
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Hepatotoxicity,+,0.9534
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,skin sensitisation,-,0.7925
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Respiratory toxicity,+,0.6111
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Reproductive toxicity,+,0.9111
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Mitochondrial toxicity,-,0.5375
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Nephrotoxicity,+,0.8467
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Acute Oral Toxicity (c),III,0.6057
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Estrogen receptor binding,+,0.6458
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Androgen receptor binding,+,0.8731
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Thyroid receptor binding,+,0.7414
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Glucocorticoid receptor binding,+,0.7035
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Aromatase binding,+,0.7685
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,PPAR gamma,+,0.8339
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Honey bee toxicity,-,0.8414
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Biodegradation,-,0.75
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Crustacea aquatic toxicity,+,0.7174
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Fish aquatic toxicity,+,0.8378
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,ADMET predicted profile --- Regressions,Value,Unit
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Water solubility,-4.523,logS
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Plasma protein binding,0.94,100%
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Acute Oral Toxicity,1.835,log(1/(mol/kg))
C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,Tetrahymena pyriformis,0.777,pIGC50 (ug/L)
,,,
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Human Intestinal Absorption,+,0.9873
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Caco-2,-,0.9372
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Blood Brain Barrier,+,0.9
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Human oral bioavailability,-,0.8143
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Subcellular localzation,Mitochondria,0.7288
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,OATP2B1 inhibitior,-,1
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,OATP1B1 inhibitior,+,0.9203
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,OATP1B3 inhibitior,+,0.9318
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,MATE1 inhibitior,-,0.6018
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,OCT2 inhibitior,-,0.6181
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,BSEP inhibitior,+,0.9158
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,P-glycoprotein inhibitior,+,0.7249
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,P-glycoprotein substrate,+,0.7421
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,CYP3A4 substrate,+,0.6901
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,CYP2C9 substrate,-,0.808
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,CYP2D6 substrate,-,0.7711
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,CYP3A4 inhibition,+,0.6066
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,CYP2C9 inhibition,+,0.6028
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,CYP2C19 inhibition,+,0.5684
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,CYP2D6 inhibition,-,0.8331
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,CYP1A2 inhibition,-,0.8616
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,CYP2C8 inhibition,-,0.7392
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,CYP inhibitory promiscuity,+,0.7814
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,UGT catelyzed,-,0
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Carcinogenicity (binary),-,0.65
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Carcinogenicity (trinary),Non-required,0.6028
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Eye corrosion,-,0.9886
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Eye irritation,-,0.9541
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Skin irritation,-,0.7829
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Skin corrosion,-,0.9314
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Ames mutagenesis,-,0.72
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Human Ether-a-go-go-Related Gene inhibition,-,0.7259
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Micronuclear,+,0.73
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Hepatotoxicity,+,0.8625
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,skin sensitisation,-,0.8638
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Respiratory toxicity,+,0.9667
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Reproductive toxicity,+,0.9444
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Mitochondrial toxicity,+,0.9625
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Nephrotoxicity,-,0.7187
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Acute Oral Toxicity (c),III,0.5622
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Estrogen receptor binding,+,0.7022
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Androgen receptor binding,+,0.7213
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Thyroid receptor binding,+,0.6168
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Glucocorticoid receptor binding,+,0.5423
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Aromatase binding,+,0.5321
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,PPAR gamma,-,0.5
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Honey bee toxicity,-,0.881
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Biodegradation,-,0.875
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Crustacea aquatic toxicity,+,0.6362
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Fish aquatic toxicity,+,0.9695
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,ADMET predicted profile --- Regressions,Value,Unit
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Water solubility,-3.748,logS
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Plasma protein binding,0.866,100%
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Acute Oral Toxicity,2.466,log(1/(mol/kg))
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,Tetrahymena pyriformis,1.759,pIGC50 (ug/L)
